MODULATORS OF TISSUE REGENERATION

Abstract: Proteins which are upregulated in injured or regenerating tissues, as well as the DNA encoding these proteins, are disclosed, as well as therapeutic compositions and methods of treatment encompassing these compounds.

Description: MODULATORS OF TISSUE REGENERATION Related Applications This is a continuation-in-part of prior U.S. Provisionals S.N. 60/047,490 and S.N. 60/047,491, both filed May 23, 1997. The teachings of both earlier-filed Provisional patent applications are incorporated herein by reference. Field of the Invention The invention relates generally to gene expression products, including nucleic acids (e.g., RNAs) and polypeptides that are upregulated in injured or regenerating tissues. Further, the invention relates generally to cDNAs and other nucleic acids encoding polypeptides that are upregulated in injured or regenerating tissues. Background of the Invention The processes of tissue development during embryogenesis, and of tissue repair and/or regeneration following injury or insult are presently the topic of intense investigation. Both processes involve a dynamic remodeling of tissue architecture, which is triggered and mediated by numerous biological interactions, including cell-cell contact, cell-matrix contact, release of soluble biological response modifiers, synthesis of structural components, and many other changes in cell phenotype, including changes in gene expression. Many of the factors involved in tissue genesis and in the response to tissue insult remain unknown or poorly understood. Several systems have been developed for modeling the events triggered by insult to particular tissues, and/or by particular types of insult. For example, several investigators have described events occurring in mammalian kidney tissue exposed to an ischemia- reperfusion insult. The kidney is able to repair damage to the proximal tubule epithelium through a complex series of events involving cell death, proliferation of surviving proximal tubule epithelial cells, formation of poorly differentiated regenerative epithelium over the denuded basement membrane, and differentiation of the regenerative epithelium to form fully functional proximal tubule epithelial cells (Wallin et al., Lab. Invest. 66:474-484, 1992; Witzgall et al., Mol. Cell. Biol. 13:1933-1942, 1994; Ichimura et al., Am. J. Physiol. 269:F653-662, 1995; Thadhani et al., N. Engl. J. Med. 334:1448-1460, 1996). Growth factors such as IGF, EGF, and HGF have been implicated in this process of repair, as has the endothelial cell adhesion molecule ICAM-1. However, the mechanisms by which the tubular epithelial cells are restored, either functionally and morphologically, remain poorly understood. There accordingly is a need for an improved understanding of the biological processes of tissue repair or regeneration. That is, there is a need to identify factors that are indicative of the initiation, development and resolution of normal wound healing or normal biological response to tissue insult. Similarly, there is a need to identify factors that are indicative of pathologies of abnormal responses to tissue insult or other stimulus, including autoimmune or other dysregulation pathologies, as well as pathologies associated with abnormal tissue growth including neoplastic growth. Further, there is a need to identify factors that constitute appropriate targets for therapeutic intervention to stimulate, modulate, enhance, suppress or otherwise manipulate biological responses to tissue insult. Similarly, there is a need to identify factors that constitute appropriate targets for therapeutic intervention to manipulate abnormal or dysregulated responses to tissue insult or other stimulus, including abnormal tissue growth associated with cancer (neoplasia) and, conversely, abnormal tissue quiescence associated with degenerative diseases. Summary of the Invention It is an object of this invention to identify factors that are indicative of the initiation, development and resolution of normal wound healing or normal biological response to tissue insult. A specific object of this invention is to identify products (e.g., RNAs, cDNAs, polypeptides) of genes that are upregulated in the context of healing tissue, or in tissue exposed to insult or injury. A particular object is to identify products of genes that are upregulated in mammalian kidney tissue exposed to insult or injury, such as ischemia- reperfusion injury. A second specific object of this invention is to identify products of genes that are upregulated in pathological conditions associated with abnormal responses to tissue insult or other stimulus, including autoimmune or other dysregulation pathologies, as well as pathologies associated with abnormal tissue growth including neoplastic growth. A third specific object is to identify gene products that constitute appropriate targets for therapeutic intervention to stimulate, modulate, enhance, suppress or otherwise manipulate biological responses to tissue insult. A particular object is to identify gene products for therapeutic intervention to manipulate responses of mammalian kidney tissue to tissue injury, such as ischemia-reperfusion injury. A fourth specific object is to identify gene products that constitute appropriate targets for therapeutic intervention to manipulate abnormal or dysregulated responses to tissue insult or other stimulus, including abnormal tissue growth associated with cancer (neoplasia) and, conversely, abnormal tissue quiescence associated with degenerative diseases. Thus, other particular objects of the invention include the identification of gene products as targets for therapeutic intervention in the clinical management (including prophylaxis, maintenance and treatment) of kidney diseases, including diseases involving renal failure, and of cancers derived from or affecting renal tissue. The present invention rests on the discovery that the expression levels of numerous genes, including many genes heretofore unknown and or uncharacterized, are upregulated in mammalian kidney tissue that has been exposed to tissue insult or injury. More specifically, the present invention rests on the discovery of a novel class of Kidney Injury- associated Molecules (each member of the class is henceforth called a "KIM"). KIMs are polypeptides encoded by genes whose expression levels are upregulated in the mammalian kidney upon exposure to tissue injury, particularly after exposure to ischemia-reperfusion injury. Any KIM is useful as an indicator of tissue status (preferably renal tissue status) or of a change therein (e.g, exposure to tissue injury, or the occurrence or stage of a tissue repair process). Any KIM further is useful as a target for therapeutic intervention to manipulate, whether by an agonist or an antagonist, a normal or abnormal tissue response to insult or other stimulus. The invention accordingly provides, in a first aspect, purified and isolated nucleic acid molecules encoding all or a unique fragment of a KIM. In one embodiment, the present nucleic acids are RNAs. In another, they are DNA molecules, such as cDNAs. In another embodiment, the invention provides the complementary strands of nucleic acids encoding all or a unique fragment of a KIM. In another embodiment, the invention provides nucleic acids (preferably DNAs) that hybridize under low or, preferably, high stringency conditions to any of the foregoing nucleic acids. In still another embodiment, the invention provides nucleic acids (preferably DNAs) which, but for the degeneracy of the genetic code, would hybridize to any of the foregoing nucleic acids. In some embodiments, a nucleic acid encoding all or a unique fragment of a KIM is an engineered (recombinant) nucleic acid, optionally in operative association with an expression control element or other regulatory element. In other embodiments, a nucleic acid encoding all or a unique fragment of a KIM is an antisense nucleic acid sufficient, when internalized within a cell, to disrupt expression of a cellular KIM gene. Specific novel KIMs (and unique fragments thereof) of the present invention are coded for by nucleic acids having the sequences disclosed herein in TABLE 1 and in the Sequence Listing. Other specific KIMs (and unique fragments thereof) are coded for by nucleic acids having sequences that are degenerate variants of any of the KIM sequences set forth in TABLE 1 and in the Sequence Listing. Still other specific KIMs (and fragments) are coded for by nucleic acids that are substantially similar to (homologous to) any of the KIM sequences in TABLE 1 and in the Sequence Listing. Such KIMs are defined herein as variants of the disclosed novel KIM sequences. In some embodiments, the present nucleic acid encodes a chimeric polypeptide comprising a novel KIM-encoding sequence (i.e., a sequence encoding part or all of a KIM) fused to a non-KIM sequence. Thus, the invention provides nucleic acids encoding novel KIM fusion proteins, non- limiting examples of which include KIM polypeptides fused to a secretable leader polypeptide, an immunoglobulin polypeptide, a binding pair partner (e.g., avidin, GST), a toxin or toxoid (e.g., ricin, tetanus), an enzyme (preferably one for which a detectable substrate is available, e.g., alkaline phosphatase, horseradish peroxidase, luciferase), or other detectable polypeptide (e.g., green fluorescent protein). Additional specific KIMs (and unique fragments thereof) are coded for by nucleic acids referred to in TABLE 2. It is believed that, in most to all instances, these specific molecules have not heretofore been appreciated to be KIMs. In a second aspect, the invention provides a vector having a KIM-encoding nucleic acid inserted therein. In some embodiments, the vector is a biologically functional plasmid or viral DNA vector. In other embodiments, the vector is a retroviral vector. In a third aspect, the invention provides a prokaryotic or eukaryotic host cell comprising an internalized vector having a KIM-encoding nucleic acid insert. The present host cell provides intracellular means for producing (synthesizing, folding, processing, or secreting) a KIM polypeptide of the present invention. In a fourth aspect, the invention provides a process for the production of a KIM polypeptide. The present production process includes growing a host cell of the invention under culture conditions sufficient for the production of polypeptides of vector origin, and recovering an expressed KIM polypeptide. In a fifth aspect, the invention provides a purified and isolated novel KIM polypeptide, preferably substantially free of non-KIM polypeptides or proteins. In some embodiments, the present polypeptide is a full-length polypeptide, i.e., a polypeptide corresponding to the full-length open reading frame of a novel KIM-encoding cDNA. In other embodiments, the present polypeptide is a unique fragment of the full-length polypeptide. Thus, specific novel KIM polypeptides (and unique fragments thereof) of the present invention are coded for by nucleic acids having the sequences disclosed herein in TABLE 1 and in the Sequence Listing. Other specific novel KIM polypeptides of the present invention are variants of the disclosed novel KIM sequences, including without limitation splice variants, truncation variants, and substitution variants. In some embodiments, the invention provides a chimeric polypeptide comprising a novel KIM polypeptide fused (preferably via a peptide bond) to a non-KIM polypeptide. Thus, the invention provides novel KIM fusion proteins, exemplified by the above-mentioned fusion constructs. Of course, the invention also provides conjugated or derivatized novel KIM polypeptides, including without limitation detectable conjugates, imageable conjugates, radiolabeled conjugates, and toxin conjugates. In still other embodiments, the invention provides chimeric polypeptides, fusion proteins and conjugates comprising a polypeptide appreciated herein as being a KIM (see TABLE 2). In a sixth aspect, the invention provides an antibody that binds selectively to a KIM polypeptide. Preferably, the antibody is a monoclonal antibody (or an engineered derivative thereof) produced by conventional means from a hybridoma derived from splenocytes of an animal immunized with a KIM polypeptide of the present invention. In some embodiments, the present antibody is conjugated or derivatized with a detectable moiety, toxin, imageable compound or radionuclide. In a seventh aspect, the invention provides a pharmaceutical composition comprising a therapeutically effective amount of a KIM nucleic acid (e.g., an antisense nucleic acid); a KIM vector; a KIM polypeptide; a KIM fusion protein; a KIM-binding antibody (also referred to as an anti-KIM antibody), dispersed, dissolved or otherwise suspended in a physiologically acceptable carrier, vehicle, solvent or excipient. In an eighth aspect, the invention provides methods and kits for detecting, either qualitatively or quantitatively, KIM expression and or KIM polypeptide. As disclosed herein, KIMs are upregulated by exposure of mammalian kidney (renal) tissue to insult or injury, particularly ischemia-reperfusion injury. Thus, any KIM (or combination or panel thereof) can be used as an indicator of tissue status (preferably renal tissue status), or of a change therein, including without limitation exposure to tissue injury, the occurrence or stage of an injury process, the occurrence or stage of a tissue repair or regeneration process, or the occurrence of an abnormal tissue response to injury or other stimulus, such as an autoimmune response or an abnormal proliferative response (e.g., a neoplastic response). In one embodiment, the invention provides a detection method and kit for diagnosis, prognosis, staging, or monitoring of renal injury or of renal disease or of the effectiveness of therapy therefor. Some specific embodiments involve detecting and/or measuring the concentration of one or more KIM polypeptides in serum, urine, or urine sediment of an individual (a mammal, preferably a human) afflicted with or at risk of developing renal injury or an impairment of renal function. Some such embodiments involve the use of at least one KIM polypeptide, anti-KIM antibody or conjugate thereof as elements of a reagent kit for immunoassay according to standard techniques. For present purposes, any KIM disclosed herein or identified as such herein can be used as a kit element, along with other elements for KIM detection. In other instances, such as where the detected KIM has biological or enzymatic activity, the kit can include reagents for detecting KIM activity, e.g., by enzyme assay. Other specific embodiments involve detecting and/or measuring the level of expression of one or more KIM-encoding nucleic acids in renal cells in a kidney biopsy, or in cells shed into urine or urine sediment of an individual afflicted with or at risk of developing renal injury or an impairment of renal function. Some such embodiments involve the use of a nucleic acid (e.g., RNA or DNA) encoding a KIM polypeptide, or a unique fragment thereof, or a probe nucleic acid capable of hybridizing to nucleic acid encoding a KIM, as elements of a reagent kit for hybridization assay according to standard techniques. As above, any KIM nucleic acid disclosed herein or appreciated herein as such can be used as a hybridization kit element, along with other reagents for detection of hybridized nucleic acids. In another embodiment, the invention provides a method and kit for diagnosis, prognosis, staging or monitoring of an abnormal response of renal tissue to tissue injury or other stimulus, including an autoimmune response or an abnormal proliferative response, such as neoplasia arising from or affecting renal tissue. Some specific embodiments involve detecting and/or measuring the concentration of one or more KIM polypeptides in serum, urine, or urine sediment of an individual (a mammal, preferably a human) afflicted with or at risk of developing renal injury or an impairment of renal function. Some such embodiments involve the use of at least one KIM polypeptide, anti-KIM antibody or conjugate thereof as elements of a reagent kit for immunoassay according to standard techniques. For present purposes, any K M disclosed herein or identified as such herein can be used as a kit element, along with other elements for KIM detection. In other instances, such as where the detected KIM has biological or enzymatic activity, the kit can include reagents for detecting KIM activity, e.g., by enzyme assay. Other specific embodiments involve detecting and or measuring the level of expression of one or more KIM-encoding nucleic acids in cells present in a kidney biopsy, or in cells shed into urine or urine sediment of an individual afflicted with or at risk of developing renal injury or an impairment of renal function. Some such embodiments involve the use of a nucleic acid (e.g., RNA or DNA) encoding a KIM polypeptide, or a unique fragment thereof, or a probe nucleic acid capable of hybridizing to nucleic acid encoding a KIM, as elements of a reagent kit for hybridization assay according to standard techniques. As above, any KIM nucleic acid disclosed herein or appreciated herein as such can be used as a hybridization kit element, along with other reagents for detection of hybridized nucleic acids. In a ninth aspect, the invention provides a method and reagent for imaging tissues, either in vitro or in vivo. In particular, the invention provides a method and reagent for imaging the presence, extent or severity of kidney injury or of kidney tissue repair or regeneration. Similarly, the invention provides a method and reagent for imaging the presence, extent, severity or stage of an abnormal response to tissue injury or other stimulus, such as autoimmunity or neoplasia, particularly neoplasia arising from or affecting renal tissue. The present invention also provides a method for targetting an imageable compound to cells or tissue expressing or producing a KIM. The present method involves the step of contacting cells or tissue with a detectable (e.g., imageable) KIM-binding reagent, which in some embodiments is an anti-KIM antibody or conjugate thereof, or a KIM fusion protein. In other embodiments, the detectable KIM-binding reagent is a nucleic acid of the invention (e.g., a probe or antisense nucleic acid) labeled with a radionuclide or other imageable compound. According to the present method, cells expressing or producing a KIM are visualized (imaged) by detecting the presence and/or location of an accumulation of the KIM-binding reagent. For imaging in vivo, the KIM- binding reagent is administered, by any appropriate route, to an individual (a mammal, preferably a human) suspected of harboring an imageable locus of KIM expression and/or production. Without being limited hereby, it is believed that the present method can be used to detect the presence and/or location of a tissue mass (e.g., a tumor) abnormally producing or expressing a KIM. In a tenth aspect, the invention provides methods for treating an individual (a mammal, preferably a human) afflicted with or at risk of developing a disease or condition contributed to or associated with a dysfunction or dysregulation of a KIM gene or protein. Further, the invention provides methods for treating an individual afflicted with or at risk of developing a disease or condition beneficially affected by therapeutic administration of a KIM protein. The present methods involve the step of administering to the individual a therapeutically effective amount of a KIM polypeptide, variant or fusion protein thereof, or, conversely, of an anti-KIM antibody. It is expected that such compounds will be useful in therapeutic methods which manipulate, e.g., stimulate or inhibit, biological responses that are dependent on KIM function. In an eleventh aspect, the invention provides a method for inhibiting the growth of KIM-expressing tumor cells, involving the step of contacting the cells with an anti-KIM antibody, conjugated to a toxin or radionuclide. In an alternative embodiment, the method involves the step of contacting the cells with an antisense KIM nucleic acid that is sufficient to suppress or disrupt expression of a KIM gene in the tumor cells. In a twelfth aspect, the invention provides a method of gene therapy. The present method involves the administration of a vector capable of directing the production of a KIM, to an individual afflicted with or at risk of a renal disorder, disease or injury. As a result of the present method, growth of new tissue, preferably renal tissue, is stimulated, or survival of existing tissue, preferably renal tissue, is promoted. The foregoing and other objects, features, aspects and advantages of the present invention, as well as the invention itself, will be more fully understood from the following description of preferred embodiments. Detailed Description of the Invention The discovery, reported herein, of a novel class of Kidney Injury-related Molecules (KIMs) was made by analyzing differences in mRNA expression between normal adult mammalian kidneys, and kidneys in the process of regenerating following exposure to tissue insult (specifically, to ischemia-reperfusion injury). Two established techniques were used for this purpose: representational difference analysis (RDA), and suppression subtractive hybridization (SSH). Both techniques were used to assess cDNAs isolated from various timepoints, e.g., 48 hours, after the onset of ischemia. In these studies, the normal adult kidney material was isolated from sham-operated subjects. Both techniques resulted in the depletion of cDNAs which are common to both postischemic and to normal kidney samples, leaving a pool of cDNAs which are significantly expressed only in injured or regenerating kidney tissue. This pool likely contains cDNAs corresponding to genes that encode proteins involved in the injury process, and proteins involved in tissue repair or regeneration processes. Therefore, cDNAs isolated from the pool likely encode parts or all of proteins likely to be therapeutically beneficial for treatment or prophylaxis of tissue injury, especially renal injury. Several cDNA clones have been obtained, sequenced and characterized. Selected Definitions A "KIM protein", herein used synonymously with "KIM", is any protein or polypeptide encoded by mRNA which is selectively upregulated following injury to a kidney. One group of KIM proteins of interest includes those coded for by mRNA which is selectively upregulated at any time within one week following any insult which results in injury to renal tissue. Examples of times at which such upregulation might be identified include 10 hours, 24 hours, 48 hours or 96 hours following an insult. Examples of tissue insults include toxin exposure, hypoxia, hyperoxia, hemodynamic disruption, ischemia, reperfusion, or mechanical compression. Many different types of proteins fall within the KIM class, including cell surface proteins (e.g., ligands or counter-receptors involved in cell-cell or cell-matrix interactions), secreted proteins (e.g., diffusable biological response modifiers, such as growth factors, differentiation factors, survival factors and the like), intracellular proteins (e.g., elements of a signalling pathway), and nuclear proteins (e.g., transcription factors). A "KIM ligand" is any molecule which noncovalently and specifically binds to a KIM protein. Such a ligand can be a protein, peptide, steroid, antibody, amino acid derivative, or other type molecule, in any form, including naturally-occurring, recombinantly produced, or otherwise synthetic. A KIM ligand can be in any form, including soluble, membrane-bound, or part of a fusion construct with immunoglobulin, fatty acid, or other moieties. The KIM ligand may be an integrin. A membrane-bound KIM ligand can act as a receptor which, when bound to or associated with KIM, triggers a cellular response. In some interactions, a KIM may associate with a plurality of KIM ligands, or may associate with a KJM ligand as part of a complex with one or more other molecules or cofactors. In a situation where both the KIM and the KIM ligand are bound to cell membranes, the KIM may associate and react with KIM ligand which is bound to the same cell as the KIM, or it may associate and react with KIM ligand be bound to a second cell. Where the KIM ligation occurs between molecules bound to different cells, the two cells may be the same or different with respect to cellular type or origin, phenotypic or metabolic condition, or type or degree of cellular response (e.g., growth, differentiation or apoptosis) to a given stimulus. "KIM ligation" refers to the contact and binding of KIM with a KIM ligand. A "unique fragment" of a nucleic acid means any fragment of sufficient length to have a sequence likely to be substantially unique in a mammalian genome. Thus, a unique fragment generally means an oligonucleotide at least 16 nucleotide bases in length. Similarly, a "unique fragment" of a polypeptide means any fragment of sufficient length to have an amino acid sequence likely to be substantially unique to a given mammalian protein, such as a KIM. Thus, a unique peptide fragment generally means a peptide at least 7 amino acids in length. A "KIM variant" means a KIM whose sequence differs from a sequence disclosed herein by the presence of one or more internal or terminal insertions, deletions or substitutions of a nucleotide (when referring to KIM nucleic acids) or of an amino acid (when referring to KIM polypeptides). Preferably, the KIM variant is "substantially similar" to the corresponding disclosed KIM, or to a unique fragment thereof. That is, the KIM variant is "homologous" to the corresponding disclosed KIM. "Substantially similar" or "homologous" variants are structurally similar to the corresponding disclosed KIM. Further, "substantially similar" or "homologous" variants have sufficient functional similarity to the corresponding disclosed KIM that they share one or more of the KIM's biological properties or functions (e.g., binding to a receptor or ligand, triggering of biological responses, transport of a metabolite, catalysis of a substrate, or the like). A KIM variant can be naturally occurring or synthesized or produced by routine techniques, such as molecular engineering techniques. By "alignment of sequences" is meant the positioning of one sequence, either nucleotide or amino acid, with that of another, to allow a comparison of the sequence of relevant portions of one with that of the other. Generally, sequences are aligned using the GAP and BESTFTT programs, which are based on the teachings of Needleman et al. (J. Mol. Biol. 48:443-453, 1970), Smith et al. (Adv. Appl. Math. 2:482-489, 1981), and Rechild et al. (CABIOS 5: 107-113, 1989). Generally, when a homologous variant of a KIM is aligned with the corresponding KIM polypeptide, it will share amino acids that contribute to the KIM's three dimensional structure, such as cysteine residues. Although the relative positions of cysteine residues is generally conserved in the variant sequence, homologous or functionally equivalent sequences can include functionally equivalent arrangements of the cysteines, including arrangements comprising amino acid insertions or deletions which alter the linear arrangement of the cysteines, but do not materially impair their relationship or ability to form disulfide bonds in the folded structure of the KIM protein. Therefore, minor internal gaps and amino acid insertions, such as occur in splice variants, are ignored when aligning sequences herein. "Sequence homology", "percent (%) homology", "sequence similarity" and "percent (%) similarity" are used interchangeably herein, and refer to the sum of the percentage of residues (whether nucleotides or amino acids) that are, when aligned with a reference sequence, the same as the corresponding reference residues, and those that are, when aligned, conservative substitutions for the corresponding reference residues. "Sequence identity" and "percent (%) identity" also are used interchangeably herein, and refer to the percentage of residues (whether nucleotides or amino acids) that are, when aligned with a reference sequence, the same as the corresponding reference residues. Both sets of terms are used according to their definitions in Altschul et al. (1990), J. Mol. Biol. 215:403-410 and in the Basic Local Alignment Search Tool (BLAST) algorithm described therein. For present purposes, the algorithm gap weight is set at 3.0 and the length weight is set at 0.1. "Hybridization" means the formation of a duplex nucleic acid molecule, in which nucleotide bases of a first polynucleotide strand bind noncovalently with cognate nucleotide bases of a second polynucleotide strand. Generally, such noncovalent binding occurrs in DNA only between adenosine (A) and thymidine (T) bases, and guanosine (G) and cytosine (C) bases. In RNA, binding occurs only between A and uracil (U), and G and C. The apposition of non-cognate bases in a duplex nucleic acid molecule, e.g., A with C, is termed a "mismatch" pairing. Under high stringency hybridization conditions, mismatches occur rarely in a given duplex nucleic acid molecule. Low stringency conditions permit the occurrence of some mismatches. Exemplary conditions which promote DNA hybridization, termed "hybridization conditions", include 6.0X sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0X SSC at 50°C. The salt concentration in the wash step can be selected from a low stringency wash of about 2.0X SSC at 50°C, to a high stringency was of about 0.2X SSC at 50°C. In addition, the temperature in the wash step can be selected from a low stringency wash at room temperature, about 22°C, to a high stringency wash at about 65°C. A "KIM agonist" is a molecule which can specifically trigger a cellular response normally triggered by the interaction of KIM with a KIM ligand. A KIM agonist can be a KIM variant, or a specific antibody to KIM, or a soluble form of the KIM ligand. A "KIM antagonist" is a molecule which can specifically associate with a KIM ligand or a KIM, thereby blocking or otherwise inhibiting KIM binding to the KIM ligand. The antagonist binding blocks or inhibits cellular responses which would otherwise be triggered by ligation of the KIM ligand with KIM or with a KIM agonist. Examples of KIM antagonists include certain KIM variants, KIM fusion proteins and specific antibodies to a KIM ligand or KIM. "Isolated" refers to a condition in which a nucleic acid or polypeptide of the present invention is essentially free of other nucleic acids, polypeptides, or of other contaminants with which it might normally be found in nature, and as such exists in a form not found in nature. "Substantially pure" refers to a condition in which a nucleic acid or polypeptide of the present invention is separated from other nucleic acids, polypeptides, or other contaminants, particularly naturally occurring contaminants, that interfere with the ability to detect, visualize or isolate the the nucleic acid or polypeptide of the invention, or that interfere with a biological function or property thereof. A substantially pure nucleic acid or polypeptide of the invention is not generally found in nature. A "chemical derivative" of another molecule contains one or more additional chemical or biochemical moieties not found naturally in association with the molecule. Such moieties may improve the molecule's solubility, absorption, biological half life, etc. The moieties may alternatively decrease the toxicity of the molecule, eliminate or attenuate any undesirable side effect of the molecule, etc. Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences. 16th ed., Mack Publishing Co., Easton, Penn. (1980). Other terms used herein, including "antisense DNA", "antisense probe", "cloning", "cDNA", "cDNA library", "DNA polymorphism", "expression", "gene", "hybridoma", "plasmid", "probe", "labeled", "recombinant", "host cells", "transformed", "transfected", "vector", and the like are used in the sense of their art-recognized meanings in the fields of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA or genetic engineering, and immunology. Such meanings are determined by consultation of one or more of the following widely available texts: Molecular Cloning. A Laboratory Manual.2nd Ed. (Sambrook, Fritsch and Maniatis, eds.), Cold Spring Harbor Laboratory Press, 1989; DNA Cloning. Volumes I and II (Glover, ed.), 1985; Oligonucleotide Synthesis (Gait, ed.), 1984; U.S. Patent 4,683,195, Mullis et al., invs.; Nucleic Acid Hybridization (Hames & Higgins, eds.), 1984; Transcription and Translation (Hames & Higgins, eds.), 1984; Culture of Animal Cells (Freshney), Alan R. Liss, publ., 1987; Immobilized Cells and Enzymes (IRL Press), 1986; A Practical Guide to Molecular Cloning (Perbal), 1984; Current Protocols in Molecular Biology. Wiley & Sons, publ., 1989; Methods in Enzvmology. Academic Press, New York NY (especially Volumes 154 and 155); Gene Transfer Vectors for Mammalian Cells (Miller and Calos, eds.), Cold Spring Harbor Laboratory Press, 1987; Immunochemical Methods in Cell and Molecular Biology (Mayer and Walker, eds.), Academic Press, London, 1987; Handbook of Experimental Immunology. Volumes I-IV (Weir and Blackwell, eds.), 1986; and, Manipulating the Mouse Embryo. Cold Spring Harbor Laboratory Press, 1986. Compounds of the Invention Specific, novel KIMs discovered through RDA or SSH techniques are set forth below in TABLE 1 and in the Sequence Listing. TABLE 1 lists KIMs for which potential full length (PFL) cDNA clones were obtained. Also shown are the predicted polypeptide sequences encoded in the open reading frames (ORFs) of many of the newly discovered KIMs. In addition, TABLE 1 provides, where relevant, the subtracted amplified clone (SAC) designations and the PFL location(s) of partial sequences, many of which were reported in prior U.S. Provisional S.N. 60/047,490 and 60/047,491. TABLE 1 TABLE 1, continued Additional KIMs, which are believed to be related to (e.g., substantially similar to) known molecules also were obtained through RDA or SSH techniques, and are set forth in TABLE 2 and in the Sequence Listing. It is believed that few to none of these molecules were previously appreciated to be KIMs, i.e., to have relevance to tissue injury or repair processes, particularly in the kidney. TABLE 2 lists these KIMs along with their clone designations. Partial sequences of some of the cDNA clones listed below were also set forth in the priority document. Also shown are the name(s) and GENBANK accession numbers of the known genes to which these KIMs may be related. TABLE 2 TABLE 2, continued TABLE 2, continued Any of the foregoing KIM cDNAs can be inserted into a vector, liposome or other carrier vehicle for internalization and production in a host cell. Furthermore, the invention encompasses derivatives and variants of each of the foregoing KIMs as listed in TABLES 1 and 2. One embodiment of the invention provides soluble variants of a KIM protein that is usually synthesized as a membrane associated protein. Soluble variants lack at least a portion of the transmembrane or intra-membrane section of a native KIM protein. In some examples, the soluble variant lacks the entire transmembrane or intra-membrane section of a native KIM protein. Soluble variants include fusion proteins which encompass derivatives of KIM proteins that lack at least a portion of the transmembrane or intra- membrane section of a native KIM protein. All types of KIM fusion proteins are included, particularly those which incorporate his-tag, Ig-tag, and myc-tag forms of the molecule. These KIM fusions may have characteristics which are therapeutically advantageous, such as the increased half-life conferred by the Ig-tag. Also included are fusion proteins which incorporate portions of selected domains of the KIM protein. Variants can differ from a naturally occurring KIM protein in amino acid sequence or in ways that do not involve sequence, or both. Variants in amino acid sequence are produced when one or more amino acids in naturally occurring KIM protein is substituted with a different natural amino acid, an amino acid derivative or non-natural amino acid. Particularly preferred substitution variants include naturally occurring KIM proteins, or biologically active unique fragments thereof, whose sequences differ from the wild type sequence by one or more conservative amino acid substitutions, which typically have minimal influence on the secondary structure and hydrophobic nature of the protein or peptide. Conservative substitutions typically include the substitution of one amino acid for another with similar characteristics, such as substitutions within the following groups: valine, glycine; glycine, alanine; valine, isoleucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. Other conservative substitutions are those which meet the criteria for an "accepted point mutation" as defined in the Atlas of Protein Sequence and Structure (Dayhoff et al., eds.), 1978. See also PCT publication no. WO97/44460. Substitution variants can also have sequences which differ by one or more non- conservative amino acid substitutions, provided however that the substitution does not abolish the native KIM protein's biological activity, ligand- or receptor-binding characteristics, or other functional property of interest. Exemplary non-conservative substitutions are those in which: (I) a hydrophilic residue, e.g., serine or threonine, is substituted for (or by) a hydrophobic residue, e.g., leucine, isoleucine, phenylalanine, or alanine; (ii) a cysteine residue is substituted for (or by) any other residue; (iii) a residue having an electropositive side chain, e.g., lysine, arginine or histidine, is substituted for (or by) a residue having an electronegative charge, e.g., glutamic acid or aspartic acid; or (iv) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having such a side chain, e.g., glycine. Other KIM variants of this invention include truncation variants (comprising at least a unique fragment of the corresponding KIM), insertion variants, and splice variants. Other KIM variants within the invention are those with modifications which increase polypeptide stability. Such variants can contain, for example, one or more non- peptide bonds (which replace the peptide bonds) in the peptide sequence. Also included are: variants that include residues other than naturally occurring L-amino acids, such as D- amino acids or non-naturally occurring or synthetic amino acids such as beta or gamma amino acids and cyclic variants. Incorporation of D- instead of L-amino acids into the polypeptide may increase its resistance to proteases. See, e.g., U.S. Patent 5,219,990. KIM variants can be naturally-occurring, or produced through synthetic or molecular engineering techniques. Those of skill in the art will understand and appreciate that an engineered KIM variant can provide advantageous properties, e.g., in facilitating purification, improving stability, modulating a biological function, or the like. Thus, in some instances, a KIM variant will be desired that lacks a glycosylation site, or that has decreased aggregation potential due to elimination of a hydrophobic surface, or that has improved folding efficiency due to elimination of a cysteine residue, or the like. In general, KIM variants have at least fifty (50) % amino acid sequence homology or similarity with the corresponding KIM protein. Preferably, the variants have at least sixty-five (65) % sequence similarity, more preferably at least eighty (80) % similarity with the corresponding KIM protein. Still more preferably, the sequence similarity is at least ninety (90) , or most preferably, at least ninety-five (95) %. Other preferred KIM variants are those which 1) share at least forty (40) % similarity to the corresponding KIM protein, and 2) share at least eighty (80) % of aligned cysteine residues with the corresponding KIM protein. Just as it is possible to replace substituents of the amino acid backbone or scaffold, it is also possible to replace, modify or add non-amino acid moieties to the scaffold. Such moieties can occur naturally in a given KIM as a result of post-translational processing, including acetylation, methylation, phosphorylation, carboxylation or glycosylation. As desired, such moieties can be removed or added by conventional synthetic or biochemical techniques. Further, non-natural moieties can be added to produce a derivative of a KIM or KIM variant of this invention. For example, polyethylene glycol (PEG) can be linked to a KIM to improve its stability or pharmacokinetic properties. As will be readily appreciated, anti-KIM and anti-KIM variant antibodies can be produced by conventional techniques. Specifically contemplated are polyclonal and monoclonal antibodies, including antigen-binding fragments thereof and engineered derivatives thereof. Antigen-binding fragments of intact antibodies include complete Fab fragments, F(ab') compounds, V H regions, and F v regions. Engineered derivatives of antibodies of the invention include single chain antibodies (see, e.g., WO 96/23071), as well as human, humanized, primatized, or chimeric antibodies (see, e.g., PCT/US 95/16709). Engineered derivatives of the present antibodies are produced, generally, using standard recombinant DNA techniques (Winter and Milstein, Nature 349: 293-99, 1991). These include "chimeric" antibodies, in which the antigen binding domain from an animal antibody is linked to a human constant domain. In this instance, an antibody with the desired KIM-binding selectivity is derived initially from a nonhuman mammal (e.g., a mouse, rat or hamster), and subjected to recombinant DNA manipulation to replace all or part of the hinge and constant regions of the heavy chain and/or the constant region of the light chain, with corresponding regions from a human immunoglobin light chain or heavy chain. (See, e.g., Cabilly et al., United States Pat. No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. 81: 6851-55, 1984). Chimeric antibodies reduce the immunogenic responses elicited by animal antibodies when used in human clinical treatments. In addition, recombinant "humanized" antibodies can be synthesized. Humanized antibodies are antibodies initially derived from a nonhuman mammal in which recombinant DNA technology has been used to substitute some or all of the amino acids not required for antigen binding with amino acids from corresponding regions of a human immunoglobin light or heavy chain. That is, they are chimeras comprising mostly human immunoglobulin sequences into which the regions responsible for specific antigen-binding have been inserted (see, e.g., PCT patent application WO 94/04679). Animals are immunized with the desired antigen, the corresponding antibodies are isolated and the portion of the variable region sequences responsible for specific antigen binding are removed. The animal-derived antigen binding regions are then cloned into the appropriate position of the human antibody genes in which the antigen binding regions have been deleted. Humanized antibodies minimize the use of heterologous (inter-species) sequences in antibodies for use in human therapies, and are less likely to elicit unwanted immune responses. Primatized antibodies can be produced similarly. If desired, fully human antibodies with KIM-binding specificity which can be produced in nonhuman animals, such as transgenic animals harboring one or more human immunoglobulin transgenes. Such animals may be used as a source for splenocytes for producing hybridomas, as is described in U.S. 5,569,825. Identification of Specific KIMs of the Invention To assess the dynamic biological processes of response to injury and tissue repair, a kidney ischemia-reperfusion model, which similates acute renal failure, was employed. The results of studies in this model system now have been published, and appear in Ichimura et al. (1998). J. Biol. Chem. 273:4135-4142, the teachings of which are incorporated by reference herein. In this model, the kidney has the capacity for cell renewal (both structurally and funcitonally) after injury to tubular epithelial cells. The nephron is damaged functionally by an ischemic reperfusion injury that results in regional areas of proximal tubule cell death. During the repair process, the kidney proximal tubule epithelium undergoes a complex series of events including (1) cell death and cast formation in the tubule lumen (casts are aggregates of dead, semi viable and viable cells, as well as of cell debris); (2) proliferation of surviving proximal tubule epithelial cells; (3) formation of a poorly differentiated regenerative epithelium over the denuded basement membrane (this simplified epithelium expresses vimentin, a mesenchymal marker); and (4) differentiation of the regenerative epithelium to form fully functional proximal tubule epithelial cells. Gene expression analysis of the kidney at various timepoints following the onset of ischemia revealed the upregulation of many KIMs anticipated to be involved in the injury and repair/regeneration processes. 1. Generation of ischemic and normal rat adult kidnevs Ischemic injured rat kidneys are generated as described by Witzgall et al. (J. Clin Invest. 93: 2175-2188, 1994). Briefly, the renal artery and vein from one kidney of an adult Sprague-Dawley rat are clamped for 40 minutes and then reperfused. Injured kidneys are harvested from the rats at 24 hours and at 48 hours after reperfusion. Kidneys from sham-operated, normal adult Sprague-Dawley rats are also harvested. 2. mRNA isolation Post-ischemic rat kidneys are prepared as described by Witzgall et al. (J. Clin. Invest. 93: 2175-2188, 1994). Briefly, the renal artery and vein of the left kidney of an adult Sprague Dawley rat are clamped for 40 minutes and then reperfused. The ischemic kidneys are removed from rats either 24 hours or 48 hours after reperfusion. Normal rat kidneys are used as controls. Total RNA is isolated with Trizol reagent (BRL catalog No. 1559-026). The kidney capsules are removed, then the kidneys are rinsed in PBS and immediately homogenized in Trizol solution. In some instances, the kidney is chopped into several pieces in PBS, frozen quickly in liquid nitrogen and kept at -70 °C until it is processed for total RNA isolation. The mRNA is purified from total RNA according to the manufacturer's instructions, using an mRNA purification kit (Pharmacia, Catalog No. 27-9258-02). 3(i). Representational difference analysis (RDA) method to clone short-fragment cDNAs up-regulated bv ischemia The RDA method of Hubank and Schatz (Nucleic Acid Research 22:5640-48, 1994) is performed as described, with modifications as follow. Double-stranded cDNA is synthesized using the Superscript Choice® system (BRL Catalog No. 18090), from mRNA isolated from rat kidney either 24 hours or 48 hours post-ischemia as a tester and normal rat kidney as a driver. The tester and driver cDNA is digested with Dpnll and ligated to R- Bgl-12/24 oligonucleotides. The adapter-ligated cDNA is amplified by PCR, and the PCR product is digested with Dpnll to remove the oligonucleotides. The tester cDNA is ligated to J-Bgl- 12-24 oligonucleotides. Full length cDNA clones for Kim-1 and NMB contained in a plasmid vector are provided by T. Ichimura. They are digested with Sau3Al, purified and used as quenching reagents. cDNA fragments, 2-3 containing a fragment of annexin π, and 3-8 containing a fragment of alpha 2 macroglobulin (both provided by T. Ichimura) are amplified by PCR with R-Bgl-24 primer, digested with Dpnll to remove the oligonucleotides and used as quenching reagents. Tester cDNA is hybridized to an excess driver cDNA including the four quenching reagents described above. After mung bean nuclease digestion. hybridization mixture is amplified by PCR to enrich the cDNA fragments upregulated by ischemia. Each of the PCR steps is tested with a range of template DNA concentrations, and the concentration giving the best signal is chosen for the next steps. The DNA mixture containing tester and driver DNA for the subtractive hybridization step is washed twice with 70% EtOH by spinning for 3 minutes. The second round cDNA subtraction is performed by hybridizing the first round cDNA subtraction product ligated to N-Bgl- 12-24 oligonucleotides to an excess of the same driver cDNA used for the first round subtraction. The third round cDNA subtraction is performed by hybridizing the second round cDNA subtraction product ligated to J-Bgl- 12/24 oligonucleotides to an excess of the same driver cDNA used for the first round of cDNA subtraction at a ratio of 1: 14,000. The final PCR product after the third round of subtraction is digested with Dpnll to remove the oligonucleotides and ligated to pCR- Script SK(+) vector. This represents a selected cDNA library by RDA. 3(ii). Suppression subtractive hybridization (SSH) method to clone short-fragment cDNAs up-regulated by ischemia SSH is perfomed according to the manufacturer's instructions (Clontech, Catalog No. Kl 804-1) with certain modifications. Briefly, double-stranded cDNA are synthesized from mRNA isolated from rat kidney 24 hours or 48 hours post-ischemia as a tester, and from nomal rat kidney as a driver with the Superscript Choice™ system for cDNA synthesis (BRL Catalog No. 18090). The cDNA is synthesized according to the manufacturer's instruction except that the first strand cDNA is synthesized at 42°C. cDNA is digested with RSAI. Tester cDNA after RSAI digestion is ligated to adaptors. For the first hybridization, tester cDNA with adaptors is hybridized with excess driver cDNA at 68°C for 12 hours. For the second hybridization, the mixture is hybridized at 68°C for 22 hours. The cDNA mixture after the second hybridization is initially amplified by PCR for 27 cycles only. Then, a portion of the PCR product is re-amplified for 10 or 13 cycles. The final subtracted PCR product is digested by RSAI to remove the adaptor, and separated on a gel. The three bands and the remaining smear are cut out separately and cloned to pCR- Script SK (+) vector (Stratagene, Catalog No. 211188). This represents a selected cDNA library by SSH. 4. Isolation and Characterization of Subtracted Amplified cDNA Clones Colonies are randomly picked from the selected RDA and SSH cDNA libraries, and plasmid DNA is isolated with Qiagen plasmid kit. Each cDNA clone, referred to as a Subtracted Amplified Clone (SAC) is sequenced with the vector primers. DNA sequences are checked against GeneBank EMBL databases for homology by the program BLAST™. Southern blots are prepared with the initial PCR products generated from normal and injured rat kidneys. The blots are hybridized to the inserts isolated from the SACs to confirm which SACs are induced by ischemia. 4. Isolation and Characterization of potential full length cDNA clones 4.25 ug of poly A+ mRNA isolated from rat kidney 24 hours post-ischemia, which has been purified twice by oligo dT chromatography, is used to generate a cDNA library. In order to obtain double-stranded cDNA with EcoRI adaptors, a Superscript Choice® system for cDNA synthesis (BRL Catalog No. 18090) is used following the supplier's protocol, except that the cDNA synthesis reaction is carried out at 42 C. The DNA is ethanol precipitated, washed, resuspended in 5 ul H2O, and ligated to 2 ug EcoRI digested and CIAP-treated Lambda ZAPII (Strategene catalog No. 236612). The ligated DNA is packaged and used to infect E. coli XL-1 Blue MRF. The complexity of the library is 3.4xl0 6 independent recombinant plaques. Another cDNA library is generated from 4 ug of polyA+ RNA from rat kidney 48 hours post-ischemia as described above. The two cDNA libraries described above are screened with inserts from the SAC clones. pBluescript plasmid vector containing cDNA inserts are excised from Lambda ZAPII vector by in vivo excision. Inserts from the longest cDNA clones, referred to as Potential Full Length (PFL) clones, are sequenced. DNA sequences are checked by the program BLAST™ against the GenBank/EMBL databases for DNA homology. Predicted protein coding regions (open reading frames, or ORFs) from some of the PFL clones also were used to search the GenBank/EMBL databases. Diagnostic Uses of the Compounds of the Invention Anti-KIM antibodies of the invention, which specifically bind to a protein of the invention or a unique fragment thereof, are useful in several diagnostic methods. These agents can be labeled with detectable markers, such as fluoroscopically or radiographically opaque substances, and administered to an individual to allow imaging of tissues which express KIM protein. The agents can also be bound to (conjugated to) substances, such as horseradish peroxidase, which can be used as immunocytochemical stains to allow visualization of areas of KIM protein-positive cells on histological sections. A specific antibody could be used alone in this manner, and sites where it is bound can be visualized in a sandwich assay using an anti-immunoglobulin antibody which is itself bound to a detectable marker. Specific antibodies to KIM protein are also useful in immunoassays to measure KIM presence or concentration in samples of body tissues and fluids. Such concentrations may be correlated with different disease states. As an embodiment of particular interest, the invention includes a method of diagnosing renal injury, or of monitoring a process of renal repair, by measuring the concentration of KIM or of KIM fragments in the urine, plasma or serum of a patient. Similarly, KIM can be measured in urine sediment, in particular in cellular debris in the urine sediment. Casts of renal tubule cells, which may be present in urine sediment from patients with ongoing renal disease, may contain elevated levels of KIM protein and mRNA. Specific antibodies to KIM protein may also be bound to solid supports, such as beads or dishes, and used to remove the ligand from a solution, either for measurement, or for purification and characterization of the protein or its attributes (such as post- translational modifications). Such characterization of an individual's KIM protein is expected to be useful in identifying deleterious mutants or processing defects which interfere with KIM function and are associated with abnormal phenotypes. Each of these techniques is routine to those of skill in the immunological arts. Additional imaging methods utilize KIM or KIM fragments, fused to imageable moieties, for diagnostic imaging of tissues that express KIM ligands, particularly tumors. Further diagnostic techniques are based on demonstration of upregulated KIM mRNA in tissues, as an indication of injury-related processes. (See, e.g., PCT publication no. WO 97/44460). Therapeutic Uses of the Compounds of the Invention The therapeutic methods of the invention involve selectively promoting or inhibiting cellular responses that are dependent on the presence or concentration of any KIM, including without limitation KIM ligation, KIM enzyme activity, KIM secretion, KIM signalling, and KIM modulation of gene expression. In instances where a KIM and a KIM ligand are both membrane bound, and expressed by different cells, the signal transduction may occur in the KIM-expressing cell, in the KIM ligand-expressing cell, or in both. KIM ligation-triggered response in a KIM ligand-expressing cell may be generated by contacting the cell with exogenous KIM, KIM fusion proteins or activating antibodies against KIM ligand, either in vitro or in vivo. Further, responses of the KIM ligand- expressing cell that would otherwise be triggered by endogenous KIM could be blocked by contacting the KIM ligand-expressing cell with a KIM ligand antagonist (e.g., an antagonist antibody that binds to KIM ligand), or by contacting the endogenous KIM with an anti- KIM antibody or other KIM-binding molecule which prevents the effective ligation of KIM with a KIM ligand. Similarly, the responses triggered by KIM ligation in the KIM-expressing cell may be promoted or inhibited with exogenous compounds. For example, KIM ligation- triggered response in a KIM-expressing cell may be generated by contacting the cell with a soluble KIM ligand, or certain anti-KIM activating antibodies. Further, responses of the KIM-expressing cell that would otherwise be triggered by interaction with endogenous KIM ligand could be blocked by contacting the KIM-expressing cell with an antagonist to KIM (e.g.., a blocking antibody that binds to KIM in a manner that prevents effective, signal-generating KIM ligation), or by contacting the endogenous KIM ligand with an anti- KIM ligand antibody or other KIM ligand-binding molecule which prevents the effective ligation of KIM with the KIM ligand. Which of the interventions described above are useful for particular therapeutic uses depend on the relevant etiologic mechanism of either the pathologic process to be inhibited, or of the medically desirable process to be promoted, as is apparent to those of skill in the medical arts. For example, where KIM ligation results in desirable cellular growth, maintenance of differentiated phenotype, resistance to apoptosis induced by various insults, or other medically advantageous responses, one of the above-described interventions that promote ligation-triggered response may be employed. In the alternative, one of the inhibitory interventions may be useful where KIM ligation invokes undesirable consequences, such as neoplastic growth, deleterious loss of cellular function, susceptibility to apoptosis, or promotion of inflammation events. Following are examples of the previously described therapeutic methods of the invention. One therapeutic use of the KIM-related compounds of the invention is for treating a subject with renal disease, promoting growth of new tissue in a subject, or promoting survival of damaged tissue in a subject, and includes the step of administering to the subject a therapeutically effective amount of a KIM protein of the invention, or of a pharmaceutical composition which includes a protein of the invention. The protein used in these methods can be a unique fragment of a full-length KIM protein, a soluble KM variant or a soluble ligand thereof, a KIM fusion protein, or a KIM agonist. These methods can also be practiced by administering to the subject a therapeutically effective amount of an agonist antibody of the invention, or a pharmaceutical composition which includes an agonist antibody of the invention. A KIM protein can be administered concurrently with a therapeutically effective amount of a second compound which exerts a medically desirable adjunct effect. While tissues of interest for these methods include any tissue, preferred tissues include renal tissue, liver, neural tissue, heart, stomach, small intestine, spinal cord, or lung. Particular renal conditions which are expected to be beneficially treated with the compounds of the invention include acute renal failure, acute nephritis, chronic renal failure, nephrotic syndrome, renal tubule defects, kidney transplants, toxic injury, hypoxic injury, and trauma. Renal tubule defects include those of either hereditary or acquired nature, such as polycystic renal disease, medullary cystic disease, and medullary sponge kidney. This list is not limited, and may include many other renal disorders (see, e.g., Harrison's Principles of Internal Medicine, 13th ed., 1994, which is herein incorporated by reference.) The subject of the methods may be human. A therapeutic intervention for inhibiting growth of undesirable, KIM- or KIM- ligand-expressing tissue in a subject includes the step of administering to the subject a therapeutically effective amount of a KIM antagonist (e.g.., an antibody blocks KIM ligation). In an embodiment of interest, the KIM antagonist or anti-KIM antibody can be used therapeutically to inhibit or block growth of tumors which depend on KIM protein for growth. Other methods of the invention include killing KIM ligand-expressing tumor cells, or inhibiting their growth, by contacting the cells with a fusion protein of a KIM and a toxin or radionuclide, or an anti-KIM ligand antibody conjugated to a toxin or radionuclide. The cell can be within a subject, and the protein or the conjugated antibody is administered to the subject. Also encompassed within the invention is a method for targeting a toxin or radionuclide to a cell expressing a KIM, comprising contacting the cell with a fusion protein comprising a KIM ligand and a toxin or radionuclide, or an anti-KIM antibody conjugated to a toxin or radionuclide. Another embodiment includes the method of suppressing growth of a tumor cell which expresses KIM, comprising contacting the cell with a fusion protein of KIM ligand and a toxin or radionuclide or with an anti-KIM antibody conjugated to a toxin or radionuclide; the cell may be within a subject, and the protein administered to the subject. The term "subject" as used herein is taken to mean any mammal to which KIM can be administered. Subjects specifically intended for treatment with the method of the invention include humans, as well as nonhuman primates, sheep, horses, cattle, goats, pigs, dogs, cats, rabbits, guinea pigs, hamsters, gerbils, rats and mice. Use of Compounds of the Invention in Gene Therapy The KIM genes of the invention are introduced into damaged tissue, or into tissue where stimulated growth is desirable. Such gene therapy stimulates production of KIM protein by the transfected or transformed cells, promoting cell growth and/or survival of cells that express the KIM protein. In a specific embodiment of a gene therapy method, a gene coding for a KIM protein is be introduced into a renal target tissue. The KIM protein is expected to be stably expressed and stimulate tissue growth, division, or differentiation, or to potentiate cell survival. Furthermore, a KIM gene can be introduced into a target cell using a variety of well-known methods that use either viral or non-viral based strategies. Once introduced into a target cell, sequences of interest can be identified by conventional methods such as nucleic acid hybridization using probes comprising sequences that are homologous/complementary to the inserted gene sequences of the vector. In another approach, the sequence(s) may be identified by the presence or absence of a "marker" gene function (e.g, thymidine kinase activity, antibiotic resistance, and the like) caused by introduction of the expression vector into the target cell. Formulation In general, compounds of the invention are suspended, dissolved or dispersed in a pharmaceutically acceptable carrier or excipient. The resulting therapeutic composition does not adversely affect the subject's homeostasis, particularly electrolyte balance. Thus, an exemplary carrier comprises normal physiologic saline (0.15M NaCl, pH 7.0 to 7.4). Other acceptable carriers are well known in the art and are described, for example, in Remington's Pharmaceutical Sciences. Gennaro, ed., Mack Publishing Co., 1990. Acceptable carriers can include biocompatible, inert or bioabsorbable salts, buffering agents, oligo- or polysaccharides, polymers, viscosity-improving agents, preservatives, and the like. In some embodiments, the term "carrier" encompasses liposomes and the HIV-1 tat protein (See Chen et al., Anal. Biochem. 227: 168-175, 1995) as well as any plasmid and viral expression vectors. Any KIM compound of this invention can be used in the form of a pharmaceutically acceptable salt. Suitable acids and bases which are capable of forming salts with the polypeptides, nucleic acids and vectors of the present invention are well known to those of skill in the art, and include inorganic and organic acids and bases. KIM compounds of the invention are dispersed in the carrier to concentrations sufficient to deliver to the subject a therapeutically effective amount of the compound, which is an amount sufficient to produce a detectable, preferably medically beneficial effect in the subject. Medically beneficial effects would include preventing, delaying or attenuating deterioration of, or detectably improving, the subject's medical condition. It is expected that the concentration or amount of a KIM compound that will produce a medically beneficial effect will vary considerably with the circumstances in which the invention is practiced. An effective amount can be determined by an ordinarily skilled physician or other practitioner through no more than routine experimentation. As an example, an indication of the status of renal injury or renal function can be monitored with one or more routine laboratory tests which measure the concentrations of relevant substances in blood or urine, other urine characteristics, or the rate of clearance of various substances from the blood into the urine. The parameters measured by these tests, either individually or in combination, can be used by a physician to assess renal function or damage. Examples of such parameters include the blood concentration of urea, creatinine or protein; the urine concentration of protein or of various blood cells such as erythrocytes or leucocytes; urine specific gravity; amount of urine; the clearance rates of inulin, creatinine, urea or p-aminohippuric acid; and the presence of hypertension or edema. In some embodiments, a KIM compound is formulated in a liposome delivery system, including without limitation any of a variety of unilamellar vesicles, multilamellar vesicles, or stable plurilamellar vesicles, all of which can prepared and administered according to methods well known to those of skill in the art, for example in accordance with the teachings of United States Patent 5,169,637, 4,762,915, 5,000,958 or 5,185,154. In addition, it may be desirable to express the novel polypeptides of this invention, as well as other selected polypeptides, as lipoproteins, in order to enhance their binding to liposomes. As an example, treatment of human acute renal failure with liposome- encapsulated KIM protein may be performed in vivo by introducing a KIM protein into cells in need of such treatment using liposomes. The liposomes can be delivered via catheter to the renal artery. The recombinant KIM protein is purified, for example, from CHO cells by immunoaffinity chromatography or any other convenient method, then mixed with liposomes and incorporated into them at high efficiency. The encapsulated protein may be tested in vitro for any effect on stimulating cell growth. Routes of Administration The compounds of the invention may be administered in any manner which is medically acceptable. Depending on the specific circumstances, local or systemic administration may be desirable. Preferably, the compound is administered via a parenteral route such as by an intravascular, intravenous, intraarterial, subcutaneous, intramuscular, intratumor, intraorbital, intraventricular, intraperitoneal, subcapsular, intracranial, intraspinal, or intranasal injection, infusion or inhalation. The compound also may be administered by implantation of an infusion pump, or a biocompatible or bioerodable sustained release implant, or by installation of a catheter (e.g., in a renal artery), into the subject. Alternatively, certain compounds of the invention, or formulations thereof, may be appropriate for oral or enteral administration. Still other compounds of the invention will be suitable for topical administration. Treatment Regimes Determining appropriate dosage and frequency of treatment with any particular KIM compound to be administered to an individual is within the skills and clinical judgement of ordinary practitioners. The general dosage and treatment schedule is established by preclinical and clinical trials, which involve extensive but routine studies to determine the optimal administration parameters of the compound. Even after such recommendations are made, the practitioner will often vary these dosages for different individuals based on a variety of considerations, such as the individual's age, medical status, weight, sex, and concurrent treatment with other pharmaceuticals. Determining the optimal dosage and administration regime for each KIM compound is a routine matter for those of skill in the pharmaceutical and medical arts. Equivalents The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative of, rather than limiting on, the invention disclosed herein. Scope of the invention thus is indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are intended to be embraced therein. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Sanicola-Nadel , Michele Hession, Catherine A Wei , Henry Cate, Richard L (ii) TITLE OF INVENTION: MODULATORS OF TISSUE REGENERATION (iii) NUMBER OF SEQUENCES: 112 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Patent Administrator, Biogen, Inc. (B) STREET: 14 Cambridge Center (C) CITY: Cambridge (D) STATE: MA (E) COUNTRY: USA (F) ZIP: 02142 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 60/047,490 (B) FILING DATE: 23-MAY-1997 (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 60/047,491 (B) FILING DATE: 23-MAY-1997 (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Fenton, Gillian M (B) REGISTRATION NUMBER: 36,508 (C) REFERENCE/DOCKET NUMBER: A028PCT (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (617) 679-2810 (B) TELEFAX: (617) 679-2838 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2058 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HWOIO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 8..646 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (1618..1885) (D) OTHER INFORMATION: /label= SAC_23807 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1 : GTCGACA GCT CGG ATC CCC CCA TCA CCT ACC TCA CAG ACT GCT CAG ACA 49 Ala Arg lie Pro Pro Ser Pro Thr Ser Gin Thr Ala Gin Thr 1 5 10 GAA GGT AGT AGG ATC ACA TCC AAA ATG CCT GTG GCG TCT ACC CAG GGG 97 Glu Gly Ser Arg lie Thr Ser Lys Met Pro Val Ala Ser Thr Gin Gly 15 20 25 30 TCC TCT CCC CCT ACC CCG GCT CTG TGG GCA ACC TCC CCC AGG GCT GCC 145 Ser Ser Pro Pro Thr Pro Ala Leu Trp Ala Thr Ser Pro Arg Ala Ala 35 40 45 ACC CTA CCT CCC AAG TCC TCC TCC ACC GGC ACA TCC TGT GAA CCA AAA 193 Thr Leu Pro Pro Lys Ser Ser Ser Thr Gly Thr Ser Cys Glu Pro Lys 50 55 60 ATG GTC ATC AAC ACG GTC CCA CAG CTC CAC TCG GAG AAG ACA GTG TAT 241 Met Val lie Asn Thr Val Pro Gin Leu His Ser Glu Lys Thr Val Tyr 65 70 75 CTC AAG TCC AGT GAC AAC CGC CTG CTC ATG TCT CTC CTC CTC TTC CTC 289 Leu Lys Ser Ser Asp Asn Arg Leu Leu Met Ser Leu Leu Leu Phe Leu 80 85 90 TTT GTC CTC TTC CTC TGC CTC TTT TCC TAC AAC TGC TAC AAG GGC TAC 337 Phe Val Leu Phe Leu Cys Leu Phe Ser Tyr Asn Cys Tyr Lys Gly Tyr 95 100 105 110 CTG CCC GGA CAG TGC TTA AAG TTC CGC TCA GCC CTG CTG CTC GCA AAG 385 Leu Pro Gly Gin Cys Leu Lys Phe Arg Ser Ala Leu Leu Leu Ala Lys 115 120 125 AAA AAA CCT AAG TCA GAG TTC TCT GAC CTG GAG CAG AGT GTG AAG GAG 433 Lys Lys Pro Lys Ser Glu Phe Ser Asp Leu Glu Gin Ser Val Lys Glu 130 135 140 ACG CTG GTA GAA CCT GGG AGC TTC TCG CAG CAG AAC GGC GAC CAG CCC 481 Thr Leu Val Glu Pro Gly Ser Phe Ser Gin Gin Asn Gly Asp Gin Pro 145 150 155 AAG CCA GCC TTG GAT ACC GGC TAT GAA ACC GAG CAG GAC ACT ATC ACC 529 Lys Pro Ala Leu Asp Thr Gly Tyr Glu Thr Glu Gin Asp Thr He Thr 160 165 170 AGC AAG GTC CCC ACC GAT CGA GAG GAC TCG CAA CGT ATC GAC GAG CTC 577 Ser Lys Val Pro Thr Asp Arg Glu Asp Ser Gin Arg He Asp Glu Leu 175 180 185 190 TCC GCC AGG GAC AAA CCG TTT GAT GTC AAG TGT GAA CTC AAG TTT GCA 625 Ser Ala Arg Asp Lys Pro Phe Asp Val Lys Cys Glu Leu Lys Phe Ala 195 200 205 GAC TCG GAT GCC GAC GGG GAC TGAGGCCAGT GTGTCCCAGC CCGTGCCCCT 676 Asp Ser Asp Ala Asp Gly Asp 210 CCGTCTTCGT GGAGAGTGTT GTGTTGAACC TATTCAGTAG CCGAGTCTTG TCACTGTGCA 736 CCAGCCTCAG TCTTTTGTCC CTTTCTCTCT TGGGTTGAGC CTGTGACTTG TCCCCTTTGT 796 CCTTTTGGGA AACAAGTATC TATTCAAGCC TCAAGTCCCG GCAGTTGTTG GAGCGCTTAC 856 TACACACCTG AGCCCTTTGT GTCCTGGGGG AGAGATGGCC ACCTCCGTGG GCTGAGAAGA 916 ACCACCCCTT CCTCTTCCGC TCCTCGAAGC AGCCACTGAG AGATAATTTA ATTCCAGATT 976 GGAAATGACC TTTTTGGTTT ATCAGATTGG TAACTTAATC TCCTGCCATC CGGGTGGCAC 1036 GGACGTTTTT CTTTCACTTC GTTATTTTTT TTAGGATTTG CGCTCCTACT GTGTTGATGT 1096 CTTAGGTCAT TTTTTTTTTT TTAAGTTACC AGAGGAGATG TTTTGATATT CATGAGAAGA 1156 AGAACATTTT CTAGATTTTT TTTTTTTTTG GTTACATATT GAGATAAAAT ATGCCTCTGT 1216 TGCTTAAGAT TCTCAGGGAT AGACGTGATT TTTGCTAATT TCTTTCCTGC TGTTCGGAAC 1276 GTAGGCCTAA AACTGTCTCT TGAGCTCACA CACTCACCCT TTCCTTTTGG TGGGTTTTTT 1336 TTTTTTTTTG TTTTGTTTTA TTAATCTTAC TCATTTCGAA GGATTTTCTT TATGAGCTTT 1396 TGTTTTGTTT TTGTTTTGTT TTTTTGTTTT TCTCTTTTTC CTGCCGTACA TCATCTACGA 1456 GGTGCGTTTT GAGTGAGGGC AGATGGCCCA GTGGCTTCGG GTGGCCCAGT GGCTGTGGGT 1516 GGCAGTTGAG CTGGTCCTGT GAGGGGAGGA GGGCTTAGAC GCCACGGCCC TGCTGCTTCT 1576 CGGCACCTCC TGTCCCGATG GGTGGCGTCT TCATGAGGAT TACATCCTGT CTCTGCTGGC 1636 TTCCATCTCG CACCTCTGCC CTTGGACTTC CACCTTGACT GTCCACAAAA GACAGAAATG 1696 GGCTGGCTAG TTGGGCTCCC GGCCTCGGAC GGTGGCCGCA ACGTCCCGTG TGGGCGGCTG 1756 CCGCTGCAGC CTGACTCCTG CCGGTGTCTT TCAGGATGTG AACGGGTGGT ACGAATCTTG 1816 ACATTTGTTT CTCACTTCCT GTGTATGAAA CGACACTCAT TCCATGTAGA GGGTGACGGA 1876 CTCTGGATCC CCCCCCTTGT CGTGTAGACA CTCATCTTCA GCGTGACCTG GTCCTGCCAT 1936 TCGGTGTAAA CATTTGTGTT TATAAGATTT ACTTTGTTTT TATTTTTCTA CTTGGAACTG 1996 TACATATTTG AAAAAGTACC CAAATAAACC AGAAGCTTTA TCGTTGAAAA AAAAAAGTCG 2056 AC 2058 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 213 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: Ala Arg He Pro Pro Ser Pro Thr Ser Gin Thr Ala Gin Thr Glu Gly 1 5 10 15 Ser Arg He Thr Ser Lys Met Pro Val Ala Ser Thr Gin Gly Ser Ser 20 25 30 Pro Pro Thr Pro Ala Leu Trp Ala Thr Ser Pro Arg Ala Ala Thr Leu 35 40 45 Pro Pro Lys Ser Ser Ser Thr Gly Thr Ser Cys Glu Pro Lys Met Val 50 55 60 He Asn Thr Val Pro Gin Leu His Ser Glu Lys Thr Val Tyr Leu Lys 65 70 75 80 Ser Ser Asp Asn Arg Leu Leu Met Ser Leu Leu Leu Phe Leu Phe Val 85 90 95 Leu Phe Leu Cys Leu Phe Ser Tyr Asn Cys Tyr Lys Gly Tyr Leu Pro 100 105 110 Gly Gin Cys Leu Lys Phe Arg Ser Ala Leu Leu Leu Ala Lys Lys Lys 115 120 125 Pro Lys Ser Glu Phe Ser Asp Leu Glu Gin Ser Val Lys Glu Thr Leu 130 135 140 Val Glu Pro Gly Ser Phe Ser Gin Gin Asn Gly Asp Gin Pro Lys Pro 145 150 155 160 Ala Leu Asp Thr Gly Tyr Glu Thr Glu Gin Asp Thr He Thr Ser Lys 165 170 175 Val Pro Thr Asp Arg Glu Asp Ser Gin Arg He Asp Glu Leu Ser Ala 180 185 190 Arg Asp Lys Pro Phe Asp Val Lys Cys Glu Leu Lys Phe Ala Asp Ser 195 200 205 Asp Ala Asp Gly Asp 210 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1727 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW011 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: GTCGACATGA TTGCTAGTGG TTCTGCTGGC TGTGAGGGCT CCCTGTCTGT GAGATCTTGT 60 TCGGGCTTTC CACATCCAGG ATCCATCCAT TCACCCCTCA CCCACTCACC CTGTGGAGCA 120 TAAAACCTTT GCAGTCAGCC AGCATGGCAG AATGTCTATG CCTTGCTTCA GTTTCCAGGG 180 TAACTAAGCA TGTTTTAATC CCACTGCCCC ACCCACTATT GCTCATTCTG TCTAGTCTTC 240 TGCTACCCAG CTTGTGTGGC TCCGTTCCTG TCACGCCTTC AGACGTCACT GTTCTGTGAC 300 AGCGGTCTCT TTCCCCTCTG CTCCACCCAT TCTGAGCTCT GGGATAGTCC TAAGCCCTGC 360 CCAGAGTAGG TGGACTGGTC GTTCCATGTC CGTGCTTGTG GGAGTTGTGG GGGTCTGTGG 420 CATCTGCTAA GGAGGTTTAT CCTCACGTCA CGGAATCCGG CAAGATGCGC CATGGTCTAC 480 ACTGCTTTCT CGAGCAGCGG CGAGAAAGGC CAGGATAACA CACGCCTCTC TGCCCTGAGA 540 TAACAAACTG TCTGAGAAAG GAAGTGGCCC GTGTCTGGAA CATTGGCCCC AGTAAAGCAG 600 AGGAGACACT GCCATGTTTC CGTCATTCTG TTTCACTGCC TTGCTCTGGG GCTCAGGGGT 660 TGAAGAATGA GGATACACCA TTCGACCTTC AGGCCTTCCT CAGACCCTCT TACAAAGCCT 720 GTTGTTGTGA GTCCAGCTCA TCAGCATGGC CGCCTTGTTC ACAGTTTAGC ACCAGTGTCT 780 GCAACCGTGT CTGAAACGTA GCAGATGTCC AGTACTTTTT GTAAATGAAA AAATGAACAG 840 AGTGAAGAGA AAGAGTCACC ATGAAATTTA CTAGTCCAGT GAGCTGACCG TAGGGGCAGT 900 ATAAACATCC CCCAGCTCTT AATGTTCTGT CCTCAAGCTG TCCCCTCCCA CCTCTCCGCT 960 GGCAGGAGAG TGCTCTGTAT ATGTGGACAG TCGTTGAATG GCAGGTCCAG GATGTCCTCT 1020 GCAGGTGGAC AAAAGAGAAT TCTGCTTCCC GGAAGTCTCC TTTGCTGGTG ATCTCCATGT 1080 CCATCCTCAC TGAGCACTAG AATTAAAACC ACTCAATAAT GTGATATGTG TGGTCACCTT 1140 CAGTTCAGTA GCAGTATTTC CTGGTCATTA A ATTCTGCA TTTTATTATG GTAAGA AGT 1200 ATAAGAAAAT GGTGGGCTGG TATATAGCCA GCCATGAGAC CACTCCTT C GTCAAGGACT 1260 GGCAGAGTCT GAGGGACCTG AGTCTGGGTC CTCCTCCTGT CCCCTCCTCC TGTAGCTATG 1320 GTGGCCTTCA GTATTCTGAG ACTGAAGGCT ACTACTTCAG GACACCTACT TGATCTTAGT 1380 ACTCTCAGAA CAGCTCTCCT CAGTTCTAGC TGTGATCGCG GGCTGCGTTT GGAACGTTAA 1440 CGTACTAATG GGTTTAAGAC TTTCAGAAAG TGATTTTAAA ACAAAATGAC TGGAAGTTTT 1500 GTCTGATAAA GCAAGTAGAA TGGAATGTCT CAGACTGTCT CGTCACATTT TCATGTTTCA 1560 TACGAAAAGA AAAGATTGAT AACCTATCTT TAGAAATAGT AATGTTAGTT CTTTCCTATT 1620 TTGTTTAAAC CTTGAAGAAG GTTTTATTTA ACTCGTGAAC TTGTTCCTTT GTTATGACAT 1680 GATTGTTCCA GATTTGAGGG ACAAAATAAA ATTAACCTTT CTAAAAA 1727 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1060 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW012 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 39..671 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: GTCGACGCAT GGGTGCAGGT GACAAATGAG CTGAAGAA ATG ATC CCC AGA GGA 53 Met He Pro Arg Gly 1 5 ATA GGA TTG TGG CTG CCT TCA GCT CTG CTC CTC TCT CGG GTC CCA GGC 101 He Gly Leu Trp Leu Pro Ser Ala Leu Leu Leu Ser Arg Val Pro Gly 10 15 20 TGT TTC CCT CTG CGT GGC CCC AGC AGT GTG ACA GGC ACT GTG GGG GAG 149 Cys Phe Pro Leu Arg Gly Pro Ser Ser Val Thr Gly Thr Val Gly Glu 25 30 35 TCC CTG AGC GTG ACT TGT CAG TAT GAG GAG AGA TTC AAG ATG AAT AAG 197 Ser Leu Ser Val Thr Cys Gin Tyr Glu Glu Arg Phe Lys Met Asn Lys 40 45 50 AAA TAC TGG TGC AGA GGG TCA CAT GTT CTA CTT TGC AAA GAT ATT GTC 245 Lys Tyr Trp Cys Arg Gly Ser His Val Leu Leu Cys Lys Asp He Val 55 60 65 AAG ACC GGA GGC TCA GAA GAA GCT AGA AAT GGC CGA GTG TCC ATC AGG 293 Lys Thr Gly Gly Ser Glu Glu Ala Arg Asn Gly Arg Val Ser He Arg 70 75 80 85 GAT GAT CCA GAC AAC CTG ACC TTC ACA GTG ACC TTG GAG AGC CTC ATC 341 Asp Asp Pro Asp Asn Leu Thr Phe Thr Val Thr Leu Glu Ser Leu He 90 95 100 CTG GAG GAT GCA GGC ACC TAC ATG TGT GGG GTG GAT ATA CCA TTT ACT 389 Leu Glu Asp Ala Gly Thr Tyr Met Cys Gly Val Asp He Pro Phe Thr 105 110 115 AAT CAC CCC TTG GGG ATT GAT GAG TTC TTC AAG GTT GAA TTG TCT GTG 437 Asn His Pro Leu Gly He Asp Glu Phe Phe Lys Val Glu Leu Ser Val 120 125 130 GTC CCA GGT TCA AGC CTT TGG AGC AGT ACA ACA GTC CCA GAG ACC ATC 485 Val Pro Gly Ser Ser Leu Trp Ser Ser Thr Thr Val Pro Glu Thr He 135 140 145 AGA TCC TCA CTG GTT CAT ACT CAG CCC AGT GTG ACC ACA GAA GAC ACA 533 Arg Ser Ser Leu Val His Thr Gin Pro Ser Val Thr Thr Glu Asp Thr 150 155 160 165 ATT CCT GCT CCT AGT GCA CGG CCT CGG TCT CTT CTG GGC AGC CTC TAC 581 He Pro Ala Pro Ser Ala Arg Pro Arg Ser Leu Leu Gly Ser Leu Tyr 170 175 180 CTC TGC ATC CTG GTG TTT CTG GAG TTG CCC CTG TTC CTG TGC ATG CTC 629 Leu Cys He Leu Val Phe Leu Glu Leu Pro Leu Phe Leu Cys Met Leu 185 190 195 TGT GCC GTC CTG TGG GTG AAC AGG CCT CAG AGG TGC AGT GGG 671 Cys Ala Val Leu Trp Val Asn Arg Pro Gin Arg Cys Ser Gly 200 205 210 TGACATAGCA TTGGGCCCTG TCATGAGTAC CAGTGAAGTC TGTTGATATG GAGGCCCTGT 731 CCCTGGATGC ATCACCTCTG GTGGCCAAGG ACAACCAATA AAGCTGTGTT CTTGAGAATG 791 CTCTGAGACT TTTAGAAGAT TCTCTGCACG TGTCAAACAC ATAAAAGAAT GTGCCCAATA 851 AATACCAGCT GGGGAATTGG CTCAGCAGGT AACAACAATG GCTGCTTTTC CAGAGGTCCT 911 GAGTTCAATT CCAATAACTA CATCGGTGGC TCACAACCAT CTCTAATGAG TTCAGATGCC 971 CTCTTCTGCT GTGCAGGTGC ACATTCACAT AGAATATTCA TACATTGAGT AAATTTATTA 1031 AAAGTAATTG CAGAATTAAA ACACAAAAA 1060 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 211 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: Met He Pro Arg Gly He Gly Leu Trp Leu Pro Ser Ala Leu Leu Leu 1 5 10 15 Ser Arg Val Pro Gly Cys Phe Pro Leu Arg Gly Pro Ser Ser Val Thr 20 25 30 Gly Thr Val Gly Glu Ser Leu Ser Val Thr Cys Gin Tyr Glu Glu Arg 35 40 45 Phe Lys Met Asn Lys Lys Tyr Trp Cys Arg Gly Ser His Val Leu Leu 50 55 60 Cys Lys Asp He Val Lys Thr Gly Gly Ser Glu Glu Ala Arg Asn Gly 65 70 75 80 Arg Val Ser He Arg Asp Asp Pro Asp Asn Leu Thr Phe Thr Val Thr 85 90 95 Leu Glu Ser Leu He Leu Glu Asp Ala Gly Thr Tyr Met Cys Gly Val 100 105 110 Asp He Pro Phe Thr Asn His Pro Leu Gly He Asp Glu Phe Phe Lys 115 120 125 Val Glu Leu Ser Val Val Pro Gly Ser Ser Leu Trp Ser Ser Thr Thr 130 135 140 Val Pro Glu Thr He Arg Ser Ser Leu Val His Thr Gin Pro Ser Val 145 150 155 160 Thr Thr Glu Asp Thr He Pro Ala Pro Ser Ala Arg Pro Arg Ser Leu 165 170 175 Leu Gly Ser Leu Tyr Leu Cys He Leu Val Phe Leu Glu Leu Pro Leu 180 185 190 Phe Leu Cys Met Leu Cys Ala Val Leu Trp Val Asn Arg Pro Gin Arg 195 200 205 Cys Ser Gly 210 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3385 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW013 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: GTCGACTTTT TTTAACAAAG ATGATTTAAT ATTTAATATC ATACCCAGAA AAATCAAACA 60 ACTTCCAGAA TCAGACAGGT AAGATTCCTT AGTATGTTTT TACCAAAATT T ATAAGATT 120 ATCTTAAATT TGAAGAATTG TGCATAAATA ACACAGGATA CCAAAGGAAA CTGAGCTGTA 180 TTTTTTGCTT TGATGGGAAA AAAAAAAAAA AAAACCTGAA ACCCAGAGAC ACTAACCATT 240 TTGTGCACTG TATAACTCAT TGTGGAAGCT GAAACTTAGA ACTCATCTTT GGAAATATAT 300 AATTGATGAA CCCACCTTTC CATTCAGCTT TTAGGGTGAT GTAAAACTGT ATGAATCCAC 360 TTACAAATAA ACTTAAAAGA CCTTTTCATG TTACCCTATC TCTTATCTTC TCAATGTATT 420 TCTATATGCT TACCTTTAGT AAGAGTACCA TGGAGTACTT TGATAGATGG AATGACAGAG 480 AAATGGATGT TTAAAGATCT TTAGGATGAA AAGGATAATT TAAGAAGCAT ATTTAAGAAG 540 CATGCTGATA TTGAAAAGGT AGTATAGGCA AGTACAGTGC ACTTCCACAG ACTACTCATA 600 CCTTCTTGTC CATCAGAAAG TCTGAGTGGG TTAGTTACAG TAAGGTCATG TTGATCTGGG 660 TCTATGCACC TGTGCTGAGG TCAGAGGACA ACTTTCAGGA GTCTGTTCTG CCCTTCCGTG 720 TGGGTCCTAA GTATGCAACT CAAAGGTTGT CTGTCAGGTT GATTCTGCCC AGTCATGAAA 780 CCTTTGAGAA GAGGAAAAGG TGTAGGAAGA ACAGGAACAG GATCATAGAA GTGACTAAGC 840 CAGAATCTGT CATATTTGAG GAAACATCAA GAGGTGCCTA TAATAGGGTT CCGAGAATGA 900 AAAAAAAAAC CAGATAACTT TACTGTCTAT TCCAGCCAGT TTGACTTAGA GGCACTGGCA 960 AAGTAGG AC AGACAGCTGA GGTAGAAAAT GTGGAACATT ACTGTGGCAA CTGCTGCATC 1020 TTCGGGTGTG GAAGTCACAC CAATTCCACT TTTGGTTGGC ACTTCCCATC TTCTAAGAGA 1080 GAACCTTTAA TTGAGCGGCC GTGAAGAACT TGATAAATCT ACGCTGCTGT GTGTCTCTCA 1140 CCACCACCCT ACCTACATAG ACACCCCCAT TTAGTTGTTT CCTGAGAATC AGAACAGAGC 1200 ACTTACACGA GGTACGGGAA GCTGTGATGC CTAGTGTAAG AAGTTAGAAG ATGACTGAAC 1260 ACAGGAAGAG AGCGGGCTTC CAGTGGGATC TAAATCAAAT CAGCGAGGAT CACTGGAAAC 1320 TGAGCTGAAA CTCAACTAAG ATTTAGCTTG CAAACAATAG AGATGTTTCA TTTTAAAACC 1380 ACAGCAGATT AACAGTATAG CTGGGAAACA ACCAAGTGTT CTTTTCAAAT TTCAGTTCCA 1440 CTATATCTGA GCATGGTTAA AATAGGGGTG AGTCCTATTT CATGGCTTTT ATCTATTAAA 1500 TATTTGTAAA CGTGCTCAAG TTCCCATTTC TTTAACCCTA CAAAATTCAG GCTTCTCACA 1560 CTGGGGCTGT AGTTCTTTAA TAGTTTTCTA ATTCCTGAGC CATCTTTAGA CTTCTGAAAA 1620 CCTCAACTTC AGTCTCTTCT CACATAGCCA ACTATGAGAA CCTCCAAAGC AGAATGCAGT 1680 TTTCCTTGTG CCTTTAGCAA CAAGGCACCT TTACAAAACT GGTTCTCAGT GAATGAAATG 1740 AAAGCATGAT CTTACAGTGT GCGACACTTC AGTAGTGATG ACTTAGAATA GTTTTAAAAT 1800 AAATAAAATT ACAGAACCTA GGGGAGGTGA AAAATGGGAA ACATGAAACA GTAGACCATA 1860 CTGCAGCTCA CAAAACAAGC AGTGAAAACA TATAAACTAC CTATAATAGC CTCATTATAA 1920 CATGCAAACA CACTAACTCT GTTACATACA GATTGGATGT ATATCTGAAG TTGTTTATAG 1980 ATACAATGGG TTTAAGTTGG TAATTAATAA ATAGTACTAC CTTAGAATGT GTTGTGCTTT 2040 TAAGTATTAT GAAAGCTCAA GAGCCAGGCA TCTTCCTCTT CAGAGCTGTT TCCTGTTACA 2100 TAATTACTGG CAAAGTTCTA AACAGTTCTT TACTAAATCA CAAAATGCAT ACAGCTAGTG 2160 CCATTGTCTC AAGTCTTTTT AGAATAGAAA TGTCGATGTG AAGCTATAAT TTTATTTTGG 2220 TTTTATGATC CTGCAAGGGT TAAGTTTGTC TGATTCTTCC CAGGGTACTG ATAAGTTCTC 2280 TAACATACCG GAGTAAGAGA ACTGAAACAG GTTATTTCCC TCATCCTCAG GAATCTGCTT 2340 GAATATGGAT CAGCATATAT TGGACTTAAT GCTGCTTTTG GGGGCCTAAT AGCAAACAGT 2400 CTATTTCGGC GAATTTTGAA CGTGACACAA GCTCGAGTAG CATCTAGCTT GCCAATGGCT 2460 GTGATCCCAT TTTTGACAGC AAACCTGTCC TACCATAGTT TTGTAAGTTT ACCTTTGAGT 2520 ACAGGTATGT TTTATTTCAT TATCATCCAA GCCTGCATTT ATGCATACTA TATACACTTA 2580 TATATACTTC ACTCAAAACT GAAGGATTAG AACCGAGTAG GTGTGAGCTT TAATGAAGTG 2640 TTTAGGGAAG ACCAAATCTA TTCAACAACT GATTCAGCTT AGGTCTGCCA ACCAACCAGT 2700 GAGTACATAT CCACAGCCGT CAGTCACACA CTTCCCTGAC CTGAAGCAGC ATTCCCAGTG 2760 CTGCCTTTGT TTCTTGTTAA TTTGCACATT ATATGCAAGT TTTCTCTTTT TAAAAAGATG 2820 TTTTTATTTA GGTATGTGTT TTGTCTGACT GTACATTTGC ACACCAGGTA GTGGTACTGG 2880 ACCCCATATA CTAGTTACAG ATAAGGGTGA GCTGCCACGT GGGTGCTGGT AATTGAACTC 2940 AGCACTTAGT GCCATTGCTC TTAATTGAGA TCTCTCTCCA GCCCTGTATG AAAGTTCTTT 3000 AAAGTATAAG TATGTTGTGG GAATACAACT CTGTAATCTC TGAAGTACTA TGTGCATTGC 3060 AGCATTTAGC AAAATGAAAG ACATAGTGTC CCATGTGTCC TGAACATGTA TTGTTATGTG 3120 TTCTATATGC ATGACCCTTC TTATTAAAAA CAGATTGGGG AAAGGGGTCA ATTTTGTGTT 3180 TTCTCCTAAA TAATAATCCA AATTTCTGAG AATCCAGAGT CAAGATTTGT TTTCCTGTTT 3240 ATCAGTATTT CCTATCCAAG GCCTTAATAC ATGCTAAGCA TGTATTCACA CCAAGCTACA 3300 GTCCATCCTC TATAATTATT CCTTTGACAT GATATGCACC ATTTTTGCTG TGTCACTGAA 3360 AATAAAATGT GAACCTTATG TCGAC 3385 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1779 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW014 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 175..804 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: GTCGACCTGG AAAGAGCTGC AGTGTTCGCG CTTGGTAGCT GGTGGACCGG GCTCAGCACC 60 TTCGGCTGGC TTTGTGTCCC AGAGGCTCAC CGGAAAAAGA CTTTCTCAGC CCTCGGACTC 120 CAGAGAGAGA TACTTTTCGT GCTCCCCAAC CTTGACTCCT GCAGAAGCTG AGCG ATG 177 Met 1 GCG TCC ATG GGG CTG CAG GTG CTG GGA ATC TCC TTG GCC GTC CTG GGC 225 Ala Ser Met Gly Leu Gin Val Leu Gly He Ser Leu Ala Val Leu Gly 5 10 15 TGG TTA GGA GTC ATC CTG AGT TGT TCG CTC CCC ATG TGG CGG GTG ACC 273 Trp Leu Gly Val He Leu Ser Cys Ser Leu Pro Met Trp Arg Val Thr 20 25 30 GCC TTC ATC GGC AGC AAC ATC GTC ACG GCG CAG ACG AGC TGG GAA GGC 321 Ala Phe He Gly Ser Asn He Val Thr Ala Gin Thr Ser Trp Glu Gly 35 40 45 CTG TGG ATG AAC TGC GTG GTG CAG AGC ACC GGC CAG ATG CAG TGC AAG 369 Leu Trp Met Asn Cys Val Val Gin Ser Thr Gly Gin Met Gin Cys Lys 50 55 60 65 ATG TAC GAC TCG ATG CTG GCC CTG CCG CAG GAC CTG CAG GCC GCC CGA 417 Met Tyr Asp Ser Met Leu Ala Leu Pro Gin Asp Leu Gin Ala Ala Arg 70 75 80 GCC CTG ATG GTC ATC AGC ATC ATC GTG GGT GCT CTG GGG ATG CTT CTC 465 Ala Leu Met Val He Ser He He Val Gly Ala Leu Gly Met Leu Leu 85 90 95 TCA GTC GTA GGG GGC AAG TGC ACC AAC TGC ATG GAG GAC GAG ACC GTC 513 Ser Val Val Gly Gly Lys Cys Thr Asn Cys Met Glu Asp Glu Thr Val 100 105 110 AAG GCC AAG GTC ATG ATC ACA GCC GGA GCC GTG TTC ATC GTG GCA AGC 561 Lys Ala Lys Val Met He Thr Ala Gly Ala Val Phe He Val Ala Ser 115 120 125 ATG CTG ATT ATG GTG CCT GTG TCC TGG ACG GCA CAC AAC GTC ATC CGC 609 Met Leu He Met Val Pro Val Ser Trp Thr Ala His Asn Val He Arg 130 135 140 145 GAC TTC TAC AAC CCT CTG GTG GCT TCC GGG CAG AAA AGG GAG ATG GGG 657 Asp Phe Tyr Asn Pro Leu Val Ala Ser Gly Gin Lys Arg Glu Met Gly 150 155 160 GCC TCG CTT TAC ATC GGC TGG GCG GCT TCT GGG CTG CTG CTC CTG GGA 705 Ala Ser Leu Tyr He Gly Trp Ala Ala Ser Gly Leu Leu Leu Leu Gly 165 170 175 GGA GGC CTC CTC TGC TGC AAT TGC CCA CCT CGC CGC AAC GAA AAG CCC 753 Gly Gly Leu Leu Cys Cys Asn Cys Pro Pro Arg Arg Asn Glu Lys Pro 180 185 190 TAC TCC GCC AAG TAC TCC GCC GCC CGC TCT GTT CCC GCC AGC AAC TAT 801 Tyr Ser Ala Lys Tyr Ser Ala Ala Arg Ser Val Pro Ala Ser Asn Tyr 195 200 205 GTG TAAGGTGGGC CACTCTCTGT CCACATTGCC TTTATTTTCT TGGATTGAAC 854 Val 210 TCATAACGGC CTGTGGCCCC TCACATTCTC CAGGACCTGA CCAGCTGTGG GCTACTGACT 914 GCTTGCAAAC CCGGACTGTG CTAAGTTACT AGCGTGTAGC CCTTGGGGAC CCACCTGGCC 974 CATCTGGACA CATCTCAAGG CTCCAGCGAG GATAGATGTA AAAATATTTC CTTGCTTGCA 1034 TCCAGATTGC TCATGGATAC GGGGCTGAAG GCAGAAGCAG CTGTCTGGGT ACGACAGTGG 1094 AGGGGGAGCT GGGTCCTGCT GGCCGGGATA GCTCAGCTGT GACTTTGGTC TCTGGAGTGG 1154 ATGTCCTGGT CATGTTAGCA AACATTCACT GCCCTTTCTC AGTGCCCTCG CTCTCTCGCC 1214 TCCACGTTAC TCCCGCGCTA CTCTTGCCGT TTCTCGCCCG CGTTTCTGAG CACACCAGGT 1274 CCTGCCTGGA GTCTTGGTGT CGAGGATGAC TGACTGAAGG GGCCTTTGAG AGCTGATGGG 1334 TTCTGCCATG GACTCCTCCC GGTGATTAGC AATGACTGGG GCCTTACCCA CCCACCTACC 1394 CTCGTAATGA AGTTCTGTGG AGTGGCTGGA CAGGTTTGAG GGAAGGGTGG AGGTGGTTTA 1454 AACTGGTTTG GGGAGTGCTA GGGCTGGGGA CCCAGAAGCA GCCCAGGGTG TCCCCACCCC 1514 TTTCCCATAC GGTCTTGCTA AATGTTCTGA TCTCTGTATA CCCCCTCCCT CTTCAGAAGG 1574 ACCCTGGGTG GGCCCCTCTG AATTCCCTAC CCTTGTCCAT TTCAAGGACG CTGGCCAGTC 1634 TGTGGAAGGT ACGGGGGTCT GATGGCATTG CACCAGGGAG CCTCCTGGAC TCCCTTGCCT 1694 TCTCTGTGGT TTCTTGTTTT GTAATTTAAG GTCTGTTCAC AGCTGTAATT ATTATTTTCT 1754 ACAATAAATG GCACCTGCAG TCGAC 1779 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 210 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Met Ala Ser Met Gly Leu Gin Val Leu Gly He Ser Leu Ala Val Leu 1 5 10 15 Gly Trp Leu Gly Val He Leu Ser Cys Ser Leu Pro Met Trp Arg Val 20 25 30 Thr Ala Phe He Gly Ser Asn He Val Thr Ala Gin Thr Ser Trp Glu 35 40 45 Gly Leu Trp Met Asn Cys Val Val Gin Ser Thr Gly Gin Met Gin Cys 50 55 60 Lys Met Tyr Asp Ser Met Leu Ala Leu Pro Gin Asp Leu Gin Ala Ala 65 70 75 80 Arg Ala Leu Met Val He Ser He He Val Gly Ala Leu Gly Met Leu 85 90 95 Leu Ser Val Val Gly Gly Lys Cys Thr Asn Cys Met Glu Asp Glu Thr 100 105 110 Val Lys Ala Lys Val Met He Thr Ala Gly Ala Val Phe He Val Ala 115 120 125 Ser Met Leu He Met Val Pro Val Ser Trp Thr Ala His Asn Val He 130 135 140 Arg Asp Phe Tyr Asn Pro Leu Val Ala Ser Gly Gin Lys Arg Glu Met 145 150 155 160 Gly Ala Ser Leu Tyr He Gly Trp Ala Ala Ser Gly Leu Leu Leu Leu 165 170 175 Gly Gly Gly Leu Leu Cys Cys Asn Cys Pro Pro Arg Arg Asn Glu Lys 180 185 190 Pro Tyr Ser Ala Lys Tyr Ser Ala Ala Arg Ser Val Pro Ala Ser Asn 195 200 205 Tyr Val 210 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2537 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW015 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 11..2176 (D) OTHER INFORMATION: /product= "predicted polypeptide" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: GTCGACCAAA ATG GCA GCC TTG GAA GAA GAA TTC ACG TTG TCT ACT GGA 49 Met Ala Ala Leu Glu Glu Glu Phe Thr Leu Ser Thr Gly 1 5 10 GTC TTA GGC GCC GGG CCT GAA GGA TTC CTA GGT GTA GAG CCC AGT GAC 97 Val Leu Gly Ala Gly Pro Glu Gly Phe Leu Gly Val Glu Pro Ser Asp 15 20 25 AAG GCC GAC CAG TTC CTA GTG ACC GAC AGA GGC AGG ACC GTC GTC CTC 145 Lys Ala Asp Gin Phe Leu Val Thr Asp Arg Gly Arg Thr Val Val Leu 30 35 40 45 TAC AAG GTT TCT GAC CAG AAA CCC TTG GGC AGC TGG TCG GTG AAA CAA 193 Tyr Lys Val Ser Asp Gin Lys Pro Leu Gly Ser Trp Ser Val Lys Gin 50 55 60 GGC CAG ACT ATA ACA TGT CCT GCT GTG TGC AAC TTT CAG ACT GGA GAG 241 Gly Gin Thr He Thr Cys Pro Ala Val Cys Asn Phe Gin Thr Gly Glu 65 70 75 TAT ATT ATG GTA CAT GAC CAT AAG GTT TTG AGA ATA TGG AAT AAT GAA 289 Tyr He Met Val His Asp His Lys Val Leu Arg He Trp Asn Asn Glu 80 85 90 GAC GTA AAC CTG GAT AAA GTA TTC AAA GCT ACA CTG TCA GCT GAG GTC 337 Asp Val Asn Leu Asp Lys Val Phe Lys Ala Thr Leu Ser Ala Glu Val 95 100 105 CAT AGG ATC CAC TCA GTA CAA AGA ACA GAA CCC CTG GTG CTG TTC CGA 385 His Arg He His Ser Val Gin Arg Thr Glu Pro Leu Val Leu Phe Arg 110 115 120 125 AGA GGC GCT GCT CGT GGG TTA GAG GCC TTG CTT GCA GAG CCA CAG CAG 433 Arg Gly Ala Ala Arg Gly Leu Glu Ala Leu Leu Ala Glu Pro Gin Gin 130 135 140 AAC ATT GAA GCT GTC ATA CCA GAT GAG GAA GTG ATC GAG TGG TCA GAG 481 Asn He Glu Ala Val He Pro Asp Glu Glu Val He Glu Trp Ser Glu 145 150 155 GTT TTC ATG TTA TTT AAG CAA CCG GTT TTA ATT TTT ATT ACT GAA AAT 529 Val Phe Met Leu Phe Lys Gin Pro Val Leu He Phe He Thr Glu Asn 160 165 170 CAT GGG AGT TAT GTT GCT TAT GTA CAA TTG TGC AAA TCA CAC AGC TTA 577 His Gly Ser Tyr Val Ala Tyr Val Gin Leu Cys Lys Ser His Ser Leu 175 180 185 AGC AAA TAC ATA CTC TTA CTT GGA AAA GAA GAA AAA TCT GCT AAA CCA 625 Ser Lys Tyr He Leu Leu Leu Gly Lys Glu Glu Lys Ser Ala Lys Pro 190 195 200 205 AAT TTT ACT GCA CGT GTG GAT GGG AAA TTC ATC TCC CTG GTG TCG CTA 673 Asn Phe Thr Ala Arg Val Asp Gly Lys Phe He Ser Leu Val Ser Leu 210 215 220 GGC TCT GAT GGG TGT GTA TAT GGA ACC TTG GTA CCA ATA TAT TCA AGT 721 Gly Ser Asp Gly Cys Val Tyr Gly Thr Leu Val Pro He Tyr Ser Ser 225 230 235 GAC ACG GAA AAC AAT CAG AGG TTA GTT AGA GCA TTG ATG CTC AAG ACG 769 Asp Thr Glu Asn Asn Gin Arg Leu Val Arg Ala Leu Met Leu Lys Thr 240 245 250 GTT GTG TCT GGC AGT GCT CGA AAT GGT TCT GCC CTC ACC ATC CTG GAT 817 Val Val Ser Gly Ser Ala Arg Asn Gly Ser Ala Leu Thr He Leu Asp 255 260 265 CAA GAC CAC ATA GCA GTC CTG GGA CCT CCA CTT CCA GCT TCT AAG GAA 865 Gin Asp His He Ala Val Leu Gly Pro Pro Leu Pro Ala Ser Lys Glu 270 275 280 285 TGC CTC TCC ATA TGG AAC ATA AAA TTT CAG ACA TTA CAG ACA TCA AAA 913 Cys Leu Ser He Trp Asn He Lys Phe Gin Thr Leu Gin Thr Ser Lys 290 295 300 GAG CTG CCA CAA GGA ACC AGT GGG CAA CTC TGG TAT CAT GGG GAA ATA 961 Glu Leu Pro Gin Gly Thr Ser Gly Gin Leu Trp Tyr His Gly Glu He 305 310 315 CTA TTT ATG CGA CAT GGG AAA AGT CTA ACT GTG ATT CCA TAC AAG TGC 1009 Leu Phe Met Arg His Gly Lys Ser Leu Thr Val He Pro Tyr Lys Cys 320 325 330 GAA GCA TCA TCT CTG GCG AGC GCT CTT GGG AAG CTC AAG CAT ACT CAA 1057 Glu Ala Ser Ser Leu Ala Ser Ala Leu Gly Lys Leu Lys His Thr Gin 335 340 345 GAG TCA GGC AGT CAT TCC GTG CCC CAT TTT GTA AAC TGG GAG ACG TGT 1105 Glu Ser Gly Ser His Ser Val Pro His Phe Val Asn Trp Glu Thr Cys 350 355 360 365 TCA GAA TAT GAA CTT GGG TCC TAC AGT GCA AAG CAG ACA AGA ACT CTT 1153 Ser Glu Tyr Glu Leu Gly Ser Tyr Ser Ala Lys Gin Thr Arg Thr Leu 370 375 380 AGA AAA AAA ACT GAA ACA AAT TTA CAC CCA GAA GTT CCA GGA GTC AAA 1201 Arg Lys Lys Thr Glu Thr Asn Leu His Pro Glu Val Pro Gly Val Lys 385 390 395 GAA CTT TTA TCA ATA ATA AAG AAA GAT TCA GAA AAG CAC ATT GAA GTA 1249 Glu Leu Leu Ser He He Lys Lys Asp Ser Glu Lys His He Glu Val 400 405 410 GAA CTA CGT AAG TTT TTG GCT AAG TCG ACA CCT GAC TTT CAT ACT ATA 1297 Glu Leu Arg Lys Phe Leu Ala Lys Ser Thr Pro Asp Phe His Thr He 415 420 425 ATT GGA GAC ATA GTG TCT GGA CTT CTG GGA AGA TGT AAA GTG GAA CCA 1345 He Gly Asp He Val Ser Gly Leu Leu Gly Arg Cys Lys Val Glu Pro 430 435 440 445 TCG TTT TAC CCC CGG AAC TGT CTG ATG CAG CTC ATC CAG ACA CAC GTG 1393 Ser Phe Tyr Pro Arg Asn Cys Leu Met Gin Leu He Gin Thr His Val 450 455 460 CTT TCC TAC AGC TTA TGC CCT GAC TTG ATG GAG ATT GCC CTA GAG CAC 1441 Leu Ser Tyr Ser Leu Cys Pro Asp Leu Met Glu He Ala Leu Glu His 465 470 475 ACA GAT GTG CAG ATG TTA CAG CTG TGT CTG CAG CAG TTC CCT GAC ATT 1489 Thr Asp Val Gin Met Leu Gin Leu Cys Leu Gin Gin Phe Pro Asp He 480 485 490 CCT GAG TCC ACC ACC TGT GCT TGC TTA AAA CTT TTC CTG AGC ATT GGT 1537 Pro Glu Ser Thr Thr Cys Ala Cys Leu Lys Leu Phe Leu Ser He Gly 495 500 505 GAT GAC TGT CTT CGG GAC AGT AAT GTC AGC ATG GAG TCA GTT TTT GAT 1585 Asp Asp Cys Leu Arg Asp Ser Asn Val Ser Met Glu Ser Val Phe Asp 510 515 520 525 TAT GGT GAT ACT ACA CAA GAT GAG AAA AAG GAA ATG GAA GAG CAA ACT 1633 Tyr Gly Asp Thr Thr Gin Asp Glu Lys Lys Glu Met Glu Glu Gin Thr 530 535 540 GAA ATT GTT CAG AAT GGC TTC GGT CCT GAA GAT GGT GGC TGC AGT AAA 1681 Glu He Val Gin Asn Gly Phe Gly Pro Glu Asp Gly Gly Cys Ser Lys 545 550 555 GAT AGT CAG CAG TTG AAC AAA AAG CCT GGT GAC ACA GCA CAG GAG CCC 1729 Asp Ser Gin Gin Leu Asn Lys Lys Pro Gly Asp Thr Ala Gin Glu Pro 560 565 570 ATC TCC TTC CCT GTG ACC TTG TGT CCT GTG GCA CCA AAG CGA GCA GCT 1777 He Ser Phe Pro Val Thr Leu Cys Pro Val Ala Pro Lys Arg Ala Ala 575 580 585 CTG CTA AAT GCA GTC CTT CAT TCA GCA TAC AGT GAG CCC TTC CTC CTG 1825 Leu Leu Asn Ala Val Leu His Ser Ala Tyr Ser Glu Pro Phe Leu Leu 590 595 600 605 CCG CAC TTG AAG GAC ATC CCT GCG AAG CAT ATA ACG CTG TTT CTG CAG 1873 Pro His Leu Lys Asp He Pro Ala Lys His He Thr Leu Phe Leu Gin 610 615 620 TAT TTG TAT TTC CTC TAT TTG AAG TGC ACT GGC AGT GCT ACC ATG ACT 1921 Tyr Leu Tyr Phe Leu Tyr Leu Lys Cys Thr Gly Ser Ala Thr Met Thr 625 630 635 CTC CCT GGA GTA AGC CCT CCA ACC GTG AGC CAG ATC ATG GAT TGG ATA 1969 Leu Pro Gly Val Ser Pro Pro Thr Val Ser Gin He Met Asp Trp He 640 645 650 TGC CTA CTT CTA GAT GCT AAT TTT ACT GTC GTC TTA ATG ATA CCA GAA 2017 Cys Leu Leu Leu Asp Ala Asn Phe Thr Val Val Leu Met He Pro Glu 655 660 665 GCA AAA AGA CTT TTG CTT AAT CTT TAC AAT TTT GTG AAA TCG CAG ATC 2065 Ala Lys Arg Leu Leu Leu Asn Leu Tyr Asn Phe Val Lys Ser Gin He 670 675 680 685 TCC ATC TAC TCC GAG CTC AAC AAG ATT GAA GTC AGC TTC CGG GAG CTG 2113 Ser He Tyr Ser Glu Leu Asn Lys He Glu Val Ser Phe Arg Glu Leu 690 695 700 CAG AGG TTA AAT CAG GAG AAG AGC AGT AGA GGA CTG TAC TCC ATC GAA 2161 Gin Arg Leu Asn Gin Glu Lys Ser Ser Arg Gly Leu Tyr Ser He Glu 705 710 715 GTT CTG GAA CTT TTC TGACAGCCAG AGACAGTCTT ACTGGTTGTC CTAGAACTGG 2216 Val Leu Glu Leu Phe 720 ATATATAGAC CAAGCTGGCC TCAAACTCAC AGAGATCCAA CCCAGAGCAC TGCGATTAAA 2276 GGTGTGGCCA CCACACCTGG CTTAATGGAT TTTTTTATAT GAATGTACCT GTTCATCCAG 2336 GGGAGAAAGT TTTGTTTGTA TCCATCTCAG TGTCCAGAGA GGAGTGTGAG TCTCTGCACC 2396 ATCACATACC ACCATTCCTC AGTGCTACGG GTTCCACAGA CATCACTTCT GGGTTGCAGA 2456 CATCACTGGA AGAATGTTAC AAACTTTTTA AACATGGAAT TGAGTTGATT TTAAGTAAAC 2516 TTATTTGTGT ACTGATAAAA A 2537 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 722 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Met Ala Ala Leu Glu Glu Glu Phe Thr Leu Ser Thr Gly Val Leu Gly 1 5 10 15 Ala Gly Pro Glu Gly Phe Leu Gly Val Glu Pro Ser Asp Lys Ala Asp 20 25 30 Gin Phe Leu Val Thr Asp Arg Gly Arg Thr Val Val Leu Tyr Lys Val 35 40 45 Ser Asp Gin Lys Pro Leu Gly Ser Trp Ser Val Lys Gin Gly Gin Thr 50 55 60 He Thr Cys Pro Ala Val Cys Asn Phe Gin Thr Gly Glu Tyr He Met 65 70 75 80 Val His Asp His Lys Val Leu Arg He Trp Asn Asn Glu Asp Val Asn 85 90 95 Leu Asp Lys Val Phe Lys Ala Thr Leu Ser Ala Glu Val His Arg He 100 105 110 His Ser Val Gin Arg Thr Glu Pro Leu Val Leu Phe Arg Arg Gly Ala 115 120 125 Ala Arg Gly Leu Glu Ala Leu Leu Ala Glu Pro Gin Gin Asn He Glu 130 135 140 Ala Val He Pro Asp Glu Glu Val He Glu Trp Ser Glu Val Phe Met 145 150 155 160 Leu Phe Lys Gin Pro Val Leu He Phe He Thr Glu Asn His Gly Ser 165 170 175 Tyr Val Ala Tyr Val Gin Leu Cys Lys Ser His Ser Leu Ser Lys Tyr 180 185 190 He Leu Leu Leu Gly Lys Glu Glu Lys Ser Ala Lys Pro Asn Phe Thr 195 200 205 Ala Arg Val Asp Gly Lys Phe He Ser Leu Val Ser Leu Gly Ser Asp 210 215 220 Gly Cys Val Tyr Gly Thr Leu Val Pro He Tyr Ser Ser Asp Thr Glu 225 230 235 240 Asn Asn Gin Arg Leu Val Arg Ala Leu Met Leu Lys Thr Val Val Ser 245 250 255 Gly Ser Ala Arg Asn Gly Ser Ala Leu Thr He Leu Asp Gin Asp His 260 265 270 He Ala Val Leu Gly Pro Pro Leu Pro Ala Ser Lys Glu Cys Leu Ser 275 280 285 He Trp Asn He Lys Phe Gin Thr Leu Gin Thr Ser Lys Glu Leu Pro 290 295 300 Gin Gly Thr Ser Gly Gin Leu Trp Tyr His Gly Glu He Leu Phe Met 305 310 315 320 Arg His Gly Lys Ser Leu Thr Val He Pro Tyr Lys Cys Glu Ala Ser 325 330 335 Ser Leu Ala Ser Ala Leu Gly Lys Leu Lys His Thr Gin Glu Ser Gly 340 345 350 Ser His Ser Val Pro His Phe Val Asn Trp Glu Thr Cys Ser Glu Tyr 355 360 365 Glu Leu Gly Ser Tyr Ser Ala Lys Gin Thr Arg Thr Leu Arg Lys Lys 370 375 380 Thr Glu Thr Asn Leu His Pro Glu Val Pro Gly Val Lys Glu Leu Leu 385 390 395 400 Ser He He Lys Lys Asp Ser Glu Lys His He Glu Val Glu Leu Arg 405 410 415 Lys Phe Leu Ala Lys Ser Thr Pro Asp Phe His Thr He He Gly Asp 420 425 430 He Val Ser Gly Leu Leu Gly Arg Cys Lys Val Glu Pro Ser Phe Tyr 435 440 445 Pro Arg Asn Cys Leu Met Gin Leu He Gin Thr His Val Leu Ser Tyr 450 455 460 Ser Leu Cys Pro Asp Leu Met Glu He Ala Leu Glu His Thr Asp Val 465 470 475 480 Gin Met Leu Gin Leu Cys Leu Gin Gin Phe Pro Asp He Pro Glu Ser 485 490 495 Thr Thr Cys Ala Cys Leu Lys Leu Phe Leu Ser He Gly Asp Asp Cys 500 505 510 Leu Arg Asp Ser Asn Val Ser Met Glu Ser Val Phe Asp Tyr Gly Asp 515 520 525 Thr Thr Gin Asp Glu Lys Lys Glu Met Glu Glu Gin Thr Glu He Val 530 535 540 Gin Asn Gly Phe Gly Pro Glu Asp Gly Gly Cys Ser Lys Asp Ser Gin 545 550 555 560 Gin Leu Asn Lys Lys Pro Gly Asp Thr Ala Gin Glu Pro He Ser Phe 565 570 575 Pro Val Thr Leu Cys Pro Val Ala Pro Lys Arg Ala Ala Leu Leu Asn 580 585 590 Ala Val Leu His Ser Ala Tyr Ser Glu Pro Phe Leu Leu Pro His Leu 595 600 605 Lys Asp He Pro Ala Lys His He Thr Leu Phe Leu Gin Tyr Leu Tyr 610 615 620 Phe Leu Tyr Leu Lys Cys Thr Gly Ser Ala Thr Met Thr Leu Pro Gly 625 630 635 640 Val Ser Pro Pro Thr Val Ser Gin He Met Asp Trp He Cys Leu Leu 645 650 655 Leu Asp Ala Asn Phe Thr Val Val Leu Met He Pro Glu Ala Lys Arg 660 665 670 Leu Leu Leu Asn Leu Tyr Asn Phe Val Lys Ser Gin He Ser He Tyr 675 680 685 Ser Glu Leu Asn Lys He Glu Val Ser Phe Arg Glu Leu Gin Arg Leu 690 695 700 Asn Gin Glu Lys Ser Ser Arg Gly Leu Tyr Ser He Glu Val Leu Glu 705 710 715 720 Leu Phe (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1305 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW016 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 385..748 (D) OTHER INFORMATION: /label= SAC_24530 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: ATTATTCTCC CCTTGTCATT AAAAGAAATC AGCAAAACCA AACAACTGGC TACACCACGA 60 ATTGTCGTTA AATTTGCTAA CTGGTGTCTA AAAGCCGTGT AGCTACCTCG GTCCTGCTTG 120 CTAGGTTTGC CACTAGAAGG AAGCATACTT AAAACAATGG CTACTTGGAT CCTCAGGGAG 180 ATCCTGTCTG CAGTCGCGTG GTCACCCTTA GCTTCATCAA AGCACTAACA GCTCACCCGG 240 CCAGGCTTCA TGAGCACTGA CCCTCAAGCA AGCAGGTTTA TTAAACATTT AGATGCCAAC 300 CTCACTTACT GTTTCCTGCA GTCATGGAGA GTTTACTTAA CAAGTTTGTA AATAATAAAC 360 TGGCACTTTG CACACAGACT TGGTACTATC CTAGGGGAAG GCCTGCTTTA TTTGGTTTCT 420 AGACCGAGTA GGAAGTGATC CATTTACCAC TGAGGGCAGC CCCATTCAGA GTCTTAAGTG 480 ACTAAGCCAG TGTTGAACAA GCAATTTCCA GGCTTTGTTC TTCAGGGAAC TTCCCATCAG 540 CTTTGAAGTC GGTCCTGTGC ACCCTAGGCA CATGGATCAG TTCACAAGTG GGGTTCAGTG 600 GAGAGAACTT CCCCCTCAGA AGTCACTTGA AACTTAGATG AGATTTGGGA CACTTGCTGG 660 TTGACTCTGT CTCATTTGTG TAAAAAGTAG TTTNTNTNAA NANTNGGTTT TNTTTTTTTT 720 TTCAAGGTTA TACTTTGTCC CATTCCTANG TTANTACAAA GTCTTGAAAG GGCCTTTGTA 780 GGGCTTTTTA ANNCAGGGTC TTAACTATGT AACTCTGGCT TGGCCTGGAA CTTGCTATGT 840 AGACCAGGTT ACCCTCAAAC TTGCCTGTCT TCCCAAATAC TGGGATTAAG GTTTCTGTGA 900 CCATACCTGG CTTTACCTGA TGAATTCCTA AACACCAGAA AACCAGTACT GTATGAGATG 960 TTAATGTGTG TTCCTTTCAG ACTGGAGTAC AGACCAGTAG ATAACAGATA ACAGCTGGTT 1020 CACCTTAATC TGCCTTTTTG TGTATTAATC TGTGTTTAGA GAACGGAACA ATAGCCAGAA 1080 TTNNNCTAGC GAGTTCGAGG CCAGTTGGTG TATATGTGGG ACTCTTAACC AAAACAGCAA 1140 GCGTTCCCTG GGGTAGTTCA CAATGATCTC CAGCTTCCTT GTTAACCAGA TAACTGCNAN 1200 TCCAGATGTA TGACCCTGGT TGGTTTATTG TATTGATATG TTTCTGTAAT ATGAGTAAAT 1260 TATTGTTACT TAAAAGTAAT AAATTCAAGT TTCAAAATTG AAAAA 1305 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 955 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW017 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 393..627 (D) OTHER INFORMATION: /label= SAC_24091 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: GTCGACAATC CTGTTATGAC AAGCCCGTCT CGATACTGAC AACTGAAGTG GAAATTGCTT 60 GAACATCAAG ATAGCTAACT CGGAAAGAAT CCCAGACTTT GGATAGTTTC TGAGTCTTCT 120 AGAATTTTCC AAGAAGAAAC CATGGTGGCA AATGCGGAGA CTCGGGCGGG CACTGGGAAC 180 ACAGCACAGT GGTCTTAGGG AGGTGCTTTG TCAGGAATGA ACAGTCATGG TTATAATCCA 240 CGTTTCCATT GCTACTCACG AATGATTCTC TTCTGTTTTG TTTTTAAAAT TTTTTTACAC 300 TGAATTTCTA TTTAGACACT AAAACATATA GGGGTGCTTG TCACCCGGAT ACATTTATCT 360 GTGAGCCAGC TATTCGGATG TCATGGCTGG GTACCTAACT TACTTCCATA TGTGAAGTGT 420 GCTAAACTCA AACCAGTTTA CAGAAACGAT GTATTTTGTG TATAGTAAAT TGTATATTCA 480 CCCTTTTACC ACGGCCGGTT TTTTAAACAA ATGAATACTC TAGATTTTTC TTCCAAATGA 540 GGTTACTGTT GGGGTGGGGT TGACTTAGTG ATGCTGTAGA AGGGAATCCG CATGCACTAA 600 AAAGTGTGTC TGCCTAAAAG TGTGTACAGC AGGCACAACC TTCCTTGTGG ATTTCCGTCT 660 GCTCACTGCA GATCTGCCTG TGGTTTAGAA ATAGAATTCA AGAGCCATCA AGGAGTGACC 720 AGCTTGACAC CACTGCCAAA TTCAGAATGA GGAACCTTGA GAGAAGGAAC TGTCGCTCAG 780 CCAGAAGCAG ATGAAGCCAC TGGTCCTGGT TCACAGTTTA GTGTCATGCT CTGGTTTATA 840 AGGATGGGCA TTACGTTCGG TGTTATCTGG TTATCTGCGA GATTCTAAAC CGAGGTGCAA 900 GAGCTCCTAT CCTGATTCTG AGATTTGAAA TAAAGCATGA ATGAACAAAG AAAAA 955 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1198 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW018 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 86..1102 (D) OTHER INFORMATION: /product= "predicted polypeptide" (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (644..994) (D) OTHER INFORMATION: /label= SAC_23880 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: GTCGACCTGG GAGTCCGGGC AGCGAGCCCC TCGCCGTCGG GTCCCACGAA GAAACTGGTG 60 GCTGAAGCCA TATTCTGCAG CATTC ATG GAG ATC AGT AAA AAT ATT ACG AAC 112 Met Glu He Ser Lys Asn He Thr Asn 1 5 CCA GAA GAA CTT TGG AAA ATG AAG CCT AAG GGG AAC CTG GAA GAT GAC 160 Pro Glu Glu Leu Trp Lys Met Lys Pro Lys Gly Asn Leu Glu Asp Asp 10 15 20 25 AGT TAC TCG ACT AAG GAC ACC GGA GAG ACA AGC ATG CTG AAA AGA CCG 208 Ser Tyr Ser Thr Lys Asp Thr Gly Glu Thr Ser Met Leu Lys Arg Pro 30 35 40 GTG CTC TCG CCT TTG CCG CAC ACG GTC CAC GTC GAC GCC TTC GAC TGC 256 Val Leu Ser Pro Leu Pro His Thr Val His Val Asp Ala Phe Asp Cys 45 50 55 CCC ACG GAG CTC CAG CAC ACG CAG GAA CTC TTT CCA AAC TGG CAA TTG 304 Pro Thr Glu Leu Gin His Thr Gin Glu Leu Phe Pro Asn Trp Gin Leu 60 65 70 CCA ATT AAA GTT GCC GCC GTC CTA TCG TCT CTC ACC TTC CTG TAC ACT 352 Pro He Lys Val Ala Ala Val Leu Ser Ser Leu Thr Phe Leu Tyr Thr 75 80 85 CTT CTG AGG GAA ATC ATT TAC CCA TTA GTC GCT TCC CGC GAA CAG TAT 400 Leu Leu Arg Glu He He Tyr Pro Leu Val Ala Ser Arg Glu Gin Tyr 90 95 100 105 TTT TAT AAG ATC CCG ATC CTG GTC GTT AAC AAA GTC TTG CCA ATG GTC 448 Phe Tyr Lys He Pro He Leu Val Val Asn Lys Val Leu Pro Met Val 110 115 120 TCC ATT ACC CTC TTG GCA TTG GTT TAT CTG CCA GGA GAG ATA GCG GCA 496 Ser He Thr Leu Leu Ala Leu Val Tyr Leu Pro Gly Glu He Ala Ala 125 130 135 GTT GTG CAG CTT CGC AAT GGG ACC AAG TAC AAG AAG TTC CCA CCC TGG 544 Val Val Gin Leu Arg Asn Gly Thr Lys Tyr Lys Lys Phe Pro Pro Trp 140 145 150 TTA GAC AGA TGG ATG CTG GCG AGG AAA CAA TTT GGG CTC CTC AGC TTC 592 Leu Asp Arg Trp Met Leu Ala Arg Lys Gin Phe Gly Leu Leu Ser Phe 155 160 165 TTC TTT GCA GTT CTG CAC GCC ATT TAC AGT CTC TCG TAC CCA ATG AGA 640 Phe Phe Ala Val Leu His Ala He Tyr Ser Leu Ser Tyr Pro Met Arg 170 175 180 185 CGG TCC TAC AGA TAC AAG CTG CTC AAC TGG GCT TAC AAA CAG GTT CAA 688 Arg Ser Tyr Arg Tyr Lys Leu Leu Asn Trp Ala Tyr Lys Gin Val Gin 190 195 200 CAA AGC AAA GAA GAT GCC TGG GTT GAG CAT GAT GTC TGG AGA ATG GAG 736 Gin Ser Lys Glu Asp Ala Trp Val Glu His Asp Val Trp Arg Met Glu 205 210 215 ATT TAT GTG TCC CTG GGG ATT GTG GGA CTG GCC ATC TTG GCT CTC TTG 784 He Tyr Val Ser Leu Gly He Val Gly Leu Ala He Leu Ala Leu Leu 220 225 230 GCT GTG ACA TCT ATC CCA TCT GTG AGC GAC TCT TTA ACC TGG AGA GAA 832 Ala Val Thr Ser He Pro Ser Val Ser Asp Ser Leu Thr Trp Arg Glu 235 240 245 TTT CAC TAT ATT CAG AGC AAA CTG GGA ATT GTC TCT CTT CTT CTG GGC 880 Phe His Tyr He Gin Ser Lys Leu Gly He Val Ser Leu Leu Leu Gly 250 255 260 265 ACG GTA CAC GCT TCG ATT TTT GCC TGG AAT AAA TGG GTA GAT ATC AGT 928 Thr Val His Ala Ser He Phe Ala Trp Asn Lys Trp Val Asp He Ser 270 275 280 CAG TTT GTC TGG TAC ATG CCT CCG ACT TTC ATG ATA GCT GTT TTC CTT 976 Gin Phe Val Trp Tyr Met Pro Pro Thr Phe Met He Ala Val Phe Leu 285 290 295 CCA ACT GTT GTT CTG ATC TGT AAA ATT GTA CTT TGC CTG CCC TGC CTG 1024 Pro Thr Val Val Leu He Cys Lys He Val Leu Cys Leu Pro Cys Leu 300 305 310 AGG AAG AAG ATA CTG AAG ATT AGA TGT GGT TGG GAA GAT GTC CGC AAA 1072 Arg Lys Lys He Leu Lys He Arg Cys Gly Trp Glu Asp Val Arg Lys 315 320 325 GTT AAC AGG ACT GAG ATG GCC TGC AGG TTG TAGAACTACT GTTTGCACAT 1122 Val Asn Arg Thr Glu Met Ala Cys Arg Leu 330 335 AATTGCTTAA TACCGATGTC TTATAAACAT TTCAAACCTG TGTCTGTTAA TAAAATGAAT 1182 ACTTCTGGAT CAAAAA 1198 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 339 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: Met Glu He Ser Lys Asn He Thr Asn Pro Glu Glu Leu Trp Lys Met 1 5 10 15 Lys Pro Lys Gly Asn Leu Glu Asp Asp Ser Tyr Ser Thr Lys Asp Thr 20 25 30 Gly Glu Thr Ser Met Leu Lys Arg Pro Val Leu Ser Pro Leu Pro His 35 40 45 Thr Val His Val Asp Ala Phe Asp Cys Pro Thr Glu Leu Gin His Thr 50 55 60 Gin Glu Leu Phe Pro Asn Trp Gin Leu Pro He Lys Val Ala Ala Val 65 70 75 80 Leu Ser Ser Leu Thr Phe Leu Tyr Thr Leu Leu Arg Glu He He Tyr 85 90 95 Pro Leu Val Ala Ser Arg Glu Gin Tyr Phe Tyr Lys He Pro He Leu 100 105 110 Val Val Asn Lys Val Leu Pro Met Val Ser He Thr Leu Leu Ala Leu 115 120 125 Val Tyr Leu Pro Gly Glu He Ala Ala Val Val Gin Leu Arg Asn Gly 130 135 140 Thr Lys Tyr Lys Lys Phe Pro Pro Trp Leu Asp Arg Trp Met Leu Ala 145 150 155 160 Arg Lys Gin Phe Gly Leu Leu Ser Phe Phe Phe Ala Val Leu His Ala 165 170 175 He Tyr Ser Leu Ser Tyr Pro Met Arg Arg Ser Tyr Arg Tyr Lys Leu 180 185 190 Leu Asn Trp Ala Tyr Lys Gin Val Gin Gin Ser Lys Glu Asp Ala Trp 195 200 205 Val Glu His Asp Val Trp Arg Met Glu He Tyr Val Ser Leu Gly He 210 215 220 Val Gly Leu Ala He Leu Ala Leu Leu Ala Val Thr Ser He Pro Ser 225 230 235 240 Val Ser Asp Ser Leu Thr Trp Arg Glu Phe His Tyr He Gin Ser Lys 245 250 255 Leu Gly He Val Ser Leu Leu Leu Gly Thr Val His Ala Ser He Phe 260 265 270 Ala Trp Asn Lys Trp Val Asp He Ser Gin Phe Val Trp Tyr Met Pro 275 280 285 Pro Thr Phe Met He Ala Val Phe Leu Pro Thr Val Val Leu He Cys 290 295 300 Lys He Val Leu Cys Leu Pro Cys Leu Arg Lys Lys He Leu Lys He 305 310 315 320 Arg Cys Gly Trp Glu Asp Val Arg Lys Val Asn Arg Thr Glu Met Ala 325 330 335 Cys Arg Leu (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1801 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW032 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (1412..1793) (D) OTHER INFORMATION: /label= SAC_24831 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: TTTTTCCAGC TTTTTAAGTT GCATTTATTT TTGATAATCT GTACTGTAGC CAATCAATTC 60 TATTCTCCAT TCTTGCTTAA TTGTATTAGC CATAAAGGAG TTCAGGTTCA TAGGACTCAG 120 TTTCTCTATT AAACCGTCAT TGATTATGGA AATACTGTCT TAAGCACTAT GCAGATTAAC 180 ACCATACTTT TCTTCCATTA CATCTTTCAA GACAGTCACT CACAACTCAG AAGACTGATA 240 CAGCATTAGA TGAAAAAAAC AAGATTCACA GATATATGTA GTGAAACTCA AACTAGGAGT 300 CTTAGAGATA AAAAAGATAA GTAGATATTT AAAATGTAGT CTGTTAAAGA TTTAATCGGT 360 TTAAAGTATA AGATTAGAAA GACAAAGTTT CTATTGTTTT GAAAGTTTTA AGTAAAGAAA 420 AAAAAACTGG AAAATATGTC TTTGTTGTTC TTTCTCCGTT CTTAATTACG AGCTATCCAA 480 CAGAAACCCC TAGGTCATAG TTTATGTTTC TGTTCTCATC AATGTAACTA GAACACTGGA 540 GAAAGAAAAA GGAAGACATA TTAACCAATG GCCGCAATCA CTTTTCACTT GCCCCACGGT 600 ACAAATCTGA TTTGGATGAA ATGGTTTGTG GCATAAAAAT TTTAAATTTT AGAAGCCAAT 660 GTGGTAGATT TCTCCATGTT TGCACAAATC CAATTTCAAC TACTTTTACT TCACTAATTA 720 ATTAAATGGA TTGGAAACAT TCTAGAAATG AAATTGTGTC TTTAGATGGA GTTGGGGAGA 780 GTACGCTTTA TTTTAAATAT TTAGTTCAAA TTTCATTTTC ACTTCTTGGT CTTATTATTT 840 CAGCTTCAGT TGGGGCTGGC TTCTGTGGGG CTTACATGCT GACTGTGTCA GGCAGCTGGA 900 GGTGATCTAC ATTGACAGGA TTCAATGACT TTCTCCTCCG CGAAAAGCCC CTGTCAGCTA 960 CACAAGGATG GGAGGTTTTC GGCACACTGT CAAGTGATTG CAGATCCTGA CTTCTCAAAT 1020 ATGAGGTGTC GGCAGTGGCA GCAGCAGCTA CTGGTAGCTG CCCCAGACTC CTCAGATAAC 1080 TTACACAGGA GCTGGTTTAT GCATCCCCTT CGTCAGAGCT TCCTCTGGGC AAGTGAAAGT 1140 TGCAAGCCTT CACTTGCCCC CATGTCTCAG CTCTCTAAGT GACCCTGCCT GTGCTGGCCC 1200 TTGTGCTTAT GGTGGTGGTG GTGGTGGTGC AAGCCTGAAG GAGGAAGACT TGTCTCAACA 1260 TCTAATGCCC CTGGTTGCTG ATTCTCTGAA GGCTTACTGC TCCCAGCAAC CGTCAGCCTC 1320 AGTCGCAGCC GGGCCTCGCT CCTCAACTTG GCAAAAATGC CTACAGAGAC TGAGAGATGC 1380 ATCGAGTCCC TGATTGCTGT TTTCCAGAAG TACAGTGGGA AGGATGGAAA TAGCTGTCAT 1440 CTCTCCAAAA CTGAGTTCCT TTCCTTCATG AACACGGAGC TGGCCGCCTT CACGAAGAAC 1500 CAGAAGGACC CCGGTGTCCT CGACCGCATG ATGAAGAAGC TGGACCTCAA CAGTGATGGG 1560 CAGCTAGATT TCCAAGAGTT TCTCAACCTT ATTGGTGGCT TAGCTATAGC ATGCCATGAG 1620 TCCTTCCTCC AGACTTCCCA GAAGCGTATC TAACCCTCTC CATTCCCTTC CAGCCACCAA 1680 GTCATCGCCT CCTCCACTCC TTCCCCCATC CACACCTGCA CTGAGCCCAC CACACCTACC 1740 ACACATGCAG CCCACGCCTG ACAGGGAAAA TAAAACAATG TCATTTTTTT AAATGTAAAA 1800 A 1801 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2646 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW033 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 50..263 (D) OTHER INFORMATION: /label= SAC_23901 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: GTCGACTTGA CTTCTTAGTT TTCTGACGGG AGCTCTCTTC CTTCTGAGTA CTAGTCTCGG 60 GCCTCCAGCC CCAGGAAGAC CCTCTGCTTT TCTCTCCACC CTTGGCTTGC TCCTCAGCAG 120 GGAAGAAGTA GATCACAGTC TCACTGCCTT CAGTTCCCAG CTTTGCCAGT CACCAGCTGT 180 GTAGTCTCAG GCCAATCACC ACCTCCTCTA GCCTAGGTAG TTGGTTTTAT GTGGGTGAAT 240 GTTTTGCCTG GATGTATGTA TGTACACCAC CTGTGTGCCT GGTGCCCCTG CAGTCAGAAG 300 AAAGTGCCAC ACCCCTAGGA ACTGGAGTTA AGATGGGTTA GAGCCTCCAT GTGGGTGCTG 360 AGAACTGAAC CTGGTTCTCT GGAAAAGCAG CCGGCACTCA ACCTCTGAGC CAGCTCTTCA 420 TCCCCGAGTC CGTTTATTTA ACCGGCTATA AAATGGATTT AAAACGACTT ACCTCACCAG 480 GCCTGTGAAA CATTTAAAAA CTTAATAAAA ATTCTACACT TAATTGTTTT TGCTTATGCT 540 TTCTAGTCCC TTTAGTCTTA GACAGTTTCT GTTTCTTGTA TTTATAAAGT TGGTATTAAA 600 TATATAGCCA GTGGACAAGA ACCTTACTGC TATGGGCTGG CCCCTGTAGG GTCCTAGACT 660 AGAGGAGCGT ACTTTGTGGT TTAAAGTGGT TTGGCCTGCC TACCTGTTTT TCCCACTGGA 720 CTCAAAACAC TAATAAAGCA GGGGTGACCT GTGTCACCTG AGCATTCAGC AGAACACTGG 780 CCCAGGCAAT GGCCTCAAAG CTGGGCTACA TTATAAAGTG AACTTTCTTG TTCATACTGG 840 GTCACAGAAG CAGGCCCAGA AAAAATAAAA AATCCTGGTC ACTCGGTTCC CCCTTGCACC 900 ATCATCTGTT CACTAGTGCC CCTCTGACCA TTCTCACCCA AGACAGGCAT CCTCTGGGAA 960 CCTTAGGCAG GTCCATTTCT TCTTTGTCAT TTGGAATGAA GCACTAACAG CCCTGGGGTC 1020 TCTGCCATTG GCTTCCCAGA GTTGTCCAAT GAGTTTTCGT GAAGGAATCT GGGTTTATCT 1080 TTCCCGGGCT TCCTGCCCTG TTAGCAGAAT TTCAAATAGC AGATAATAGA TTCTGACCTG 1140 TGAGGCCATT TTTCTCTCAA TCCCTTTCTT CTGAGACATT AGCCTTGGGC ATGCAGCAGC 1200 TGCGCACTGG TTTCAGGGAG GAAAGGGGTG AATGGTGAGC GAACTTGGCC CTGTGGATGC 1260 TAACTCCACT GAGATGAAAA CATGGGGGCT TTTCTCTGAA GACGCAGGGC CGTGTAAACA 1320 TATGACTTTG ACCATATTCT CAGGTTTGGG GATGTGGGAA GTTCCAGGAA CAGAAATCCC 1380 CTGCTGAGTT CTTGGGCACT GTGGCTATTT GTTCCCATGA GGACCTCTCC CTGCAGTCTG 1440 CCCTCTGGCA GGGTGGAGTA TAGAAGACTC AAGAGCTACA GATGCCCCCG TCACTGGAGC 1500 TCCCCTGCAC CTAGGCCATC AATCACGTCC ACCATCACCA GAGGGGCTTA GGCCTAGGGT 1560 GTATGCTGAG GGAAAGACGA GGGCCTGTCC CACTACTCGA GTAGAGCAGA TGGCCTTCTG 1620 TGTAGGCAGT GAATTTCATA GCAGTGCCTT GAGGAGCCCA GCATGTTCTC AAGCACCTCC 1680 TCCCAGTTTA TATTTGGAAG TCTGCTTCAC AGGGACCAGA GGGCATAAAC CTAACCTACC 1740 CACTTCCCAT CAGGGACAGC CCAAAGCACA CCAGTATATG TAAGGGGTGC AGGGAGGTAT 1800 CATGGGTCTC TTCTCTCCTC TCAGTGCTCA AACTCAGGTG GAGGCTATGG ATTCAGGATC 1860 TTGGTTAGGA GTTGCAAGCA ATGGACAAGA AAGAGCATTA GGGAAACCAG AATCCCAGCC 1920 TGTCCCTGTG CCTCCACCCC AGCTAGACTT GAGGCTTAGG TCCTGATACT CTGCCCTTAC 1980 ACACCCTCTC TCCATTTCCC AGGAGTTAGT AAAAAACAGG CAAGGGTAAT ATGCTATCAT 2040 CTGTGGTCCT GAGCCTTCTC CAGACTTCCC CTTCACTCCG CCGCCACTGC CACCACCACA 2100 GAGACATCTT CGGAAGCATT AGGTTTATTT CTTGAACTGA ACTCCTGGGG AGAAGATGAC 2160 TGGTGCCACC ACATGTGCTC TGTCTGGTTA GGGGCCTTGA GGTGGCACAG TCCAGCCATA 2220 GAAGGATCAG CCTTCCTGCC CATACAGATT AATGCCAGGG AGTCAGATAG TTGATGCGAC 2280 TGTAAAGAGA AAGAGAGGTG AGATGGGGAC TCCAAGGTAC TGTAAAGAGA AATCAAGTTT 2340 TTCTTCCCTA GCTCCATCCT CCACTCCAAA GCCTCAGGGA TCTGAAAACA GTCTTCATCC 2400 AGTCTATGTG CCCACAACCT TCAATGGTTC CCTACTTCCT CTTGTATATT TTTGGCTATT 2460 CTCTTCACCT CTAATTAGCT CATACTGTTT CCCACTGACT CCCGTCTTTA ATGGCTTCAT 2520 AGGTTTTCAG TCACGTATGA ATCTACACTG CATCACACAG TTACAAAACC CAGAGTTGGG 2580 GTTGGGGATT TAGCTCAGTG GCCTAGCAAG CGTAAGGCCC TGGGTTCGGT CCCCAGCCCC 2640 GAAAAA 2646 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4339 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW034 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 91..837 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 3101..4162 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 3561..3862 (D) OTHER INFORMATION: /label= SAC_23897 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: GTCGACGGAA GAGCTGTTGT GACTGCGGTA CTGCGGAGGG CTCTCGGCGG CCCGCGACAA 60 GGCTGAGTCC CGGGAGGTCC ATGCCCCACC ATG CTT TCC TGT GAC ATC TGT GGT 114 Met Leu Ser Cys Asp He Cys Gly 1 5 GAA ACT GTA ACC TCA GAA CCA GAT AGG AAG GCT CAC CTA ATT GTT CAC 162 Glu Thr Val Thr Ser Glu Pro Asp Arg Lys Ala His Leu He Val His 10 15 20 ATG GAA AAT GAA ATT ATC TGT CCG TTT TGC AAG CTG TCG GGT ATA AAT 210 Met Glu Asn Glu He He Cys Pro Phe Cys Lys Leu Ser Gly He Asn 25 30 35 40 TAC AAT GAA ATG TGT TTT CAT ATT GAA ACC GCT CAT TTT GAA CAG ACT 258 Tyr Asn Glu Met Cys Phe His He Glu Thr Ala His Phe Glu Gin Thr 45 50 55 ACG CCA GAA AAA AGC TTC GAG ACG CTA GCC GCA GTG CAA TAT GAA AAT 306 Thr Pro Glu Lys Ser Phe Glu Thr Leu Ala Ala Val Gin Tyr Glu Asn 60 65 70 TCA GAC CTC GGT AAT ACC AAG CTG CAC AGT ACA GTG GAA GTT ACC TCA 354 Ser Asp Leu Gly Asn Thr Lys Leu His Ser Thr Val Glu Val Thr Ser 75 80 85 GGC ATC CAT TCA GCT TGT GCA TCG AAC TTT CCA AAG GAG TCG TCC GAA 402 Gly He His Ser Ala Cys Ala Ser Asn Phe Pro Lys Glu Ser Ser Glu 90 95 100 AGC CTT TCT AAA GAT AGG ACT TTA AAA CAA GAA GCT TTT TAT ACA GAG 450 Ser Leu Ser Lys Asp Arg Thr Leu Lys Gin Glu Ala Phe Tyr Thr Glu 105 110 115 120 AGC GTA GCT GAA TCT AGA AAG TAC CAG AAA AGC AGA GAA AAG CAG TCC 498 Ser Val Ala Glu Ser Arg Lys Tyr Gin Lys Ser Arg Glu Lys Gin Ser 125 130 135 GGA TTG TCT GAG GCC CAA GGA TCA ATT TAT GAA ACA ACA TAC AGT CCC 546 Gly Leu Ser Glu Ala Gin Gly Ser He Tyr Glu Thr Thr Tyr Ser Pro 140 145 150 CCC GAA TGT CCG TTC TGT GGG AGA ATT GAG AGG TAC AGT CAA GAT ATG 594 Pro Glu Cys Pro Phe Cys Gly Arg He Glu Arg Tyr Ser Gin Asp Met 155 160 165 GAA ATT CAT GTG AAA ACA AAG CAT GCC AGC CTT CTA GAA AGT CCG TTA 642 Glu He His Val Lys Thr Lys His Ala Ser Leu Leu Glu Ser Pro Leu 170 175 180 GAA GAC TGT CAT CAA CCA CTC TAT GAC TGT CCC ATG TGT GGG CTT GTC 690 Glu Asp Cys His Gin Pro Leu Tyr Asp Cys Pro Met Cys Gly Leu Val 185 190 195 200 TGT ACA AAT TAT CAC ATT CTC CAA GAA CAT GTG GAC TTG CAT TTA GAA 738 Cys Thr Asn Tyr His He Leu Gin Glu His Val Asp Leu His Leu Glu 205 210 215 GAA AGC AGC TTT CAA CAA GTA CTT GTG AGT GGG TAT GTG CCT GTG TGG 786 Glu Ser Ser Phe Gin Gin Val Leu Val Ser Gly Tyr Val Pro Val Trp 220 225 230 ACA CCC GAC CTG CGA TGT CAT CCT CAG GAA GGC CGT ACA ACT CCT TTA 834 Thr Pro Asp Leu Arg Cys His Pro Gin Glu Gly Arg Thr Thr Pro Leu 235 240 245 AGA TGAGTTTCTT AGTATCTTGG AACACACCAG TTAAGCTCCC AAGTTTGCTT 887 Arg CTATCTCCAC CTCCCTAATA ATGCTGGAGT TACAATCATG GACAACCATA CACACATGTT 947 TCACATGATT CTGGGCACTG AGCTTAGGTC CTTATGTCTG TGAGGCAAGC TCTTCCTGAC 1007 CGAGCTATCT CCTGAGCCTG CTGTCTGTCT CTTTAAATAA TATTAAATAC TTCATATAGA 1067 GCTCTCGAAG GTATAGGGTC TTGTATGAGT CTCCTAGGGC CACTGAAAAA TAAAGTGACC 1127 TCTAAGAGAA GTTGTTTATA TTTTTATTAC TCTGTCAGTA TTTGGGAGTA TGTAGACAGC 1187 TCCTGGTAAA GTAGGAGATT TTAGCGTTCG ATGATTTACC ACCAATAACC GTGATCTCTA 1247 TGCATCATGT ACCTGCTTTG CTCATTACCA CAAGAGGAAA ATTAGTAGAA TATTCTTTTT 1307 TTTCCTTTTC CTTTTTTTTC TTTTTTTCGG AGCTGGGGAC CGAACCAAGG GCCTTGCACT 1367 CGCTAGGCAA GCGCTCTACC ACTGAGCTAA ATCCCCAACC CCAAATTAGT AGAATATTGA 1427 TGGAAGATTA TTTCACGTCA GTGGTCTTCT GCTGTCTACC CCAGTTGGCA TGCCACTGTC 1487 GTTGTTTAGG GTTCCTGTTG CTGTAATAAA ACACTACCAA CAAGAGTAAC CTGGGCAGGA 1547 AAGGGTTTAT TTTATCCAAA CATTTCCAGT TCACCACTGA GGGAATTCAG GGAAGGGACT 1607 CAAGGCAGGA ACCTGTAGGC AGGAGCTGAT GCAAAGGCCA TGAAGTGCTG CTGAGTGGCT 1667 TGTTTTGCCC TGACTTGTTC AGACTCCTTT CTTAGAGCAC CCAGGGATAT CAGCCCAGGG 1727 GTGGCATCAC CTACAAGGAC TGGGCCTTCC AACACCAGTC ACTACAGAAC GCACTACAGA 1787 CTTGCCTGCA CTCGGTCTTT CTTTACTGTT GTATTGTTTT TTGAGATGGA GTCTCACTAT 1847 GTAGCTCTGG CTAAGTGTAA ACTCTAGCTT GTGTCAAGTT GACCTAAAAC TAGCCAGCAC 1907 AGCTATCTTC CTTTGAGTAA GATTGTAAGA GGATGCTGTG GAAGGGGTAA TTTTTTCAAA 1967 GCAGAATGTC TGATAATTCT TACTTTAGGG ATAGGCTTTG TATTGTATTC TATAAACCAA 2027 TGAAACAGTC TCAGGGCATG CTAAAAATCA GTTGTGCAGT ACATGCCCAA GAGTGGAAAC 2087 TAGAACCAGT GGGAAGGTGT AAAATGGGTT AATCAACAGG TGTGTGCATT GTACTGTCTC 2147 TGAATTGAGG AGACCTAGA AGACTCCTAA CTGTTTCTTC TGGGTGTATC TCTGAGGATG 2207 TTTTCAGAAT AACTGATGGG TGCGTTGGCA AACAGAATGA AGAAGATGTG CATTCAGCGT 2267 GGGCAAGTAG TGTCCAGTGT CGCTAGTACT ATAGGTGGAC CAGGAAAGCC GAAGCAGTGG 2327 CAGAATCACT TTGGCTCCTC CTTCTGGATG GGGCTTTCTT TCCCTGCAGC TGCTCCCTGG 2387 GTGCAGCTGC TCCCTGGGTT ATACTCCAGG ATGTCTGACT TTTGGATGCT GGAACTCTGA 2447 TAATCCCTAC CAGAAATTTT GAGCCTTTGA CCTCACACTG GGATATCTGA TTTTGCCAAA 2507 CTGGTTCTGG CACTTTCAAC TTTCACTACT GGTTTCTCTG TGTCTCAGGC TATCAAGAAC 2567 TTTTCATTTG TATCATTATG TGATCTATTC CCGTATGATT CGTGATATTT AATAAGGTTT 2627 TCTATATCTT TCTGTCTGTC TGTCTCTGTG TGTGTGTGTA CATACACACA CACGCCTGTG 2687 TGTGGTGTTT TCTTATCTTG CCCTCAGTCC TGTTACTGGA GGACCCTGAC CAGTAAAGAA 2747 TTTAGGAAAC AAGACTCAAT ACATTACAAT ACAATACAAG CCATTGACTA AAGAATCTGA 2807 GTTTCAGTGG GAGAGAGGAA GCATGGCATT ATGCTATAAA ATTATTCAGC TTGTTCGGGT 2867 AAAAACTGTA ATGTAATGAA ACAGTTGGAG GTTGTGAATA TATATTTTAT ATTATTTATT 2927 ACTTTTTTCT TTCCATTAGT TGTGTTCAGA GATATCAATG ATAAGGGTCT TTCAACCGCT 2987 CACCCTTTGT TTTTCTCCCT AAAGGTGTTA GGATGTTCAC AATTGCTAGT TAATGAGAAA 3047 TGCTTGTTAG AGCCTAAGCA CTGACTCATT CGGGTTGTCC CTCTCCAATA GGC ATG 3103 Met 1 GAC AGA GTC CAG TGT TCT AGT GAC AGA GAA TTA GCT CAC CAG CTT CAG 3151 Asp Arg Val Gin Cys Ser Ser Asp Arg Glu Leu Ala His Gin Leu Gin 5 10 15 CAA GAA GAA GAG AGA AAG AGG AAA TCT GAA GAA TCA AGA CAA GAA AGG 3199 Gin Glu Glu Glu Arg Lys Arg Lys Ser Glu Glu Ser Arg Gin Glu Arg 20 25 30 GAA GAG TTT CAG AAA TTG CAG CGG CAG TAC GGC TTA GAT AAT TCT GGA 3247 Glu Glu Phe Gin Lys Leu Gin Arg Gin Tyr Gly Leu Asp Asn Ser Gly 35 40 45 GGA TAC AAA CAA CAG CAG CTG CGA CAC ATG GAG CTA GAA GTA ACG AGG 3295 Gly Tyr Lys Gin Gin Gin Leu Arg His Met Glu Leu Glu Val Thr Arg 50 55 60 65 GGA CGA ATG CAT CCA TCT GAG TTC CAC AGC AGA AAA GCT GAC ATG TTG 3343 Gly Arg Met His Pro Ser Glu Phe His Ser Arg Lys Ala Asp Met Leu 70 75 80 GAA TCA ATC GCT GTT GGT ATT GAT GAT GGA AAA ACA AAA ACT TCT GGA 3391 Glu Ser He Ala Val Gly He Asp Asp Gly Lys Thr Lys Thr Ser Gly 85 90 95 ATT ATT GAA GCC CTC CAC AGG TAT TAT CAG AAC ATT GCC ACA GAT GTA 3439 He He Glu Ala Leu His Arg Tyr Tyr Gin Asn He Ala Thr Asp Val 100 105 110 AGG TGT GTG TGG CTG TCT ACA GTG GTG GAT CAC TTT CAT TCA TCT TTT 3487 Arg Cys Val Trp Leu Ser Thr Val Val Asp His Phe His Ser Ser Phe 115 120 125 GGG GAC AAA GGT TGG GGT TGC GGT TAT AGA AAT TTC CAG ATG CTG CTT 3535 Gly Asp Lys Gly Trp Gly Cys Gly Tyr Arg Asn Phe Gin Met Leu Leu 130 135 140 145 TCA TCA TTA CTG CAG AAT GAA GTG TAC AGT GAC TGC TTG AAA GGT ATG 3583 Ser Ser Leu Leu Gin Asn Glu Val Tyr Ser Asp Cys Leu Lys Gly Met 150 155 160 TCA GTT CCT TGT ATT CCA AAA ATT CAG TCC ATG ATT GAA GAT GCG TGG 3631 Ser Val Pro Cys He Pro Lys He Gin Ser Met He Glu Asp Ala Trp 165 170 175 AAT GAA GGT TTT GAT CCT CAG GGG GCC TCT CAA CTT AAT AAC AAG TTG 3679 Asn Glu Gly Phe Asp Pro Gin Gly Ala Ser Gin Leu Asn Asn Lys Leu 180 185 190 CAG GGG ACC AAG GCC TGG ATT GGA GCA TGT GAG ATC TAT ACA CTT CTG 3727 Gin Gly Thr Lys Ala Trp He Gly Ala Cys Glu He Tyr Thr Leu Leu 195 200 205 ACC TCA CTG AAA GTC AAG TGC CGC ATT ATT GAT TTT CAC AAG TCA ACT 3775 Thr Ser Leu Lys Val Lys Cys Arg He He Asp Phe His Lys Ser Thr 210 215 220 225 GGT CCT TCA GGC ACA CAC CCT CGC TTA TTC GAG TGG ATA CTG AAC TAT 3823 Gly Pro Ser Gly Thr His Pro Arg Leu Phe Glu Trp He Leu Asn Tyr 230 235 240 TAT TCC TCA GAG ACG GAA GGG GCG CCA AAG GTC GTG TGT ACA TCC AAA 3871 Tyr Ser Ser Glu Thr Glu Gly Ala Pro Lys Val Val Cys Thr Ser Lys 245 250 255 CCT CCT GTC TAT CTC CAG CAT CAG GGT CAC AGT CGA ACA GTT GTT GGG 3919 Pro Pro Val Tyr Leu Gin His Gin Gly His Ser Arg Thr Val Val Gly 260 265 270 ATT GAA GAG AGA AAA AAC CGA ACA TTA TGT TTG CTA ATA TTT GAT CCT 3967 He Glu Glu Arg Lys Asn Arg Thr Leu Cys Leu Leu He Phe Asp Pro 275 280 285 GGA TGT CCT TCT CGA GAA ATG CAG AAG CTG TTA AAG CAA GAC ATG GAG 4015 Gly Cys Pro Ser Arg Glu Met Gin Lys Leu Leu Lys Gin Asp Met Glu 290 295 300 305 GCT GGT AGT CTC AGG CAG CTC CGG AAA TGT GTG GGA AAT CTG AAG CAT 4063 Ala Gly Ser Leu Arg Gin Leu Arg Lys Cys Val Gly Asn Leu Lys His 310 315 320 AAG CAG TAC CAG ATA GTA GCA GTG GAG GGT ATC CTG TCC CCA GAG GAG 4111 Lys Gin Tyr Gin He Val Ala Val Glu Gly He Leu Ser Pro Glu Glu 325 330 335 AGA GCT GCC AGG AAA CAA GCT TCT CAA GTG TTT ACA GCG GAG AAG ATT 4159 Arg Ala Ala Arg Lys Gin Ala Ser Gin Val Phe Thr Ala Glu Lys He 340 345 350 CCT TGACCCAGAT ATTTTGTAAT TATCCTTTTT GTTTCCGATA TTGAACTCTG 4212 Pro ATACAGTTGA AGAATTTGAC TTCACTGAAG TCGGTGATAA ATTATTTAAG TTATAAATGC 4272 CTGTTGTACT CCTTAGCATT TCGTTGTCTG GTAATCAGTT GAATAAATTC CTTGTTTACA 4332 TTAAAAA 4339 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 249 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: Met Leu Ser Cys Asp He Cys Gly Glu Thr Val Thr Ser Glu Pro Asp 1 5 10 15 Arg Lys Ala His Leu He Val His Met Glu Asn Glu He He Cys Pro 20 25 30 Phe Cys Lys Leu Ser Gly He Asn Tyr Asn Glu Met Cys Phe His He 35 40 45 Glu Thr Ala His Phe Glu Gin Thr Thr Pro Glu Lys Ser Phe Glu Thr 50 55 60 Leu Ala Ala Val Gin Tyr Glu Asn Ser Asp Leu Gly Asn Thr Lys Leu 65 70 75 80 His Ser Thr Val Glu Val Thr Ser Gly He His Ser Ala Cys Ala Ser 85 90 95 Asn Phe Pro Lys Glu Ser Ser Glu Ser Leu Ser Lys Asp Arg Thr Leu 100 105 110 Lys Gin Glu Ala Phe Tyr Thr Glu Ser Val Ala Glu Ser Arg Lys Tyr 115 120 125 Gin Lys Ser Arg Glu Lys Gin Ser Gly Leu Ser Glu Ala Gin Gly Ser 130 135 140 He Tyr Glu Thr Thr Tyr Ser Pro Pro Glu Cys Pro Phe Cys Gly Arg 145 150 155 160 He Glu Arg Tyr Ser Gin Asp Met Glu He His Val Lys Thr Lys His 165 170 175 Ala Ser Leu Leu Glu Ser Pro Leu Glu Asp Cys His Gin Pro Leu Tyr 180 185 190 Asp Cys Pro Met Cys Gly Leu Val Cys Thr Asn Tyr His He Leu Gin 195 200 205 Glu His Val Asp Leu His Leu Glu Glu Ser Ser Phe Gin Gin Val Leu 210 215 220 Val Ser Gly Tyr Val Pro Val Trp Thr Pro Asp Leu Arg Cys His Pro 225 230 235 240 Gin Glu Gly Arg Thr Thr Pro Leu Arg 245 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 354 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: Met Asp Arg Val Gin Cys Ser Ser Asp Arg Glu Leu Ala His Gin Leu 1 5 10 15 Gin Gin Glu Glu Glu Arg Lys Arg Lys Ser Glu Glu Ser Arg Gin Glu 20 25 30 Arg Glu Glu Phe Gin Lys Leu Gin Arg Gin Tyr Gly Leu Asp Asn Ser 35 40 45 Gly Gly Tyr Lys Gin Gin Gin Leu Arg His Met Glu Leu Glu Val Thr 50 55 60 Arg Gly Arg Met His Pro Ser Glu Phe His Ser Arg Lys Ala Asp Met 65 70 75 80 Leu Glu Ser He Ala Val Gly He Asp Asp Gly Lys Thr Lys Thr Ser 85 90 95 Gly He He Glu Ala Leu His Arg Tyr Tyr Gin Asn He Ala Thr Asp 100 105 110 Val Arg Cys Val Trp Leu Ser Thr Val Val Asp His Phe His Ser Ser 115 120 125 Phe Gly Asp Lys Gly Trp Gly Cys Gly Tyr Arg Asn Phe Gin Met Leu 130 135 140 Leu Ser Ser Leu Leu Gin Asn Glu Val Tyr Ser Asp Cys Leu Lys Gly 145 150 155 160 Met Ser Val Pro Cys He Pro Lys He Gin Ser Met He Glu Asp Ala 165 170 175 Trp Asn Glu Gly Phe Asp Pro Gin Gly Ala Ser Gin Leu Asn Asn Lys 180 185 190 Leu Gin Gly Thr Lys Ala Trp He Gly Ala Cys Glu He Tyr Thr Leu 195 200 205 Leu Thr Ser Leu Lys Val Lys Cys Arg He He Asp Phe His Lys Ser 210 215 220 Thr Gly Pro Ser Gly Thr His Pro Arg Leu Phe Glu Trp He Leu Asn 225 230 235 240 Tyr Tyr Ser Ser Glu Thr Glu Gly Ala Pro Lys Val Val Cys Thr Ser 245 250 255 Lys Pro Pro Val Tyr Leu Gin His Gin Gly His Ser Arg Thr Val Val 260 265 270 Gly He Glu Glu Arg Lys Asn Arg Thr Leu Cys Leu Leu He Phe Asp 275 280 285 Pro Gly Cys Pro Ser Arg Glu Met Gin Lys Leu Leu Lys Gin Asp Met 290 295 300 Glu Ala Gly Ser Leu Arg Gin Leu Arg Lys Cys Val Gly Asn Leu Lys 305 310 315 320 His Lys Gin Tyr Gin He Val Ala Val Glu Gly He Leu Ser Pro Glu 325 330 335 Glu Arg Ala Ala Arg Lys Gin Ala Ser Gin Val Phe Thr Ala Glu Lys 340 345 350 He Pro (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2415 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW035 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (1738..1910) (D) OTHER INFORMATION: /label= SAC_24468 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: GTCGACGGGC CCTATTCTGC CTCCTTCAGG ATCTGCGTCT TCCAGGGATC CGCTGTTCGA 60 CTTGGAGGTG CTTCTCTGCA GGTCCCAAGC CTGCCTCCTC ACCCCAGCTT TCCAGTGGAG 120 GCTGCCCCCT TCCAGGCTTG GCTCAGGAAG CTCCTCATAG GCGGATGCCC ACCCATAAGA 180 GGCTACATCC CTTTGTGGTC ACATGGCCTG TAGCCTCTTG CTGACATTGC TGGTGTCTTC 240 TCTGGGGCCC TGGATCCCTG ACAAGCACAG AAATGTGATC TGGTAAAAGG AAAGACTGTG 300 GCCTGATAGG CCTTTACCTC GTAGGCAGCA GGATTTTCAC TCAGTTTGAC ACAGCATGCA 360 GTGCTCTGGG AGCAGGACCT CTGCCACCCT GGCATTTTTG GTAGGCTGGT TTGGCTCAAG 420 GTGCTCAGAC ACTCCCATTG ATGCCTGAGT CGGATATGGG TGGAAATCTG GACTGTTGAT 480 TATAAGTTAC CAGGTGACCT CATTCCCTCC CTTTGTCTCT TAACTGGTAT CCAGTGAGTT 540 GCTGATGCCG ACTGGCAAGC AGAGCTGGCC CATGCCTAGA GGAGGAGAGG GACAGGCTTT 600 CTGAGTGCTT TGATTCTGGC TGGGCTGTAG TGTATAGCTG AGAATGGCCT CCTGCATGGG 660 TCCAGCCTTT TGGGAGGATG AGGAAGAGGA GGCTGAGGCT AGATGTGTGT TAAACAGGAG 720 TAGCAGATCT TTGCTTCTGA ACCGGATAGA GCCGTGCTCA AGGCTTTCAG GTTTGCAGTA 780 TCTTCTTATT GAGTCTGGGG AACGTTCCCT ATTGAGCCAG CCCTGCAGCT CCACTCCCTG 840 CCCCATTCCC CTGATTTCTT GACAGTAAAT CCTGTGTCCA GTTGTGACTG TTGGCTGTTT 900 TCCTGATCAT TGTTAATTCC GTTTTCCTAC TGTGAGGGTG TTGTGTTTGA CTTTCTGACA 960 CAGCGAATGG AGAGCTTGGG CTGAGGCCAG GTCTCCCAAA CTTCTCCGCT AAGTAAACCG 1020 TAATGTGTGA CTTCCCTCCT ATCTTGACTG CCCGACTCCT TCCTTCCACA TGGACACTCA 1080 GATTTCAAAG AAAACCCGCA GGAGGTGGGT CAGTTTCCTC TGTAGAATAT GGTCCCAGAG 1140 AGTCCTCCCC TCTGTTGTGT CTAGCTGCTA GTCTGGGTGT TGTACCATCA GTGCAGGGAG 1200 TCCACGGCAA CACTGAGTTA TACAGGGACC ACTACCATCG CCAGGCTTCC TAGCAGGCTG 1260 TTCTCAGTTC ATCTTTCAGG TCCGTGTGTA CTCTGTGCTA GCAGCAGCCT TGGTGTTCAA 1320 GGCCAGGATT TGCAGTTTTG ATAAGCTACA GCCCACTTGG AGATGGTGAG GCCACTTCCC 1380 TGCTACCTCC CTCTCTGGTG TGGCCACTTG GCCAAAGCTC CCATCCACAG CTGGGGTGTC 1440 TGAGCCACAG CCTGCTACAC TGTTTCCGCT CTGGGATCTT CTGAGTTACT CTTTTAGGCT 1500 GTGGTTTGGT GAAAGGAACC AACACATTAA CGATCTCCCC CCCCCCCCCC AAAGCCACTG 1560 AGTAATTCTT GGCATGTTTT CTAAGTGCTG TTGGCTGCCT GGTTTGGGAG CAGTTGTGGA 1620 GAGGACAGAC TTAGTACCAC ACAGAGGCAT GGGTGTGCGA GCTGCTCACA GCTTCCTTGT 1680 TTCTGGCATG TGTCCTGGGT GCGTGCTATA CCTCCCGGGC CAGCTGCACA CCTATGTACT 1740 CTGCCCCTGA GAGGTAGAGT GTTCAGGAAG TGTCCCTGAT AGATTCCCTG TTCTCTGTGG 1800 CCCCAGTTGG GCTTTTGGCT CCTCCAGCAA CTTCATGCCC CAACCCTACC TTTCCTCCCA 1860 TTTCTCTCTG TCTGCTAGTC CCTGAAGCCT TTAACCAAAT GGGAATGGGT ACAGAAAGCC 1920 TTCTCCTGGC AACTTAGGGC AACAGGACAA GGGCTATTGT GTGTCCAACT CTGTTGGTCT 1980 CCTGGTGCTG AGAGGTGTGT CCAAGCAGAG TTGATCAGCC CCTGCCTGCC CTGCAGGGCT 2040 GAAGCCAGGG GGAGGTTAGT AGAGAGTACC CTAAATGGGG TGAGGGTCCT TAAACATCCA 2100 AGTGAGGAGG GGCTGTTGTG TGGCTGCAAG GTGAGACCCT GTCTCCAGCA CCTGGGTAGG 2160 GCCATCGGGG ATCTGGCTGC AAGGTGAGGT CTGGACTTGG CATCAGTGCA GAGCGATCAA 2220 GTCACCTGGC CTCAGCAGGC AGCAGCCTTG GTGCCCACCC GTGCCCTGCG CAGTATTTAT 2280 TGCTAAATTA TTGTCCAGGA GGGGCGGCAC TGGGCCTGGC CCCCCGGGTA TTTATTGCTG 2340 TACATAGTGT ATGTTTGTGA TATATAAGGT TTTCTTTATT TTGTATATGA TCAATAAACG 2400 CCTTTTAAAG AAAAA 2415 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3531 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW036 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (2541..2575) (D) OTHER INFORMATION: /label= SAC_24406 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: GTCGACTGAA AACCACTCAG AATTTTCTCT GGTCCTTAAC AGAAAAGAAT CAAAGTAGGA 60 AGCACAGTAG CTGCCACATC TGTTCAACCT CTGGGCCTCC CAAGTACACC AGAGAAAACA 120 GATCAATGCT GTTTCTGAAT GATTCTGCTG GTTAAAGTCA TTTATAGAAG ATTCACGATA 180 CTGAACAACT ATGGGTTAAG AACTTACTGT GTTTTGTGAA TTGCCCAATG GAGAGAGTGT 240 GTTCAAGGAT GACTCTTGAT CAGATTACAC AGTATGTGCA TCCAGGAGGC CACATGAAAT 300 CAGCATAGTT AGTAACATAG AATCTGTTGT CAGCCTCCTC CAACTCGTGT CTGTTTCTTG 360 GTTTCAATTT TAGGCCAGCC CTCTCCTCAT AAAGGGGTGA TAGTAGCCAC AGTCCACAGC 420 CTCAAGGTCT GGTCTCCAAA AAGAAGAGTG TGAGCTGGGC CACAATCATA CCCTCCTGAA 480 GAACTCTGGT CTTTTCTGGT CATATGCTCC TGCCCCACCC TTGGTGATCC TGGCTAGATC 540 ATGGTCTCCC GTACTGTGCC GACACCATTC ACAGTAACAT AGGATGAGTT ATGGGCCTCA 600 TCCCTAAACA CTGGAACTTG CAGCAAATGA TGTAGCAGAT ATTCACTCTA GATAACAAAT 660 GTCAGTGACA TGAAGTGGCT AGGAAAGTTT AGAACCCTGA TCATTTTATT TTTACCACTT 720 AACACAGTAG AGAGCCATCA GGACTAAATC TTTGGTGTGA TTCTTGCCAT TGAAGTCATT 780 ATAGCTTCCA TATTGTTCCG TAGTTCACTG GAAAGTGCAC TTGCTGTTAA AAGTTTTGAA 840 GCTGTGAGGA TTCCCTAGGG TGTCACTGAA GTCTGCTCTG TATACTGCCC CCACTGGGAG 900 TGCACGGTAC TGCACCCTTA AATCCTGCCG CCTGTGTCCC AAACATGGTG TCTGCGTGCA 960 GTGTGGAGTA GTGCGCCTTC TTTTTTTTTT TTTTTTTTTT CCTATTCTTT TTTTGGAGCT 1020 GGGAACCGAA CCCAGGGCCT TGTGCTTGCT AGGCAAGTGC TCTACCACTG AGCCAAATCC 1080 CCAACCCCTG TAGTGCGCCT TCTATACTAG AAAGCTTGAC CACTGAGCCA CACCTCCCAC 1140 TAGTGCTTCA ATGTCAACCG AGAGTAAAAT GTGTTTGTAT GAAATGCCTC CATTTGACTA 1200 GATAGAGCTT TATTTGGAGA AAGTCACATA TAACATAATT GAACTTTGAA TTATACAATC 1260 CCGTGGATTT TAGAGTGCTC CTGGAGCAGG TGGCAGTCAC CACTATCTAC TTCCAGAACA 1320 GTCTCATCCT TTCCAGAAAC CCACACTCTG TCTTTCCTCT ATTCCAGATC TGTTAGACGA 1380 GTGGAATTAC ATAGTCCGGT CTTTTCTGAG TTCTGTTACT AAGTTTTAAA GGTTTATTCT 1440 CAGGTAGCAT CAGTCCGTAA TGTATTACTG CTGAATAGTG TTCCGTGTAT ACAGACACCG 1500 TGTGTGTCTT CTTCCAGCGA GCAGAGGAAC TCTGAGCTGT TTCTACTTTG GGGCTTTTGA 1560 CTAATGCTAT GAACATCTGT GAAAAAGTTC GAAATGTTTG ATTTAGTACA GACCCTAGTG 1620 GGGAGCTCCG GGGTCATATT ATGACAGCCT CAATTGTACT TCCTACAGTG GTTTTACCAC 1680 CATTTCCTGC TCTCGTGGGA TCTAGGCTCC AGCATCCCTC ACAACTTTCT GCCTGAGATG 1740 AAGAGGCATC TGATTGGGAT CTTGGTTTGC ATTTCCCTAA TGTCTAATAA TCTGAGCTTT 1800 TTTTCATGTG TTCATTGGCT TTCTATGCTG CTTTGCAGAA TGTTTATTTC AGGCTACAGT 1860 CTGCCTTTCA GCTGGGTTAT CTTTCTGTTT TTCTGTAGGA TTTTTTATTT ACGGTCAACT 1920 CATCTCTTAA AGATTAATTG GCATTTTTTT TTTTCTCAAC TTGTGGTTTG CCCTTCTCAA 1980 TGTCTTGATG CTCTCTGAAG CACAGTTTTT ATTTTTATAT ATTGCCTTTC TGCGTCTTAG 2040 CCCAGGCTGG CCAGGAATCC CCAAAGCCTT GTACACAGAG TGAGCATTTT CACCGCCTCA 2100 CTTCCCAGAA GGCACACGGC GCTGCTCCTG CCTAGAGCAG TTTTCATATT GGAAAATAAC 2160 AATGTGTTTT TTCTTTCAGT GTATCCTAAG AAACCATTCC TAACCTGGAC TTACAGAAGC 2220 TTATGTCTTC ACTAAAGAAT TTTTAAATTT TACCTCTTAC CTGTAGGCCT GTGCTCTCAA 2280 AATGTTACAC ACCTTTATTC ATGGCCATAT TTAAAATTAA GTAGAAATAG TGAGTATGTA 2340 GATATGCCTG TATCGTGATG AGCACATTCA CAGTGCAGTG CAGTTGGCCT GCAGCCCAGT 2400 TCTGCATCCA CCTCAGAAAA TGCCCAGTGA GCCCATCTAA TGACTCCCAG CCCCTGCCAG 2460 GTCCTCCCTC CCTGCCCTGT CTTGGCATAC TCTCTTCTCC ATGGCAATCA CCATTCTCTG 2520 TCCTGTTTCT GAATTTGAGT ACCCTAAGTG CCTGGTATAC ATAGATTCTC AGTGCGTGTG 2580 TGTGTGTGTG TGTGTGTGTG TGTGCGTGCG TGTTCATGTA GCAGAATGCC GTGAAGGCTT 2640 GTATCATGTA TGAGTTTCCT TTGTAAGGAC AAATAGTACT TTAGACTTTA GTGTGTGTTG 2700 TATGTATGCT GTATGTTTCT TGTTACCTAC TCATCCAGCC GTGGGTACCT CAGTTGTTCC 2760 CACCCTGGAG CTCCTGACTA TGCTGTGAAC ATGTATATAC AAATATCCCT CGGATCCTGC 2820 TTAGCATACA CGCAGCAGAT TGTATGTCTT AGGGTAACTC TGCTGTTATT AGTAGGCACT 2880 GCCGTAGTCT CCATAGTGAC CACACTATTG TATGTCCTGG CAGCAGTGCA CAGAGATTAG 2940 AAGTGCCCAT GTCCTTGTGA GTCTTACTCT TTTTTTAGTG GCTGTTCTAG TAGGTGTTAA 3000 GATCTGCTAG TGCTTCTGCT TCCCATCTCT CTGACTACTG ATGTCACATG TTTTATATGC 3060 TTGGTGGCCT TCTTTATATA TCGTTTGAAG AAATCTCTTT AGGTCCACTG CCCATTAATA 3120 GTTGGGTCGT TGGCTCTGGT TGAATTTTTG GTAGTCACAT CCACAAAAGC ATTAACCCAC 3180 CCAAGGGAGC CTACTACAGC TTGCCCTAGG AAACTTGATT TTAGCTCTTA GCTTTGCTCT 3240 CTGGTATATT TTGAGTTCAT TTGTGTGTGA GATGTAAGGT CTGACTTTCT ACTCTACCCA 3300 TGTGGATACC TGGCTTTGCA TGTTGCCCTT GGTGGGAAAA CATCCCGCTG TGCATGGTGG 3360 GGCTGTTTCT GAGCCTGGTC TCTTCCATGA CCTCTGTCTG CCTTCATGCC AACGCCACTG 3420 CTTTGATTAC TGGAGAATTA TAATAGAAAT TTGAAATCAG AAAATGTTTG TTCTGTAATA 3480 AAAATTTGAA ATCAGAAAGT GTTCTATAAT AAAAATTTGA AATCAGAAAA A 3531 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2127 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW037 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 280..1422 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1370..1796 (D) OTHER INFORMATION: /label= SAC_24354 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: GTCGACCTGC GGCTGGCCGG CGGGGCAGGC CCCGGACCCG TGCGGTTCCT GGGCATGGTG 60 AGCAAGGGGC TGCTGCGCCT TGTCTCTTCA GTCAACCGCA GGAAGATGAA GCTTCTGCTG 120 GGCATCGCGC TGTTCGCCTA CGCCGCCTAA CTTGCTCATG ATGGAGTGCC AAGTGCCTCA 180 GAGAAACAGG CCACCAGAAG AACAGTGCAT TCTCAGTACA AGGGCAGCGT TCAGCATTTG 240 GATATTGGAG TTGAAGCTGT TTGGGGCAAC TTTGTTAAC ATG AGG TCT ATC CAG 294 Met Arg Ser He Gin 1 5 GAA AAT GGT GAA CTA AAG ATT GAA AGC AAG ATT GAA GAG ATT ATT GAA 342 Glu Asn Gly Glu Leu Lys He Glu Ser Lys He Glu Glu He He Glu 10 15 20 CCA TTA AGA GAG AAA ATC AGA GAT TTG GAA AAA AGT TTC ACC CAG AAA 390 Pro Leu Arg Glu Lys He Arg Asp Leu Glu Lys Ser Phe Thr Gin Lys 25 30 35 TAC CCA CCA GTA AAG TTT TTG TCA GAA AAG GAC CGG AAG AGG ATT TTG 438 Tyr Pro Pro Val Lys Phe Leu Ser Glu Lys Asp Arg Lys Arg He Leu 40 45 50 ATC ACT GGA GGT GCG GGC TTT GTG GGC TCC CAT CTA ACT GAC AAA CTC 486 He Thr Gly Gly Ala Gly Phe Val Gly Ser His Leu Thr Asp Lys Leu 55 60 65 ATG ATG GAT GGC CAT GAG GTG ACC GTG GTG GAC AAC TTC TTC ACA GGC 534 Met Met Asp Gly His Glu Val Thr Val Val Asp Asn Phe Phe Thr Gly 70 75 80 85 AGG AAG AGA AAT GTG GAA CAC TGG ATT GGC CAT GAG AAC TTC GAG CTG 582 Arg Lys Arg Asn Val Glu His Trp He Gly His Glu Asn Phe Glu Leu 90 95 100 -72- SUBST1TUTE SHEET (RULE 26) ATT AAC CAT GAT GTG GTA GAG CCA CTC TAC ATC GAA GTT GAC CAG ATC 630 He Asn His Asp Val Val Glu Pro Leu Tyr He Glu Val Asp Gin He 105 110 115 TAC CAT CTG GCT TCT CCA GCC TCC CCT CCA AAC TAC ATG TAC AAC CCC 678 Tyr His Leu Ala Ser Pro Ala Ser Pro Pro Asn Tyr Met Tyr Asn Pro 120 125 130 ATC AAG ACC CTG AAG ACA AAT ACA ATT GGA ACA CTA AAC ATG TTG GGA 726 He Lys Thr Leu Lys Thr Asn Thr He Gly Thr Leu Asn Met Leu Gly 135 140 145 CTG GCA AAG CGT GTG GGT GCC CGT CTG CTC CTA GCC TCC ACA TCT GAG 774 Leu Ala Lys Arg Val Gly Ala Arg Leu Leu Leu Ala Ser Thr Ser Glu 150 155 160 165 GTA TAT GGA GAT CCT GAG GTC CAC CCT CAA AGT GAG GAC TAC TGG GGC 822 Val Tyr Gly Asp Pro Glu Val His Pro Gin Ser Glu Asp Tyr Trp Gly 170 175 180 CAC GTG AAT CCC ATA GGA CCC CGA GCC TGC TAT GAC GAG GGC AAA CGT 870 His Val Asn Pro He Gly Pro Arg Ala Cys Tyr Asp Glu Gly Lys Arg 185 190 195 GTT GCG GAA ACC ATG TGC TAT GCC TAC ATG AAG CAG GAA GGT GTG GAG 918 Val Ala Glu Thr Met Cys Tyr Ala Tyr Met Lys Gin Glu Gly Val Glu 200 205 210 GTG CGG GTG GCC AGG ATC TTC AAC ACC TTT GGG CCA CGA ATG CAC ATG 966 Val Arg Val Ala Arg He Phe Asn Thr Phe Gly Pro Arg Met His Met 215 220 225 AAT GAT GGG AGG GTG GTC AGC AAC TTC ATC TTA CAA GCG CTA CAA GGG 1014 Asn Asp Gly Arg Val Val Ser Asn Phe He Leu Gin Ala Leu Gin Gly 230 235 240 245 GAG CCG CTC ACA GTA TAT GGA TCT GGG TCT CAG ACA CGG GCA TTC CAG 1062 Glu Pro Leu Thr Val Tyr Gly Ser Gly Ser Gin Thr Arg Ala Phe Gin 250 255 260 TAT GTT AGC GAT CTA GTG AAT GGC CTG GTA GCA CTG ATG AAC AGC AAT 1110 Tyr Val Ser Asp Leu Val Asn Gly Leu Val Ala Leu Met Asn Ser Asn 265 270 275 GTC AGC AGC CCT GTC AAC CTG GGA AAT CCA GAA GAA CAC ACA ATC CTG 1158 Val Ser Ser Pro Val Asn Leu Gly Asn Pro Glu Glu His Thr He Leu 280 285 290 GAA TTT GCT CAG TTA ATT AAA AAC CTT GTT GGT AGT GGA AGT GAA ATT 1206 Glu Phe Ala Gin Leu He Lys Asn Leu Val Gly Ser Gly Ser Glu He 295 300 305 CAG TTT CTC TCT GAA GCT CAG GAT GAT CCA CAG AAA AGA AAA CCA GAC 1254 Gin Phe Leu Ser Glu Ala Gin Asp Asp Pro Gin Lys Arg Lys Pro Asp 310 315 320 325 ATC AAA AAA GCA AAA CTG ATG CTG GGG TGG GAG CCT GTG GTT CCA TTG 1302 He Lys Lys Ala Lys Leu Met Leu Gly Trp Glu Pro Val Val Pro Leu 330 335 340 GAG GAA GGA TTG AAC AAA GCC ATC CAC TAT TTC CGG AAG GAA CTA GAG 1350 Glu Glu Gly Leu Asn Lys Ala He His Tyr Phe Arg Lys Glu Leu Glu 345 350 355 TAC CAG GCT AAT AAC CAG TAC ATC CCT AAA CCC AAG CCT GCC AGA GTG 1398 Tyr Gin Ala Asn Asn Gin Tyr He Pro Lys Pro Lys Pro Ala Arg Val 360 365 370 AAG AAG GGC CGG ACG CGC CAC AGC TGAGTTAGCC TTGGGATGCG AGACTCTATT 1452 Lys Lys Gly Arg Thr Arg His Ser 375 380 TTACTTTATA AGGTGGACTT TTGTGGGATT TTTTTTTTTT TTTTAAGACT TAAACAGGTG 1512 TCATGAAGAA CAAACTGGAA TTTTATTCTG AAGCTTGCTT TAAAGACACT GATGTGCCTA 1572 AAAGCTCCCT TGAACTCTGC AGACTTTGCC TTGCACTTTT TAACTCTGTC TTTTTTATGC 1632 ACAACAGCCT AGATGCATTC TCTGCTATTT TCAGGTTTTT TTATCTTGCT GTTAGAGTGT 1692 ATGCTGTAAC TGTCACTGAC AGTTTTATTT ACTGGTTTCT TTGTGAAGCT GAAAAGAAAC 1752 ATTAAATGGG GTGGAAAATG CCAATTTTAT TTATAAAAGT GAGTACTTTA TAAATGAGAT 1812 GTTACACTAT GCATAAAGAA TACAAACCTA GAGGTATGGC CAGCTGGGCA GTGCACCAGT 1872 GTTTATTTGG GGACAGATGA AAGAACTCCA TTGGAAAGCT TTGCATTTCT TTTTTAATTC 1932 TGAATTTTCT GAAGGTCTAG TTTTCAGTTA CAGACTTGAC TTTGAAACAT CCCTGTTGGT 1992 TCTTGATCAA AGATATTTGA AATCACTACT GTGTTGTGCT GCATATTGGG GTGGGGGTGG 2052 GGACAATGTT AACATATTCT TGGTTAACCA TGGTTAAATA TGCTATTTTA ATAAAATATT 2112 GAAACTCGTC AAAAA 2127 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 381 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: Met Arg Ser He Gin Glu Asn Gly Glu Leu Lys He Glu Ser Lys He 1 5 10 15 Glu Glu He He Glu Pro Leu Arg Glu Lys He Arg Asp Leu Glu Lys 20 25 30 Ser Phe Thr Gin Lys Tyr Pro Pro Val Lys Phe Leu Ser Glu Lys Asp 35 40 45 Arg Lys Arg He Leu He Thr Gly Gly Ala Gly Phe Val Gly Ser His 50 55 60 Leu Thr Asp Lys Leu Met Met Asp Gly His Glu Val Thr Val Val Asp 65 70 75 80 Asn Phe Phe Thr Gly Arg Lys Arg Asn Val Glu His Trp He Gly His 85 90 95 Glu Asn Phe Glu Leu He Asn His Asp Val Val Glu Pro Leu Tyr He 100 105 110 Glu Val Asp Gin He Tyr His Leu Ala Ser Pro Ala Ser Pro Pro Asn 115 120 125 Tyr Met Tyr Asn Pro He Lys Thr Leu Lys Thr Asn Thr He Gly Thr 130 135 140 Leu Asn Met Leu Gly Leu Ala Lys Arg Val Gly Ala Arg Leu Leu Leu 145 150 155 160 Ala Ser Thr Ser Glu Val Tyr Gly Asp Pro Glu Val His Pro Gin Ser 165 170 175 Glu Asp Tyr Trp Gly His Val Asn Pro He Gly Pro Arg Ala Cys Tyr 180 185 190 Asp Glu Gly Lys Arg Val Ala Glu Thr Met Cys Tyr Ala Tyr Met Lys 195 200 205 Gin Glu Gly Val Glu Val Arg Val Ala Arg He Phe Asn Thr Phe Gly 210 215 220 Pro Arg Met His Met Asn Asp Gly Arg Val Val Ser Asn Phe He Leu 225 230 235 240 Gin Ala Leu Gin Gly Glu Pro Leu Thr Val Tyr Gly Ser Gly Ser Gin 245 250 255 Thr Arg Ala Phe Gin Tyr Val Ser Asp Leu Val Asn Gly Leu Val Ala 260 265 270 Leu Met Asn Ser Asn Val Ser Ser Pro Val Asn Leu Gly Asn Pro Glu 275 280 285 Glu His Thr He Leu Glu Phe Ala Gin Leu He Lys Asn Leu Val Gly 290 295 300 Ser Gly Ser Glu He Gin Phe Leu Ser Glu Ala Gin Asp Asp Pro Gin 305 310 315 320 Lys Arg Lys Pro Asp He Lys Lys Ala Lys Leu Met Leu Gly Trp Glu 325 330 335 Pro Val Val Pro Leu Glu Glu Gly Leu Asn Lys Ala He His Tyr Phe 340 345 350 Arg Lys Glu Leu Glu Tyr Gin Ala Asn Asn Gin Tyr He Pro Lys Pro 355 360 365 Lys Pro Ala Arg Val Lys Lys Gly Arg Thr Arg His Ser 370 375 380 (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1785 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW038 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1440..1714 (D) OTHER INFORMATION: /label= SAC_24332 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: GTCGACGGTT GAGTCTGATG AGGAAGATCA AGAAAAGACT GAGGAGACTC CTTCCCAGCT 60 GGACCAGGAT ACTCAAGTAC AGGACATGGA TGAGGGTTCA GACGATGAAG AAGAAGGACA 120 GAAAGTGCCT CCACCCCCAG AGACACCCAT GCCTCCACCT CTGCCCCCAA CACCAGACCA 180 AGTCATTGTG CGAAAGGACT ATGATCCCAA AGCTTCCAAG CCCCTTCCTC CAGCTCCTGC 240 TCCTGATGAG TATCTTGTGT CCCCCATAAC TGGGGAGAAG ATTCCTGCCA GCAAAATGCA 300 AGAACACATG CGCATCGGGC TTCTTGACCC CCGCTGGCTG GAGCAACGGG ATCGCTCCAT 360 CCGAGAGAAG CAGAGCANTG ATGAGGTGTA CGCACCAGGT CTGGATATTG AGAGCAGCCT 420 AAAGCAGTTG GCTGAGCGAC GTACTGACAT CTTTGGGGTA GAAGAGACAG CCATTGGTAA 480 GAAGATTGGT GAAGAGGAGA TCCAGAAGCC AGAGGAAAAG GTGACTTGGG ATGGCCATTC 540 AGGCAGCATG GCCCGGACCC AGCAGGCTGC CCAGGCCAAC ATCACCTCCA GGAGCAGATT 600 GAGGCCATCC ATAAGGCCAA GGGCCTGGTG CCAGAAGATG ACACCAAAGA GAAGATTGGC 660 CCTAGCAAGC CCAATGAAAT CCCTCAGCAG CCACCGCTCC ATCTTCAGCC ACCAATATCC 720 CCAGCTCAGC GCCCCCCATC ACGTCATTCC CCGGCCACCT GCGATGCCAC CTCCAGTCCG 780 CACCACTGTC GTATCTGCAG TGCCTGTCAT GCCTCGGCCC CCCATGGCAT CTGTGGTCCG 840 GCTGCCCCCA GGCTCAGTGA TTGCCCCGAT GCCACCCATC ATCCACGCAC CTAGGATCAA 900 CGTGGTACCC ATGCCTCCTG CAGCACCNCC CATCATGGCA CCCCGNCCAC CTCCCATGAT 960 TGTGCCAACA GCCTTTGTGC CTGCTCCCCC CTGTGGCTCC AGTGCCAGCC CCAGCTCCAA 1020 TGCCTCCCGT ACACCCCCCA CCTCCTATGG AAGATGAGCC TCCATCCAAG AAACTAAAGA 1080 CCGAGGACAG CCTCATGCCT GAGGAAGAGT TCCTGCGCAG GAACAAGGGT CCAGTATCCA 1140 TCAAGGTGCA GGTACCCAAC ATGCAGGATA AGACAGAATG GAAGCTGAAT GGGCAGGGGC 1200 TGGTCTTCAC TCTCCCGCTC ACAGACCAGG TCTCTGTCAT CAAAGTGAAG ATTCATGAAG 1260 CNACGGGCAT GCCTGCAGGG AAGCAGAAAC TACAGTATGA AGGCATCTTC ATCAAGGACT 1320 CCAACTCCCT GGCTTACTAC AACATGGCCA GTGGTGCTGT CATCCACTTG GCCCTCAAGG 1380 AAAGAGGCGG CCGGAAGAAG TAGCCTCGAG AGATACTGCA AGTGGACTCC TGCCATTGTA 1440 CCTCTTTCCA CCACCAATTC CGGGAGTTTC CCTGGGACCT CGGGCACAGC CTGGGCATTT 1500 GTCTCCCTCT AAGGCAGTCT ATGGAATGGA TATCTGTTTA GATTTGGATT GGAGGTCCTT 1560 CAAGGAAGCC CATTAGGAAT TGAAAACCCA GGGTTCTCCC ACAGGAGAGC TTCATAATAC 1620 CAAGTAATGT TTGGCTAATA GAGTATGGTT ACTACCATTC ATCATTGTGT ATCATGCTTT 1680 GGCCTCTAAT AAACCTCTTG AAGCCAGGCA TGGTACACAC ATGCCTGTAA TCCCGGGACT 1740 TGGGGGGCGG GCAGAAGAAT TAAATGTTCA TCTTGGCTGT AAAAA 1785 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1054 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW039 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 231..617 (D) OTHER INFORMATION: /label= SAC_24045 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: TTTTTCAGAA TTGGCTGACT TTAATTTGGA AACAGCTTTT GGCTACAGAC ATTCAGGTTT 60 AAGGCACATT CCAAACTACA AGGATCCCTG CCACTGGCAC GGGGCCTGGC TTTAATTCTT 120 GCATGGTTTT ACATGGAAAG TGGAACAAAT GATTTTCTGG CCTCTTCTAA AAAAGAGTGT 180 GAGTTTGGCA AAAACAAAAC TCATGACACA TTCTCACCAG ACACCACAGT ACCGTTACAA 240 GACCTCCCTT TTGTCCTAGG CAAAGACGGG TGGCCCGCTC ACCTACCATT CTCTCCAGAA 300 ACATGTATAC AGTAAGCATG CTTGTATGCG TCTGTCTGGC AGCGATGGTT AAAAAAAGTT 360 TTCAAATAAA AATACAAAAA TCACACGTCT ATAACAAAGC TAAGAGTCTT AGCCACAAGC 420 AGCGAGGAAT GAGTGTAGGA ACCAGGAGAG ATAAACATCA ATTCTGCACA GCAAGGGGCT 480 GTGAGGGCCA GGGAGATGGT CACCTGAGAA CCTGGCCCAC CTGGGCCCTT CGGCACAATA 540 CGTGGATGAG GGGGGACCAG AAGGAAAAGG TCATGGCTTT GGGGATGGGT GGATGGCTGG 600 GGGGTGCACT TGTGGGTACT AGATAGATTG GGGGAACTGG TGTGCTCTTC GGGACGTTTC 660 CTGGCCACTG CCAGCAGGGG GCCAGCAGGG GGCACAGGTG AGCCACTGCC ACCGCTCAGT 720 CGTTGCCACC ACAGATCTTC AGCAGGATCT TCCGATAATC CCCAGAAGTG TCTCCCGTGA 780 TATCGTGGTA CAGTGACTTG CCGTACATCC GCTTATACTC TGCTCGGATA TCCAGCAGGT 840 CAAGCTCGCT TCGAGACACC ATGATGCGAA TCAGGGTCCG GTCTTTTGTT CCTGCTCCCC 900 CTCATAGCCT TGTTGAGCCT TTCGGCAAAG AAGGCAGGGG TGTTCTTGAG GCATTTCACC 960 ACAGCCAGCA TGCCCTGCTC CAGGTCCCCA GACATCTCCG GCAGATGCTC TTCTCGATGT 1020 CTCGGCCTGT CATCCTCTGA TACTCGTTGA AACT 1054 (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3306 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW040 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 481..2433 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (2395..2588) (D) OTHER INFORMATION: /label= SAC_24520 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: GTCGACGCCT GGTGTGGCTG GCGGCACCAG CTGAGTATTC CCTGAAAGAA TGAAGATGAC 60 TGGCCTAGAG GAGTCAGGAA TGTGACTGCT GGGAGATCCA GCTAGAGCAA CCATACCTGC 120 TTTTCCAGGA CCTTCCCCCT AACAGCTAAG GAGCCTTAGG TCTGGGAGAG GCAGGCACCT 180 GGCTGCAGAA GGGGAAACAA CCTTTTTCTC TTTCTCTCCT CCACTACTCT CCTGATGGCT 240 GCAGAAGAAG AAAGATCTAC CACGGGAAAC TCGGAGAGCT AGTCGGTTAA CTGAGCTGTT 300 GGATCTCCAC GGCACGAGGC AAATCCGTGA TGTGACTTTT TGTTTTTTCT CCTAGGTCAG 360 CTGAGGGAAC AGCTCAGTTA CCTTAAGGGC GATAACTTTT TCAGGTTTAC TTGTGCCGAT 420 TGCTCGGCAG ACGGCAAGGA GCAGTCCGAG AGGCTGAAGC TGACATGGCA GCAAGTGGTC 480 ATG CTG GCT ATG TAC AAC TTG TCT CTG GAA GGA AGT GGA CGT CAA GGC 528 Met Leu Ala Met Tyr Asn Leu Ser Leu Glu Gly Ser Gly Arg Gin Gly 1 5 10 15 TAC TTC CGG TGG AAA GAA GAT ATC TGT GCT TTT ATT GAG AAA CAT TGG 576 Tyr Phe Arg Trp Lys Glu Asp He Cys Ala Phe He Glu Lys His Trp 20 25 30 ACT TTT TTA CTA GGA AAT AGG AAA AAG ACT TCG ACG TGG TGG AGC ACA 624 Thr Phe Leu Leu Gly Asn Arg Lys Lys Thr Ser Thr Trp Trp Ser Thr 35 40 45 GTA GCA GGT TGC CTC AGC GTG GGA AGT CCT GTT TAT TTC CGT TCA GGT 672 Val Ala Gly Cys Leu Ser Val Gly Ser Pro Val Tyr Phe Arg Ser Gly 50 55 60 GCT CAG GAA TTT GGA GAG CCT GGA TGG TGG AAA CTT GTT CAT AAC AGA 720 Ala Gin Glu Phe Gly Glu Pro Gly Trp Trp Lys Leu Val His Asn Arg 65 70 75 80 CCC CCA ACA ATG AGA CCA GAG GGA GAG AAG CTG TCT GCC TCC ACT TTG 768 Pro Pro Thr Met Arg Pro Glu Gly Glu Lys Leu Ser Ala Ser Thr Leu 85 90 95 AAA GTG AAA GCT TCA AAA CCA ACA CTG GAT CCC ATC ATT ACC GTT GAA 816 Lys Val Lys Ala Ser Lys Pro Thr Leu Asp Pro He He Thr Val Glu 100 105 110 GGA CTC AGA AAA CGA GCA AGC CGG AAT CCT GTG GAA TCA GCC ATG GAA 864 Gly Leu Arg Lys Arg Ala Ser Arg Asn Pro Val Glu Ser Ala Met Glu 115 120 125 TTG AAA GAG AAG CGG TCT CGA ACA CAG GAA GCT AAA GAC ATC AGA AGA 912 Leu Lys Glu Lys Arg Ser Arg Thr Gin Glu Ala Lys Asp He Arg Arg 130 135 140 GCA CAG AAA GAA GCA GCC GGC CTC CTT GAC AGA AGC ACC TCT TCT ACC 960 Ala Gin Lys Glu Ala Ala Gly Leu Leu Asp Arg Ser Thr Ser Ser Thr 145 150 155 160 CCT GTC AAG TTC ATA AGC CGA GGC CGG AGG CCG GAT ATG ATT TTG GAG 1008 Pro Val Lys Phe He Ser Arg Gly Arg Arg Pro Asp Met He Leu Glu 165 170 175 AAA GGA GAA GTG ATT GAC TTT TCA TCC CTG AGC TCC TCG GAC CGT ACC 1056 Lys Gly Glu Val He Asp Phe Ser Ser Leu Ser Ser Ser Asp Arg Thr 180 185 190 CCC CTC ACA AGC CCC TCT CCT TCT CCC TCT CTG GAT TTC TCT GCC CCA 1104 Pro Leu Thr Ser Pro Ser Pro Ser Pro Ser Leu Asp Phe Ser Ala Pro 195 200 205 GGG ACA CCA GCG TCA CAT TCT GCC ACG CCT AGC TTG CTC TCT GAA GCA 1152 Gly Thr Pro Ala Ser His Ser Ala Thr Pro Ser Leu Leu Ser Glu Ala 210 215 220 GAC CTC ATC CCA GAC GTG ATG CCA CCC CAA GCT CTA TTT CAT GAT GAT 1200 Asp Leu He Pro Asp Val Met Pro Pro Gin Ala Leu Phe His Asp Asp 225 230 235 240 GAT GAG CTG GAA GGA GAT GGA GTC ATA GAC CCA GGG ATG GAG TAC ATC 1248 Asp Glu Leu Glu Gly Asp Gly Val He Asp Pro Gly Met Glu Tyr He 245 250 255 CCA CCC CCA GCT GGG TCA GCT TCT GGG CTG ATG GGG AGC AGA AAG AAG 1296 Pro Pro Pro Ala Gly Ser Ala Ser Gly Leu Met Gly Ser Arg Lys Lys 260 265 270 GTC AGA GCT GCA GAG CAG ATA AAA CAG GAA GTC GAC AGC GAG GAG GAG 1344 Val Arg Ala Ala Glu Gin He Lys Gin Glu Val Asp Ser Glu Glu Glu 275 280 285 AAG CCA GAC AGG ATG GAT GGA GAT AGC GAA GAC ACA GAT TCA AAC ACT 1392 Lys Pro Asp Arg Met Asp Gly Asp Ser Glu Asp Thr Asp Ser Asn Thr 290 295 300 TCT TTG CAC ACT AGA GCT CGA GAA AAG AGG AAG CCA CCC CTG GAG AAG 1440 Ser Leu His Thr Arg Ala Arg Glu Lys Arg Lys Pro Pro Leu Glu Lys 305 310 315 320 GAC ACG AAG CCC AAG GGG CCC AGG TAT ACG CCT GTG AGC ATC TAT GAG 1488 Asp Thr Lys Pro Lys Gly Pro Arg Tyr Thr Pro Val Ser He Tyr Glu 325 330 335 GAG AAG CTG CTG CTC AAG AGG CTG GAG GCA TGC CCT GGT GCC GTG GCC 1536 Glu Lys Leu Leu Leu Lys Arg Leu Glu Ala Cys Pro Gly Ala Val Ala 340 345 350 ATG ACT CCA GAA GCC CGG AGG CTG AAA CGG AAG CTG ATC GTC CGG CAA 1584 Met Thr Pro Glu Ala Arg Arg Leu Lys Arg Lys Leu He Val Arg Gin 355 360 365 GCA AAA AGG GAT CGG GGC TTA CCA CTG TTT GAC TTG GAC GAG GTT GTG 1632 Ala Lys Arg Asp Arg Gly Leu Pro Leu Phe Asp Leu Asp Glu Val Val 370 375 380 AAC GCA GCA CTT CTG TTA GTG GAT GGG ATT TAT GGA GCC AAA GAT GGA 1680 Asn Ala Ala Leu Leu Leu Val Asp Gly He Tyr Gly Ala Lys Asp Gly 385 390 395 400 GGA GCT TCC CGG CTT CCA GCT GGA CAA GCT ACA TAC CGG ACC ACC TGC 1728 Gly Ala Ser Arg Leu Pro Ala Gly Gin Ala Thr Tyr Arg Thr Thr Cys 405 410 415 CAG GAC TTC AGG ATC CTT GAC CGG TAC CAG ACT GCC TTA CCA GCC AGG 1776 Gin Asp Phe Arg He Leu Asp Arg Tyr Gin Thr Ala Leu Pro Ala Arg 420 425 430 AAA GGA TTC CGG CAC CAG ACC ACC AGA TTT TTG TAT CGT CTG GTG GGA 1824 Lys Gly Phe Arg His Gin Thr Thr Arg Phe Leu Tyr Arg Leu Val Gly 435 440 445 TCA GAA GAT CTG GCT GTG GAC CAA AGT ATT GTC AGC CCT TAC ACT TCT 1872 Ser Glu Asp Leu Ala Val Asp Gin Ser He Val Ser Pro Tyr Thr Ser 450 455 460 CGG ATC TTG AAA CCT TAT ATC AGG CGT GAT TAT GAG ACA AAG CCA CCC 1920 Arg He Leu Lys Pro Tyr He Arg Arg Asp Tyr Glu Thr Lys Pro Pro 465 470 475 480 AAA CTA CAG CTG CTG TCC CAG ATT CGC TCC CAC CTG CAC AAG AGT GAC 1968 Lys Leu Gin Leu Leu Ser Gin He Arg Ser His Leu His Lys Ser Asp 485 490 495 CCT CAC TGG ACA CCT GAA CCT GAT GCA CCT CTC GAT TAC TGC TAT GTC 2016 Pro His Trp Thr Pro Glu Pro Asp Ala Pro Leu Asp Tyr Cys Tyr Val 500 505 510 CGA CCA AAT CAC ATC CCA ACG ATC AAC TCC ATG TGT CAG GAA TTT TTC 2064 Arg Pro Asn His He Pro Thr He Asn Ser Met Cys Gin Glu Phe Phe 515 520 525 TGG CCT GGC ATT GAC CTG TCT GAG TGT CTG CAG TAT CCA GAC TTC AGT 2112 Trp Pro Gly He Asp Leu Ser Glu Cys Leu Gin Tyr Pro Asp Phe Ser 530 535 540 GTC GTA GTC CTT TAT AAA AAA GTC ATT GTT GCC TTT GGC TTC ATG GTT 2160 Val Val Val Leu Tyr Lys Lys Val He Val Ala Phe Gly Phe Met Val 545 550 555 560 CCC GAT GTG AAG TAC AAC GAA GCT TAC ATT TCA TTT CTG CTT GTT CAT 2208 Pro Asp Val Lys Tyr Asn Glu Ala Tyr He Ser Phe Leu Leu Val His 565 570 575 CCC GAG TGG AGG AGA GCA GGG ATT GCC ACG TTC ATG ATC TAT CAT CTG 2256 Pro Glu Trp Arg Arg Ala Gly He Ala Thr Phe Met He Tyr His Leu 580 585 590 ATT CAG ACG TGC ATG GGC AAG GAT GTG ACT CTT CAC GTC TCG GCG AGC 2304 He Gin Thr Cys Met Gly Lys Asp Val Thr Leu His Val Ser Ala Ser 595 600 605 AAC CCT GCC ATG CTG CTG TAC CAG AAG TTT GGC TTC AAG ACA GAG GAG 2352 Asn Pro Ala Met Leu Leu Tyr Gin Lys Phe Gly Phe Lys Thr Glu Glu 610 615 620 TAT GTT TTG GAT TTT TAT GAT AAG TAT TAC CCA CTG GAG AGT ACA GAG 2400 Tyr Val Leu Asp Phe Tyr Asp Lys Tyr Tyr Pro Leu Glu Ser Thr Glu 625 630 635 640 TGT AAA CAT GCA TTC TTC CTG AGG CTC CGA CGC TGAGGTGAAC TCAGTTCTTC 2453 Cys Lys His Ala Phe Phe Leu Arg Leu Arg Arg 645 650 CCAGCAAACA GCAGATGCTG TCAGAGAGTG GCCTCAGAAG TCGTGCAGGC CCTTCTCCTC 2513 GAAGTGGGCC CTGGCCTCCT GTGAGTAATG GCCTCCACAG GGTCCAGCTG GGTGAGTGAA 2573 GCCATGTGCA GAGGTACAAG TGGCTGTTCA ATCCAGAAAC CATCCAGCAG GCCCTGCGTG 2633 GCCTTCCAGC AGTATCTTGG ACTCCACTGT GGACCAGAAC CAAGTGACTC TGCCATTCTT 2693 TTTCCACACA ATGAGTGGGC ACAAAAGAGC TTCTGAGCTG AAGCATTTGA GAATGGGCCT 2753 GCTCCTCCTA TGTGAGAGCT CAGGAAGTAT GAAAGATGTT AAAGACTGCC AGGGCCCTCA 2813 CTGTCCTGGG CCGAGAGGTT ATGAGGTGTC AGGAATGACT CCAACCCTGT CTCAGCCTGT 2873 GCTGTGCTGT CATCGAACCC CAGAGGATTC ATGGGGCACT GAAGTCCTTT TGTCTCTTAC 2933 TGACTTTCGT CCTGGTCAGG AAAAAGATAC TCGGTGTCTG TTTCCAGACT GCTGCTGCTT 2993 TACTTATCTA CCTGTCAGCA CCCCTTGCAG GGACATTGAC CTGGTACAAG AAGTTTACTC 3053 TTGGCATGGC CTGGAAAGTA GCCCGAGAGG AACGGTTGAG CTTGATACAT TAGATGCCTT 3113 CCCAGGCCCT TCTCATGCTC AGGACAGTTG CACCACAGAA GTGGAGGTGT GGAATGGCGC 3173 AGGCAGGCCT GGGCGCCCTG TCCACCTCAT GAAGCTGCTT CCTGGGTTGC ACATGTTGGA 3233 GTTGGACTAC AGGTATCTAA GTGCATTCCA AAAGCATCAG ATATCTCCAA TAAAAATCCT 3293 TACCATACAA AAA 3306 81- SUBST1TUTE SHEET (RULE 26) (2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 651 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: Met Leu Ala Met Tyr Asn Leu Ser Leu Glu Gly Ser Gly Arg Gin Gly 1 5 10 15 Tyr Phe Arg Trp Lys Glu Asp He Cys Ala Phe He Glu Lys His Trp 20 25 30 Thr Phe Leu Leu Gly Asn Arg Lys Lys Thr Ser Thr Trp Trp Ser Thr 35 40 45 Val Ala Gly Cys Leu Ser Val Gly Ser Pro Val Tyr Phe Arg Ser Gly 50 55 60 Ala Gin Glu Phe Gly Glu Pro Gly Trp Trp Lys Leu Val His Asn Arg 65 70 75 80 Pro Pro Thr Met Arg Pro Glu Gly Glu Lys Leu Ser Ala Ser Thr Leu 85 90 95 Lys Val Lys Ala Ser Lys Pro Thr Leu Asp Pro He He Thr Val Glu 100 105 110 Gly Leu Arg Lys Arg Ala Ser Arg Asn Pro Val Glu Ser Ala Met Glu 115 120 125 Leu Lys Glu Lys Arg Ser Arg Thr Gin Glu Ala Lys Asp He Arg Arg 130 135 140 Ala Gin Lys Glu Ala Ala Gly Leu Leu Asp Arg Ser Thr Ser Ser Thr 145 150 155 160 Pro Val Lys Phe He Ser Arg Gly Arg Arg Pro Asp Met He Leu Glu 165 170 175 Lys Gly Glu Val He Asp Phe Ser Ser Leu Ser Ser Ser Asp Arg Thr 180 185 190 Pro Leu Thr Ser Pro Ser Pro Ser Pro Ser Leu Asp Phe Ser Ala Pro 195 200 205 Gly Thr Pro Ala Ser His Ser Ala Thr Pro Ser Leu Leu Ser Glu Ala 210 215 220 Asp Leu He Pro Asp Val Met Pro Pro Gin Ala Leu Phe His Asp Asp 225 230 235 240 Asp Glu Leu Glu Gly Asp Gly Val He Asp Pro Gly Met Glu Tyr He 245 250 255 Pro Pro Pro Ala Gly Ser Ala Ser Gly Leu Met Gly Ser Arg Lys Lys 260 265 270 Val Arg Ala Ala Glu Gin He Lys Gin Glu Val Asp Ser Glu Glu Glu 275 280 285 Lys Pro Asp Arg Met Asp Gly Asp Ser Glu Asp Thr Asp Ser Asn Thr 290 295 300 Ser Leu His Thr Arg Ala Arg Glu Lys Arg Lys Pro Pro Leu Glu Lys 305 310 315 320 Asp Thr Lys Pro Lys Gly Pro Arg Tyr Thr Pro Val Ser He Tyr Glu 325 330 335 Glu Lys Leu Leu Leu Lys Arg Leu Glu Ala Cys Pro Gly Ala Val Ala 340 345 350 Met Thr Pro Glu Ala Arg Arg Leu Lys Arg Lys Leu He Val Arg Gin 355 360 365 Ala Lys Arg Asp Arg Gly Leu Pro Leu Phe Asp Leu Asp Glu Val Val 370 375 380 Asn Ala Ala Leu Leu Leu Val Asp Gly He Tyr Gly Ala Lys Asp Gly 385 390 395 400 Gly Ala Ser Arg Leu Pro Ala Gly Gin Ala Thr Tyr Arg Thr Thr Cys 405 410 415 Gin Asp Phe Arg He Leu Asp Arg Tyr Gin Thr Ala Leu Pro Ala Arg 420 425 430 Lys Gly Phe Arg His Gin Thr Thr Arg Phe Leu Tyr Arg Leu Val Gly 435 440 445 Ser Glu Asp Leu Ala Val Asp Gin Ser He Val Ser Pro Tyr Thr Ser 450 455 460 Arg He Leu Lys Pro Tyr He Arg Arg Asp Tyr Glu Thr Lys Pro Pro 465 470 475 480 Lys Leu Gin Leu Leu Ser Gin He Arg Ser His Leu His Lys Ser Asp 485 490 495 Pro His Trp Thr Pro Glu Pro Asp Ala Pro Leu Asp Tyr Cys Tyr Val 500 505 510 Arg Pro Asn His He Pro Thr He Asn Ser Met Cys Gin Glu Phe Phe 515 520 525 Trp Pro Gly He Asp Leu Ser Glu Cys Leu Gin Tyr Pro Asp Phe Ser 530 535 540 Val Val Val Leu Tyr Lys Lys Val He Val Ala Phe Gly Phe Met Val 545 550 555 560 Pro Asp Val Lys Tyr Asn Glu Ala Tyr He Ser Phe Leu Leu Val His 565 570 575 Pro Glu Trp Arg Arg Ala Gly He Ala Thr Phe Met He Tyr His Leu 580 585 590 He Gin Thr Cys Met Gly Lys Asp Val Thr Leu His Val Ser Ala Ser 595 600 605 Asn Pro Ala Met Leu Leu Tyr Gin Lys Phe Gly Phe Lys Thr Glu Glu 610 615 620 Tyr Val Leu Asp Phe Tyr Asp Lys Tyr Tyr Pro Leu Glu Ser Thr Glu 625 630 635 640 Cys Lys His Ala Phe Phe Leu Arg Leu Arg Arg 645 650 (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4234 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW041 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 3407..3482 (D) OTHER INFORMATION: /label= SAC_24317 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: GTCGACCCTC CTTCTGCCCT GGCTCCTGTT GATGAGCACA GTGCCGTCCC TGATCAGTTC 60 TTTCTTCCTG TGAATTTGCT TCGTAGCCCA TCAGGCTGGT AGACTGGCAG CACGGTCAGT 120 GTCACACGAG GGACAGGACT TCCCTGAAGT GAAGCAGCAA TGTCATGGAA GCAAACCCCT 180 GTGAGCGAGA GACAGGCCCC GAGGCTGCTG CCACAAGGTC TCATGTTCAT TGCTGGGGAC 240 ACTAGCTTCC TACAAACCCC AGGAGACGCT GCCCATAGCA CGGGTGGCCC TTCAGGCTCC 300 TGAACTATCT ATCCCCAGAT CAGTAGGATT TGTTTTCCAA GTCCCCTTCC TCATTCCTTC 360 TTTGCTCAAG AGAAAAAAGA AAAGTGGTAA CTCTGTGACT CTAAGTCCCT CTTAAATGCA 420 GCGCTGAATC TAGCTTGGCT CGGAGATCTC TGACTTGTCC CTAGGGTGAG ACTGTGGCCT 480 CCCCAGGTTG AGGTGGCACG TGTATTGTGA GAGATTAGCC TGGAGAGCAG AGAAGGGGGG 540 AGGGGGGATA GGGAGGAGAG AGCAATCGTG TCTCCCTACA GGACCCTGGG CCATCTGACA 600 AGACAGAGGA GGTGGGACTG GCTTCCCCAT GCTGCACATG GCAGTGGGAA CCAGGCTTGG 660 AGTCCCCCAC CCCCTCCTTA CCTCTTCTCT CAGACCTTGT AGCCCTAGCT TGCCCTGTGC 720 TCTGCAGGGA AGGGGATGAG AGGACAGCAT AAGAAGTCTT GCCAGTTGAG GTGGGGCTGG 780 AAGATGAAGC AGGTGGGTGT AGGAATCATT TTGGATAGGG CATGTTGTTT GGTTGACGGC 840 AACTAATTCT CTTAAGAGCA TATTGTCTCC AGTTAATGTT GGAGACAACC CAGAAAGGGA 900 AGGGTATAGA GATGGGTAAT TAATGAGATA TTCCAGCCCT GGAGCAATGT CTGAGCCACC 960 CCAAACTTAG GCTGTCTCCC AGCATAGGAG TGGGGCACTG CCCCTTACTC AAATTCTAGT 1020 CTAAGTGTTC CAGACACATT GTACACTTGG ACAGGAAATC TCCTGTTCCA GCATACCCTC 1080 TCCCCCATAC CCTCTCCCCC ATACCCCCTC CCCCATACCT TCTCCCCCAT ACTGTTAGTA 1140 CGTTTCAGTT GTTCAAAAGC AAAGGGGGCG CAGACTAGGC TTTAACTGCA TGTGGAGTGT 1200 AGATTTTGCC TAAGAATCCA TGTTGAAGAA GAGAGAGGCT ATGTCTTTAA GGTCGAGGCC 1260 CTTCAGTCTT CTGTCCTTGT AATTCTCTTG AAGCGTGAGC CCCAGGCACT CAGAAGCCAT 1320 GTTGTACTCC GGGAAGTTCA TGGGACCTGA ACTCCTTCAA CACCGGGAAC AACAGTACTG 1380 CATAGGTACT TTGGTACTGA CTGTGCAAGC ACTAGAAAAA GTACCCGTTG AATGGCCCTC 1440 ACAGCATCAG GGAAACGAGG CCGAGTTCAC TCTCCTGATT GCTCAGATGC AGAAGCTGGA 1500 CCCGTGAGGT GTACCAGCCC ACCTCCAAGC TTGACACAGA GGCTAGCACT TAAAGCAAAG 1560 ACTCAGAAGA GGAGTCTCAG TCACAGGCTG CACAGCCTTG AACATGATAT CTAGAACTAT 1620 GCCTGGGTGA TCGGTGGCCC AACTTGTGAC ACTTGTGTGC ACATAGGGAA GCTGACGCTC 1680 CTCTCGGGGC CTGAAAACAG GACTAAACCC AAACCCCATA TAACTAACCA TACCACTGCC 1740 ATCCACAGGC GTGGATGGAA GTCTTCACGG TCTGTTACAA GCACAAGTAC AAAGCCGATA 1800 AAAATAAGTC AAAGCCCTTC CTCGTGGTGC AGAGGGCTCC TCCTCAGATC TCTTGGAGCC 1860 TTTGATCATA GAGCTTGACG GTCTCCTCTC GGGATAAAGG ACAGGTAAAG GCTGTGGCCT 1920 TCAGCGGTGA CTGCCCCACA CCCTGCTTTC CTTAGGGGTG GAGACAAGGA ATGGTGGGGC 1980 CAGTGTTGTT CAGAGAGAAG TCTCTCTTTG GAGCCCATGT ATGGGGCTTG ACCTTTTGCT 2040 GTGAGTGCAT TTAGAGGCAA GTGAATTCTG GCCTCAGTAC AGAGAACCCA GCGGTTTCAG 2100 CACTCAAGAA AGAAGCCGCA GTGTCCCCTA CAGAGAGGCT CTGTCCTGCT TGGCCCCAGC 2160 CACCTGCGCC ACACATTTAA TAAAGTGGCT GAAACTCCTC CTTTCCAAGA GCTAGTGTGC 2220 TGGGTCCTGT CCTCCCCACA GCCTTCTGAG TCCCAGAGAC TTGTGTGAGC AGTCGGATAA 2280 GGCCAATCTG GGAGACAGGG GATGACCATG ACACAAGGTG TTTCCAGGCA GGTCCCTTGT 2340 GCGTAGGCTG CAGAGAGCTG TCCTGACTGG GAGCTTGGGT TGTACGAACA CATGGTGCCT 2400 TCTTTGTCTG TGCTGAACGA GTAGGGTGTG TTTCTCTGTG TTCTCTGAGT AAGATCACAC 2460 CCTCTTTAAG CAAAGGGGTG TTGTGGATAT TAGAAGCAAG ATTGATAAAT GTTCTTAAAT 2520 GGTGGTGCTA GAGAAAAGTC AGTCCCCGTA ACTTCCTAAA AGCTGAGTCA GCCAGTCTCT 2580 AAGTATGTAC ATGTTGGCTT TCTTCTATTT TTTTTCTAGT TAATCAGTGT GTTTTAAATG 2640 TTTTTAGTTG ATGTGAGGAT TTTTTTAAAG GCATTTGTGT GTGGTGTGGC TCCATGGGAG 2700 ATAGGCTGTG TAATAAGAAC CCTCAGAAGC CAGCCAGTCA TCCAAGGGGC GCCCAAGTTC 2760 AGTGGATTTC TTCAGGAATT GGAGAGCAGT ATTTTTCCCT CTTTTCAGTA GTATGCCTGT 2820 TCTCATTTAG TAATTTAATG GTATATTGCA TTATATGTGA ATGCATACAT AAACGGTGGA 2880 ATTTCTCTTA ATATCCAAAA AAGTCCTTCT GTTGCCCTCT GAGCTCTCTC CTTGGGGAGG 2940 ACTGCAGGGC TCACTGTGTA AAATGGTTGT GGACTCCTCT AGCAGAATGG CTTCCAAGGC 3000 CTGGCCCATT CCTCAGATTC CCTTTGAAGT GAGAGGTCAT TGTCTTTTGA GAATGGATTT 3060 AAGTTTTGGA AATACCCCAC GCTGTTCACA GTGCAAGCGA CTGAACACAG AACAATTAGT 3120 CAGAATCAGA ATCCCAGGGC CATCAAGATG ACTCCACGGA AAAGGGACTG CCACCAACCA 3180 GAGCCAAGAC CTGAGTTTGG TCCCCAGGAA CCCCATGGCA GCAGGAGAGA GTCAGCCGAT 3240 GCAAGTGTCA CACACACACA TAAACACACA CATACACATG CAACACATAC ACACAAACAC 3300 ATACATACAC ACACACAAAC ACATACACAC ATGCACACAC ACACACACAC ACACACACAC 3360 AGAGTTTTTG GAAGAATATC TATGATGTAG GAAAAGGTTT GTTAGTACCT GCAACCTCTA 3420 GGGCCTCATT TCCAAGCCTG CTGCTTCTCT TGCCAGGACT TATACGTGTG CAACCCCTGC 3480 GTACACTACA GACCTAAGTA CATACTCGCT AACATGAACA CCCAGTAGGT ATTCTGTAAA 3540 ACGGATATAC TTAAGTGCAT GTTATTGTCG TGTGTGCCGC GACTGAGCTG TGTCTTTGTC 3600 ATGAAACTTT GCTTCTTTGC CAAATTAAGA CTCTGCCCTC CCTCCGAGGA AGGAAATATA 3660 CAGCAGTTTC TGGAATCAGC TTCTCAAGTT TTCCCGCCTG TGTTGTGTTT ACTTGTGGCT 3720 TTGCCTGAGA GTCTGTCCTC ACGTACACAC CTGTGAGTAT TTATTACAAG GCAGAACGGG 3780 GACAGGCGTA GCCATAGTAC TTGTGTTTGA ATGTTTCCAG GGAGGGACAA TGGAGCCCCC 3840 TCCTCAGTGA GGTGCTCACA GAATCTGTGT CAAATTCTGT GAACGGGGTC CAACACTAGT 3900 ACCAGCTTCA CCCCAACCCT GAGTGCCCTG GAGCCACTGC CCTCTCTACT GCCTTGTGTG 3960 TGCATGGGTG TGGTTGTGTG TGTCTCTGTT GGGGCATGTG CCGCATTTCG CAGTGGACTT 4020 TGGTATCCAC ATGTAACCTT TGGCATCTGT GTTCCTGGAC CGCATTGACA GATCTGTGGT 4080 GTGCAGATCT GTGTAGATGG GTCTGTGTGC AAAGTGGGGA GTCCCCTGAA AGTGACTATG 4140 GATATTGTTG GTCAGCCAAA GACTTTCCTA TTCTTTGCTG CTTAAACTTT GTGCCTTAAT 4200 ATTGTAAATA TAAACGGTTA AAACAAAAGT CGAC 4234 (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1792 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE : HW042 ( ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 8..889 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (1409..1618) (D) OTHER INFORMATION: /label= SAC_24017 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: GTCGACC AAG GAT GGT GGA AGT TTC AGT GGT ACT GGT GGC CTT CCA GAT 49 Lys Asp Gly Gly Ser Phe Ser Gly Thr Gly Gly Leu Pro Asp 1 5 10 TAT TCT GCC CCC AAT CCC ATT AAA GTG ACC CAT CGG TGC TAC ATC CTT 97 Tyr Ser Ala Pro Asn Pro He Lys Val Thr His Arg Cys Tyr He Leu 15 20 25 30 GAG AAT GAC ACA GTC CAG TGT GAC TTG GAC CTG TAC AAG TCC CTG CAG 145 Glu Asn Asp Thr Val Gin Cys Asp Leu Asp Leu Tyr Lys Ser Leu Gin 35 40 45 GCT TGG AAA GAC CAC AAA TTG CAC ATC GAC CAT GAG ATT GAA ACC CTG 193 Ala Trp Lys Asp His Lys Leu His He Asp His Glu He Glu Thr Leu 50 55 60 CAG AAC AAA ATT AAG AAC CTT CGA GAA GTC AGG GGT CAC CTG AAG AAG 241 Gin Asn Lys He Lys Asn Leu Arg Glu Val Arg Gly His Leu Lys Lys 65 70 75 AAG CGG CCA GAA GAA TGT GAC TGT CAC AAA GTC AGT TAC CAC AGC CAA 289 Lys Arg Pro Glu Glu Cys Asp Cys His Lys Val Ser Tyr His Ser Gin 80 85 90 CAC AAA GGC CGC CTC AAG CAC AAG GGC TCC AGC CTG CAC CCT TTC AGG 337 His Lys Gly Arg Leu Lys His Lys Gly Ser Ser Leu His Pro Phe Arg 95 100 105 110 AAG GGT CTG CAG GAG AAA GAC AAG GTG TGG CTG TTG CGG GAG CAG AAA 385 Lys Gly Leu Gin Glu Lys Asp Lys Val Trp Leu Leu Arg Glu Gin Lys 115 120 125 CGC AAG AAG AAA CTG CGC AAG CTG CTG AAG CGA CTG CAG AAC AAT GAC 433 Arg Lys Lys Lys Leu Arg Lys Leu Leu Lys Arg Leu Gin Asn Asn Asp 130 135 140 ACG TGC AGC ATG CCG GGC CTC ACG TGC TTT ACT CAC GAC AAC CAC CAC 481 Thr Cys Ser Met Pro Gly Leu Thr Cys Phe Thr His Asp Asn His His 145 150 155 TGG CAG ACC GCG CCG CTC TGG ACG TTG GGA CCC TTC TGC GCC TGC ACC 529 Trp Gin Thr Ala Pro Leu Trp Thr Leu Gly Pro Phe Cys Ala Cys Thr 160 165 170 AGC GCC AAC AAT AAC ACG TAC TGG TGC CTG CGG ACC ATC AAC GAG ACC 577 Ser Ala Asn Asn Asn Thr Tyr Trp Cys Leu Arg Thr He Asn Glu Thr 175 180 185 190 CAC AAC TTC CTC TTC TGT GAA TTC GCA ACT GGC TTC ATA GAA TAC TTT 625 His Asn Phe Leu Phe Cys Glu Phe Ala Thr Gly Phe He Glu Tyr Phe 195 200 205 GAC CTC AGT ACG GAC CCC TAC CAG CTG ATG AAC GCG GTC AAC ACA CTG 673 Asp Leu Ser Thr Asp Pro Tyr Gin Leu Met Asn Ala Val Asn Thr Leu 210 215 220 GAC AGG GAC GTT CTC AAC CAG CTG CAC GTC CAG CTC ATG GAG CTA AGG 721 Asp Arg Asp Val Leu Asn Gin Leu His Val Gin Leu Met Glu Leu Arg 225 230 235 AGC TGC AAA GGC TAC AAG CAG TGT AAC CCC CGG ACC CGC AAT ATG GAC 769 Ser Cys Lys Gly Tyr Lys Gin Cys Asn Pro Arg Thr Arg Asn Met Asp 240 245 250 CTG GGG CTT AGA GAC GGA GGA AGC TAT GAG CAA TAC AGG CAG TTT CAG 817 Leu Gly Leu Arg Asp Gly Gly Ser Tyr Glu Gin Tyr Arg Gin Phe Gin 255 260 265 270 CGT CGA AAA TGG CCA GAA ATG AAG AGA CCC TCT TCC AAA TCA CTG GGA 865 Arg Arg Lys Trp Pro Glu Met Lys Arg Pro Ser Ser Lys Ser Leu Gly 275 280 285 CAG CTA TGG GAA GGT TGG GAA GGC TAATCGGCCA TGGAGAGGAA CCTCCAAAAC 919 Gin Leu Trp Glu Gly Trp Glu Gly 290 CAGAGGCCTC CTGTGGCTGC CCAGGCGTGC AAAAATCACC CAATTCCGAG GAGATCGATG 979 CTGGAACTGG GAGACTTGAC AGGAGGCAGG GTCTGCACTT GGGACAGGAA ATCCCGAGGA 1039 GAACGCCAAG ACTTCCAGAG GCTCATTGTT TTGCCCCGCT TTGCTTCGGA TTGAACCTCA 1099 CCGGCCGCAC AAGGATGCGT CCTGACACCT GGAGTCTCCG CTCACCCTTT CAGAGGCTCA 1159 CCAAGACAAA GGAACTAATT CCCATGGACT TTCCTCCAGA GATGGAAATT GCTGGGATTT 1219 ACCCATCCCC TCCCCTGTAC CCCCTTCCCC ACTAGGGAAA CAAGCTTGTT TTAACCTTCT 1279 TATTCTTTGG AGAAAGCACG GATGTCCCAG GTGCTGTCAA CAGCGCAGTC TTGACAATGG 1339 TCTATAGCAC AAAACAGTAC CATTCACCTG GCTGGATGAG CCGGCTGCCC CAGAAGCTGC 1399 CTTCACTGTA CATATGTGAC TGCTCACATG TAACCAACAC AGGGACTTGT AGGGGGAATC 1459 TCACTAATAC GAAATCCCAT TTTCAAGAGT CGCGGTGTCA ATAAACACTC TGTGGCTGGT 1519 GTCAAGGGTA ATCCCTTGAG CTTTCAGACA TTTCTGTTCC TGCCCAGGAT TCGTTCCTTT 1579 GTTATCCATA TCCATCCCAG AACTGATGTT TTCTAAGGTA CTGAAACCCC AAGTTGATGT 1639 GTGTCCTGTG TTTTAATGAC ATTGTATTTG TAAAGCAATT TTGTAGTATA AAAGTACCAT 1699 CTTCCAGTGT TCACATCCCC CCCAGCCAAT GACTAGCTCT TGGTATGAAA AAAAAAATCT 1759 TTGAATTTTT GTAAAAAAAA AAAAAAAGTC GAC 1792 (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 294 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: Lys Asp Gly Gly Ser Phe Ser Gly Thr Gly Gly Leu Pro Asp Tyr Ser 1 5 10 15 Ala Pro Asn Pro He Lys Val Thr His Arg Cys Tyr He Leu Glu Asn 20 25 30 Asp Thr Val Gin Cys Asp Leu Asp Leu Tyr Lys Ser Leu Gin Ala Trp 35 40 45 Lys Asp His Lys Leu His He Asp His Glu He Glu Thr Leu Gin Asn 50 55 60 Lys He Lys Asn Leu Arg Glu Val Arg Gly His Leu Lys Lys Lys Arg 65 70 75 80 Pro Glu Glu Cys Asp Cys His Lys Val Ser Tyr His Ser Gin His Lys 85 90 95 Gly Arg Leu Lys His Lys Gly Ser Ser Leu His Pro Phe Arg Lys Gly 100 105 110 Leu Gin Glu Lys Asp Lys Val Trp Leu Leu Arg Glu Gin Lys Arg Lys 115 120 125 Lys Lys Leu Arg Lys Leu Leu Lys Arg Leu Gin Asn Asn Asp Thr Cys 130 135 140 Ser Met Pro Gly Leu Thr Cys Phe Thr His Asp Asn His His Trp Gin 145 150 155 160 Thr Ala Pro Leu Trp Thr Leu Gly Pro Phe Cys Ala Cys Thr Ser Ala 165 170 175 Asn Asn Asn Thr Tyr Trp Cys Leu Arg Thr He Asn Glu Thr His Asn 180 185 190 Phe Leu Phe Cys Glu Phe Ala Thr Gly Phe He Glu Tyr Phe Asp Leu 195 200 205 Ser Thr Asp Pro Tyr Gin Leu Met Asn Ala Val Asn Thr Leu Asp Arg 210 215 220 Asp Val Leu Asn Gin Leu His Val Gin Leu Met Glu Leu Arg Ser Cys 225 230 235 240 Lys Gly Tyr Lys Gin Cys Asn Pro Arg Thr Arg Asn Met Asp Leu Gly 245 250 255 Leu Arg Asp Gly Gly Ser Tyr Glu Gin Tyr Arg Gin Phe Gin Arg Arg 260 265 270 Lys Trp Pro Glu Met Lys Arg Pro Ser Ser Lys Ser Leu Gly Gin Leu 275 280 285 Trp Glu Gly Trp Glu Gly 290 (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2261 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW043 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 8..634 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 582..808 (D) OTHER INFORMATION: /label= SAC_24533 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: GTCGACG GCT CCA CCA GGT TCA AGA CAC AAA CCT GTG CCT ACC AAG TCA 49 Ala Pro Pro Gly Ser Arg His Lys Pro Val Pro Thr Lys Ser 1 5 10 ACA CCA GCT GGC ACA GAA CTA GGT AGC ACA GGA AGC GAC GGG GGA GAT 97 Thr Pro Ala Gly Thr Glu Leu Gly Ser Thr Gly Ser Asp Gly Gly Asp 15 20 25 30 GCA GTA GAA TAC AAC CCC AAC CTC CTG GAT GAC CCA CAG TGG CCG TGT 145 Ala Val Glu Tyr Asn Pro Asn Leu Leu Asp Asp Pro Gin Trp Pro Cys 35 40 45 GGG AAG CAC AAG CGT GTA CTC ATC TTT GCC TCA TAC ATG ACC ACT GTT 193 Gly Lys His Lys Arg Val Leu He Phe Ala Ser Tyr Met Thr Thr Val 50 55 60 ATA GAG TAT GTG AAG CCT GCA GAC CTC AAA AAG GAC ATG AAC GAG ACC 241 He Glu Tyr Val Lys Pro Ala Asp Leu Lys Lys Asp Met Asn Glu Thr 65 70 75 TTC AGG GAG AAG TTC CCT CAT ATC AAA CTG ACA TTG AGC AAA ATT AGG 289 Phe Arg Glu Lys Phe Pro His He Lys Leu Thr Leu Ser Lys He Arg 80 85 90 AGT TTA AAA CGG GAG ATG CGG AAC CTT TCT GAA GAG TGC AGC TTG GAG 337 Ser Leu Lys Arg Glu Met Arg Asn Leu Ser Glu Glu Cys Ser Leu Glu 95 100 105 110 CCT GTG ACT GTG TCC ATG GCC TAT GTG TAC TTT GAG AAG CTT GCA CTG 385 Pro Val Thr Val Ser Met Ala Tyr Val Tyr Phe Glu Lys Leu Ala Leu 115 120 125 CAG GGC AAG CTC AAC AAA CAG AAC CGC AAA CTG TGT GCT GGC GCC TGT 433 Gin Gly Lys Leu Asn Lys Gin Asn Arg Lys Leu Cys Ala Gly Ala Cys 130 135 140 GTT CTG TTG GCT GCC AAG ATC AGC AGT GAC CTC CGC AAG AGT GAA GTG 481 Val Leu Leu Ala Ala Lys He Ser Ser Asp Leu Arg Lys Ser Glu Val 145 150 155 AAG CAG CTT ATT GAC AAG CTG GAG GAA AGG TTC CGG TTC AAC AGG AAG 529 Lys Gin Leu He Asp Lys Leu Glu Glu Arg Phe Arg Phe Asn Arg Lys 160 165 170 GAT CTC ATT GGA TTT GAG TTC ACG GTG CTT GTG GCT TTG GAA CTG GCC 577 Asp Leu He Gly Phe Glu Phe Thr Val Leu Val Ala Leu Glu Leu Ala 175 180 185 190 CTG TAC CTC CCG GAG AAC CAA GTA TTA CCT CAC TAC AGA CGC CTC ACC 625 Leu Tyr Leu Pro Glu Asn Gin Val Leu Pro His Tyr Arg Arg Leu Thr 195 200 205 CAG CAG TTC TAGCCCAGAA CAGTGCACCC CACAGGGAGC CTGCTTTGGC 674 Gin Gin Phe AGGAAGGCGA GTAGCTTGGC TAGAGCACTG ACTAGTAGTG TCCCTGTCCT TCCTCTAGTA 734 ACTGCACTTG CCCCTCAGTC CAGGGCTGCA CTTAGCTTCC CTTGGAAAGA GGCACTGCTC 794 TTATTTTGGA GTGTACCCCA TCTTCACCTT GAGGCCCTGT TGAGGGTTTT CCTGAAGCAA 854 ATGAACATCG TGGGGCTTGG TTTGCTTTTC ATGTGCCTGA GACCAGCCTG GTTTATGTTG 914 TCAATCCTGA GGTCCAGCTT TCATTTTGCC TAGCCATGAA ACCATTCCTG TAGAGACCTA 974 GGTGTCCAGA CCTTCTGAAC A ACTGGAAT TGCCAGGCTT CTGTCTCCTG GTGCCTCCAC 1034 CCAGGCAGAG CTCCCCCATC AGCACTTTTT TTTGGTCAAG ATGCAGGAAA GGGCAGTCTG 1094 CTCACACTGG ACCTTGTTAA AGCATCTGCC ACTGTGAAAC CCCTGTGCCA CCACATACAG 1154 TGTTTGGCCA ACACCACCAC CCACCCCAAC CCCTGCCTCC TGCCAGCACT TATCCCTGCG 1214 GTACTGGACC ATTTAAGACA ACCGCTGACT GCGGGCTCTT GACTTTCCTG AGCAATATCA 1274 TGATGGAGAA AAGGTATTAA CTTGAGATTT GGTTTCTATA ACAGAAAAGA CGGCCCATTA 133 AGGCCTGCTG CTGACTCTGC ACCACACTTG ATCCTCAAGC AGGAAGGTAC TGACCCTGCC 1394 ACCTAACAGC ACATCAGTGA CTCCTCACAA ATAGATGCCA TCCAGGCCAA CTTGCCTGTG 1454 TATTGACTGT GCCACTGTCT TCCTACTGGC ACCAGACAAG AGCCATCCTC CACCTTCCCA 1514 GGCCTGTTAT TCCCTACAAC TGGTCACCAG CCTGGCAGAT GCCAGTCCCA CTGCTCTCAA 1574 GTGCTTGGTT CCACAGCCAC TCATCCCAGA AATGCTTACC CTCTCAAGCC TGACACCACT 1634 CAACTACCTA ATGGATGTTA GTAGCTTAAA CAGAGACCTT GAAGGATAGT AGAAGGATAG 1694 TAAACTCTAG CCTTCTACCC TGCCCATGCT TATGCTGGTG TAAGCACGCT ATCCTTAGAG 1754 CACCTGGGTG CCATCTGCAG ACAGTGATGT CTTACTTAAA ATGAACTTTA GATACAGCTG 1814 ACTGGTCGGC TATCCCTGGG GGTGATACCC TGGTAGCTTA TTCTAGTTAT GTTAAAGCTG 1874 GCAACAGTGA TAATTTAAGC TTCTATATTT ATGATCTTAC CAAGCTGGTG TGCTGTTAGT 1934 CCTTCCCTCC TTGCCCTCAG TAATGCTAAG AGCTGCTGAC ATGTGGTATG ATAAGCACTG 1994 TTACAACAAA ACCAACCTTT AAACCAAATG ACAGGCTAAA CACAGTGTCT GTCCTAGACT 2054 AAGTCCAGAA ATCCGAGGTG TGCCCACGGT GTCCAGCTGG ACTGTGACCC AATGCCACAG 2114 ACCTGGTGCT GTACCTTCAG CACTCAACAG GCACAGCTGT GTGTGTGACC TCAGAATGCT 2174 GCTTATGTAT GTCCAGCCGG TTCTGAATGG AAGGTGTTAA ATGTTTTTGT TAAAAGTAAA 2234 ACTTGTTTTT GCAAAAAAAA AGTCGAC 2261 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 209 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: Ala Pro Pro Gly Ser Arg His Lys Pro Val Pro Thr Lys Ser Thr Pro 1 5 10 15 Ala Gly Thr Glu Leu Gly Ser Thr Gly Ser Asp Gly Gly Asp Ala Val 20 25 30 Glu Tyr Asn Pro Asn Leu Leu Asp Asp Pro Gin Trp Pro Cys Gly Lys 35 40 45 His Lys Arg Val Leu He Phe Ala Ser Tyr Met Thr Thr Val He Glu 50 55 60 Tyr Val Lys Pro Ala Asp Leu Lys Lys Asp Met Asn Glu Thr Phe Arg 65 70 75 80 Glu Lys Phe Pro His He Lys Leu Thr Leu Ser Lys He Arg Ser Leu 85 90 95 Lys Arg Glu Met Arg Asn Leu Ser Glu Glu Cys Ser Leu Glu Pro Val 100 105 110 Thr Val Ser Met Ala Tyr Val Tyr Phe Glu Lys Leu Ala Leu Gin Gly 115 120 125 Lys Leu Asn Lys Gin Asn Arg Lys Leu Cys Ala Gly Ala Cys Val Leu 130 135 140 Leu Ala Ala Lys He Ser Ser Asp Leu Arg Lys Ser Glu Val Lys Gin 145 150 155 160 Leu He Asp Lys Leu Glu Glu Arg Phe Arg Phe Asn Arg Lys Asp Leu 165 170 175 He Gly Phe Glu Phe Thr Val Leu Val Ala Leu Glu Leu Ala Leu Tyr 180 185 190 Leu Pro Glu Asn Gin Val Leu Pro His Tyr Arg Arg Leu Thr Gin Gin 195 200 205 Phe (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1538 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW044 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 24..1100 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (1161..1378) (D) OTHER INFORMATION: /label= SAC_24216 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: GTCGACCTCC ATAGAGTTCC GGC ATG AAG CCA CCG CAG AGA CGG CGG AAG 50 Met Lys Pro Pro Gin Arg Arg Arg Lys 1 5 GTC CCC GCA CGC TAC ACA GGT GAA GCT ACC GGC CCC ACA GCT TGG AGC 98 Val Pro Ala Arg Tyr Thr Gly Glu Ala Thr Gly Pro Thr Ala Trp Ser 10 15 20 25 CCC CGC GAG ATG CGG CAC CTA CTG AGA CTA CTC CAG GCT CGG CGC GGC 146 Pro Arg Glu Met Arg His Leu Leu Arg Leu Leu Gin Ala Arg Arg Gly 30 35 40 CAG CCG GAG CCA GAC GCC AAG GAG CTG GCC AAG GAG CTG CGA GGC CGG 194 Gin Pro Glu Pro Asp Ala Lys Glu Leu Ala Lys Glu Leu Arg Gly Arg 45 50 55 AGC GAG GCC GAG ATC TGT CGC TTT ATC CAG CAG CTC AAA GGC CGG GTG 242 Ser Glu Ala Glu He Cys Arg Phe He Gin Gin Leu Lys Gly Arg Val 60 65 70 GTT CGA GAG GCT ATT CGG AAG GTG CAA CCA GGT GGC AGA GAT GGT CCA 290 Val Arg Glu Ala He Arg Lys Val Gin Pro Gly Gly Arg Asp Gly Pro 75 80 85 AGG CAT CGA GAG ACA CAG CTC CCA GCC CCC ATA GAG GTA TGG ATG GAT 338 Arg His Arg Glu Thr Gin Leu Pro Ala Pro He Glu Val Trp Met Asp 90 95 100 105 CTT GCT GAG AAA TTA ACA GGC CCA CTG GAG GAA GCC CTG ACT GCA GCT 386 Leu Ala Glu Lys Leu Thr Gly Pro Leu Glu Glu Ala Leu Thr Ala Ala 110 115 120 TTC TCC CAG GTA CTC ACC ATT GCT GCT GCG GAA CCT CTC AGC CTC CTG 434 Phe Ser Gin Val Leu Thr He Ala Ala Ala Glu Pro Leu Ser Leu Leu 125 130 135 CAT TCC AAG CCA GGC AAG CCC ACA AAG GCC TGT GGA AGG GCA CTG GTG 482 His Ser Lys Pro Gly Lys Pro Thr Lys Ala Cys Gly Arg Ala Leu Val 140 145 150 TTC TTG AGC ACC CAA GAT GCG CAG AAG GAT TCT GCC CCT GAA GGT TCT 530 Phe Leu Ser Thr Gin Asp Ala Gin Lys Asp Ser Ala Pro Glu Gly Ser 155 160 165 GGG CCT GAA CCT ATG ACT GCT GCT GAC CCC ACT CCT GAG GCC TCT GTC 578 Gly Pro Glu Pro Met Thr Ala Ala Asp Pro Thr Pro Glu Ala Ser Val 170 175 180 185 CCT GAA CCT AAG GCC TCC GGT ACC AAC CCT GAG ACC TCT GGC CTT GTC 626 Pro Glu Pro Lys Ala Ser Gly Thr Asn Pro Glu Thr Ser Gly Leu Val 190 195 200 CCA GAG GTC TCT GTC CCT GAC CCT GAT GCA CCA ACT GAG TCC CTG GCT 674 Pro Glu Val Ser Val Pro Asp Pro Asp Ala Pro Thr Glu Ser Leu Ala 205 210 215 GGA TCC TCC ACA GAG AGA GAC TTT GCC GTG GAC TTT GAG AAG ATC TAC 722 Gly Ser Ser Thr Glu Arg Asp Phe Ala Val Asp Phe Glu Lys He Tyr 220 225 230 AAA TAC CTG TCC TCC TCC TCC AGA GGT GGC CAT GGC CCT GAG CTC TCA 770 Lys Tyr Leu Ser Ser Ser Ser Arg Gly Gly His Gly Pro Glu Leu Ser 235 240 245 GCA GTT GAG TCC GCC GTG GTC CTT AAC CTG CTC ATG TCA CTT GCA GAG 818 Ala Val Glu Ser Ala Val Val Leu Asn Leu Leu Met Ser Leu Ala Glu 250 255 260 265 GAA CTG CCC CAC CTG CCT TGC ACA GCC CTG GTG GAC CAT CTG ACT AAA 866 Glu Leu Pro His Leu Pro Cys Thr Ala Leu Val Asp His Leu Thr Lys 270 275 280 ACA TAT GCT CAA CTG ACG GCT CCC CAG GCC TCT CTC GAT AGA GAA AAG 914 Thr Tyr Ala Gin Leu Thr Ala Pro Gin Ala Ser Leu Asp Arg Glu Lys 285 290 295 AGG CCC AGG CCG GGG ACT GAA GAT GGA GGG ACT GAC TCC ACG GGG CCA 962 Arg Pro Arg Pro Gly Thr Glu Asp Gly Gly Thr Asp Ser Thr Gly Pro 300 305 310 GAA GAG ACT GGC CAA GGC AGT CCT CAA GCT TCT GAG CCC ACA GAA CCG 1010 Glu Glu Thr Gly Gin Gly Ser Pro Gin Ala Ser Glu Pro Thr Glu Pro 315 320 325 AGG CTG ACC TGG AAA GCA GCT GGG GTC TGC CCA CTG AAC CCA TTC CTG 1058 Arg Leu Thr Trp Lys Ala Ala Gly Val Cys Pro Leu Asn Pro Phe Leu 330 335 340 345 GTG CCC CTG GAC CTC CTG AGC CAG GCC CTC GCC CCT GCC AGG 1100 Val Pro Leu Asp Leu Leu Ser Gin Ala Leu Ala Pro Ala Arg 350 355 TGAAGGATGC AGCAGGCTGG CTATGCTGGT TTCTTTCTAC ATCGTCTGTC CAGCACTGGT 1160 ACTGGTGTCG GGAACGTGAT TGTGGCTTCC TGACAGTGTC CGGCCATAGG CAAGCCCTTC 1220 AGACACTGCA TGCACTAGTA GCCTGGAAAG TGAAGCACAG TTGAAGGAAG GGGTTTAACT 1280 ATTGGGGATT TGAGACTGCA CAAAGGCGGA ATTCCTGGGC TGGTAGATTG CGGCAAGTGT 1340 CCCTGGCCCC GCTGTGCCTG GTTCTCTGCC ATAAGAGTAC CACATCATCA TCCCTTTGTG 1400 CATGGCACTC GAACCCACCC CCAGCACACC CTCCCCACCT CAACTGACCA CTGTACCATC 1460 CTCTTCGCCC TTCTCTGGGT GTCCTGTGAC CCTCAATAAA GCTGTCATCT AACTAGCTGT 1520 GAAAAAAAAA AAGTCGAC 1538 (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 359 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: Met Lys Pro Pro Gin Arg Arg Arg Lys Val Pro Ala Arg Tyr Thr Gly 1 5 10 15 Glu Ala Thr Gly Pro Thr Ala Trp Ser Pro Arg Glu Met Arg His Leu 20 25 30 Leu Arg Leu Leu Gin Ala Arg Arg Gly Gin Pro Glu Pro Asp Ala Lys 35 40 45 Glu Leu Ala Lys Glu Leu Arg Gly Arg Ser Glu Ala Glu He Cys Arg 50 55 60 Phe He Gin Gin Leu Lys Gly Arg Val Val Arg Glu Ala He Arg Lys 65 70 75 80 Val Gin Pro Gly Gly Arg Asp Gly Pro Arg His Arg Glu Thr Gin Leu 85 90 95 Pro Ala Pro He Glu Val Trp Met Asp Leu Ala Glu Lys Leu Thr Gly 100 105 110 Pro Leu Glu Glu Ala Leu Thr Ala Ala Phe Ser Gin Val Leu Thr He 115 120 125 Ala Ala Ala Glu Pro Leu Ser Leu Leu His Ser Lys Pro Gly Lys Pro 130 135 140 Thr Lys Ala Cys Gly Arg Ala Leu Val Phe Leu Ser Thr Gin Asp Ala 145 150 155 160 Gin Lys Asp Ser Ala Pro Glu Gly Ser Gly Pro Glu Pro Met Thr Ala 165 170 175 Ala Asp Pro Thr Pro Glu Ala Ser Val Pro Glu Pro Lys Ala Ser Gly 180 185 190 Thr Asn Pro Glu Thr Ser Gly Leu Val Pro Glu Val Ser Val Pro Asp 195 200 205 Pro Asp Ala Pro Thr Glu Ser Leu Ala Gly Ser Ser Thr Glu Arg Asp 210 215 220 Phe Ala Val Asp Phe Glu Lys He Tyr Lys Tyr Leu Ser Ser Ser Ser 225 230 235 240 Arg Gly Gly His Gly Pro Glu Leu Ser Ala Val Glu Ser Ala Val Val 245 250 255 Leu Asn Leu Leu Met Ser Leu Ala Glu Glu Leu Pro His Leu Pro Cys 260 265 270 Thr Ala Leu Val Asp His Leu Thr Lys Thr Tyr Ala Gin Leu Thr Ala 275 280 285 Pro Gin Ala Ser Leu Asp Arg Glu Lys Arg Pro Arg Pro Gly Thr Glu 290 295 300 Asp Gly Gly Thr Asp Ser Thr Gly Pro Glu Glu Thr Gly Gin Gly Ser 305 310 315 320 Pro Gin Ala Ser Glu Pro Thr Glu Pro Arg Leu Thr Trp Lys Ala Ala 325 330 335 Gly Val Cys Pro Leu Asn Pro Phe Leu Val Pro Leu Asp Leu Leu Ser 340 345 350 Gin Ala Leu Ala Pro Ala Arg 355 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2277 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW045 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 9..1628 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1973..2134 (D) OTHER INFORMATION: /label= SAC_24028 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: GTCGACCA GGG CGT GAT GGC TCC TAC TAC CAG CTC TTT GTT CAT GGT GGC 50 Gly Arg Asp Gly Ser Tyr Tyr Gin Leu Phe Val His Gly Gly 1 5 10 96- SUBST1TUTE SHEET (RULE 26) CGC CTC CAG CCA GTC CTA AGG CAG AAA GCC TGC CGA GGC ATG AAC TGG 98 Arg Leu Gin Pro Val Leu Arg Gin Lys Ala Cys Arg Gly Met Asn Trp 15 20 25 30 ATA GCT GGG CTT CGG ATG GTG CCC GAT GGC AGT ATG GTC GTC TTG GGT 146 He Ala Gly Leu Arg Met Val Pro Asp Gly Ser Met Val Val Leu Gly 35 40 45 TTC CAT GCC AAC GAG TTT GTA GTG TGG AGC CCG CGG TCC CAT GAG AAG 194 Phe His Ala Asn Glu Phe Val Val Trp Ser Pro Arg Ser His Glu Lys 50 55 60 CTG CAC ATC GTC AAC TGC GGG GGA GGG CAC CGC TCC TGG GCC TTT TCT 242 Leu His He Val Asn Cys Gly Gly Gly His Arg Ser Trp Ala Phe Ser 65 70 75 GAT ACT GAG GCA GCC ATG GCC TTT GCC TAC CTT AAG GAT GGT GAT GTC 290 Asp Thr Glu Ala Ala Met Ala Phe Ala Tyr Leu Lys Asp Gly Asp Val 80 85 90 ATG CTC TAC CGG GCT CTA GGA GGC TGC ATC AGG CCA AAC GTG ATT CTC 338 Met Leu Tyr Arg Ala Leu Gly Gly Cys He Arg Pro Asn Val He Leu 95 100 105 110 CGG GAG GGT CTG CAT GGC CGG GAA ATC ACA TGT GTA AAG CGT GTG GGC 386 Arg Glu Gly Leu His Gly Arg Glu He Thr Cys Val Lys Arg Val Gly 115 120 125 ACT GTT ACC CTG GGC CCT GAA TTT GAG GTA CCC AAC TTG GAG CAT CCT 434 Thr Val Thr Leu Gly Pro Glu Phe Glu Val Pro Asn Leu Glu His Pro 130 135 140 GAC TCC CTG GAG CCT GGC AGT GAG GGG CCT GGT CTG ATT GAC ATC GTG 482 Asp Ser Leu Glu Pro Gly Ser Glu Gly Pro Gly Leu He Asp He Val 145 150 155 ATA ACA GGC AGT GAG GAC ACT ACT GTC TGT GTG CTA GCA CTT CCC ACC 530 He Thr Gly Ser Glu Asp Thr Thr Val Cys Val Leu Ala Leu Pro Thr 160 165 170 ACC ACA GGC GCA GCC CAC GCC CTC ACT GCT GTC TGT AAC CAT ATC TCC 578 Thr Thr Gly Ala Ala His Ala Leu Thr Ala Val Cys Asn His He Ser 175 180 185 190 TCC GTG CGA GCC CTG GCA GTG TGG GGT GTT GGC ACC CCA GGT GGC CCA 626 Ser Val Arg Ala Leu Ala Val Trp Gly Val Gly Thr Pro Gly Gly Pro 195 200 205 CAG GAT TCT CAC CCA GGG CTC ACG GCT CAG GTA GTG TCT GCA GGG GGT 674 Gin Asp Ser His Pro Gly Leu Thr Ala Gin Val Val Ser Ala Gly Gly 210 215 220 CGA GCC GAG ATG CAC TGC TTC AGC CTC ATG ATC ACT CCG GAT GCC AGC 722 Arg Ala Glu Met His Cys Phe Ser Leu Met He Thr Pro Asp Ala Ser 225 230 235 ACC CCA AGC CGC CTT GCC TGC CAC ATC ATG CAC CTT TCA TCC CAC CGG 770 Thr Pro Ser Arg Leu Ala Cys His He Met His Leu Ser Ser His Arg 240 245 250 CTA GAT GAG TAC TGG GAC CGG CAG CGC AAC CGG CAC CGG ATG ATC AAG 818 Leu Asp Glu Tyr Trp Asp Arg Gin Arg Asn Arg His Arg Met He Lys 255 260 265 270 GTG GAC CCT GAG ACC AGG TAC ATG TCT CTT GCC ATT TGT GAG CTT GAC 866 Val Asp Pro Glu Thr Arg Tyr Met Ser Leu Ala He Cys Glu Leu Asp 275 280 285 TCC GAT AGG CCT GGC CTT GGC CCC GGC CCC CTT GTG GCT GCA GCC TGT 914 Ser Asp Arg Pro Gly Leu Gly Pro Gly Pro Leu Val Ala Ala Ala Cys 290 295 300 AGT GAC GGG GCA GTG AGG CTT TTT CTC TTG CAG GAC TCT GGG CGA ATT 962 Ser Asp Gly Ala Val Arg Leu Phe Leu Leu Gin Asp Ser Gly Arg He 305 310 315 CTG CAT CTC CTT GCT GAG ACT TTC CAC CAT AAG CGG TGT GTC CTC AAG 1010 Leu His Leu Leu Ala Glu Thr Phe His His Lys Arg Cys Val Leu Lys 320 325 330 GTC CAT TCG TTC ACA CAT GAG GCA CCC AAC CAG CGT CGG AGG CTG ATC 1058 Val His Ser Phe Thr His Glu Ala Pro Asn Gin Arg Arg Arg Leu He 335 340 345 350 CTG TGC AGT GCA GCT ACA GAT GGC AGC ATA GCC TTC TGG GAT CTC ACC 1106 Leu Cys Ser Ala Ala Thr Asp Gly Ser He Ala Phe Trp Asp Leu Thr 355 360 365 ACG GCA ATG GAC CGA GGC TCT ACT ACC CTG GAG CCT CCA GCA CAC CCT 1154 Thr Ala Met Asp Arg Gly Ser Thr Thr Leu Glu Pro Pro Ala His Pro 370 375 380 GGG CTT CCC TAC CAG ATG GGC ACC CCC TGC CTG ACC GTC CAG GCC CAT 1202 Gly Leu Pro Tyr Gin Met Gly Thr Pro Cys Leu Thr Val Gin Ala His 385 390 395 AGC TGT GGT GTC AAC AGC CTG CAC ACT TTG CCT ACA CCT GAG GGC CAT 1250 Ser Cys Gly Val Asn Ser Leu His Thr Leu Pro Thr Pro Glu Gly His 400 405 410 CAT CTT GTG GCC AGT GGC AGT GAG GAC GGG TCC CTG CAT GTC TTC ACG 1298 His Leu Val Ala Ser Gly Ser Glu Asp Gly Ser Leu His Val Phe Thr 415 420 425 430 CTT GCT GTG AAG ATG CCA GAG CTG GAA GAG GCT GAT GGG GAG GCT GAG 1346 Leu Ala Val Lys Met Pro Glu Leu Glu Glu Ala Asp Gly Glu Ala Glu 435 440 445 TTG GTG CCC CAG TTA TGT GTC CTA GAT GAA TAT TCT GTC CCC TGT GCA 1394 Leu Val Pro Gin Leu Cys Val Leu Asp Glu Tyr Ser Val Pro Cys Ala 450 455 460 CAT GCT GCC CAT GTG ACG GGC ATC AAG ATC CTA AGT CCC AAG CTG ATG 1442 His Ala Ala His Val Thr Gly He Lys He Leu Ser Pro Lys Leu Met 465 470 475 GTC TCA GCC TCC ATA GAC CAA CGG CTG ACC TTC TGG CGT CTT GGA AAT 1490 Val Ser Ala Ser He Asp Gin Arg Leu Thr Phe Trp Arg Leu Gly Asn 480 485 490 GGT GAG CCC ACC TTC ATG AAT AGC ACT GTG TAC CAC GTG CCA GAT GTG 1538 Gly Glu Pro Thr Phe Met Asn Ser Thr Val Tyr His Val Pro Asp Val 495 500 505 510 GCT GAC ATG GAC TGC TGG CCT GTG AAC CCT GAG TTT GGC CAC CGC TGT 1586 Ala Asp Met Asp Cys Trp Pro Val Asn Pro Glu Phe Gly His Arg Cys 515 520 525 GCT CTT GCG GGT CAG GGA CTC GAG GTT TAC AAC TGG TAT GAC 1628 Ala Leu Ala Gly Gin Gly Leu Glu Val Tyr Asn Trp Tyr Asp 530 535 540 TGAGTTACCA CAGTAGTTGG AGGACTGAGC CTGGGGCTTG ACCACAGACA GCGGAGCAGG 1688 GATCAGCTGT CTGTGTCATG CTCTATGTGC TCTGAGGAGG TGAGGCAGTA CCATGGGTTC 1748 CTGTAGGGTG TTGCATAGGT GGACCAAGAA TATGCCTCAC TCTTCACAAT AGGATGAAAC 1808 TGTATTTATT CTGACTTTAA GTGCCCAACA TCTGTGAGGT TTCTGTGAGG TCTTGTTTTT 1868 TTCCCAGTTG ATGCTTTTAT AAACATTCCC AGCTATTGGG CCCTTAGATG TGGCTCAGCG 1928 GAGGGAGGCC CAGCATGGCC AAGCCTGTGT GGAACACCTC ACGTACTGCC CTCAAAAGCT 1988 GTAGGCGAGC AAACATCTGA CCAAAGAGGT GTGGCCGAGG TTCCTGAAAG AAAAGCAACC 2048 AGGCCCATCC TCATTTCCCG AGCCTGAGCC CTTGTCCATA TTTCCCACAG ACCCTCCCTT 2108 GCTGTATGCT CACCCCTAGA ATGTGTACGC GGTTATAGTA TGAGCTGAAA TCCATGCTGA 2168 GCTGCACCAG GAACTTGCAC ACCTAGAGAC AGAGGTTGGA TCGTTGAGCT GTTGTCTTTT 2228 TTCTTGTGTC ACAACCCAGA ATAAAGAATA GTGTGTGTAG TGTCAAAAA 2277 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 540 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: Gly Arg Asp Gly Ser Tyr Tyr Gin Leu Phe Val His Gly Gly Arg Leu 1 5 10 15 Gin Pro Val Leu Arg Gin Lys Ala Cys Arg Gly Met Asn Trp He Ala 20 25 30 Gly Leu Arg Met Val Pro Asp Gly Ser Met Val Val Leu Gly Phe His 35 40 45 Ala Asn Glu Phe Val Val Trp Ser Pro Arg Ser His Glu Lys Leu His 50 55 60 He Val Asn Cys Gly Gly Gly His Arg Ser Trp Ala Phe Ser Asp Thr 65 70 75 80 Glu Ala Ala Met Ala Phe Ala Tyr Leu Lys Asp Gly Asp Val Met Leu 85 90 95 Tyr Arg Ala Leu Gly Gly Cys He Arg Pro Asn Val He Leu Arg Glu 100 105 110 Gly Leu His Gly Arg Glu He Thr Cys Val Lys Arg Val Gly Thr Val 115 120 125 Thr Leu Gly Pro Glu Phe Glu Val Pro Asn Leu Glu His Pro Asp Ser 130 135 140 Leu Glu Pro Gly Ser Glu Gly Pro Gly Leu He Asp He Val He Thr 145 150 155 160 Gly Ser Glu Asp Thr Thr Val Cys Val Leu Ala Leu Pro Thr Thr Thr 165 170 175 Gly Ala Ala His Ala Leu Thr Ala Val Cys Asn His He Ser Ser Val 180 185 190 Arg Ala Leu Ala Val Trp Gly Val Gly Thr Pro Gly Gly Pro Gin Asp 195 200 205 Ser His Pro Gly Leu Thr Ala Gin Val Val Ser Ala Gly Gly Arg Ala 210 215 220 Glu Met His Cys Phe Ser Leu Met He Thr Pro Asp Ala Ser Thr Pro 225 230 235 240 Ser Arg Leu Ala Cys His He Met His Leu Ser Ser His Arg Leu Asp 245 250 255 Glu Tyr Trp Asp Arg Gin Arg Asn Arg His Arg Met He Lys Val Asp 260 265 270 Pro Glu Thr Arg Tyr Met Ser Leu Ala He Cys Glu Leu Asp Ser Asp 275 280 285 Arg Pro Gly Leu Gly Pro Gly Pro Leu Val Ala Ala Ala Cys Ser Asp 290 295 300 Gly Ala Val Arg Leu Phe Leu Leu Gin Asp Ser Gly Arg He Leu His 305 310 315 320 Leu Leu Ala Glu Thr Phe His His Lys Arg Cys Val Leu Lys Val His 325 330 335 Ser Phe Thr His Glu Ala Pro Asn Gin Arg Arg Arg Leu He Leu Cys 340 345 350 Ser Ala Ala Thr Asp Gly Ser He Ala Phe Trp Asp Leu Thr Thr Ala 355 360 365 Met Asp Arg Gly Ser Thr Thr Leu Glu Pro Pro Ala His Pro Gly Leu 370 375 380 Pro Tyr Gin Met Gly Thr Pro Cys Leu Thr Val Gin Ala His Ser Cys 385 390 395 400 Gly Val Asn Ser Leu His Thr Leu Pro Thr Pro Glu Gly His His Leu 405 410 415 Val Ala Ser Gly Ser Glu Asp Gly Ser Leu His Val Phe Thr Leu Ala 420 425 430 Val Lys Met Pro Glu Leu Glu Glu Ala Asp Gly Glu Ala Glu Leu Val 435 440 445 Pro Gin Leu Cys Val Leu Asp Glu Tyr Ser Val Pro Cys Ala His Ala 450 455 460 Ala His Val Thr Gly He Lys He Leu Ser Pro Lys Leu Met Val Ser 465 470 475 480 Ala Ser He Asp Gin Arg Leu Thr Phe Trp Arg Leu Gly Asn Gly Glu 485 490 495 Pro Thr Phe Met Asn Ser Thr Val Tyr His Val Pro Asp Val Ala Asp 500 505 510 Met Asp Cys Trp Pro Val Asn Pro Glu Phe Gly His Arg Cys Ala Leu 515 520 525 Ala Gly Gin Gly Leu Glu Val Tyr Asn Trp Tyr Asp 530 535 540 (2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2373 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW046 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 9..1160 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (1523..1760) (D) OTHER INFORMATION: /label= SAC_24036 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: GTCGACGT GAC TTC CTT GTC AGG TTC ACC CCC GCT GCA GCA GGG CTC TGC 50 Asp Phe Leu Val Arg Phe Thr Pro Ala Ala Ala Gly Leu Cys 1 5 10 TCT CTG ACT GAG TGG TGC TGT GTT ACA TGG ATC TGT CAT TTC TAT TCA 98 Ser Leu Thr Glu Trp Cys Cys Val Thr Trp He Cys His Phe Tyr Ser 15 20 25 30 GTC ATC AGT TGG CAT TGC AGT AAC ACC TAT GGC AAT GAA GAA AGA GAC 146 Val He Ser Trp His Cys Ser Asn Thr Tyr Gly Asn Glu Glu Arg Asp 35 40 45 AGA ATT TGG GAT TTT CAT CTA AGG AAA ATG ATA AAT AAC AAC CAG ACG 194 Arg He Trp Asp Phe His Leu Arg Lys Met He Asn Asn Asn Gin Thr 50 55 60 TGT GCT GCA GGG CAG GAC TCC GTG CCC TAC GTG ACC TGT ATG CTT CAC 242 Cys Ala Ala Gly Gin Asp Ser Val Pro Tyr Val Thr Cys Met Leu His 65 70 75 GTG CTG GAA GAG TGG TTG GGT GTG GAA CAG TTG GAG GAC TAC CTG AAT 290 Val Leu Glu Glu Trp Leu Gly Val Glu Gin Leu Glu Asp Tyr Leu Asn 80 85 90 TTT GCG AAC CAT CTC TTG TGG GTC TTC ACC CCG CTG ATC CTT TTA ATA 338 Phe Ala Asn His Leu Leu Trp Val Phe Thr Pro Leu He Leu Leu He 95 100 105 110 CTT CCG TAC TTT ACC ATC TTC CTT CTC TAC CTT ACT ATT ATT TTC CTC 386 Leu Pro Tyr Phe Thr He Phe Leu Leu Tyr Leu Thr He He Phe Leu 115 120 125 CAC ATC TAT AAG AGG AAG AAT GTG TTA AAA GAA GCC TAC TCT CAC AAC 434 His He Tyr Lys Arg Lys Asn Val Leu Lys Glu Ala Tyr Ser His Asn 130 135 140 TTG TGG GAT GGC GCG AGG AAA ACA GTG GCA ACC CTG TGG GAT GGA CAT 482 Leu Trp Asp Gly Ala Arg Lys Thr Val Ala Thr Leu Trp Asp Gly His 145 150 155 GCG GCG GTT TGG CAT GGT TAT GAA GTT CAC GGG ATG GAA AAG ATA CCA 530 Ala Ala Val Trp His Gly Tyr Glu Val His Gly Met Glu Lys He Pro 160 165 170 GAA GGA CCA GCA CTT ATA ATT TTT TAT CAT GGA GCT ATT CCC ATA GAC 578 Glu Gly Pro Ala Leu He He Phe Tyr His Gly Ala He Pro He Asp 175 180 185 190 TTT TAC TAC TTC ATG GCT AAA ATT TTC ATC CAC AAA GGC AGA ACT TGC 626 Phe Tyr Tyr Phe Met Ala Lys He Phe He His Lys Gly Arg Thr Cys 195 200 205 CGA GTG GTA GCT GAC CAC TTT GTC TTT AAA ATC CCA GGG TTC AGT TTA 674 Arg Val Val Ala Asp His Phe Val Phe Lys He Pro Gly Phe Ser Leu 210 215 220 TTA CTT GAT GTA TTT TGT GCT CTT CAT GGA CCA AGA GAA AAA TGT GTT 722 Leu Leu Asp Val Phe Cys Ala Leu His Gly Pro Arg Glu Lys Cys Val 225 230 235 GAA ATC TTG AGG AGT GGT CAC TTG TTA GCT ATT TCA CCG GGT GGA GTT 770 Glu He Leu Arg Ser Gly His Leu Leu Ala He Ser Pro Gly Gly Val 240 245 250 CGA GAA GCC TTA CTT AGT GAT GAA ACC TAC AAC ATC ATA TGG GGT AAT 818 Arg Glu Ala Leu Leu Ser Asp Glu Thr Tyr Asn He He Trp Gly Asn 255 260 265 270 CGT AAA GGC TTT GCT CAG GTT GCA ATC GAT GCA AAA GTG CCC ATT ATT 866 Arg Lys Gly Phe Ala Gin Val Ala He Asp Ala Lys Val Pro He He 275 280 285 CCT ATG TTT ACA CAA AAC ATC CGA GAA GGA TTT AGA TCA CTC GGA GGA 914 Pro Met Phe Thr Gin Asn He Arg Glu Gly Phe Arg Ser Leu Gly Gly 290 295 300 ACA AGA TTG TTT AAA TGG CTT TAT GAA AAA TTC CGC TAT CCG TTT GCT 962 Thr Arg Leu Phe Lys Trp Leu Tyr Glu Lys Phe Arg Tyr Pro Phe Ala 305 310 315 CCA ATG TAT GGA GGT TTT CCT GTG AAG TTG CGG ACC TTC TTG GGT GAT 1010 Pro Met Tyr Gly Gly Phe Pro Val Lys Leu Arg Thr Phe Leu Gly Asp 320 325 330 CCT ATT CCG TAT GAC CCA GAG GTA ACA GCA GAA GAA TTA GCT GAA AAG 1058 Pro He Pro Tyr Asp Pro Glu Val Thr Ala Glu Glu Leu Ala Glu Lys 335 340 345 350 ACT AAG AAC GCT GTT CAA GCT TTG ATC GAC AAG CAC CAA AGG ATA CCG 1106 Thr Lys Asn Ala Val Gin Ala Leu He Asp Lys His Gin Arg He Pro 355 360 365 GGG AAC ATT AGG AGT GCT TTG CTG GAC CGC TTT CAT AAA GAG CAG AAG 1154 Gly Asn He Arg Ser Ala Leu Leu Asp Arg Phe His Lys Glu Gin Lys 370 375 380 GCT AAT TGACAGATAA TTTCGTGTGT CTCTAATGCC AAGTTTGCAT CTGTGGTACT 1210 Ala Asn GCCTTTTAAA CTTTTGTAGG TTGTATAATA GTCTTTTTAA AACCTGCTAA TGAGCATCTT 1270 TCTTTAGAAT TTAAACTTTC TATGGTTAAT CTTACCCTTT CAATCAGTTT TGTCAAATGT 1330 AGTAAGTAAC TCACCATTTG CTTGACTCAG AAGATGATCA TGTTGCATTT GCAATCCTTA 1390 GTAGTATATG ATAGGCACAA GTCTTCCTGG ATAACAGCAG TCTAGGTTAG GCAGACTTCA 1450 CTAAATTATG CTTCTGTGTT TGTGTCTGTT GTGCCAATGG GATGGTGAGA GGTACCTGAG 1510 CTGGGGTGTA GCACTTGCTT AGTTTAGGTG AGCGGTGCCT TTGTATCCAT CCTTCATTCC 1570 ACTCACAACT GCTGGTAAGT TGTGGAACGC TTTTGCACCT CCGTGGTTTA TGTTAAGCAT 1630 GGTAATACTG TGGTGGTGAA CATTAAGTTG CTTATGTCTA CTGTGATATA TCCGTATCTA 1690 TATATCTGAT AGATATCTGT AGTGAGAAAT CTGTAATTGA ATTGATTCCT GAATCCTTTA 1750 GGAGTTATGT ACATTTTTGT CCATTGGGTA TTGAAATTAC TCCTTCAGGG ATGATGTCCA 1810 GTTGCCAAGC ACAATGAAAG AGATGTACTA TTTTGTAAAT CAAATCATTG TTACTTGTAG 1870 TATTTATTAA CAGAGTTGTT TGGTATTTAT TTTAAACAAG GATCTAAGTA AATGTATAGG 1930 ATGGATTGTC AGCACGTGTC TTACACGGTG TAAAGATAAA ATCGTGGGCA CGCTCTGCAG 1990 TTTATGTTAG AGCAGATCCT AGGCTGAGGA GTGACAACTG AGGAAGCTCT GCCTCGCTTA 2050 TCCCAGGGCT CGCTTCCGTG CTCTGCAGCC AGTCACGTGG TTATATCTGT AAAATGTACT 2110 TGAATGATGA ATTTCTGTAA ACATGGAGTC CTCTGAAAAT GTAATTACTT TGAATTGTTG 2170 TCTTCTTGAA AACTTATTTT AAAAGTATTT AAACAGCCAA GTATCATGAA TTCATCGCAG 2230 TGTGTCTTCC CCCTTTGCAG TACTTGGGTT TTATATGGAC TTTTTAACTA CAAGTGTATA 2290 TTTGTGATAT GTATAATGTA TGTATAATGT ATATAGAAAT GGTGTGAAAA TAAAGCTGAA 2350 CTGCAACTCC TCTCTAGTAA AAA 2373 (2) INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 384 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: Asp Phe Leu Val Arg Phe Thr Pro Ala Ala Ala Gly Leu Cys Ser Leu 1 5 10 15 Thr Glu Trp Cys Cys Val Thr Trp He Cys His Phe Tyr Ser Val He 20 25 30 Ser Trp His Cys Ser Asn Thr Tyr Gly Asn Glu Glu Arg Asp Arg He 35 40 45 Trp Asp Phe His Leu Arg Lys Met He Asn Asn Asn Gin Thr Cys Ala 50 55 60 Ala Gly Gin Asp Ser Val Pro Tyr Val Thr Cys Met Leu His Val Leu 65 70 75 80 Glu Glu Trp Leu Gly Val Glu Gin Leu Glu Asp Tyr Leu Asn Phe Ala 85 90 95 Asn His Leu Leu Trp Val Phe Thr Pro Leu He Leu Leu He Leu Pro 100 105 110 Tyr Phe Thr He Phe Leu Leu Tyr Leu Thr He He Phe Leu His He 115 120 125 Tyr Lys Arg Lys Asn Val Leu Lys Glu Ala Tyr Ser His Asn Leu Trp 130 135 140 Asp Gly Ala Arg Lys Thr Val Ala Thr Leu Trp Asp Gly His Ala Ala 145 150 155 160 Val Trp His Gly Tyr Glu Val His Gly Met Glu Lys He Pro Glu Gly 165 170 175 Pro Ala Leu He He Phe Tyr His Gly Ala He Pro He Asp Phe Tyr 180 185 190 Tyr Phe Met Ala Lys He Phe He His Lys Gly Arg Thr Cys Arg Val 195 200 205 Val Ala Asp His Phe Val Phe Lys He Pro Gly Phe Ser Leu Leu Leu 210 215 220 Asp Val Phe Cys Ala Leu His Gly Pro Arg Glu Lys Cys Val Glu He 225 230 235 240 Leu Arg Ser Gly His Leu Leu Ala He Ser Pro Gly Gly Val Arg Glu 245 250 255 Ala Leu Leu Ser Asp Glu Thr Tyr Asn He He Trp Gly Asn Arg Lys 260 265 270 Gly Phe Ala Gin Val Ala He Asp Ala Lys Val Pro He He Pro Met 275 280 285 Phe Thr Gin Asn He Arg Glu Gly Phe Arg Ser Leu Gly Gly Thr Arg 290 295 300 Leu Phe Lys Trp Leu Tyr Glu Lys Phe Arg Tyr Pro Phe Ala Pro Met 305 310 315 320 Tyr Gly Gly Phe Pro Val Lys Leu Arg Thr Phe Leu Gly Asp Pro He 325 330 335 Pro Tyr Asp Pro Glu Val Thr Ala Glu Glu Leu Ala Glu Lys Thr Lys 340 345 350 Asn Ala Val Gin Ala Leu He Asp Lys His Gin Arg He Pro Gly Asn 355 360 365 He Arg Ser Ala Leu Leu Asp Arg Phe His Lys Glu Gin Lys Ala Asn 370 375 380 (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2241 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW047 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 8..511 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (1675..1833) (D) OTHER INFORMATION: /label= SAC_23915 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39: GTCGACC AGG GCC TTC CAT CAG ACC TGC CCA AAC TTT GTC ATA GAG AAG 49 Arg Ala Phe His Gin Thr Cys Pro Asn Phe Val He Glu Lys 1 5 10 ATT GAA AGG ATT CAA AAT CCA GCT CTT TGG AGG AGG TAC CAG GCG TAC 97 He Glu Arg He Gin Asn Pro Ala Leu Trp Arg Arg Tyr Gin Ala Tyr 15 20 25 30 AAA AAA ATT ATG GAT GAA AAG AAT GGC AAT GTG ATA AAT GAG AAG CAA 145 Lys Lys He Met Asp Glu Lys Asn Gly Asn Val He Asn Glu Lys Gin 35 40 45 CTC TTC CAT GGG ACG GAG TTT GGC TCT CTG GCA CAG CTC AAC AGT AAT 193 Leu Phe His Gly Thr Glu Phe Gly Ser Leu Ala Gin Leu Asn Ser Asn 50 55 60 GGA TTT AAC CGC AGC TAT GCT GGG AAG AAC GCT ACG GCT TAT GGG AAA 241 Gly Phe Asn Arg Ser Tyr Ala Gly Lys Asn Ala Thr Ala Tyr Gly Lys 65 70 75 GGA ACC TAT TTT GCA GTC AAT GCT TCC TAT TCT GCC CAT GAC ACA TAT 289 Gly Thr Tyr Phe Ala Val Asn Ala Ser Tyr Ser Ala His Asp Thr Tyr 80 85 90 TCC AAA CCA GAT GCC AAT GGG AAA AAG TAT ATG TAT TAT GTG CGG GTC 337 Ser Lys Pro Asp Ala Asn Gly Lys Lys Tyr Met Tyr Tyr Val Arg Val 95 100 105 110 CTC ACT GGA AAC TAC ACA CAA GGA AAC GCA TCA CTG ATT GTG CCT CCT 385 Leu Thr Gly Asn Tyr Thr Gin Gly Asn Ala Ser Leu He Val Pro Pro 115 120 125 TCA AGG GAC CCT CAA AAT GCT ACT GAC TTG TTT GAC ACT GTC GCA GAT 433 Ser Arg Asp Pro Gin Asn Ala Thr Asp Leu Phe Asp Thr Val Ala Asp 130 135 140 AAT GTT ATA AAT CCG AGT ATA TTT GTA GTG TTT TAT GAC AAT CAA GCA 481 Asn Val He Asn Pro Ser He Phe Val Val Phe Tyr Asp Asn Gin Ala 145 150 155 TAC CCT GAG TAT CTT ATC ACA TTT AGG AAG TAACACTTTG GGGTGCCTTC 531 Tyr Pro Glu Tyr Leu He Thr Phe Arg Lys 160 165 TGAAAGACAT TGGTATCTGC CGTAGGACAA ATTTTAGCTG TTTTCCTTCT TAGACTTTCT 591 TCTCTAAGAG CACGAGGTCT TTCTCTGCCA CGGATTGTTT CCTCAGCTGC CCCTTCATAG 651 TGAACATGAA CCTACTTGAG GGCCAACCAC .TTGAGAATTT CAAGCAGGTG ACAGCTTTAG 711 CTGCCTTCAC AAATGTGAAC CTCAAATCCA CGGAAAAGAA CAAACTTACG TTCTGGAAGG 771 ACAATAAAAC CTTTATGCAC TTTCAGAAAG CCCACAATAC ACCCACCACC AGTGGAGTTA 831 CATCAGAGCA CCACTGTGCT GAGGGGCACC CAGGACCACT GAGCCAGTAA GGCTGCCAAC 891 TGAACAGATT CCAAGACAGA GAACTTCGTT CATCACTAAC AGCGCCGTGT CCTGTGGGTT 951 GGACAGTTCC AGCCAGGGTT ATGTACAGAC TGGGTTCTGG GATGTGGCTC TGGGTCTGTG 1011 TGAACTGAGC CCCCCAAGGA GAGGCACAGC TGAAGCCCTG TCAGGGGGCC CTTTTAATGT 1071 TGACACCAAT GTTGAGGCTA CCTAGTGAAG AAATGGGATG GGGCCTGCTA CCTCTCCTGT 1131 GGAAGTCCTT CTACTGGGTG AAAATGAATG AACTCTAACA GTATTGGCTA GCGTCTTTCT 1191 TGTGGCAGGC TGGCTTGTGA TAACTTGAAG CTTTATGACT AAGTCAGTCA TTTTGCTAAC 1251 TCACTAACAG TATCTACTGG ATGCGATTTG TTTCTTGTGA TGCCAGAGAT CACCCAGAGC 1311 CTCACATGGG CCAGGCAAGC ACTCTACTAC TGAACTATAT TCCCAGCCTC TTAGTGAGGC 1371 AAGACTCCAC TAAGTTGCCC TGGCAGGTTT GAACTCATTA TCTTCCTGCA TTGGCTACTT 1431 ATTGGGGTGG GGTGGGGTGC TTAAATTGTT CTTTTAATTT TCTCCTGTAC TCCCATTTAT 1491 TGAGTGCCTG GACCCTTGTC AGGTAGAATA AGAGGTGTGT TCACATAGAT AATTTTGTTT 1551 CCATAAAAAA AAATGCACTG TAAGAATTAT GTCAAGGCCT AGGAGCAGGC TCAGAGTACA 1611 AGAGCTGTCC TTGCCAAAGG TCACTAAGGC AGGAACCGCA GAGCCAGCCA CCAGAGTCTT 1671 GGTACTGGGT TGAGCCCCTC ACTATTCCCA GCACAGGGCC TGGCCCTGAG GTAAGCCTGT 1731 GCTGCTTCAG AAGTTGGCTT TTCTCCTTCT GGGATTGGTG TCCACTCTGC CCCTTTTCTA 1791 GGTCATGGAG CTAGTGCGGT GTAATGTTCC CAGGAGGTAG GTACACTCTT AGGTGTTGTG 1851 GGGATCCAAG TGCTGGTTCC CACCATTGGC ATTAACAGTG GACTGCAAGC AGAGAGAGGG 1911 GTCCCCATCA TTGTTTCGTG GACACTGAGG CCTTGAGACC TTGGCTGCTG TGTCTATGTG 1971 GACTGGCAAA GACTGTGGCT TGGGAGGGGC TTCCTCAGCA CTGGCACCTG AACTCAGCAC 2031 CAAGGATGGC CCCAAGAGGC TTGTTTTCAT TTGCCTTTGT TCTCCAGTGC TTTGGTTACC 2091 TCAGGGCAGG GCTGAACAAT AGTGTGATGT TACATTGAAG AATAAAGACC CAACCAACAA 2151 ATGTTAGTGT CATTTTCAGT CTAAGTAAAT AAGCCATTAT GTCATTTCCC TTACTTCCTA 2211 GTAAAGTTAT GTAATTACAT AATGTAAAAA 2241 (2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 168 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40: Arg Ala Phe His Gin Thr Cys Pro Asn Phe Val He Glu Lys He Glu 1 5 10 15 Arg He Gin Asn Pro Ala Leu Trp Arg Arg Tyr Gin Ala Tyr Lys Lys 20 25 30 He Met Asp Glu Lys Asn Gly Asn Val He Asn Glu Lys Gin Leu Phe 35 40 45 His Gly Thr Glu Phe Gly Ser Leu Ala Gin Leu Asn Ser Asn Gly Phe 50 55 60 Asn Arg Ser Tyr Ala Gly Lys Asn Ala Thr Ala Tyr Gly Lys Gly Thr 65 70 75 80 Tyr Phe Ala Val Asn Ala Ser Tyr Ser Ala His Asp Thr Tyr Ser Lys 85 90 95 Pro Asp Ala Asn Gly Lys Lys Tyr Met Tyr Tyr Val Arg Val Leu Thr 100 105 110 Gly Asn Tyr Thr Gin Gly Asn Ala Ser Leu He Val Pro Pro Ser Arg 115 120 125 Asp Pro Gin Asn Ala Thr Asp Leu Phe Asp Thr Val Ala Asp Asn Val 130 135 140 He Asn Pro Ser He Phe Val Val Phe Tyr Asp Asn Gin Ala Tyr Pro 145 150 155 160 Glu Tyr Leu He Thr Phe Arg Lys 165 (2) INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1918 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW049 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (1289..1612) (D) OTHER INFORMATION: /label= SAC_24337 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41: GTCGACGTGG TGATTATCTT AAAGGTAAGG GAGGTTTTTT TTTCCCTGAT ACTGATGAAG 60 GCTGAGTGTG ACTGTTTAGT ATAGCTAGTG GGCTTTGTCA CTTAAGCCTT CCTTAGCATG 120 TTCCCTTTCC CTTATTTTTC CTGGATACTT ACGTGCTAAC GTGCTAACAA CTCCAGATCA 180 AACTGAGTAT GGAGATTTTT GCTTTAACAA TTTAGGAGTG GCAAACAATT TATAACTGGC 240 AGGGTTTGAG GACAGCCGTG TTGAAAAACC AAAAGAAAAT GCTAAGGCAG GTCTTGACCA 300 ATGTGGATAC TTTGACTAAT TAACTTCGTT ACTTTAGGAG GAGGTTGTTC CTGCACGCCA 360 TCCATCTCCA GCGTTCGAAG GTTAGATTGT TGGGGTGGTG TGTCTTGTTC ACCAGATTGG 420 CTGTTTCTGT GATGAATCAA CTAGCTCACT ATGACTGCTA ATGAAAACAC TGGAACACCT 480 GAGAAACTGA AGGGTGGCGT GTTGGGGCAA GGGTGCTTAC ATATCAAGCC TTTTCAATAG 540 TTTGTTTTTC TCCAGGTTCT GTTAGCAGTG CTGTTACTTG GTGCTTCAGA GGTAAGTAAT 600 TGCAGCCAGC GTGCAGTGGT GTGCACACTG CTGGACTCAG GTCCTAAGTA CTTCATATAT 660 ATGATGACTT TCATAGAATC TCGTTCGGCT GATGATTGCT GTTGAGACTT GGAAATCTGA 720 TTTTTCTGAG GATGATGGGT TGGATGGGAA CAATCTGCCA GGATTTTTAA CATTGCCCAT 780 CTCGTGTGTT TCAGATATGG TGACTGGCCG AGCGCAAAGG AGCCATGCCA GGTAAATGTT 840 CTAGCAATAT TATTGTTTAT TAGGTAGATA CGTAATGGCT TGATCCAGTG CTTTCCTGCT 900 CACCCTGATG AACTGAATAC CGCCCCAGTC TGATAGCTGT GGAGAAAGGT ATTTTCTGAG 960 TTGAGCTCAT CTTGGATCAA ACAGGAAGGG TTTTATGCTA GTTAGTATAT GATCTCTGTA 1020 GGATACGTTT AGGCAATAAG GATAATGACC CAAATTTATT TACTGTTTTG CAGGAAAACT 1080 AAGAGCACAT CTTCATAAAG TCCAGGCTAA AGTAAGGTGA GAAAACTAAG ATGTAAAGTG 1140 TACCAAGTTA GTAACTTCCC TATGAAGAAA CATTCACACG TCTTACTTCC TGTCCTAGCT 1200 CCAGAGCCTG AAAAGGTGAA CCCACTGGGG CTGGCTGGGG GAAAAGAGGA AATTTTGTTC 1260 CAGAAGGAAC TGTCTGAGGG ATCATTTGTA TGTGTGGAAA GGGAAGAATT AAACTTTGAT 1320 TAAAAAGGAA ACAAGGTGGT TTGTCTGTTT TTCAGGTCTG AGGAGAGGGA TGAGGTGTGT 1380 GTTAGAGGTA GGTAGCCCTT CAAGTCATTG TAATTAGGTG GGCAGGGTAG ATTTTGCTTT 1440 CTGCTAATTA AAACTTTTAC CTTACAGGAA CTGAAATCAA AGATCCGATT ACCTAGGCCA 1500 GTGGCACGGC AAACTTCAGA ACTCATGGAA TACAGCCTGT TGATTCCTTG TGGATTTTTA 1560 GCATCTGAGC AGTATCAGTG GCACTCCAAG TGAAATGGTT GATCTCTTCA GTACCGCTGG 1620 AGCAGATTAA TATTTATTTC ACTGCCAGAG GCTATATTTC TCTGCCCCCC CATACCCCCT 1680 TCCTCTTCTC CTTAGACTAC TTAAGATTGA AATATTTGCA ACTCCAAATT TATCTTCCTT 1740 GCTTACCACT TTTTTTTCCG AGCTGGGGAC CAAACCCAGG GCCTTGCGCT TCCTAGGTAA 1800 GCGCTCTATC ACTGAGCTAA ATCCCCAGCC CCGCTTACCA CATTGTTAAT CTGATCCTTC 1860 CGCAGTTATT TGTGCTGTTC TTTTTGTTCC TGGCAATAAA TGCTTTTTAT GCTAAAAA 1918 (2) INFORMATION FOR SEQ ID NO: 42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3942 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW050 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 7..1326 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (3542.-3733) (D) OTHER INFORMATION: /label= SAC_24644 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42: GTCGAC ATA AAT ATG GCC GTC CGG GTA CCC CTC GGC TGC ACG GGC TCC 48 He Asn Met Ala Val Arg Val Pro Leu Gly Cys Thr Gly Ser 1 5 10 TTC TGC CCG CGG CTG CTA CCA CTG CTG GCA TTG TTG GAG CTG CTC GTC 96 Phe Cys Pro Arg Leu Leu Pro Leu Leu Ala Leu Leu Glu Leu Leu Val 15 20 25 30 GAC CCC AGC TTG GGC CGC GTC CAT CAC CTG GCG CTC AAA GAT GAC GTG 144 Asp Pro Ser Leu Gly Arg Val His His Leu Ala Leu Lys Asp Asp Val 35 40 45 CGG CAC AAA GTC CAT CTC AAC ACC TTC GGC TTC TTC AAG GAC GGG TAC 192 Arg His Lys Val His Leu Asn Thr Phe Gly Phe Phe Lys Asp Gly Tyr 50 55 60 ATG GTG GTC AAC ATC AGC AGC CTC TCT GTG AAC GAG CCT GAG GGA GTC 240 Met Val Val Asn He Ser Ser Leu Ser Val Asn Glu Pro Glu Gly Val 65 70 75 AAG GAC AAA GAC ACT GAG ATT GGC TTC AGT CTT GAT CGG ACC AAG AAT 288 Lys Asp Lys Asp Thr Glu He Gly Phe Ser Leu Asp Arg Thr Lys Asn 80 85 90 GAT GGC TTT TCT TCT TAC CTG GAT GAA GAT GTG AAT TAC TGT ATT TTA 336 Asp Gly Phe Ser Ser Tyr Leu Asp Glu Asp Val Asn Tyr Cys He Leu 95 100 105 110 AAA AAA AAG TCC ATG TCT TCT GTC ACT CTG CTC ATC TTA GAC ATC TCC 384 Lys Lys Lys Ser Met Ser Ser Val Thr Leu Leu He Leu Asp He Ser 115 120 125 GGA AGT GGA GTC AAG GTC AGA TCC CCA CCA GAA GCT GGC AAG CAG TTA 432 Gly Ser Gly Val Lys Val Arg Ser Pro Pro Glu Ala Gly Lys Gin Leu 130 135 140 CCC GAG ATT GTC TTC AGC AAG GAT GAG AAA GTC CCG AGT CGG AGC CAG 480 Pro Glu He Val Phe Ser Lys Asp Glu Lys Val Pro Ser Arg Ser Gin 145 150 155 GAG CCT GCT GTC AGC TCC AAC CCC AAA GAC AGC AAG GTG CAG AGA ACC 528 Glu Pro Ala Val Ser Ser Asn Pro Lys Asp Ser Lys Val Gin Arg Thr 160 165 170 CCT GAT GGT TCC AAG GCT CAA CGA AGT ACA GTG GAT TCA AAG ACT ATA 576 Pro Asp Gly Ser Lys Ala Gin Arg Ser Thr Val Asp Ser Lys Thr He 175 180 185 190 GCA GAG AAA TTC TTC TCA ATT CAT AAG AAT GAT GGG GCA GTT TCA TTT 624 Ala Glu Lys Phe Phe Ser He His Lys Asn Asp Gly Ala Val Ser Phe 195 200 205 CAG TTC TTC TTT AAC ATC AGC ACC AGT GAC CAG GAA GGC CTC TAC AGC 672 Gin Phe Phe Phe Asn He Ser Thr Ser Asp Gin Glu Gly Leu Tyr Ser 210 215 220 CTT TAC TTC CAC AAG TGC CCA AGC AGC AAG CTG AGG TCT GGT GAG CAG 720 Leu Tyr Phe His Lys Cys Pro Ser Ser Lys Leu Arg Ser Gly Glu Gin 225 230 235 GTC TCA TTC AGC CTA AAT ATT GAT ATC ACC GAG AAG AAT CCT GAC AGC 768 Val Ser Phe Ser Leu Asn He Asp He Thr Glu Lys Asn Pro Asp Ser 240 245 250 TAC CTG TCT GCA GGG GAA ATC CCT CTC CCC AAG TTA TAC GTT TCC ATG 816 Tyr Leu Ser Ala Gly Glu He Pro Leu Pro Lys Leu Tyr Val Ser Met 255 260 265 270 GCC TTG TTG TTC TTC CTG TCT GGG ACC GTG TGG ATT CAC ATC CTT CGT 864 Ala Leu Leu Phe Phe Leu Ser Gly Thr Val Trp He His He Leu Arg 275 280 285 AAA CGA AGG AAT GAT GTA TTT AAA ATT CAC TGG TTG ATG GCG GCC CTT 912 Lys Arg Arg Asn Asp Val Phe Lys He His Trp Leu Met Ala Ala Leu 290 295 300 CCT TTC ACC AAG TCT CTC TCC TTG GTG TTC CAT GCA ATC GAC TAC CAC 960 Pro Phe Thr Lys Ser Leu Ser Leu Val Phe His Ala He Asp Tyr His 305 310 315 TAC ATC TCC TCG CAG GGC TTT CCG ATT GAA GGC TGG GCT GTT GTG TAC 1008 Tyr He Ser Ser Gin Gly Phe Pro He Glu Gly Trp Ala Val Val Tyr 320 325 330 TAC ATA ACT CAC CTG CTG AAG GGT GCA CTG CTG TTC ATC ACC ATC GCC 1056 Tyr He Thr His Leu Leu Lys Gly Ala Leu Leu Phe He Thr He Ala 335 340 345 350 CTC ATT GGC ACT GGC TGG GCC TTC ATC AAG CAC ATC CTG TCT GAT AAG 1104 Leu He Gly Thr Gly Trp Ala Phe He Lys His He Leu Ser Asp Lys 355 360 365 GAC AAG AAG ATC TTC ATG ATT GTC ATT CCG CTC CAG GTA CTG GCG AAT 1152 Asp Lys Lys He Phe Met He Val He Pro Leu Gin Val Leu Ala Asn 370 375 380 GTG GCC TAC ATC ATC ATA GAG TCT ACT GAG GAG GGC ACA ACT GAG TAT 1200 Val Ala Tyr He He He Glu Ser Thr Glu Glu Gly Thr Thr Glu Tyr 385 390 395 GGC TTG TGG AAG GAC TCT CTA TTC CTG GTG GAT TTG CTG TGC TGC GGC 1248 Gly Leu Trp Lys Asp Ser Leu Phe Leu Val Asp Leu Leu Cys Cys Gly 400 405 410 GCC ATC CTC TTC CCA GTG GTG TGG TCA ATC AGG CAT TTA CAA GAA GCC 1296 Ala He Leu Phe Pro Val Val Trp Ser He Arg His Leu Gin Glu Ala 415 420 425 430 TCG GCC ACA GAT GGA AAG CTG CCA TTA ACC TAGCAAAGCT GAAGCTTTTC 1346 Ser Ala Thr Asp Gly Lys Leu Pro Leu Thr 435 440 AGACATTACT ACGTCCTGAT CGTGTGCTAC ATCTACTTCA CCAGGATCAT CGCCTTTCTT 1406 CTCAAGTTCG CTGTTCCCTT CCAGTGGAAG TGGCTCTACC AGCTGCTGGA TGAAACAGCC 1466 ACACTGGTGT TCTTTGTCCT GACGGGGTAT AAATTTCGCC CAGCTTCAGA TAACCCCTAC 1526 CTGCAGCTCT CTCAGGAAGA AGATGACCTG GAGATGGAGT CTGTAGTGAC GACGTCAGGA 1586 GTAATGGAGA ACATGAAGAA GGTGAAGAAA GTGAGCAATG GTGCTGTGGA GCCCCAGGGC 1646 AGCTGGGAAG GCACCGCGTG ACAGCGCAGC TGAGGACCGC AGGCCGTCAA TGAACCTAGC 1706 TTATCCATAG CCCTATCAGT GAGCACGCCT GTTCCTGACA GACGATGGCA TCTCCCAGCA 1766 GCGACACCCC GGCGCTCAGC ACCATGGCCG AGCCGAGTGC TATGGACACA CACTTTTGTA 1826 CTCTTAGGGA TCTGGATTGA GGTGGGCTAC AGGCAGTGAG GACTGCCCTC AGTGAGGGCG 1886 GAGGCTTAGA GGAGGAGTAA AGACTGTCTG TCTGATTTAC CTTGCTAATT GGGAGCCTGG 1946 GTCTGTGCAG GGGAGCCCCC AGTGGCTGCT ACTCAGAAAG GCTGTGGGTG TGGCACGGGT 2006 CTGCCACTCG CTGGTCACAG TTCTGTGGAG GCTGGGAGGA TGTGACTCAC TGCTTGGCCT 2066 AGCATTTACG AGGCTTTGGG TTCAATTCCT AGTGCCAGGG TGGGGGGAAA AGAAGTTACT 2126 TTGGGACTAG TCAGGTATCT ACCAAGGGCA CAGAGAAGAG AAAGAGATTG TCAGCCTTTG 2186 GGAACAAGAA CAACAGAAAT GATTGAAATT CTTTTAAATA GCCAATAAAC CCCTAGGTGG 2246 CAGAAGACAC CTGTCCAGGG TCACTGGCCC CCAGGCACCA CTCTAAATGT CCCTGCCCCT 2306 GATGTGACCT ACAACAGTGG TGCTAGAGGC CAGAGGGAGG GAGGGAGGGG GCCTGTTACA 2366 TGGCTGGCTG CAGGGGAGAA GAGCCTTGGC TCTCCAGAAG TGTTCTCCAG TTGGCTCTCA 2426 GGACTCCATC CCCTGGCTGC CTGCCCAGAG CAGCCGCCTG GCTTCCTCTC CTTCCACCTG 2486 TGTCTTCTGA TCCGAGAAAA CAGTTTTCCT GAAGGAGCAG CCGAGGACAG AAAGGGTAGT 2546 CTCTAAACAA ACACTTAGGT TAAGCATCTT CCACAGCTCG CATGGGCCAG GCAGGACCTC 2606 TGAGCCTCAG CTATAGTCCA AGCATGCGTG AAGGAAGTGT TTGAGCCACT CATGCTCAGA 2666 GACCTGAGGC AGCCGGGTCT GCTCAGAGCT TGGACAGGGA CACCAGCGGC ACCTGCGGAA 2726 GGCCTGTGAG GGGCCACAGG AGACCAGCTC AGCACCTCAG AGCTGCTGCC TGCCCAGAAC 2786 TGGCGGGCGA GTTGCACCTT CAAGGAACAG GCACTTCCGG GAGGGGGGTG AGTTACTCCA 2846 CCTCCCAGTG CAGAAGACAA AGGTCTGGTC TCCACACCAC ACCCCAAGTC CCTGTCCTGT 2906 GCCACCAGTG AGAAGCTGCT GTCTGCTGCC CTAGCAGGTC CGTCACTACC GCAGGTGCTC 2966 CATCTTGAGA AAGGTCGACA GGCCTGAAGG ATCCACCTAA AGGACCTTTT TCTCCTGTTT 3026 TGTTTGCTTT GTTTATACTT GTTTAAAGTA TGTGGTGGGA AGGGAGTGTC GAGGAGACAA 3086 GGTGTTAATG CTTTGTCTTC TGCACATAAG CACTCCTCCA GCACTGCAGA AGTGTGTCCC 3146 TGTGGTGACT CTAAGCCACA GCTGTCCCTC AGAGGGCGCG ATCTTTATGG AAGGAGCCTC 3206 CTTTCACTTG CTGGGTTTTA ATAAGGCCAC TCTGACAGAG AGCAGAGGGA GCTGTGTACA 3266 ACCCAGCCAC AGAGCTCTCT GGGTGCACAG CTGAGCGGCT ATGGGAGACA GCCCGCTCCT 3326 TCCAGAGCAT GGGTGCACAG GCAGGGAGGT GTGCTACAGC AGCGGCCCTC CCAAGTCCTG 3386 CCCTGTGACT GCTGTAGGTG GGAAGCCAGG CATGTTGGGG GTTGTGGTGG GGAGGGGGGA 3446 TCAGAAGCCT AACATGGGGC TGGGAAGAAC TGGCCTGGTG CCCAGGCTGT GGAAAGGAAA 3506 ACTCCCAGCC CTCAGCATGC ACTGTAAGGT GTCTGTCTCA TCTGCATCGC TTGAGAGCTG 3566 GGAGCCCGCA TTCAGCAGTG TCCTTGGGTA GAGGAGTCTG ATTGGCATCC AGCCGCCCCA 3626 GTTCATGAGC TGCCCTCTGC AGCCTTGAGT CTTAGCCTAC CCAGCTCCAC AACCGTGTTT 3686 GAGTGGTGAA GCCCTTGTGT TGGAGGGGCT GAGCAGAAAT GGGGTGTACA TTGCACTGCC 3746 ACTGTGGTAT TAATAGCTCT GTGTTGTGTC CCCACCCCCA CCCCCCATCT TCTGCCTGCG 3806 TGAGGTATCC ATACTTGTTT TGAGAGTGCT GTGGACTGGA AGCTGTGGGC TGTGACATTT 3866 AATAAAGTGT GGATTTTGTT AGATAATTAT TTCTTGGACA ACAGGAACAA GTGTTCAGCT 3926 CTGAAAAAAA GTCGAC 3942 (2) INFORMATION FOR SEQ ID NO: 43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 440 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43: He Asn Met Ala Val Arg Val Pro Leu Gly Cys Thr Gly Ser Phe Cys 1 5 10 15 Pro Arg Leu Leu Pro Leu Leu Ala Leu Leu Glu Leu Leu Val Asp Pro 20 25 30 Ser Leu Gly Arg Val His His Leu Ala Leu Lys Asp Asp Val Arg His 35 40 45 Lys Val His Leu Asn Thr Phe Gly Phe Phe Lys Asp Gly Tyr Met Val 50 55 60 Val Asn He Ser Ser Leu Ser Val Asn Glu Pro Glu Gly Val Lys Asp 65 70 75 80 Lys Asp Thr Glu He Gly Phe Ser Leu Asp Arg Thr Lys Asn Asp Gly 85 90 95 Phe Ser Ser Tyr Leu Asp Glu Asp Val Asn Tyr Cys He Leu Lys Lys 100 105 110 Lys Ser Met Ser Ser Val Thr Leu Leu He Leu Asp He Ser Gly Ser 115 120 125 Gly Val Lys Val Arg Ser Pro Pro Glu Ala Gly Lys Gin Leu Pro Glu 130 135 140 He Val Phe Ser Lys Asp Glu Lys Val Pro Ser Arg Ser Gin Glu Pro 145 150 155 160 Ala Val Ser Ser Asn Pro Lys Asp Ser Lys Val Gin Arg Thr Pro Asp 165 170 175 Gly Ser Lys Ala Gin Arg Ser Thr Val Asp Ser Lys Thr He Ala Glu 180 185 190 Lys Phe Phe Ser He His Lys Asn Asp Gly Ala Val Ser Phe Gin Phe 195 200 205 Phe Phe Asn He Ser Thr Ser Asp Gin Glu Gly Leu Tyr Ser Leu Tyr 210 215 220 Phe His Lys Cys Pro Ser Ser Lys Leu Arg Ser Gly Glu Gin Val Ser 225 230 235 240 Phe Ser Leu Asn He Asp He Thr Glu Lys Asn Pro Asp Ser Tyr Leu 245 250 255 Ser Ala Gly Glu He Pro Leu Pro Lys Leu Tyr Val Ser Met Ala Leu 260 265 270 Leu Phe Phe Leu Ser Gly Thr Val Trp He His He Leu Arg Lys Arg 275 280 285 Arg Asn Asp Val Phe Lys He His Trp Leu Met Ala Ala Leu Pro Phe 290 295 300 Thr Lys Ser Leu Ser Leu Val Phe His Ala He Asp Tyr His Tyr He 305 310 315 320 Ser Ser Gin Gly Phe Pro He Glu Gly Trp Ala Val Val Tyr Tyr He 325 330 335 Thr His Leu Leu Lys Gly Ala Leu Leu Phe He Thr He Ala Leu He 340 345 350 Gly Thr Gly Trp Ala Phe He Lys His He Leu Ser Asp Lys Asp Lys 355 360 365 Lys He Phe Met He Val He Pro Leu Gin Val Leu Ala Asn Val Ala 370 375 380 Tyr He He He Glu Ser Thr Glu Glu Gly Thr Thr Glu Tyr Gly Leu 385 390 395 400 Trp Lys Asp Ser Leu Phe Leu Val Asp Leu Leu Cys Cys Gly Ala He 405 410 415 Leu Phe Pro Val Val Trp Ser He Arg His Leu Gin Glu Ala Ser Ala 420 425 430 Thr Asp Gly Lys Leu Pro Leu Thr 435 440 (2) INFORMATION FOR SEQ ID NO: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1838 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW051 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 114..1505 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1411..1603 (D) OTHER INFORMATION: /label= SAC_24170 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44: GTCGACGGCT GGTTTGAAAA GTGACAACGG CCGGTGGATT TTAGGAGTTT GCTCGGTTTG 60 TAACTGCTCT TTGGTGAGCT ACTGGGACTG CAGACTAGGA GGAGACTCCC AAA ATG 116 Met 1 GAA ACT CTG TCC TTC CCC AGA TAC AAC ATA GCT GAG ATT GTA GTT CAT 164 Glu Thr Leu Ser Phe Pro Arg Tyr Asn He Ala Glu He Val Val His 5 10 15 ATT CGC AAT AAA CTG TTA ACT GGA GCG GAT GGC AAA AAC CTC TCC AAG 212 He Arg Asn Lys Leu Leu Thr Gly Ala Asp Gly Lys Asn Leu Ser Lys 20 25 30 AGC GAT TTT CTT CCA AAC CCG AAG CCT GAA GTC CTG TAC ATG ATT TAC 260 Ser Asp Phe Leu Pro Asn Pro Lys Pro Glu Val Leu Tyr Met He Tyr 35 40 45 ATG AGA GCC TTA CAG TTA GTG TAT GGG GTC CGG CTG GAG CAT TTC TAC 308 Met Arg Ala Leu Gin Leu Val Tyr Gly Val Arg Leu Glu His Phe Tyr 50 55 60 65 ATG ATG CCG GTG AAC ATA GAA GTC ATG TAT CCA CAT ATA ATG GAG GGC 356 Met Met Pro Val Asn He Glu Val Met Tyr Pro His He Met Glu Gly 70 75 80 TTC TTA CCG GTC AGC AAT TTG TTC TTC CAC CTG GAC TCG TTT ATG CCC 404 Phe Leu Pro Val Ser Asn Leu Phe Phe His Leu Asp Ser Phe Met Pro 85 90 95 ATT TGC CGG GTG AAT GAC TTT GAG ATC GCC GAT ATT CTT TAT CCA AAA 452 He Cys Arg Val Asn Asp Phe Glu He Ala Asp He Leu Tyr Pro Lys 100 105 110 GCA AAC CGG ACA AGT CGT TTT TTA AGT GGC ATT ATC AAC TTT ATT CAC 500 Ala Asn Arg Thr Ser Arg Phe Leu Ser Gly He He Asn Phe He His 115 120 125 TTC AGA GAA ACA TGC CTG GAG AAG TAT GAA GAA TTT CTT TTG CAA AAT 548 Phe Arg Glu Thr Cys Leu Glu Lys Tyr Glu Glu Phe Leu Leu Gin Asn 130 135 140 145 AAA TCC TCT GTG GAC AAA ATA CAG CAG TTA AGC AAT GCA CAC CAG GAA 596 Lys Ser Ser Val Asp Lys He Gin Gin Leu Ser Asn Ala His Gin Glu 150 155 160 GCA TTG ATG AAA CTG GAA AAA CTC AAT TCG GTT CCC GTG GAG GAG CAG 644 Ala Leu Met Lys Leu Glu Lys Leu Asn Ser Val Pro Val Glu Glu Gin 165 170 175 GAA GAG TTC AAA CAG CTG AAG GAT GAC ATC CAG GAG CTG CAG CAC TTG 692 Glu Glu Phe Lys Gin Leu Lys Asp Asp He Gin Glu Leu Gin His Leu 180 185 190 CTG AAT CAA GAC TTC AGA CAG AAA ACG ACA CTG CTG CAG GAG AGA TAT 740 Leu Asn Gin Asp Phe Arg Gin Lys Thr Thr Leu Leu Gin Glu Arg Tyr 195 200 205 ACC AAA ATG AAA TCA GAT TTT TCA GAG AAA ACC AAG CAT GTT AAT GAG 788 Thr Lys Met Lys Ser Asp Phe Ser Glu Lys Thr Lys His Val Asn Glu 210 215 220 225 CTA AAG TTG TCA GTA GTT TCT TTG AAA GAA GTT CAA GAC AGT TTG AAA 836 Leu Lys Leu Ser Val Val Ser Leu Lys Glu Val Gin Asp Ser Leu Lys 230 235 240 AGC AAA ATT GTG GAT TCT CCA GAG AAG CTG AAG AAC TAT AAA GAG AAG 884 Ser Lys He Val Asp Ser Pro Glu Lys Leu Lys Asn Tyr Lys Glu Lys 245 250 255 ATG AAG GAC ACC GTC CAG AAG CTC CGC AGT GCC AGG GAA GAA GTG ATG 932 Met Lys Asp Thr Val Gin Lys Leu Arg Ser Ala Arg Glu Glu Val Met 260 265 270 GAG AAG TAT GAT ATC TAT AGA GAT TCT GTG GAT TGC TTG CCT TCC TGT 980 Glu Lys Tyr Asp He Tyr Arg Asp Ser Val Asp Cys Leu Pro Ser Cys 275 280 285 CAG CTG GAG GTG CAG TTA TAT CAA AAG AAA TCA CAG GAC CTT GCA GAT 1028 Gin Leu Glu Val Gin Leu Tyr Gin Lys Lys Ser Gin Asp Leu Ala Asp 290 295 300 305 AAT AGG GAG AAA CTA AGC AGT ATC TTA AAG GAG AGC CTG AAC CTG GAG 1076 Asn Arg Glu Lys Leu Ser Ser He Leu Lys Glu Ser Leu Asn Leu Glu 310 315 320 GGC CAG ATT GAT AGT GAT TCA TCA GAA CTA AAG AAA CTG AAG ACT GAA 1124 Gly Gin He Asp Ser Asp Ser Ser Glu Leu Lys Lys Leu Lys Thr Glu 325 330 335 GAG AAC TCC CTC ATA AGA CTG ATG ACT CTA AAG AAG GAG AGA CTT GCT 1172 Glu Asn Ser Leu He Arg Leu Met Thr Leu Lys Lys Glu Arg Leu Ala 340 345 350 ACC ATG CAG TTC AAA ATA AAC AAG AAG CAG GAG GAT GTG AAA CAG TAC 1220 Thr Met Gin Phe Lys He Asn Lys Lys Gin Glu Asp Val Lys Gin Tyr 355 360 365 AAG CGG ACC ATG ATT GAA GAT TGC AAT AAA GTT CAA GAA AAA AGA GAT 1268 Lys Arg Thr Met He Glu Asp Cys Asn Lys Val Gin Glu Lys Arg Asp 370 375 380 385 GCT GTC TGC GAG CAA GTA ACC GCC ATT AAT CAA GAC ATC CAC AAG ATT 1316 Ala Val Cys Glu Gin Val Thr Ala He Asn Gin Asp He His Lys He 390 395 400 AAA TCT GGG ATT CAG CAG CTA AGA GAC GCC GAA AAA CGG GAG AAA CTG 1364 Lys Ser Gly He Gin Gin Leu Arg Asp Ala Glu Lys Arg Glu Lys Leu 405 410 415 AAG TCT CAG GAA ATC TTG GTA GAC TTG AAA AGT GCT TTG GAG AAG TAC 1412 Lys Ser Gin Glu He Leu Val Asp Leu Lys Ser Ala Leu Glu Lys Tyr 420 425 430 CAT GAG GGC ATC GAG AAG ACG ACG GAG GAG TGC TGC ACT AGA ATA GGA 1460 His Glu Gly He Glu Lys Thr Thr Glu Glu Cys Cys Thr Arg He Gly 435 440 445 GGG AAG ACT GCC GAG CTG AAG AGG AGG ATG TTC AAA ATG CCG CCC 1505 Gly Lys Thr Ala Glu Leu Lys Arg Arg Met Phe Lys Met Pro Pro 450 455 460 TGATCAACAG CCACCCGAAA ATGGCCTTTC GCTTTCTGTT TGGAGTAGTT ATATTGAAGC 1565 TAATAGAAGG ACCGCAGTCT CAGCTAACTA GCGTGGGTAC CATTGGTTCT CTGTCCTTTT 1625 ATGACCATGT GCTCCCTGTG TTTTTTTCTT GGTGATGGGG ATACAACTCA GGGCCTTGCA 1685 GGCTACACTG ACTTGCCTCC CTAGGCTCTA ATGTACCATG TACTATGTAG GCTTTTGCTA 1745 CAATTAAAGT AACGTGTACA GCTTTTATGT CCCTACTCTG TCTCCTTTTG TATGTGCTGG 1805 TTGGAATAAA CAAATAGTTA CTGACGTCAA AAA 1838 (2) INFORMATION FOR SEQ ID NO: 45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 464 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45: Met Glu Thr Leu Ser Phe Pro Arg Tyr Asn He Ala Glu He Val Val 1 5 10 15 His He Arg Asn Lys Leu Leu Thr Gly Ala Asp Gly Lys Asn Leu Ser 20 25 30 Lys Ser Asp Phe Leu Pro Asn Pro Lys Pro Glu Val Leu Tyr Met He 35 40 45 Tyr Met Arg Ala Leu Gin Leu Val Tyr Gly Val Arg Leu Glu His Phe 50 55 60 Tyr Met Met Pro Val Asn He Glu Val Met Tyr Pro His He Met Glu 65 70 75 80 Gly Phe Leu Pro Val Ser Asn Leu Phe Phe His Leu Asp Ser Phe Met 85 90 95 Pro He Cys Arg Val Asn Asp Phe Glu He Ala Asp He Leu Tyr Pro 100 105 110 Lys Ala Asn Arg Thr Ser Arg Phe Leu Ser Gly He He Asn Phe He 115 120 125 His Phe Arg Glu Thr Cys Leu Glu Lys Tyr Glu Glu Phe Leu Leu Gin 130 135 140 Asn Lys Ser Ser Val Asp Lys He Gin Gin Leu Ser Asn Ala His Gin 145 150 155 160 Glu Ala Leu Met Lys Leu Glu Lys Leu Asn Ser Val Pro Val Glu Glu 165 170 175 Gin Glu Glu Phe Lys Gin Leu Lys Asp Asp He Gin Glu Leu Gin His 180 185 190 Leu Leu Asn Gin Asp Phe Arg Gin Lys Thr Thr Leu Leu Gin Glu Arg 195 200 205 Tyr Thr Lys Met Lys Ser Asp Phe Ser Glu Lys Thr Lys His Val Asn 210 215 220 Glu Leu Lys Leu Ser Val Val Ser Leu Lys Glu Val Gin Asp Ser Leu 225 230 235 240 Lys Ser Lys He Val Asp Ser Pro Glu Lys Leu Lys Asn Tyr Lys Glu 245 250 255 Lys Met Lys Asp Thr Val Gin Lys Leu Arg Ser Ala Arg Glu Glu Val 260 265 270 Met Glu Lys Tyr Asp He Tyr Arg Asp Ser Val Asp Cys Leu Pro Ser 275 280 285 Cys Gin Leu Glu Val Gin Leu Tyr Gin Lys Lys Ser Gin Asp Leu Ala 290 295 300 Asp Asn Arg Glu Lys Leu Ser Ser He Leu Lys Glu Ser Leu Asn Leu 305 310 315 320 Glu Gly Gin He Asp Ser Asp Ser Ser Glu Leu Lys Lys Leu Lys Thr 325 330 335 Glu Glu Asn Ser Leu He Arg Leu Met Thr Leu Lys Lys Glu Arg Leu 340 345 350 Ala Thr Met Gin Phe Lys He Asn Lys Lys Gin Glu Asp Val Lys Gin 355 360 365 Tyr Lys Arg Thr Met He Glu Asp Cys Asn Lys Val Gin Glu Lys Arg 370 375 380 Asp Ala Val Cys Glu Gin Val Thr Ala He Asn Gin Asp He His Lys 385 390 395 400 He Lys Ser Gly He Gin Gin Leu Arg Asp Ala Glu Lys Arg Glu Lys 405 410 415 Leu Lys Ser Gin Glu He Leu Val Asp Leu Lys Ser Ala Leu Glu Lys 420 425 430 Tyr His Glu Gly He Glu Lys Thr Thr Glu Glu Cys Cys Thr Arg He 435 440 445 Gly Gly Lys Thr Ala Glu Leu Lys Arg Arg Met Phe Lys Met Pro Pro 450 455 460 (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1483 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW052 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 247..765 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (660..1062) (D) OTHER INFORMATION: /label= SAC_24882 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46: GTCGACCAAA AACAGGACAG ATTGCAACAG CCTCTACACT TCCTTCATGG CCTGCTCTTG 60 GGCCGTGGCG ACAAGCAGAA AGAAGCTTGA TTGTGGAGAG GTGCCCTAGC GGAGGGATGT 120 CTGCCACAGT CCAGGCACCC CACAGAGGGT AGGAGCTCCA TGTACGAGTG GCTTTGCATT 180 TCTTCAGAAA AGAATAGCTG ATGTGCAATC TCAGCCTTTC TGCAGAAGGA TTTATCAGGG 240 GCCAGC ATG GGC TCT GTG AAT TCT AGA GGC CAT AAG GCC CAG GTG GTA 288 Met Gly Ser Val Asn Ser Arg Gly His Lys Ala Gin Val Val 1 5 10 ATG CTG GGC CTC GAC TGT GCT GGC AAG ACC ACA ATC CTG TAC AAA CTG 336 Met Leu Gly Leu Asp Cys Ala Gly Lys Thr Thr He Leu Tyr Lys Leu 15 20 25 30 AAA GGA AAC CGG CTG GTG GAT ACC CTA CCC ACT GTT GGT TTT AAT GTA 384 Lys Gly Asn Arg Leu Val Asp Thr Leu Pro Thr Val Gly Phe Asn Val 35 40 45 GAG CCT CTT GAG GCT CCT GGA CAT GTG TCG CTG ACT CTC TGG GAC ATT 432 Glu Pro Leu Glu Ala Pro Gly His Val Ser Leu Thr Leu Trp Asp He 50 55 60 GGG GGA CAG ACC CAG CTC AGG GCT ACG TGG AAG GAC TAC CTG GAA GGC 480 Gly Gly Gin Thr Gin Leu Arg Ala Thr Trp Lys Asp Tyr Leu Glu Gly 65 70 75 ATT GAC CTC CTT GTG TAC GTG CTG GAC AGC ACA GAT GAA GCC CGC TTG 528 He Asp Leu Leu Val Tyr Val Leu Asp Ser Thr Asp Glu Ala Arg Leu 80 85 90 CCC GAG GCA GTG GCT GAG CTC GAG GAA GTC CTA GAA GAC CCC AAC ATG 576 Pro Glu Ala Val Ala Glu Leu Glu Glu Val Leu Glu Asp Pro Asn Met 95 100 105 110 GCT GGT GTT CCT TTC TTG GTA CTG GCC AAC AAG CAG GAG GCT CCT GAT 624 Ala Gly Val Pro Phe Leu Val Leu Ala Asn Lys Gin Glu Ala Pro Asp 115 120 125 GCT CTA CCA TTG CTT GAA ATC AGA AAC AGG CTG GAC CTG GAA AGG TTC 672 Ala Leu Pro Leu Leu Glu He Arg Asn Arg Leu Asp Leu Glu Arg Phe 130 135 140 CAA GAC CAT TGC TGG GAG CTG CGG GCT TGC AGC GCT CTC ACA GGT CAG 720 Gin Asp His Cys Trp Glu Leu Arg Ala Cys Ser Ala Leu Thr Gly Gin 145 150 155 GGG CTA CAG GAA GCC CGG CAG AGC CTG CTG CAT TTG CTG AGA TCC 765 Gly Leu Gin Glu Ala Arg Gin Ser Leu Leu His Leu Leu Arg Ser 160 165 170 TGATGAAATG CAGTAACCTC TAACTCCAGG CTGGAGCAGG ACAGGGAGCA GGGTCAGCCA 825 GACCCCCTGA GCAGGCAAAT AGATTATCCT TGCTTCTAAG AACAGGAGGG GCCAGCTGAT 885 CCTTGAGAAA GTGAAGCTCC GTTTGCCACA TGAGAAACCA CGTTTCTCTT GGACGGTGTG 945 TTTTCTTCTC AGGACTTCTT CTCAGTGGCG GTTATGCGGA AAATCAACTG TTCTTCAAGT 1005 AACAATCGTC AGAGGGAATA TAAAAACCCT CAGAATACCC CCATGTAACA GCTCAGTACC 1065 AAGTGTCAAA GTCACAAACT TGGTGACATA ATTATTGATG ACCAAGTTCA CAAATGAAAA 1125 GAGGTTTCAA AACTACATCT GAGTGTCACT GGGCCTATCG CTGTTATCCG AGTGTCACTG 1185 GGCCTATCAT TGTCATCCGA GTGTCACCAG GCCTATCACG GTCATCTGCC TGTCACTGGG 1245 CCTATCACAG TCATCAGGAG CGACTCTTCC TACTGGCCTT GGGGCAGAAG CCACTGTCAC 1305 TGGTGGGCTC ACAGCAGGAG GGGCAGGTCT GCTCTCATAA TGCTGCAGAA GGCAGAAGTC 1365 CATGGGGCCC TAGATCCTCC CAGAATTCCC CCTGATCTCC AACTCTGACT AACTCTTTTC 1425 TGCCCTATAT CCTCTGTTGT AAAAAAGTAA AATAAAACTC CTCTTATACT CTCAAAAA 1483 (2) INFORMATION FOR SEQ ID NO: 47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 173 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47: Met Gly Ser Val Asn Ser Arg Gly His Lys Ala Gin Val Val Met Leu 1 5 10 15 Gly Leu Asp Cys Ala Gly Lys Thr Thr He Leu Tyr Lys Leu Lys Gly 20 25 30 Asn Arg Leu Val Asp Thr Leu Pro Thr Val Gly Phe Asn Val Glu Pro 35 40 45 Leu Glu Ala Pro Gly His Val Ser Leu Thr Leu Trp Asp He Gly Gly 50 55 60 Gin Thr Gin Leu Arg Ala Thr Trp Lys Asp Tyr Leu Glu Gly He Asp 65 70 75 80 Leu Leu Val Tyr Val Leu Asp Ser Thr Asp Glu Ala Arg Leu Pro Glu 85 90 95 Ala Val Ala Glu Leu Glu Glu Val Leu Glu Asp Pro Asn Met Ala Gly 100 105 110 Val Pro Phe Leu Val Leu Ala Asn Lys Gin Glu Ala Pro Asp Ala Leu 115 120 125 Pro Leu Leu Glu He Arg Asn Arg Leu Asp Leu Glu Arg Phe Gin Asp 130 135 140 His Cys Trp Glu Leu Arg Ala Cys Ser Ala Leu Thr Gly Gin Gly Leu 145 150 155 160 Gin Glu Ala Arg Gin Ser Leu Leu His Leu Leu Arg Ser 165 170 (2) INFORMATION FOR SEQ ID NO: 48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2288 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW054 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1952..2152 (D) OTHER INFORMATION: /label= SAC_24183 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48: GTCGACGGTG GGGTCTAACT GAGGTCTTGT ATTTGGTTTT TCCTGAAGAT CGACCTCTGG 60 CATCAGGAGG CTTGAGCAAG GAGAAGAGTG GATGATGAAG GAAAGAGACA AGGAAAGAAA 120 GAGAAGTGTG CACAAAGAAA CTTGTATTAT TATTAATTAG CACCTAGCTT GTTTGTGTCT 180 GATACACCAC CAAGTAGTAA TTGTTGAAAA AAGCGAAGAA GAAAAAAAAA AAAACAAAAA 240 AACCAAACAG TGGGTACTCA AATAAGATAG GAGAAAAATG AAGAGAACAG ACCCAGTTCT 300 CGACCCTTGC TTCTCGAAGG TCCTCCCACC AGGCTGCCAA AGCAAGATGG TGTTGCTCTG 360 ATCCAGTCAG TATTCTTTTG ACTTTTTTTT TTAATCTCCA GGTTTTGGTT CAGGCTCCCA 420 TATTCATACC CTGGCTCATT TAGCTTTCCC TCATGTTGTG GGTTCTTCTG TCCCTCACCC 480 CCTTACTCTC CCCACTGATA TTCTTCCCAC GTCAAGACTG TGGCTCTGGA AGAAATATCC 540 ACCATTTGCA GAGCTGATGT TCTGTAGATC GTAATGTTGA AGCGCTGGGT GTCCTGGTTG 600 GCAGAATCAC TCCTGTATTA CTCTGGTACA TAGGTGTCTC CTGNTAGACT CCCTGGCCTT 660 AGTCATGGGG TGTTTTCTAG AGGCAGACTA AGACAGGAGT CAAAAAAGAT TTAGAGGAAG 720 GAGCTGAGGA AAGAAAGACA GTTGTGGGAG GAAAATCAAG TTCTACTCAG GATCCCGAGT 780 GTTTCTGTAG ATGTAGATTG GAATGTGTCC ATAACAGAGA GGCCAGTGAG AGACATCCCC 840 AAGGACCTGC CAGGCTTTCC TTCGCTCCAG GAAGACGCAC CATCACTCAA AAGGGGTTTC 900 CTAGAAAGAA AGACAAGTGA CTTAAAAAAT CTGCCAGTGG GTTCTTGAAG TCATCGAACC 960 TAGGAGGTAG AAAGCTCACG GGGGTCATGT TATCGAAGGG AGGTGAGGTT CAGTCAGGCT 1020 AACTATTAGG GAGANTGTCA AAGGAGGCTA CAGAAATGGG ATTCTGGCTG TGGGGCATTA 1080 AAGGCTATCA AGTCAACAGG TAAGAGTGGA GTGGCTCAGC AGCTTCTCTG GCGCTGAAAG 1140 TGGTGTCTCT TAACAGTTAA TTCCCTTCCC TTTTCCATCA CAGAAGGAAT CATTCCAGCC 1200 CTCCCTGGGA TTATGGTCCC CCAGTGACCA TGTTCCATCT GCTGGATTTT TGATCAGTTT 1260 AGAAGGAAAA AAACACTTGG GTTCGGTGGT ATTTGCTTAT GACCTTAGCA CTTTGGAGCT 1320 GAGAAGAGGA TTGCCATAGT TTCCAGACCA GTCTGGTTTA CATAGTGAGT TCTAGGGCTG 1380 CGTAATGAGA TGTCTCAAGA ATGGAGAGGG GCGTTAGGGA GAACTTACTT AGCTCTTCAA 1440 GAAACTGTCC TGTAAACAAA GAGAAATGAG TCGATGGGTG ACCAGTGGGA GCCTNCCCCC 1500 CACCTCCTCA GACAACCCTT CTTTTCCATT AAGGGGCCTG TGCATCTCAG TAAGTGGTCC 1560 TCAGTTTTCC TGAGGATTCT GATGGTGAGA GTAGAGAGAG CAAAAAGATT CTCAGCCCTG 1620 GGATCTAGAA CCTTGGTTCC ACTCTTTTCC CGTTCTGGTC TGCCTGAGCT CCCCCCCCCC 1680 GCCCCCCAGT GGTCCTGTTT GCTGTCCAGA CATTGCACCT GCCAGTCTTC GGTGCAGCCA 1740 GTTGTAGCAG ATGATCAAAG CAACCAGNGG TCCAAGAACA GGGACAATCA ACAAACAGTG 1800 TTATCTTCCA GCAGGGCACT CTCAGGAAGT GAGGATCTGA ATGGTAAAGC AGAACAGAGT 1860 GTTTCCCTCT ATGCCACAGC CGCTCATGCC ACACCCACTT GAAGCCTCCA AAGCCAGNAC 1920 AAGCTGTAGA GTCCATGAAT GTAGATGAGG TACATTGTGC GCCTTGCTTT TACTTCCTTT 1980 AGCTTCTGAT TGAATTTAGC TGTATCTTTT TAACCGATTT ATCGTAGAAN ACAATGGGTG 2040 GTGTGACCCT NTCATGCTTT GTTGATCTTC AGCCACACGC TGCCCTCCCT CGCCCCCACT 2100 TCTAGCATTT GTGTGTGTGC GCGTGTTTTT TTGAAGAGGG GTTNTTGCTT GTACAATCCC 2160 TGGCTGGCCT TGAACTTGAG AAGTCCTCCT GCCTCCGCCT TCCAGGTGCT GGGATTACAA 2220 GTTGTCAACC CTGCTTTCAC TAATGTTTCC TTTTTATTAA AGATTTATTT ATTATTTAAA 2280 AAGTCGAC 2288 (2) INFORMATION FOR SEQ ID NO: 49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2349 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW055 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 214..1329 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1953..2065 (D) OTHER INFORMATION: /label= SAC_24449 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: GTCGACAATG CTTTCAAGCA AACAGCCGCT ACCAGAACAA CTCTGTGACT AGGAGAAAGA 60 GGCCAAGGCG CGAGTTCCCA AACCCTGAAG CCACAGGAGC CCAAGGGGGA GACTGGAGAG 120 AAGGTATTTC TAGCCGTGCA CAGTGACTGA TCAGCCGAGG ACCTACCCTC GAGTTCTATT 180 CTGCAACAGT GAACAGTGAA GGTCTCCAAA GAG ATG GAG TAC GAG GGT TAC AAC 234 Met Glu Tyr Glu Gly Tyr Asn 1 5 GAC TCC AGC ATC TAC GGT GAG GAG TAT TCT GAC GGC TCG GAC TAC ATC 282 Asp Ser Ser He Tyr Gly Glu Glu Tyr Ser Asp Gly Ser Asp Tyr He 10 15 20 GTG GAC TTG GAG GAG GCG GGT CCA CTG GAG GCC AAG GTG GCC GAG GTC 330 Val Asp Leu Glu Glu Ala Gly Pro Leu Glu Ala Lys Val Ala Glu Val 25 30 35 TTC CTG GTG GTA ATC TAC AGC TTG GTG TGC TTC CTC GGG ATC CTA GGC 378 Phe Leu Val Val He Tyr Ser Leu Val Cys Phe Leu Gly He Leu Gly 40 45 50 55 AAT GGC CTG GTG ATT GTC ATC GCC ACC TTC AAG ATG AAG AAG ACG GTG 426 Asn Gly Leu Val He Val He Ala Thr Phe Lys Met Lys Lys Thr Val 60 65 70 AAC ACC GTG TGG TTT GTC AAC CTG GCC GTG GCT GAC TTC CTG TTC AAC 474 Asn Thr Val Trp Phe Val Asn Leu Ala Val Ala Asp Phe Leu Phe Asn 75 80 85 ATC TTC TTG CCC ATC CAC ATC ACC TAT GCC GCT ATG GAC TAC CAC TGG 522 He Phe Leu Pro He His He Thr Tyr Ala Ala Met Asp Tyr His Trp 90 95 100 GTG TTC GGG AAA GCC ATG TGC AAG ATT AGT AGC TTT CTG CTA AGC CAC 570 Val Phe Gly Lys Ala Met Cys Lys He Ser Ser Phe Leu Leu Ser His 105 110 115 AAC ATG TAC ACC AGC GTC TTC CTG CTC ACT GTC ATC AGC TTC GAC CGC 618 Asn Met Tyr Thr Ser Val Phe Leu Leu Thr Val He Ser Phe Asp Arg 120 125 130 135 TGC ATC TCC GTG CTC CTC CCC GTC TGG TCC CAG AAC CAC CGC AGC GTG 666 Cys He Ser Val Leu Leu Pro Val Trp Ser Gin Asn His Arg Ser Val 140 145 150 CGT CTG GCC TAC ATG ACC TGC GTG GTT GTC TGG GTC CTG GCT TTC TTC 714 Arg Leu Ala Tyr Met Thr Cys Val Val Val Trp Val Leu Ala Phe Phe 155 160 165 CTG AGT TCC CCG TCC CTC GTC TTC CGG GAC ACG GTC AGC ACC AGC CAC 762 Leu Ser Ser Pro Ser Leu Val Phe Arg Asp Thr Val Ser Thr Ser His 170 175 180 GGG AAG ATA ACC TGC TTC AAC AAC TTC AGC CTG GCC GCG CCC GAG CCT 810 Gly Lys He Thr Cys Phe Asn Asn Phe Ser Leu Ala Ala Pro Glu Pro 185 190 195 TTC TCT CAT TCC ACC CAC CCG CGA ACA GAC CCG GTA GGG TAC AGC AGA 858 Phe Ser His Ser Thr His Pro Arg Thr Asp Pro Val Gly Tyr Ser Arg 200 205 210 215 CAT GTG GCG GTC ACC GTC ACC CGC TTC CTC TGT GGC TTC CTG ATC CCC 906 His Val Ala Val Thr Val Thr Arg Phe Leu Cys Gly Phe Leu He Pro 220 225 230 GTC TTC ATC ATC ACG GCC TGT TAC CTC ACC ATC GTC TTC AAG TTG CAG 954 Val Phe He He Thr Ala Cys Tyr Leu Thr He Val Phe Lys Leu Gin 235 240 245 CGC AAC CGC CTG GCC AAG ACC AAG AAG CCC TTC AAG ATC ATC ATC ACC 1002 Arg Asn Arg Leu Ala Lys Thr Lys Lys Pro Phe Lys He He He Thr 250 255 260 ATC ATC ATC ACC TTC TTC CTC TGC TGG TGC CCC TAC CAC ACA CTC TAC 1050 He He He Thr Phe Phe Leu Cys Trp Cys Pro Tyr His Thr Leu Tyr 265 270 275 CTG CTG GAG CTC CAC CAC ACG GCT GTG CCA GCC TCT GTC TTC AGC CTG 1098 Leu Leu Glu Leu His His Thr Ala Val Pro Ala Ser Val Phe Ser Leu 280 285 290 295 GGA CTG CCC CTG GCC ACA GCC GTT GCC ATC GCC AAC AGC TGT ATG AAC 1146 Gly Leu Pro Leu Ala Thr Ala Val Ala He Ala Asn Ser Cys Met Asn 300 305 310 CCC ATC CTG TAC GTC TTC ATG GGC CAC GAC TTC AAA AAA TTC AAG GTG 1194 Pro He Leu Tyr Val Phe Met Gly His Asp Phe Lys Lys Phe Lys Val 315 320 325 GCC CTT TTC TCC CGC CTG GTG AAT GCC CTG AGC GAG GAC ACA GGA CCC 1242 Ala Leu Phe Ser Arg Leu Val Asn Ala Leu Ser Glu Asp Thr Gly Pro 330 335 340 TCC TCC TAC CCC AGT CAC AGG AGC TTC ACC AAG ATG TCC TCA TTG ATT 1290 Ser Ser Tyr Pro Ser His Arg Ser Phe Thr Lys Met Ser Ser Leu He 345 350 355 GAG AAG GCT TCA GTG AAT GAG AAA GAG ACC AGC ACC CTC TGAGCCTTCC 1339 Glu Lys Ala Ser Val Asn Glu Lys Glu Thr Ser Thr Leu 360 365 370 CTGGGACTGT CCCCAATGGG CTCCACAGCC CAGGGACTTG TCTCCTGAGG TAGGAGACAC 1399 GCCTGGAGCC TTTGGGTATG CCCCAGCGCC CGCTACGTCT TGCGCAAGGC GGCCCATTGT 1459 TTTGGGTGGA GTTCCCAAGT GTGGACACTC TTCCAGCAAA ATGGCAGACA AGCAACCTGA 1519 GCCCCTGCAG CAGGAGTATA GGACCAACTT CCACCGGCTC AGAAAAGGGA GGGTCTCTGA 1579 AACCAAGGTC TGAGCTGTGA CCCACATACA GGCACACAAT TTCACTGTGG ATGCCCCAAA 1639 CATGCTGCAC AGTCTCCAGT GTGGGTGAGG ACGTCACTGC AGACCTGTTA TGGCGACATG 1699 ACAGTCAAAC CAGCAAATAC CCCACCACCA CTGTCATCCT CCAAGATCTT GACTTTGGAT 1759 TTCAGAAAAA TGGGGAGGAC CAGGACCTGA GGGGCTTCAT AGAACTTGCT TGCAAGGGCA 1819 GCCCAGGTGT GTGTGTGTGT ATGTGCTTGT GTGTGTGTGT GTGTGTATGT GCATGTGTGT 1879 GTGTGTGTGT GTGTGTGTGT GTGTGTGTTG AAGAGGTGGA GACAGAGAGC AGAGAACCCC 1939 AAAGGATGTG GGTACAGGAT ATCTCACACC ATCATGCCAC AGGGAGACAG AGCTACAACG 1999 ATGGGTGCTT GGGGGTTCAG ATGGTGGCAG CTCTTTGCTT CAGTGTGTAT ACCCCCCTAG 2059 CACTGTACCC CCAGGCTGGA GGGGGGCTCT TCACAGAAGC TTCCAACCCA TTCCAGCACT 2119 GGCTGGAAGG GCTTGGGATG TCCCTGGAGA CTGGTCTGGG ACTATCTTCA AAGCGTCTTC 2179 CAAAGGCTGC TGCTGACCAG CTCACCTGAC TCCTCCTTGA ACACACTCCC CACGTGGGGC 2239 ATCACAGCCC CGATGGCAGC CCAGGATCAG GCCTCCCTCC CTTGACAGGG AAATGACTCA 2299 CCCAACCCCA TGCACTGTCA GTAACAAAGA CCCAGGCCCA GCTCCAAAAA 2349 (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 372 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50: Met Glu Tyr Glu Gly Tyr Asn Asp Ser Ser He Tyr Gly Glu Glu Tyr 1 5 10 15 Ser Asp Gly Ser Asp Tyr He Val Asp Leu Glu Glu Ala Gly Pro Leu 20 25 30 Glu Ala Lys Val Ala Glu Val Phe Leu Val Val He Tyr Ser Leu Val 35 40 45 Cys Phe Leu Gly He Leu Gly Asn Gly Leu Val He Val He Ala Thr 50 55 60 Phe Lys Met Lys Lys Thr Val Asn Thr Val Trp Phe Val Asn Leu Ala 65 70 75 80 Val Ala Asp Phe Leu Phe Asn He Phe Leu Pro He His He Thr Tyr 85 90 95 Ala Ala Met Asp Tyr His Trp Val Phe Gly Lys Ala Met Cys Lys He 100 105 110 Ser Ser Phe Leu Leu Ser His Asn Met Tyr Thr Ser Val Phe Leu Leu 115 120 125 Thr Val He Ser Phe Asp Arg Cys He Ser Val Leu Leu Pro Val Trp 130 135 140 Ser Gin Asn His Arg Ser Val Arg Leu Ala Tyr Met Thr Cys Val Val 145 150 155 160 Val Trp Val Leu Ala Phe Phe Leu Ser Ser Pro Ser Leu Val Phe Arg 165 170 175 Asp Thr Val Ser Thr Ser His Gly Lys He Thr Cys Phe Asn Asn Phe 180 185 190 Ser Leu Ala Ala Pro Glu Pro Phe Ser His Ser Thr His Pro Arg Thr 195 200 205 Asp Pro Val Gly Tyr Ser Arg His Val Ala Val Thr Val Thr Arg Phe 210 215 220 Leu Cys Gly Phe Leu He Pro Val Phe He He Thr Ala Cys Tyr Leu 225 230 235 240 Thr He Val Phe Lys Leu Gin Arg Asn Arg Leu Ala Lys Thr Lys Lys 245 250 255 Pro Phe Lys He He He Thr He He He Thr Phe Phe Leu Cys Trp 260 265 270 Cys Pro Tyr His Thr Leu Tyr Leu Leu Glu Leu His His Thr Ala Val 275 280 285 Pro Ala Ser Val Phe Ser Leu Gly Leu Pro Leu Ala Thr Ala Val Ala 290 295 300 He Ala Asn Ser Cys Met Asn Pro He Leu Tyr Val Phe Met Gly His 305 310 315 320 Asp Phe Lys Lys Phe Lys Val Ala Leu Phe Ser Arg Leu Val Asn Ala 325 330 335 Leu Ser Glu Asp Thr Gly Pro Ser Ser Tyr Pro Ser His Arg Ser Phe 340 345 350 Thr Lys Met Ser Ser Leu He Glu Lys Ala Ser Val Asn Glu Lys Glu 355 360 365 Thr Ser Thr Leu 370 (2) INFORMATION FOR SEQ ID NO: 51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2577 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW056 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 8..523 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (738..953) (D) OTHER INFORMATION: /label= SAC_24326 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51: GTCGACG GGC TAC CTT AGC CAG CTG ATG CTT CCA GTG ACA GAG CCA CTT 49 Gly Tyr Leu Ser Gin Leu Met Leu Pro Val Thr Glu Pro Leu 1 5 10 TGT CCT TTG CAC AGC CTG ACA CCC TAT CAG GTC CCC TTC AAT GCA GTT 97 Cys Pro Leu His Ser Leu Thr Pro Tyr Gin Val Pro Phe Asn Ala Val 15 20 25 30 GCT ATC CGG GTC ACG CAC GCC GAC GTT GCA CCT ACC CAC ATA CTG TAC 145 Ala He Arg Val Thr His Ala Asp Val Ala Pro Thr His He Leu Tyr 35 40 45 GCT ATG AAT GCC AGC TGG GTC GGC CTT TGC AAG ATT GTG GAT GAT ATG 193 Ala Met Asn Ala Ser Trp Val Gly Leu Cys Lys He Val Asp Asp Met 50 55 60 AAA GGC TAC ACT CGG GGC CCC ATT CTG CTG GCC CAG AAC CCC ATA TGT 241 Lys Gly Tyr Thr Arg Gly Pro He Leu Leu Ala Gin Asn Pro He Cys 65 70 75 GAC TGT TTG GGC TTT GGT ATC TGC AGA GGC ATT GAC ATG GAC AAG CGG 289 Asp Cys Leu Gly Phe Gly He Cys Arg Gly He Asp Met Asp Lys Arg 80 85 90 CTG TAC CAC ATC CTC ACC CCT CTA CCA CCA GAG GAG TTA AGA ACT GTG 337 Leu Tyr His He Leu Thr Pro Leu Pro Pro Glu Glu Leu Arg Thr Val 95 100 105 110 AAC TGT CTG CTG GTT GGC ACC ATT TCC ATT CCA CAT TGT ATT TTC AAG 385 Asn Cys Leu Leu Val Gly Thr He Ser He Pro His Cys He Phe Lys 115 120 125 AAT CAG CCT GGG ACT GAA GGG ACA GTT CCT TAT GTC ACC AGG GAT TAT 433 Asn Gin Pro Gly Thr Glu Gly Thr Val Pro Tyr Val Thr Arg Asp Tyr 130 135 140 AAT TTA AAA CTT CTT GGA GCA TCA GAG AAA ATT GGG GAG AGA GAG TAT 481 Asn Leu Lys Leu Leu Gly Ala Ser Glu Lys He Gly Glu Arg Glu Tyr 145 150 155 AGA AAT ATA CTA CCT AGA CAC AAA TCA CGG CAA AGA AGA AAA 523 Arg Asn He Leu Pro Arg His Lys Ser Arg Gin Arg Arg Lys 160 165 170 TGAAGCCTGG GTGTACAGAG AGACTTTCGC CTCGACACAT TGTCCCCAAG CCTAGAGTCA 583 GCAGACTGAG CGGGCTGTGT GGCTGCTGAC CTCGTGCCCA TGCCCAGTGT TCATATAACT 643 GGAAAATGTG CTGTGGTAAG AGTCATTCAA GCCCCTTCGT TTTTTTCCCC TCTAAGACAT 703 GGAGGGCCTC ATATAGCTCA GACTGGCCTC AGTACTCTGG TCCTCCTGTC TCACTGTCCA 763 AGGGCTGCGC ATCCGGCTTT TGGTCTCATA CTTGGCCCAG ACCTTGCCGA CTGGTTGTCC 823 TGGGTGTGTG GTGCTCCTGG AGAGCTGGGA AGCATTGAAG AAAGCTGTGG TGTCCTCCAA 883 GAAGACCAGG GCCACAAAAG TGTGCCTAGA AACTGAGTAG CAGGCTGACC ACAGGTTCTC 943 GGGTGCAGTG TACGGACTGG CAGGGACCTG AGCAGGCTCA GTGGCCGTGA GTAAGAGGCT 1003 TACTCCGTTG AACCTTGTGG ACCTTAGCAC CCCAGTGTGG CGGCTCATTG GCCTGATCCT 1063 TTGATGCTTG CCATCGAATC TCCCAATGCT GCAATCAAGT GTTAGAGGAC GGTACGTCGT 1123 CTTGTTAATT TCTGGGTCTT TAATCATGAG GCTTTATGTT GAAGAACTTG CTCTGACATT 1183 CAGAAAGCCT CACGTTAGTT AAAGAAATCC ATGGTTCCCT AATTCTGGGG ATGTTCTGAC 1243 AGACCTTGAG GCTGTAGATA CGTCAGAAAG CCTCCATGTT AGTTAAGGAA ATCCATGGTT 1303 CCCTAATTCT GGGGATGTTC TGACTGGGAA TGTTCTGACA GACCTTGAGG CTGAGATACT 1363 ACCATGGGCC CACTAGCCTG GGACAGGCAC ACATATGCCT GGCTTGGGCA GACCTTTGCT 1423 ATCAACGATT TCTTCTAAGG CCCCAGAGGC CACTGCAAGT GGATGTTGCA ATCCGGAGTG 1483 ACTGGGTCGG GTCATTTTTG TGGTTGCAAA GCAGGACCCT GAGGAGCCTC TTGGGCTGGC 1543 ATGATGGATC TGACAAGACT CCACCTTGCA TGGAATCAGG AAGGACCAAG GCTATGGAAG 1603 GCTCACAACA TTGATTGTCT CCGTCTTGTC TGTAGTCATA GGAGTGTGGC CAGTCTCCTC 1663 TGCTTGGCGC CATCTTTGTG GTGGCCTCAG CATCTGAAAA TCCTCCGAGG AGGCAGAGCT 1723 GCCTCTTCTG GATTAGTCGG ATTCCCTGTA GATCACTCGG GCTCACAACT ACTCCCTGCC 1783 CCACCCCCAA CACCATCTCT GTCTCACTTG AGCTTGTGGT GAGCCTTTGC AGAGGGGAGG 1843 AGCTCTTCCT GCCCAGGCAC TCTCTGGGCT CCTGATCCTC AAGCCTCTGC TTCCTGGGTG 1903 CTCAGATCAC AGGTGTGTGC CGTCTTAGCC TTGCGGACAG TTTTAAGACA GCCTTGGTCA 1963 CCTTCATCTC CCTCCCCGGG TCTTCCTGTC TTCACAATAA AGATCCCGAG TCCAAAAAAA 2023 AAAAAAAAAA AAATTCCAGG AGGAAATCTG GGTGCACAGA ACTTATCTGA GTCGGCTTTG 2083 GTGAAGGAGA TCCTCAAGGA GCAGGAGAAC AGGAAGGGCC TCATAGCTGC CATCTGTGCG 2143 GGTCCTACGG CCCTGCTGGC TCACGAAGTA GGCTTTGGAT GCAAGGTTAC ATCGCACCCA 2203 TTGGCTAAGG ACAAAATGAT GAACGGCAGT CACTACAGCT ACTCAGAGAG CCGTGTGGAG 2263 AAGGACGGCC TCATCCTCAC CAGCCGTGGG CCTGGGACCA GCTTCGAGTT TGCGCTGGCC 2323 ATTGTGGAGG CACTCAGTGG CAAGGACATG GCTAACCAAG TGAAGGCCCC GCTTGTTCTC 2383 AAAGACTAGA GCCCAAGCCC TGGACCCTGG ACCCCCAGGC TGAGCAGGCA TTGGAAGCCC 2443 ACTAGTGTGT CCACAGCCCA GTGAACCTCA GGAACTAACG TGTGAAGTAG CCCGCTGCTC 2503 AGGAATCTCG CCCTGGCTCT GTACTATTCT GAGCCTTGCT AGTAGAATAA ACAGTTCCCC 2563 AAGCTCCTGA AAAA 2577 (2) INFORMATION FOR SEQ ID NO: 52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 172 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: Gly Tyr Leu Ser Gin Leu Met Leu Pro Val Thr Glu Pro Leu Cys Pro 1 5 10 15 Leu His Ser Leu Thr Pro Tyr Gin Val Pro Phe Asn Ala Val Ala He 20 25 30 Arg Val Thr His Ala Asp Val Ala Pro Thr His He Leu Tyr Ala Met 35 40 45 Asn Ala Ser Trp Val Gly Leu Cys Lys He Val Asp Asp Met Lys Gly 50 55 60 Tyr Thr Arg Gly Pro He Leu Leu Ala Gin Asn Pro He Cys Asp Cys 65 70 75 80 Leu Gly Phe Gly He Cys Arg Gly He Asp Met Asp Lys Arg Leu Tyr 85 90 95 His He Leu Thr Pro Leu Pro Pro Glu Glu Leu Arg Thr Val Asn Cys 100 105 110 Leu Leu Val Gly Thr He Ser He Pro His Cys He Phe Lys Asn Gin 115 120 125 Pro Gly Thr Glu Gly Thr Val Pro Tyr Val Thr Arg Asp Tyr Asn Leu 130 135 140 Lys Leu Leu Gly Ala Ser Glu Lys He Gly Glu Arg Glu Tyr Arg Asn 145 150 155 160 He Leu Pro Arg His Lys Ser Arg Gin Arg Arg Lys 165 170 (2) INFORMATION FOR SEQ ID NO: 53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1339 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW057 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 7..1023 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1032..1176 (D) OTHER INFORMATION: /label= SAC_23926 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53: GTCGAC GGC GCG CTG GAG GAC GCA CGG CTT GGC GGG AAG GCG AGG GGA 48 Gly Ala Leu Glu Asp Ala Arg Leu Gly Gly Lys Ala Arg Gly 1 5 10 CCG TGC GGA GCC TCC GGT GCT GGC GGC GGC CAC CAG TTC GGG AGC CGG 96 Pro Cys Gly Ala Ser Gly Ala Gly Gly Gly His Gin Phe Gly Ser Arg 15 20 25 30 GAG CCG GCC GCA GCA CGC GGA ACA GAG CAG AGG GTG GCG GGG CCC GGC 144 Glu Pro Ala Ala Ala Arg Gly Thr Glu Gin Arg Val Ala Gly Pro Gly 35 40 45 GAA ACC ACG ATG AAG CCG AAC AGC GAG GAA GAG GAG GAG TTG GTG CAG 192 Glu Thr Thr Met Lys Pro Asn Ser Glu Glu Glu Glu Glu Leu Val Gin 50 55 60 GGC GTG GGC CCC TGG GAC GAG TGC TTC GAG GTG GCC GTG CAG TTG GCG 240 Gly Val Gly Pro Trp Asp Glu Cys Phe Glu Val Ala Val Gin Leu Ala 65 70 75 TTG CGT GCG GGA CAA ATC ATC AGA AAG GCC CTC ACT GAG GAA AAA CAC 288 Leu Arg Ala Gly Gin He He Arg Lys Ala Leu Thr Glu Glu Lys His 80 85 90 GTC TCG ACG AAA ACA TCT GCT GCA GAT CTT GTG ACA GAA ACA GAT CAC 336 Val Ser Thr Lys Thr Ser Ala Ala Asp Leu Val Thr Glu Thr Asp His 95 100 105 110 CGA GTA GAA GAC TTA ATT GTT TCT GAG TTG CGA AAG CGG TTC CCT TCA 384 Arg Val Glu Asp Leu He Val Ser Glu Leu Arg Lys Arg Phe Pro Ser 115 120 125 CAC AGG TTC ATT GCA GAA GAG GCC ACA GCC TCC GGG GCC AAG TGT GTG 432 His Arg Phe He Ala Glu Glu Ala Thr Ala Ser Gly Ala Lys Cys Val 130 135 140 CTC ACC CAC AGC CCG ACC TGG ATC ATC GAC CCC ATC GAC GGC ACC TGC 480 Leu Thr His Ser Pro Thr Trp He He Asp Pro He Asp Gly Thr Cys 145 150 155 AAC TTT GTG CAC AGA TTC CCC ACT GTG GCA GTT AGC ATC GGA TTT GCT 528 Asn Phe Val His Arg Phe Pro Thr Val Ala Val Ser He Gly Phe Ala 160 165 170 GTT CAC CAG GAG CTG GAA TTC GGA GTG ATT CAC CAC TGC ACA GAG GAG 576 Val His Gin Glu Leu Glu Phe Gly Val He His His Cys Thr Glu Glu 175 180 185 190 CGG CTG TAC ACC GGC AGG AGG GGC CAG GGC GCC TTT TGC AAT GGC CAG 624 Arg Leu Tyr Thr Gly Arg Arg Gly Gin Gly Ala Phe Cys Asn Gly Gin 195 200 205 AGG CTC CAG GTC TCC AGG GAG ACA GAT CTC GCA AAG GCC TTG GTT CTG 672 Arg Leu Gin Val Ser Arg Glu Thr Asp Leu Ala Lys Ala Leu Val Leu 210 215 220 ACA GAA ATC GGG CCC AAA CGT GAC CCC GAT ACT CTG AAA GTA TTC CTG 720 Thr Glu He Gly Pro Lys Arg Asp Pro Asp Thr Leu Lys Val Phe Leu 225 230 235 AGC AAC ATG GAG CGG CTG CTG CAC GCC AAG GCT CAT GGG GTC CGA GTG 768 Ser Asn Met Glu Arg Leu Leu His Ala Lys Ala His Gly Val Arg Val 240 245 250 ATT GGC AGC TCC ACC TTG GCG CTC TGC TAC TTG GCC TCG GGG GCT GCT 816 He Gly Ser Ser Thr Leu Ala Leu Cys Tyr Leu Ala Ser Gly Ala Ala 255 260 265 270 GAT GCC TAT TAC CAG TTC GGC CTC CAC TGC TGG GAT CTG GCA GCT GCC 864 Asp Ala Tyr Tyr Gin Phe Gly Leu His Cys Trp Asp Leu Ala Ala Ala 275 280 285 ACA GTC ATC ATC AGA GAA GCA GGT GGC ATT GTG ATT GAC ACC TCA GGT 912 Thr Val He He Arg Glu Ala Gly Gly He Val He Asp Thr Ser Gly 290 295 300 GGA CCC CTT GAC CTC ATG TCG TGC AGA GTG GTG GCT GCT GGC ACC AGA 960 Gly Pro Leu Asp Leu Met Ser Cys Arg Val Val Ala Ala Gly Thr Arg 305 310 315 GAG ATG GCA GTG CTC ATA GCT CAG GCC CTA CAA ACC ATT AAC TAC GGC 1008 Glu Met Ala Val Leu He Ala Gin Ala Leu Gin Thr He Asn Tyr Gly 320 325 330 CGG GAC GAT GAG AAG TGAGCCGTAC AGAGCTCTAA GGCTGACATG AGCAGCTCCC 1063 Arg Asp Asp Glu Lys 335 TGGGAAAGAG CTGTCCGGGG GCTTGAGTTC CGGGATAGTC TACCATAGCT GTCCCCGGAC 1123 CTCGGTGCTT AGCTGATCCT CTCTAATCTC GGGTAGCCCC TTTCCAGGTC GGTACATGGT 1183 CTTTCATCAG AGCCAAACCC AAATCTTGTG AGGTGTGTTA GTCACCCATC CTGGTTGTTC 1243 GGAATGCAAA TCTCAGGTAA TAAAGCTTTA GAACGAGCTC TCAGGCCCTC CCCTGCCCGT 1303 GGTGATACAG AATGCAATAA ATCAGAACTT TAAAAA 1339 (2) INFORMATION FOR SEQ ID NO: 54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 339 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54: Gly Ala Leu Glu Asp Ala Arg Leu Gly Gly Lys Ala Arg Gly Pro Cys 1 5 10 15 Gly Ala Ser Gly Ala Gly Gly Gly His Gin Phe Gly Ser Arg Glu Pro 20 25 30 Ala Ala Ala Arg Gly Thr Glu Gin Arg Val Ala Gly Pro Gly Glu Thr 35 40 45 Thr Met Lys Pro Asn Ser Glu Glu Glu Glu Glu Leu Val Gin Gly Val 50 55 60 Gly Pro Trp Asp Glu Cys Phe Glu Val Ala Val Gin Leu Ala Leu Arg 65 70 75 80 Ala Gly Gin He He Arg Lys Ala Leu Thr Glu Glu Lys His Val Ser 85 90 95 Thr Lys Thr Ser Ala Ala Asp Leu Val Thr Glu Thr Asp His Arg Val 100 105 110 Glu Asp Leu He Val Ser Glu Leu Arg Lys Arg Phe Pro Ser His Arg 115 120 125 Phe He Ala Glu Glu Ala Thr Ala Ser Gly Ala Lys Cys Val Leu Thr 130 135 140 His Ser Pro Thr Trp He He Asp Pro He Asp Gly Thr Cys Asn Phe 145 150 155 160 Val His Arg Phe Pro Thr Val Ala Val Ser He Gly Phe Ala Val His 165 170 175 Gin Glu Leu Glu Phe Gly Val He His His Cys Thr Glu Glu Arg Leu 180 185 190 Tyr Thr Gly Arg Arg Gly Gin Gly Ala Phe Cys Asn Gly Gin Arg Leu 195 200 205 Gin Val Ser Arg Glu Thr Asp Leu Ala Lys Ala Leu Val Leu Thr Glu 210 215 220 He Gly Pro Lys Arg Asp Pro Asp Thr Leu Lys Val Phe Leu Ser Asn 225 230 235 240 Met Glu Arg Leu Leu His Ala Lys Ala His Gly Val Arg Val He Gly 245 250 255 Ser Ser Thr Leu Ala Leu Cys Tyr Leu Ala Ser Gly Ala Ala Asp Ala 260 265 270 Tyr Tyr Gin Phe Gly Leu His Cys Trp Asp Leu Ala Ala Ala Thr Val 275 280 285 He He Arg Glu Ala Gly Gly He Val He Asp Thr Ser Gly Gly Pro 290 295 300 Leu Asp Leu Met Ser Cys Arg Val Val Ala Ala Gly Thr Arg Glu Met 305 310 315 320 Ala Val Leu He Ala Gin Ala Leu Gin Thr He Asn Tyr Gly Arg Asp 325 330 335 Asp Glu Lys (2) INFORMATION FOR SEQ ID NO: 55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2285 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW059 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 9..1271 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1991..2162 (D) OTHER INFORMATION: /label= SAC_24457 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55: GTCGACAG CCC GCC ACT CCA GGC GCG ATG CTG TTC TGG ACT GTG CTC AGC 50 Pro Ala Thr Pro Gly Ala Met Leu Phe Trp Thr Val Leu Ser 1 5 10 ATG GCT TTG AGT CTG CGG TTG GCA CTG GCG CAG AGC GGC ATA GAG CGC 98 Met Ala Leu Ser Leu Arg Leu Ala Leu Ala Gin Ser Gly He Glu Arg 15 20 25 30 GGT CCC ACA GCA TCA GCC CCC CAG GGG GAC CTG TTG TTC CTG CTG GAC 146 Gly Pro Thr Ala Ser Ala Pro Gin Gly Asp Leu Leu Phe Leu Leu Asp 35 40 45 AGC TCA GCC AGT GTG TCA CAC TAT GAG TTC TCA AGA GTT CGA GAG TTT 194 Ser Ser Ala Ser Val Ser His Tyr Glu Phe Ser Arg Val Arg Glu Phe 50 55 60 GTG GGG CAG CTG GTG GCT ACG ATG CCT TTC GGA CCC GGG GCT CTG CGT 242 Val Gly Gin Leu Val Ala Thr Met Pro Phe Gly Pro Gly Ala Leu Arg 65 70 75 GCT AGT CTG GTG CAC GTG GGC AGC CGG CCT CAC ACG GAG TTT ACT TTT 290 Ala Ser Leu Val His Val Gly Ser Arg Pro His Thr Glu Phe Thr Phe 80 85 90 GAT CAG TAC AGT TCA GGC CAG GCC ATA CAG GAT GCT GTA CGT GTT GCG 338 Asp Gin Tyr Ser Ser Gly Gin Ala He Gin Asp Ala Val Arg Val Ala 95 100 105 110 CCC CAA CGT ATG GGT GAC ACC AAC ACG GGC CTG GCA CTG GCT TAT GCC 386 Pro Gin Arg Met Gly Asp Thr Asn Thr Gly Leu Ala Leu Ala Tyr Ala 115 120 125 AAA GAA CAA TTA TTT GCT GAG GAA GCA GGT GCC CGG CTA GGG GTT CCC 434 Lys Glu Gin Leu Phe Ala Glu Glu Ala Gly Ala Arg Leu Gly Val Pro 130 135 140 AAG GTA CTG GTG TGG GTG ACA GAT GGG GCC TCC AGT GAC TCT GTG GGC 482 Lys Val Leu Val Trp Val Thr Asp Gly Ala Ser Ser Asp Ser Val Gly 145 150 155 CCC CCT ATG CAG GAG CTC AAG GAC CTG GGT GTC ACC ATC TTC ATT GTC 530 Pro Pro Met Gin Glu Leu Lys Asp Leu Gly Val Thr He Phe He Val 160 165 170 AGC ACT GGC CGA GGC AAC CTG TTG GAG CTG TTG GCA GCT GCC TCA GCT 578 Ser Thr Gly Arg Gly Asn Leu Leu Glu Leu Leu Ala Ala Ala Ser Ala 175 180 185 190 CCG GCT GAG AAG CAC CTA CAC TTT GTG GAT GTG GAT GAC CTT CCT ATC 626 Pro Ala Glu Lys His Leu His Phe Val Asp Val Asp Asp Leu Pro He 195 200 205 ATT GCC CGG GAG CTT CGG GGT GCC ATT ATT GAT GCG ATG CAG CCA CAT 674 He Ala Arg Glu Leu Arg Gly Ala He He Asp Ala Met Gin Pro His 210 215 220 CAG CTT CAT GCT TCG GAG ATT CTG TCC AAT GGC TTC CGC CTG TCC TGG 722 Gin Leu His Ala Ser Glu He Leu Ser Asn Gly Phe Arg Leu Ser Trp 225 230 235 CCG CCC CTG CTG ACA GCG GAC TCT GGT TAC TAC GTG CTG GAG TTG GTG 770 Pro Pro Leu Leu Thr Ala Asp Ser Gly Tyr Tyr Val Leu Glu Leu Val 240 245 250 CCC AGT GGC AAA CTG GCA GCC ACA AGA CGC CAA CAG CTG CCC GGG AAT 818 Pro Ser Gly Lys Leu Ala Ala Thr Arg Arg Gin Gin Leu Pro Gly Asn 255 260 265 270 GCT ACC AGC TGG ACC TGG ACC GAC CTC AAC CCA GAC ACA GAT TAC GAA 866 Ala Thr Ser Trp Thr Trp Thr Asp Leu Asn Pro Asp Thr Asp Tyr Glu 275 280 285 GTA TCG CTG TTG CCG GAG TCC AAT GTG CGC CTC CTG AGG CCC CAG CAC 914 Val Ser Leu Leu Pro Glu Ser Asn Val Arg Leu Leu Arg Pro Gin His 290 295 300 TTG CGA GTA CGC ACA CTG CAA GAG GAG GCA GGG CCA GAA CGC ATC GTC 962 Leu Arg Val Arg Thr Leu Gin Glu Glu Ala Gly Pro Glu Arg He Val 305 310 315 ATC TCG CAT ACT AGG CCG CGC AGC CTC CGT GTA AGT TGG GCC CCC GCA 1010 He Ser His Thr Arg Pro Arg Ser Leu Arg Val Ser Trp Ala Pro Ala 320 325 330 CTT GGC CCG GAC TCC ACT CTC GGC TAC CTT GTA CAG CTC GGA CCT CTG 1058 Leu Gly Pro Asp Ser Thr Leu Gly Tyr Leu Val Gin Leu Gly Pro Leu 335 340 345 350 CAG GGC GGA TCC CTA GAA CAC GTG GAG GTG CCA GCT GGC CAG AAC AGC 1106 Gin Gly Gly Ser Leu Glu His Val Glu Val Pro Ala Gly Gin Asn Ser 355 360 365 ACT ACC ATC CAG GGC CTG ACG CCC TGC ACC ACT TAC CTG GTG ACT GTG 1154 Thr Thr He Gin Gly Leu Thr Pro Cys Thr Thr Tyr Leu Val Thr Val 370 375 380 ACT GCC GCC TTC CGC TCG GGC CGC CAG AGG GCG CTG TCG GCT AAG GCC 1202 Thr Ala Ala Phe Arg Ser Gly Arg Gin Arg Ala Leu Ser Ala Lys Ala 385 390 395 TGT ACG GCA TCT GGC GAG CGG ATC CGT GTC CCG CAG GCC ATG CGG CCG 1250 Cys Thr Ala Ser Gly Glu Arg He Arg Val Pro Gin Ala Met Arg Pro 400 405 410 GAG GCC GGA CTG CGG GAG CCC TGACCTTCCT GCCTCGTCCA CCCGAGGGGC 1301 Glu Ala Gly Leu Arg Glu Pro 415 420 CCTCTTCCCT AATCCAGTGA GAGAGGCACC GCTGCTCGTG GTTTTTCTTG TGGATGGAGT 1361 GGGGTGGGGA GATGGGGGTG CTGGTCCTAC CTTTGACCTG CGTAACTCCT CCGGTCGTTT 1421 CCCCACTGGT CATCACCGCC CTTGCCTGAC TCCCGGGAAA CCTGTAGCAA CCCTGGTAGC 1481 CTCACGCGCA ATGACAATCC TCTCCGGTTG CCAGTGGAGT TGAGCACACG GTGGTCCTTG 1541 GGCAACATTT GGCGAGGGGA TGGACAGTGT TTGAGGTCAG GTTGAGACCC AGGAGAAGCA 1601 TTCAGGAGAG GAGGCCACAG AGTTTTCTAC CTGTGCCAAA GACTGGGCCC TCTGGTGGCA 1661 AGGACTACAC ATGGCTTGGA GGAAATGTCC AGGACCCTTC AAGTCCTGCC TGTGCCTAGA 1721 AAGTGGGTAG GAGAAAGGGA GGAGAGAGTA GTGTAGGCAA GGTTCCCAAA GACTTCCTTA 1781 GGGCAAGGAA AGGTAGGGAG AGATACCGGG AGGCTGATGA TGTTGCCAAC TAGTTTTCAT 1841 CAAGATTTTC TGCCAGCCTG GAGGCCAGGA TCTGTCAGGG TCACTGACTC TGCCTTCCTG 1901 CCCAGGACCT GCACTGGGCC CCGCTATCAG TGCGGGGGGG GGGGTGCAGA GTCTTCACAG 1961 GAATGGGGGA TGAGACCTTG GCATGTAGTA CATTGGGGAT AGGAGAGCCC TGCCGTGACA 2021 GACTTACAGG GAGTCTCCTG CTTTAGTGTA GGGAGCAAGG TGACATGCAG GTGGGCTACC 2081 TCCTGTCATC ACTACTGCCC TGGGGCATCT GACAGATACC TAAGGGTAGT CAGGAACAGG 2141 CTTCCTCTCC AGTCCCTATG TACGCAGAGC CCCTCCTCCC CAGAACCTCT TGCCCTAACC 2201 TAAGCTTACT CCATCTCTCT TCCCCACTAA TGACCCAGAC TCTAACAATA ATACAGTAAG 2261 CCAGATGTAA ACTGTGAAGT CGAC 2285 (2) INFORMATION FOR SEQ ID NO: 56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 421 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56: Pro Ala Thr Pro Gly Ala Met Leu Phe Trp Thr Val Leu Ser Met Ala 1 5 10 15 Leu Ser Leu Arg Leu Ala Leu Ala Gin Ser Gly He Glu Arg Gly Pro 20 25 30 Thr Ala Ser Ala Pro Gin Gly Asp Leu Leu Phe Leu Leu Asp Ser Ser 35 40 45 Ala Ser Val Ser His Tyr Glu Phe Ser Arg Val Arg Glu Phe Val Gly 50 55 60 Gin Leu Val Ala Thr Met Pro Phe Gly Pro Gly Ala Leu Arg Ala Ser 65 70 75 80 Leu Val His Val Gly Ser Arg Pro His Thr Glu Phe Thr Phe Asp Gin 85 90 95 Tyr Ser Ser Gly Gin Ala He Gin Asp Ala Val Arg Val Ala Pro Gin 100 105 110 Arg Met Gly Asp Thr Asn Thr Gly Leu Ala Leu Ala Tyr Ala Lys Glu 115 120 125 Gin Leu Phe Ala Glu Glu Ala Gly Ala Arg Leu Gly Val Pro Lys Val 130 135 140 Leu Val Trp Val Thr Asp Gly Ala Ser Ser Asp Ser Val Gly Pro Pro 145 150 155 160 Met Gin Glu Leu Lys Asp Leu Gly Val Thr He Phe He Val Ser Thr 165 170 175 Gly Arg Gly Asn Leu Leu Glu Leu Leu Ala Ala Ala Ser Ala Pro Ala 180 185 190 Glu Lys His Leu His Phe Val Asp Val Asp Asp Leu Pro He He Ala 195 200 205 Arg Glu Leu Arg Gly Ala He He Asp Ala Met Gin Pro His Gin Leu 210 215 220 His Ala Ser Glu He Leu Ser Asn Gly Phe Arg Leu Ser Trp Pro Pro 225 230 235 240 Leu Leu Thr Ala Asp Ser Gly Tyr Tyr Val Leu Glu Leu Val Pro Ser 245 250 255 Gly Lys Leu Ala Ala Thr Arg Arg Gin Gin Leu Pro Gly Asn Ala Thr 260 265 270 Ser Trp Thr Trp Thr Asp Leu Asn Pro Asp Thr Asp Tyr Glu Val Ser 275 280 285 Leu Leu Pro Glu Ser Asn Val Arg Leu Leu Arg Pro Gin His Leu Arg 290 295 300 Val Arg Thr Leu Gin Glu Glu Ala Gly Pro Glu Arg He Val He Ser 305 310 315 320 His Thr Arg Pro Arg Ser Leu Arg Val Ser Trp Ala Pro Ala Leu Gly 325 330 335 Pro Asp Ser Thr Leu Gly Tyr Leu Val Gin Leu Gly Pro Leu Gin Gly 340 345 350 Gly Ser Leu Glu His Val Glu Val Pro Ala Gly Gin Asn Ser Thr Thr 355 360 365 He Gin Gly Leu Thr Pro Cys Thr Thr Tyr Leu Val Thr Val Thr Ala 370 375 380 Ala Phe Arg Ser Gly Arg Gin Arg Ala Leu Ser Ala Lys Ala Cys Thr 385 390 395 400 Ala Ser Gly Glu Arg He Arg Val Pro Gin Ala Met Arg Pro Glu Ala 405 410 415 Gly Leu Arg Glu Pro 420 (2) INFORMATION FOR SEQ ID NO: 57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2521 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW061 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 7..1422 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (2089..2287) (D) OTHER INFORMATION: /label= SAC_24029 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57: GTCGAC GCG ACG GTG GCG GAG CAG TGG GTG CTG GTG GAG ATG GTG CAG 48 Ala Thr Val Ala Glu Gin Trp Val Leu Val Glu Met Val Gin 1 5 10 GCG CTG TAC GAG GCT CCA GCA TAC CAT CTA ATT CTG GAA GGA ATC CTC 96 Ala Leu Tyr Glu Ala Pro Ala Tyr His Leu He Leu Glu Gly He Leu 15 20 25 30 ATA CTT TGG ATA ATC AGA CTC GTT TTC TCT AAA ACT TAC AAG TTG CAG 144 He Leu Trp He He Arg Leu Val Phe Ser Lys Thr Tyr Lys Leu Gin 35 40 45 GAG CGT TCT GAC CTT ACA GCC AAG GAA AAG GAA GAA CTG ATT GAA GAA 192 Glu Arg Ser Asp Leu Thr Ala Lys Glu Lys Glu Glu Leu He Glu Glu 50 55 60 TGG CAG CCA GAG CCC CTC GTC CCC CCG GTC TCC AGG AAC CAT CCT GCT 240 Trp Gin Pro Glu Pro Leu Val Pro Pro Val Ser Arg Asn His Pro Ala 65 70 75 CTC AAC TAC AAC ATC GTC TCC GGC CCT CCA ACC CAT AAC ATC GTG GTG 288 Leu Asn Tyr Asn He Val Ser Gly Pro Pro Thr His Asn He Val Val 80 85 90 AAC GGA AAA GAG TGT GTC AAC TTT GCC TCC TTT AAT TTC CTC GGG TTG 336 Asn Gly Lys Glu Cys Val Asn Phe Ala Ser Phe Asn Phe Leu Gly Leu 95 100 105 110 CTG GCC AAC CCT CGG GTT AAG GCT GCG GCT TTT GCA TCA TTA AAG AAG 384 Leu Ala Asn Pro Arg Val Lys Ala Ala Ala Phe Ala Ser Leu Lys Lys 115 120 125 TAT GGC GTG GGT ACC TGT GGT CCC AGA GGG TTT TAT GGC ACA TTT GAT 432 Tyr Gly Val Gly Thr Cys Gly Pro Arg Gly Phe Tyr Gly Thr Phe Asp 130 135 140 GTC CAT CTG GAT TTG GAA GAG CGC CTG GCA AAG TTT ATG AAG ACC GAA 480 Val His Leu Asp Leu Glu Glu Arg Leu Ala Lys Phe Met Lys Thr Glu 145 150 155 GAA GCT ATC ATT TAC TCC TAT GGC TTC TCC ACC ATA GCC AGT GCG ATT 528 Glu Ala He He Tyr Ser Tyr Gly Phe Ser Thr He Ala Ser Ala He 160 165 170 CCT GCG TAC TCT AAG AGA GGG GAC ATT GTT TTT GTG GAC AGT GCA GCC 576 Pro Ala Tyr Ser Lys Arg Gly Asp He Val Phe Val Asp Ser Ala Ala 175 180 185 190 TGC TTT GCT ATC CAG AAA GGA CTA CAG GCA TCA CGC AGT GAC ATT AAG 624 Cys Phe Ala He Gin Lys Gly Leu Gin Ala Ser Arg Ser Asp He Lys 195 200 205 TTA TTC AAG CAC AAT GAC GTA GCT GAC CTG GAG CGA CTG CTA AAA GAA 672 Leu Phe Lys His Asn Asp Val Ala Asp Leu Glu Arg Leu Leu Lys Glu 210 215 220 CAA GAG ATT GAA GAT CAA AAG AAT CCT CGA AAG GCC CGT GTG ACT CGG 720 Gin Glu He Glu Asp Gin Lys Asn Pro Arg Lys Ala Arg Val Thr Arg 225 230 235 CGA TTC ATC GTC GCG GAA GGA TTG TAT ATG AAC ACT GGA ACC ATC TGC 768 Arg Phe He Val Ala Glu Gly Leu Tyr Met Asn Thr Gly Thr He Cys 240 245 250 CCT CTT CCA GAA CTG GTG AGG TTA AAG TAT AAA TAC AAA GCA AGG ATC 816 Pro Leu Pro Glu Leu Val Arg Leu Lys Tyr Lys Tyr Lys Ala Arg He 255 260 265 270 TTC CTG GAG GAG AGC CTG TCG TTC GGA GTC CTT GGG GAG CAT GGG CGA 864 Phe Leu Glu Glu Ser Leu Ser Phe Gly Val Leu Gly Glu His Gly Arg 275 280 285 GGA GTC ACC GAG CAC TAT GGG ATC AGT ATT GAC GAC ATC GAC CTT ATC 912 Gly Val Thr Glu His Tyr Gly He Ser He Asp Asp He Asp Leu He 290 295 300 AGT GCT AAC ATG GAG AAT GCG CTC GCT TCT GTT GGG GGC TTC TGC TGT 960 Ser Ala Asn Met Glu Asn Ala Leu Ala Ser Val Gly Gly Phe Cys Cys 305 310 315 GGC CGC TCT TTC GTG GTT GAC CAT CAG CGG CTC TCT GGC CAA GGA TAC 1008 Gly Arg Ser Phe Val Val Asp His Gin Arg Leu Ser Gly Gin Gly Tyr 320 325 330 TGC TTT TCA GCT TCA CTG CCC CCC CTG CTA GCC GCT GCC GCC ATT GAG 1056 Cys Phe Ser Ala Ser Leu Pro Pro Leu Leu Ala Ala Ala Ala He Glu 335 340 345 350 GCC CTC AAC ATC ATG GAG GAG AAC CCA GGG ATT TTT GCA GTT TTA AAG 1104 Ala Leu Asn He Met Glu Glu Asn Pro Gly He Phe Ala Val Leu Lys 355 360 365 AAA AAG TGC CAG ACC ATC CAC AAG TCC CTA CAA GGG GTT TCC GGT TTA 1152 Lys Lys Cys Gin Thr He His Lys Ser Leu Gin Gly Val Ser Gly Leu 370 375 380 AAA GTG GTG GGG GAG TCC CTT TGC CCA GCG CTT CAC CTC CAG CTG GAA 1200 Lys Val Val Gly Glu Ser Leu Cys Pro Ala Leu His Leu Gin Leu Glu 385 390 395 GAG AGC ACG GGC TCT CGG GAG AGA GAT ATG AAG CTG CTT CAG GAG ATT 1248 Glu Ser Thr Gly Ser Arg Glu Arg Asp Met Lys Leu Leu Gin Glu He 400 405 410 GTA GAG CAA TGC ATG AAT AAG GGC ATC GCA TTG ACT CAG GCA CGC TAC 1296 Val Glu Gin Cys Met Asn Lys Gly He Ala Leu Thr Gin Ala Arg Tyr 415 420 425 430 TTG GAC AAG GAA GAG AAG TGC CTT CCT CCT CCA AGC ATC AGG GTT GTG 1344 Leu Asp Lys Glu Glu Lys Cys Leu Pro Pro Pro Ser He Arg Val Val 435 440 445 GTC ACC GTG GAG CAG ACA GAC GAA GAG CTG CAG AGG GCT GCA GCC ACC 1392 Val Thr Val Glu Gin Thr Asp Glu Glu Leu Gin Arg Ala Ala Ala Thr 450 455 460 ATC AGG GAG GCG GCC CAG GCT GTG CTT TTG TAGGCTCCTG CCCAGTGCTT 1442 He Arg Glu Ala Ala Gin Ala Val Leu Leu 465 470 GCGACCATGT CACCTGCAGA CAGAACTACT CAGACCTCCA GCTGCCCAGG GCGTGGAGTG 1502 CTGCCCAGGG CGTGGCTGCC CTTGAGTCCA CAGCCAGAAT GGATGGCTTT ACCCAGCAGG 1562 CTTCCAGAGG ATGGCAGACG ACGGTGTAAC ACTGGTGTTT ATGCGGTGCC ATGGCTCTGT 1622 CTCTTATACT CGCCTTTGTT TAAAACTGGA GCTTCCGTTT TCCCTCTCCC GCCTGTGGGA 1682 ACAATTCGAT AAGCACTCCT CTGTATTCCA TACAAAAGGA CTTGCAGCTG AGAGGAAGTC 1742 TCCACGCACC ACAGTTACTG TGGGATGATA GACTGTGGCC TCCCAGGTCC TTCGGGTAGA 1802 GCTCAGTGGT GGCTGCTGTG CAGACAACTC CTGTGTGTCA AAACTGTCAT AGAACATGTT 1862 GATCCTAGAA CTCTGTGTGC TCCAGTTACT GATGCTGTCG TGTCTAATCT GAGCTTCACT 1922 AACAATAGTC ATACCGCTCC CTAAGCAATA ATCTGAATCA AACATTATTT TATTTTTGTG 1982 TAATTGACTT TATATTTTTT ATATATTCTC TAGTCAGTTT TGGGAAGAGG GTTATTATTC 2042 TGGTCCCCAA ATATATAAAT CATATCCTTG GTATTTTTTA ATATGTACGG TGTCCTTTTT 2102 CATGGTGGTT TTGTCCAGGA ACATAGAACT GTGGGCCTTT TCTAAGCTGA GAAAAGAGAG 2162 AACTTTCTTC TTTCGTTCTA TAAATTCCAG ATGCCTCAGA AAATAGGAAT GCTCTGAAAA 2222 CTGCTGCTGT CCTTAGCGAG CGTGCTGAGG GGTGTAACGG CTTGTGACAT GTGCCGCGAT 2282 CGTGTACATG GAAGGCCATT ACTCCCTCTC GCTGCACAGG CAGAGGAATG GGGCCTCTAA 2342 CCGTCGTTTT CGGATGTTCA TTCATGTTAA CAGTGGACGG CATCTTCCTA AGTGATCTGT 2402 GACATGTTTA ATGTGTCTAT TTCATACGTG CCTTGTGAAT GCTGCTGCTG TGAGGGTACG 2462 GGGATGAGTC TGTTTTGGTT TGGTTTTTAA TGAAATAAAC CTCCAAGAGC CTACAAAAA 2521 (2) INFORMATION FOR SEQ ID NO: 58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 472 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58: Ala Thr Val Ala Glu Gin Trp Val Leu Val Glu Met Val Gin Ala Leu 1 5 10 15 Tyr Glu Ala Pro Ala Tyr His Leu He Leu Glu Gly He Leu He Leu 20 25 30 Trp He He Arg Leu Val Phe Ser Lys Thr Tyr Lys Leu Gin Glu Arg 35 40 45 Ser Asp Leu Thr Ala Lys Glu Lys Glu Glu Leu He Glu Glu Trp Gin 50 55 60 Pro Glu Pro Leu Val Pro Pro Val Ser Arg Asn His Pro Ala Leu Asn 65 70 75 80 Tyr Asn He Val Ser Gly Pro Pro Thr His Asn He Val Val Asn Gly 85 90 95 Lys Glu Cys Val Asn Phe Ala Ser Phe Asn Phe Leu Gly Leu Leu Ala 100 105 110 Asn Pro Arg Val Lys Ala Ala Ala Phe Ala Ser Leu Lys Lys Tyr Gly 115 120 125 Val Gly Thr Cys Gly Pro Arg Gly Phe Tyr Gly Thr Phe Asp Val His 130 135 140 Leu Asp Leu Glu Glu Arg Leu Ala Lys Phe Met Lys Thr Glu Glu Ala 145 150 155 160 He He Tyr Ser Tyr Gly Phe Ser Thr He Ala Ser Ala He Pro Ala 165 170 175 Tyr Ser Lys Arg Gly Asp He Val Phe Val Asp Ser Ala Ala Cys Phe 180 185 190 Ala He Gin Lys Gly Leu Gin Ala Ser Arg Ser Asp He Lys Leu Phe 195 200 205 Lys His Asn Asp Val Ala Asp Leu Glu Arg Leu Leu Lys Glu Gin Glu 210 215 220 He Glu Asp Gin Lys Asn Pro Arg Lys Ala Arg Val Thr Arg Arg Phe 225 230 235 240 He Val Ala Glu Gly Leu Tyr Met Asn Thr Gly Thr He Cys Pro Leu 245 250 255 Pro Glu Leu Val Arg Leu Lys Tyr Lys Tyr Lys Ala Arg He Phe Leu 260 265 270 Glu Glu Ser Leu Ser Phe Gly Val Leu Gly Glu His Gly Arg Gly Val 275 280 285 Thr Glu His Tyr Gly He Ser He Asp Asp He Asp Leu He Ser Ala 290 295 300 Asn Met Glu Asn Ala Leu Ala Ser Val Gly Gly Phe Cys Cys Gly Arg 305 310 315 320 Ser Phe Val Val Asp His Gin Arg Leu Ser Gly Gin Gly Tyr Cys Phe 325 330 335 Ser Ala Ser Leu Pro Pro Leu Leu Ala Ala Ala Ala He Glu Ala Leu 340 345 350 Asn He Met Glu Glu Asn Pro Gly He Phe Ala Val Leu Lys Lys Lys 355 360 365 Cys Gin Thr He His Lys Ser Leu Gin Gly Val Ser Gly Leu Lys Val 370 375 380 Val Gly Glu Ser Leu Cys Pro Ala Leu His Leu Gin Leu Glu Glu Ser 385 390 395 400 Thr Gly Ser Arg Glu Arg Asp Met Lys Leu Leu Gin Glu He Val Glu 405 410 415 Gin Cys Met Asn Lys Gly He Ala Leu Thr Gin Ala Arg Tyr Leu Asp 420 425 430 Lys Glu Glu Lys Cys Leu Pro Pro Pro Ser He Arg Val Val Val Thr 435 440 445 Val Glu Gin Thr Asp Glu Glu Leu Gin Arg Ala Ala Ala Thr He Arg 450 455 460 Glu Ala Ala Gin Ala Val Leu Leu 465 470 (2) INFORMATION FOR SEQ ID NO: 59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 598 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW062 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (87..223) (D) OTHER INFORMATION: /label= SAC_24443 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59: TTTTTGTGAG CAAATCCAAA TTTATTTTAA TGCCATGTCA TTTCAAAAAC CCCAGCCTTG 60 GTTCCCTGGA ACAGCATGCC AGAGGTACAA AGTGTAACCT TCCTCTATAA ACCCCCAGCA 120 AGTCATCCAA GTCCTCAGCT TCAGAAAGTC AGTTCTCTTC AGTCTACTCC TCTGGTTCCT 180 GGTTTTTCTT TCAAGGAAGG CAACTTAAAA ATTAGGTAGC TGAGGTTCCA ATGTTGGTGG 240 CTAACCTTGC CTCCTCTTTT GTTCTGTAGT AGGGCCACAA ACCTTGACCA GGCAGAGTAG 300 TAGAAAAGTA GAAAGAGGGG CTTGACGACG GTGGATTTTG ACTCCTGATT TTATTATTCA 360 ATTTCTTTTT CTACTAAAAG TAGTCTTCGG TGGTTGGGAA GCCTGGCCTC CCAACACCAG 420 AGTCAGTCGG AGCTGGTTTT TTTGTTGAAA GGAGTGGGCG GGTGGGTGGG GGACCGGGAT 480 GAGGGCAGAA CCCCGCTCTG CTGGTAGTCT TGGGTGGAGA AGACGAACTG CACTTGACAG 540 AGCCTGGGGG TGCGGTGGGA GGGGGTGAGG CAGGAGTGAC AGCTGGGGAG GGGACCCA 598 (2) INFORMATION FOR SEQ ID NO: 60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3305 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW066 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 759..906 (D) OTHER INFORMATION: /label= SAC_24521 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60: ATTCGCGGCC GGCTCGACTT TTTTTTTTGT GATATAAAAA ATTTATTTTA GAAATCACAT 60 CTTTAAAAAA CAACATAGAA GGTTATCCTG ACCAGATATA AATTCTTCAT TCAATGCCAG 120 GGTGTTATGT GGTACAATTA GCGGGATGTT CTGTGAGGAG AATGAGTCTG TGTGATACTC 180 TCGACATGTA CACCAGCTCA AACGTTAATG CGGCTTTTAA AAGGAAGGAG AGAGGAAGGC 240 AGCGAGAGAG GAGGAAACTG TTTTGGAAAC AGAAGAGCAT CTCCGTCCTG CACCTGTCAG 300 CCCTGAAACT CCCGGCCCTT GAGACCAGCC CAGCAGAGGC TGCACGAANN NGCATCATTT 360 TAATTCACAA GTGACTGCAG CACCCTGGCA TCTTGTGCTG GGAGTGTGGG TGGGAACAGA 420 GGTGACAAGT CTGCTCTGTA GTGTCATAGC CAGAGAGCAA CAGGGACTCT AGAGGAAGAA 480 GAGCAAAGCT TGCCTAGACA GAACGGGTTG TCCCTGTCCC TGTCCATCAG CTTTCTTATA 540 ACCTATGGNT AGCCAGGATC AAATACCTGA AAGTCAGAAT GTAAAATAAA AGTGTCAGTT 600 AACACTTATT GCGGACAGAA ATACAGCTCT TTACGCCTAC AACCATAAAC CCAGTGGTGA 660 GGCTGGGACA GACCTTTTAT GCCGAAGTTC TCACAACTCG GGACTGACTT ACTGGGGCCT 720 GGTCACTGCT TAATTGGTGA CCTCACACCA TTTCAGGTAC TTCTGCCCAG CTCCTGATTC 780 CTCTTCAGGA GAAACAGGAA GCAGACTTTG TTAGTAAGTG GGTCATGCAG GGCTGGGCCG 840 CCTACATGGG ACTTAACACA GAGAGAATAC TGCCAGCTTC CCAAACACTT CAAGAGAGAA 900 AAATGTCCAG ACGTGGGTGC TGCAGCAACC TTCCAAGAGT GAGGCCCCTG CACCCTCCTG 960 CACCCTCGGC TGGGGACAGT GGGCTCTGGT GGCTTGAACT GAGTAGATCG GATCATTCCC 1020 TCCTCTTTCT GAGACAAGGC TTCACTGTGT AGCCCNNGCT GCCCTGGAGC TCACTATTTA 1080 GACCAGGCTA GGATCTCACA GAGAACCACC TGCCTCTGGC CTCTCAAGAG CTGGGATTAA 1140 GGTGTGAAAA GGGGGCTAAT GTAGCCCAGG CTGGCTCCTG CTCCACAGGG CTTGCAGGCC 1200 AGTTCTGGAT CCTACCAGCA AGTACAAGCT GGTACCCAGA GGACGCTGCA GGATGGAAGG 1260 ACGGAAGGCC AGGAGCCTTC GTTTGATTTG ACGGGAAGGA GGAGGAACAG TGAGGTTGTG 1320 CATCTGAGCT TTATTACCAG GACGATGATG TCACCTCAGG AAGGGACTGG GATCCCTGCA 1380 AGTGGTTCCA CATGGGACCC AGGTCCTCAG AGATGTGGCC CTCCTTGTGT GCCAAAATGC 1440 ATCTGGAAAG AAAATACAGA AGGGGAGGGA CAGCATAGGA GGAGACAAGT GTGACCCGAG 1500 GCCCAGGAAG TACTTCCATA TTCTGTCCTT CTCCAGGCAC GAGAGTTGAA GGCCGTGCCA 1560 AGCCCTGCAC TCGCTAAGCT GGTGAAGACC ACACCAAAAT CACTGTGACA GGACAGCTGC 1620 ACAGATCTGT TTCCGACTTT TCCCACCACG ATTCTACACC AAGGTAAAAA AGAGCTTCCA 1680 CCACAAATCC AAGGCAGGAG CTGGGCGGCC ACACACCCGC CACAGATGGT GCAAGTTGCT 1740 CACTTCCGCA GCCGGTGGCA GGACAGGGAG GAGGGCAGAG TCCTGAGACA AGAACCCCAG 1800 AGCGGGGCCA GTTCAGTCAG TGGTGGACCT CCGGTACCAG AACCGAGCTC GGAAGTCGTC 1860 GCTGCACGTC ATGAAGCCAG GGTTGGTCGG GGAGTGCACT ATGCAGCGCA CAATGTTGTT 1920 GTGGCCCAGG GACAGCAGGT TCCTGCGCTC AGCTGTCCTA GAGTCCCAGC AGCACAGGCT 1980 GATGGTCCTT TCGTCCGGCA GCAAAATATA GTCCTCAGTG TGGTTGAACA CAGCCTGTGT 2040 CCGGGTGCAC TTGCCGTCCA CTCAGCCCTG CGCCTGTGTA CCTCACCAGT GTCCGTCCCG 2100 TGGATATTTC CCCAGAGTTT AGCTACAGAG TCTTTYCCNN GAGTTTAGGC CTACAGAGTC 2160 TTTTCCACTT GAGAGGATGT ACTTGGAATT CTTGGAGAAA ATGGCAGAAC AGACTTCTGC 2220 CCCGTCGTGA GCTTTCTCAA AGGTTGTGAT GCAGCGATTG GAGACGCCGT CCCACAGCTT 2280 GATGCAGCCG TCCTTGCTGC CAGTGACATA CATGTTGGCA CTAGGGTTAT AGTTGACAGA 2340 GCAGATGGCG TCGGTGTGCT GGTCTTGGGG ATTGCAGGAG ACGAAACACT GGAAGGTGTT 2400 GATGTCATAG AGGCGAAGCG TGGGATGCTG GGTCCCGACC AGGATGAAGT CTCCAGAAGG 2460 GTGGAACGAG ATGGAGCGCA GCATCTCAGC TTCCTGAATG TATTTAAAGG CTCTTTTTGC 2520 AGAGGGTTTG GAATAATCAA ACAATTTTAG AGTATAATCC CTTGAGCCGG AGGCCAGGAT 2580 CTGTTCTGTT GGGTGAAAAG CGAGACACGT GACTTCATCC ACATGGTCGT AAAGAGTTCG 2640 GATCACTGGG TGGTTCTCCA TGTTCTGTTG TGCAGTCTCA TTCATCATGA CCCTCGATGG 2700 GCATGGCGCT CTTGGCCAGC ATCCTCTCTG TGTCCAGTAT CTTGATGGAA GCATCCGCAG 2760 ACCCTGTGGC TATCAACTGC CCATCTCTGC TGTAGGTGGC CACTCGGCAT GGGCCTTTGT 2820 GGGAGGTGAC ATAACAGGTT TCATACTCCG AAGCCTCGGG TGACATTGTT TGGACGTCTG 2880 CATCAAACTC CAGGTCAATN CTGTGCCAGG GGCAACCGTG TCAGAGCGAC CAATGGCATA 2940 CTGAACTGCA GTGTCATCGT TCTCCATCCC TAGCTTGATG AGGTGCAGGA GCTGCTCCGA 3000 GGGCGCACAC ACCGACTGTG GCTTGATCTC GTTGATGAGG CCATTGCGAT GCTAATGTAT 3060 CCGTCATAGA GCAGCTGGCT GATGATCAGC TTGTAGAGCT GCTGGCGGTC CTTCAGGCCC 3120 ACTTTGGTTC TGTACATTCT GCACAAGAGG ATGACAGTTC CCCTGACTTC TCCGAGCTGA 3180 TCACCTCCGC GACAGCCTTG AATCCAAAGG ACTGTGAGTG ACCGGCAAAC GCCCGANCCT 3240 TGGAGAGCAC NGCGGGCGAT AGAACGGCCG TAGATCGGAC AGGCCGTTGG TGCACCGTCG 3300 ACCGG 3305 (2) INFORMATION FOR SEQ ID NO: 61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2099 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW069 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1360..1893 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1744..1885 (D) OTHER INFORMATION: /label= SAC_24477 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61: GTCGACGCAT CCAGGCAGGC ATGGAGCAGG TAGGGCTCAG AGTTCTACAT CTTCATCTGG 60 AGGCTACTAT GAGGAGACCG ACTTCCAGGC AGCTAGGAAG CCCATGCTCA CAGTGACAGA 120 CCTTCTCCAA CAAGGTTATA CCTCCTAATC GTGCCGCTCC CTGGGCCAAG CATATGCAAA 180 CCTTCACACA GGTCTTCCTC CTACACAGTG GGGCTTCTGG GCCCCACTCA CGGCCAGTAC 240 ATGGCAAAAG ACATTAAAGA TGCACTTGGA CCAGCTCAGG GCCCTGTTCT GCAGCCAGGT 300 ATCATGGATG GAGGAAGTCC TGACTGAAAC AAAAATGTCT GTCCGCATTG TCATCTTTGA 360 GAGCCTGAAC AAACCCCGAA CACCTCTGAC CTGGCACAGG GACCCTGAGT CTGCCTGCCT 420 GGCACTCTGA ACTTGCTGGC TACTGGGCTG AAGTCTCAGG ATCGAGGTAC AAGGACAAAG 480 CCTGTTGGTA TTATGTAGAC AGGAGCCCCA GGGGGCTCAG AGCAGGGGTT TACCGTTACT 540 CTTGGTCCAG CCGGCACAGT GGTCTTCCCT CAGTTTTTGT TTTTGTTTTT TTGTTTTTTT 600 GTTTTGTTTT TTGTTTTTTG TTTGTTTGTT TGTTTTGTTT TGTTTTTTGG TGCTGTTGAC 660 CCTGCAGTCT GGACTGCCCC CTTGGGCAAT ACATTTTGAT GGAAACCAAC TTCTGTGTTC 720 CCAGATCGGC AGCCTCTCCA TGCCGAGCAC CCCTGTTCTA GCTAACCCGG ACATGCTACA 780 CCCCTGCCGT GGTTGGTTCA TCTCCCCACT CCCCGCCGTG TCTTAATAAC ACGGTGGATG 840 GATGGACAGA CGGACAGATG AAGCTTTGAC AGCTAGCCAC TGCTCTGCTC CTTTTCTCTT 900 GTCTTCTGAG TAAATTCTCA AACTCAAGCC TCCCAGGGGG AGCCCAGAAC CCCACCCACC 960 ACTAGTGAAA AAGCAGCTTT TTAGGCAGCT CAGAGAGTGT CCGGAGCAGG GTTCCTACAG 1020 GCTCAGGTTG GGGGCAGTTT CAGTGTGTGG CTGCCGGCCC AGGGCCCTCC CTGGTCAGCA 1080 CCTAGGTAGA GAGGAAGCAG GAAGGACCAA GTCCAGCTCA AAGGAACCAG TGAGGCTGGT 1140 TGAGAGCAGA CGGTGGGTAT GGGTCTGTGA AAAGAAAAGT AGGCCGTTGG GAGCCCACCG 1200 GAGGACAGTC TGGCTCAAGG CATCACACCT GGTTGCAGCA GCCTCCGAGA CAGCAGCCCG 1260 TGGGTGTGAA CTTGGCTCCA TCTTGGCTGA ATTCTGCTGC CCCAGAGAAG AATCTGGCAC 1320 CGGAGTGGAC CCAGATACGT GTCACAGCCT TGGAAATCG ATG GCA GCG AGA CCC 1374 Met Ala Ala Arg Pro 1 5 TTT ATT GGG CAC CTA GAG ATT TCC GAG AGG CGG TTC CTA ACA TTG TCA 1422 Phe He Gly His Leu Glu He Ser Glu Arg Arg Phe Leu Thr Leu Ser 10 15 20 TTC CTT TCC CAC AGG CCT CAG GTC CAG GCC CAA AGC CAA GTG ACT GCC 1470 Phe Leu Ser His Arg Pro Gin Val Gin Ala Gin Ser Gin Val Thr Ala 25 30 35 CTC ATC GGC TCA GCA CAT CGG CGG GTG CTG GAT GTG CCG CCT GCA GAG 1518 Leu He Gly Ser Ala His Arg Arg Val Leu Asp Val Pro Pro Ala Glu 40 45 50 GCT CTT CGG GGC CAG GCT GGG ACT GGG CCC CTG AGA AAA CCC AAA CTC 1566 Ala Leu Arg Gly Gin Ala Gly Thr Gly Pro Leu Arg Lys Pro Lys Leu 55 60 65 TGT GCC TTA CCC AGT CAG GAT CCT TGG GAG CCT TGG CCC TCG ATG CCA 1614 Cys Ala Leu Pro Ser Gin Asp Pro Trp Glu Pro Trp Pro Ser Met Pro 70 75 80 85 GGA CCT GGC CTA GCA TCA CCC TGG GCC ACC TGC ACG TTC ATG GCC TCA 1662 Gly Pro Gly Leu Ala Ser Pro Trp Ala Thr Cys Thr Phe Met Ala Ser 90 95 100 CCA TCT GCT TTG CGA ACC ACT ACC CAC CCC CTG TCG CAT GCA CCT TCC 1710 Pro Ser Ala Leu Arg Thr Thr Thr His Pro Leu Ser His Ala Pro Ser 105 110 115 ACC CCT GCG GTG TCT GAC TCT AGG GAG ATA GGT ACA GAT GTC TGT GAT 1758 Thr Pro Ala Val Ser Asp Ser Arg Glu He Gly Thr Asp Val Cys Asp 120 125 130 GGG CTG AGA CAT CCC CCA CCC CCC ACG GCT CAT TGG TTT CTT TTA GCT 1806 Gly Leu Arg His Pro Pro Pro Pro Thr Ala His Trp Phe Leu Leu Ala 135 140 145 GAG TGC TGT TTT CTG TGT CTT TAC TCT GCT ATG ATG ACT TGG GGG GTT 1854 Glu Cys Cys Phe Leu Cys Leu Tyr Ser Ala Met Met Thr Trp Gly Val 150 155 160 165 AGT GAG GGC CTG AGG GAT GCT TGT TGG AAG TAC TGT GGG TAGGGCCTGG 1903 Ser Glu Gly Leu Arg Asp Ala Cys Trp Lys Tyr Cys Gly 170 175 TAGGTCCTTA GGGAACAAAC AAACAAAAGG CTCATCTGCT CCTGGGTGGT GACCTGGCCA 1963 CAGCACCTGT CATCTCCCTT GGTGTCTGCC CAGTGGGGAC GAGCTTCCCT GGCTCAACCC 2023 CTATCAGGTG TGCACTGTTG AGTCTGCGGG CCAGCCGGGA CTTTAACCAA TAAAGAGCAA 2083 CCTTGTCTGT CAAAAA 2099 (2) INFORMATION FOR SEQ ID NO: 62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 178 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62: Met Ala Ala Arg Pro Phe He Gly His Leu Glu He Ser Glu Arg Arg 1 5 10 15 Phe Leu Thr Leu Ser Phe Leu Ser His Arg Pro Gin Val Gin Ala Gin 20 25 30 Ser Gin Val Thr Ala Leu He Gly Ser Ala His Arg Arg Val Leu Asp 35 40 45 Val Pro Pro Ala Glu Ala Leu Arg Gly Gin Ala Gly Thr Gly Pro Leu 50 55 60 Arg Lys Pro Lys Leu Cys Ala Leu Pro Ser Gin Asp Pro Trp Glu Pro 65 70 75 80 Trp Pro Ser Met Pro Gly Pro Gly Leu Ala Ser Pro Trp Ala Thr Cys 85 90 95 Thr Phe Met Ala Ser Pro Ser Ala Leu Arg Thr Thr Thr His Pro Leu 100 105 110 Ser His Ala Pro Ser Thr Pro Ala Val Ser Asp Ser Arg Glu He Gly 115 120 125 Thr Asp Val Cys Asp Gly Leu Arg His Pro Pro Pro Pro Thr Ala His 130 135 140 Trp Phe Leu Leu Ala Glu Cys Cys Phe Leu Cys Leu Tyr Ser Ala Met 145 150 155 160 Met Thr Trp Gly Val Ser Glu Gly Leu Arg Asp Ala Cys Trp Lys Tyr 165 170 175 Cys Gly (2) INFORMATION FOR SEQ ID NO: 63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1210 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW070 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (639..928) (D) OTHER INFORMATION: /label= SAC_24286 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63: GTCGACGCAG ATTTTGATGG CGTCCTTTAT CATATTTCAA ATCCTAATGG AGACAAAACA 60 AAAGTGATGG TCAGTATTTC TTTGAAATTC TACAAGGAAC TTCAGGCACA CGGAGCTGAT 120 GAGTTACTAA AGAGAGTATA CGGAAGTTTC TTGGTGAACC CAGAATCAGG ATACAATGTG 180 TCTTTGCTAT ATGACCTGGA AAATCTACCT GCATCCAAGG ATTCTATTGT GCATCAGGCT 240 GGCATGTTGA AGCGAAATTG TTTTGCCTCT GTGTTTGAGA AATACTTCCA ATTCCAAGAA 300 GAGGGCAAAG AAGGAGAGAA CAGAGCAGTT ATCCATTATA GAGATGATGA GACCATGTAT 360 GTGGAATCTA AAAAAGACAG AGTCACAGTA GTCTTCAGCA CAGTTTTTAA GGATGACGAC 420 GATGTGGTCA TTGGAAAGGT GTTCATGCAG GAGTTCAAAG AAGGACGAAG AGCCAGCCAC 480 ACAGCCCCCC AGGTCCTTTT TAGCCACAGG GAACCTCCTC TAGAACTGAA AGACACAGAT 540 GCTGCCGTGG GTGACAACAT TGGCTACATC ACCTTTGTGC TGTTCCCTCG CCACACCAAT 600 GCCACTGCTC GAGACAACAC CATCAACCTG ATCCACACGT TCCGGGACTA TCTGCACTAC 660 CACATTAAGT GCTCTAAGGC CTATATTCAT ACACGAATGC GAGCAAAAAC ATCCGACTTC 720 CTTAAGGTGC TCAACCGTGC ACGCCCAGAT GCCGAGAAAA AAGAAATGAA AACAATCACG 780 GGGAAGACTT TTTCATCCCG CTAACTCTTG GGAACTGAGG AGGAAGCACT GTTGACCGAA 840 GGCTGGACCG CTTGCTACTG GATAATCGTA GCCCTTCATG TTGCACCTTC TCCAGGTTCT 900 TAAGGGATTC TCCGTTTGGG TTCCATTTTG TACGAGTTTG GCAAATACGC TGCAGAAACG 960 AGCTGTGCTT GCAAGGACTT GATAGTTCCT AAGAATTAAA AACTCACTTG ATCAACTTAA 1020 TTCCCTTTTA TTTTTCCTCC CTCACTCCCC TTCCTTTTCC AAGCTGTTTG CTTTGCAATA 1080 TGTTACTGGT AATGAGTTGC AGGTAATGCA ATCTTAACTT GTTTTCTTCT AAGTATTTGA 1140 GTTCAAAACT CCTGTATCTA AAGAAATACG GTTGGGGTCA TTAATAAAGA AAATCTTTCT 1200 ATCTTAAAAA 1210 (2) INFORMATION FOR SEQ ID NO: 64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1844 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW073 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 9..1223 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 598..1036 (D) OTHER INFORMATION: /label= SAC_24456 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64: GTCGACCT GCC GGC CGA CAG GGC CGC GGG ATG AGG AAG CGG ACC GAG CCC 50 Ala Gly Arg Gin Gly Arg Gly Met Arg Lys Arg Thr Glu Pro 1 5 10 GTC ACC TTG GAG CAT GAG CGC TGC GCC GCC TCA GGC TCG TCT TCC TCC 98 Val Thr Leu Glu His Glu Arg Cys Ala Ala Ser Gly Ser Ser Ser Ser 15 20 25 30 GGC TCG GCC GCC GCG GCG CTG GAC GCC GAC TGC AGC TTG AAG CAG AAC 146 Gly Ser Ala Ala Ala Ala Leu Asp Ala Asp Cys Ser Leu Lys Gin Asn 35 40 45 CTG CGT CTG GCG GGC AAG GGG ACG GCA GAG CCG CAC AGC GCA TCC GAC 194 Leu Arg Leu Ala Gly Lys Gly Thr Ala Glu Pro His Ser Ala Ser Asp 50 55 60 GCG GGC ATG AAG CGG GCT CTG GGC AGA CGG AAG AGC CTG TGG TTC CGA 242 Ala Gly Met Lys Arg Ala Leu Gly Arg Arg Lys Ser Leu Trp Phe Arg 65 70 75 CTA AGG AAG ATA CTT CTC TGT GTT TTG GGG TTC TAC ATT GCC ATT CCA 290 Leu Arg Lys He Leu Leu Cys Val Leu Gly Phe Tyr He Ala He Pro 80 85 90 TTT CTT GTC AAA CTG TGT CCT GGG ATA CAG GCC AAA CTG ATA TTC TTA 338 Phe Leu Val Lys Leu Cys Pro Gly He Gin Ala Lys Leu He Phe Leu 95 100 105 110 AAT TTC GTG AGG GTT CCC TAT TTC ATT GAC TTA AAA AAG CCA CAG GAT 386 Asn Phe Val Arg Val Pro Tyr Phe He Asp Leu Lys Lys Pro Gin Asp 115 120 125 CAA GGT TTG AAT CAC ACC TGC AAT TAC TAC CTC CAG CCC GAG GAT GAT 434 Gin Gly Leu Asn His Thr Cys Asn Tyr Tyr Leu Gin Pro Glu Asp Asp 130 135 140 GTC ACT ATT GGA GTC TGG CAC ACC ATT CCC TCT GTC TGG TGG AAG AAT 482 Val Thr He Gly Val Trp His Thr He Pro Ser Val Trp Trp Lys Asn 145 150 155 GCC CAA GGG AAG GAC CAG ATG TGG TAT GAG GAT GCT CTG GCT TCT AAC 530 Ala Gin Gly Lys Asp Gin Met Trp Tyr Glu Asp Ala Leu Ala Ser Asn 160 165 170 CAC CCC ATC ATC CTG TAC CTG CAT GGG AAT GCA GGC ACC AGA GGA GGT 578 His Pro He He Leu Tyr Leu His Gly Asn Ala Gly Thr Arg Gly Gly 175 180 185 190 GAC CAC CGT GTG GAG CTG TAC AAG GTG CTG AGT TCC CTT GGT TAC CAC 626 Asp His Arg Val Glu Leu Tyr Lys Val Leu Ser Ser Leu Gly Tyr His 195 200 205 GTG GTC ACC TTC GAC TAC AGA GGT TGG GGT GAC TCA GTA GGA ACA CCA 674 Val Val Thr Phe Asp Tyr Arg Gly Trp Gly Asp Ser Val Gly Thr Pro 210 215 220 TCA GAG CGA GGC ATG ACA TAT GAT GCA CTC CAT GTT TTT GAC TGG ATC 722 Ser Glu Arg Gly Met Thr Tyr Asp Ala Leu His Val Phe Asp Trp He 225 230 235 AAA GCA AGA AGT GGT GAT AAT CCT GTG TAT ATC TGG GGC CAT TCG CTG 770 Lys Ala Arg Ser Gly Asp Asn Pro Val Tyr He Trp Gly His Ser Leu 240 245 250 GGC ACT GGA GTG GCA ACA AAT CTG GTC CGG CGC CTT TGT GAG CGA GAG 818 Gly Thr Gly Val Ala Thr Asn Leu Val Arg Arg Leu Cys Glu Arg Glu 255 260 265 270 ACG CCA CCA GAT GCC CTT ATA TTG GAG TCT CCG TTC ACA AAT ATT CGT 866 Thr Pro Pro Asp Ala Leu He Leu Glu Ser Pro Phe Thr Asn He Arg 275 280 285 GAA GAA GCA AAG AGT CAT CCA TTT TCA GTG ATA TAC AGA TAC TTC CCA 914 Glu Glu Ala Lys Ser His Pro Phe Ser Val He Tyr Arg Tyr Phe Pro 290 295 300 GGC TTT GAC TGG TTC TTC CTC GAC CCC ATT ACA AGC AGT GGA ATT AAA 962 Gly Phe Asp Trp Phe Phe Leu Asp Pro He Thr Ser Ser Gly He Lys 305 310 315 TTT GCA AAT GAC GAA AAC ATG AAG CAC ATC TCC TGT CCC CTG CTC ATC 1010 Phe Ala Asn Asp Glu Asn Met Lys His He Ser Cys Pro Leu Leu He 320 325 330 TTG CAC GCT GAG GAT GAC CCA GTT GTA CCC TTT CAT CTC GGC AGG AAG 1058 Leu His Ala Glu Asp Asp Pro Val Val Pro Phe His Leu Gly Arg Lys 335 340 345 350 CTA TAC AAT ATT GCT GCG CCA TCC CGA AGT TTC CGA GAC TTC AAA GTC 1106 Leu Tyr Asn He Ala Ala Pro Ser Arg Ser Phe Arg Asp Phe Lys Val 355 360 365 CAG TTC ATC CCC TTT CAC TCA GAC CTT GGC TAC AGA CAT AAG TAC ATC 1154 Gin Phe He Pro Phe His Ser Asp Leu Gly Tyr Arg His Lys Tyr He 370 375 380 TAC AAG AGC CCA GAG CTT CCA CGG ATA CTG AGG GAA TTC CTA GGG AAG 1202 Tyr Lys Ser Pro Glu Leu Pro Arg He Leu Arg Glu Phe Leu Gly Lys 385 390 395 TCG GAA CCA GAG CGC CAG CAC TGAGCCTGGC CCGTGAAGGA GCATGGAGAC 1253 Ser Glu Pro Glu Arg Gin His 400 405 CCACCTTCCT TCCCTTCTCC CTGAACAGCA GTCTGGCACC CAGAAGCTCA GAGTGCCACC 1313 ACCTGTGGTG CTCAGGAGCC CAGCCTAGAA AGAGGACTCC GACACAGCGG GCAGAGGCTC 1373 CACAGACGGA TCTATGAGGA AAATACGGTG GCAGGCAGGC AGGCAGGCGA CCCCCTGACC 1433 CTCTGGTGGC CGCTGTATCT GAGCCCTTTT GGGAAGGCTT ATAGACAACA GGTGGAGCCC 1493 ATACGCTGGG CATAGGGAGC CTGGGAAGGG CTCAGGAGCT CAGGACCACT CCAGGCTCTC 1553 TAGCACCACC GCTTAAAATA CAGGAAAAAG GTTCTTTCTG CCCTTCCTGG CGTACACAGA 1613 ACAGATTCCA AGTGGTTCAA TTTGTCCCCT ACAGCTCATG TACCTGCTTG CCTTCCTCAG 1673 CTGTCCCTGC CTCTCCTGGC ATCTGTACAC CCACAGTGAG GGGCACCTGG ACTTGCACTT 1733 CCATTCTGCC CACCTGTCTG TCACCTAACC TGGCCGTAGA CTGAGCATTT ATTTAAGAAT 1793 AAAATCTCGG TGGTGGTCTA TTTGTTTTTT TCTACAAAAA AAAAAGTCGA C 1844 (2) INFORMATION FOR SEQ ID NO: 65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 405 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65: Ala Gly Arg Gin Gly Arg Gly Met Arg Lys Arg Thr Glu Pro Val Thr 1 5 10 15 Leu Glu His Glu Arg Cys Ala Ala Ser Gly Ser Ser Ser Ser Gly Ser 20 25 30 Ala Ala Ala Ala Leu Asp Ala Asp Cys Ser Leu Lys Gin Asn Leu Arg 35 40 45 Leu Ala Gly Lys Gly Thr Ala Glu Pro His Ser Ala Ser Asp Ala Gly 50 55 60 Met Lys Arg Ala Leu Gly Arg Arg Lys Ser Leu Trp Phe Arg Leu Arg 65 70 75 80 Lys He Leu Leu Cys Val Leu Gly Phe Tyr He Ala He Pro Phe Leu 85 90 95 Val Lys Leu Cys Pro Gly He Gin Ala Lys Leu He Phe Leu Asn Phe 100 105 110 Val Arg Val Pro Tyr Phe He Asp Leu Lys Lys Pro Gin Asp Gin Gly 115 120 125 Leu Asn His Thr Cys Asn Tyr Tyr Leu Gin Pro Glu Asp Asp Val Thr 130 135 140 He Gly Val Trp His Thr He Pro Ser Val Trp Trp Lys Asn Ala Gin 145 150 155 160 Gly Lys Asp Gin Met Trp Tyr Glu Asp Ala Leu Ala Ser Asn His Pro 165 170 175 He He Leu Tyr Leu His Gly Asn Ala Gly Thr Arg Gly Gly Asp His 180 185 190 Arg Val Glu Leu Tyr Lys Val Leu Ser Ser Leu Gly Tyr His Val Val 195 200 205 Thr Phe Asp Tyr Arg Gly Trp Gly Asp Ser Val Gly Thr Pro Ser Glu 210 215 220 Arg Gly Met Thr Tyr Asp Ala Leu His Val Phe Asp Trp He Lys Ala 225 230 235 240 Arg Ser Gly Asp Asn Pro Val Tyr He Trp Gly His Ser Leu Gly Thr 245 250 255 Gly Val Ala Thr Asn Leu Val Arg Arg Leu Cys Glu Arg Glu Thr Pro 260 265 270 Pro Asp Ala Leu He Leu Glu Ser Pro Phe Thr Asn He Arg Glu Glu 275 280 285 Ala Lys Ser His Pro Phe Ser Val He Tyr Arg Tyr Phe Pro Gly Phe 290 295 300 Asp Trp Phe Phe Leu Asp Pro He Thr Ser Ser Gly He Lys Phe Ala 305 310 315 320 Asn Asp Glu Asn Met Lys His He Ser Cys Pro Leu Leu He Leu His 325 330 335 Ala Glu Asp Asp Pro Val Val Pro Phe His Leu Gly Arg Lys Leu Tyr 340 345 350 Asn He Ala Ala Pro Ser Arg Ser Phe Arg Asp Phe Lys Val Gin Phe 355 360 365 He Pro Phe His Ser Asp Leu Gly Tyr Arg His Lys Tyr He Tyr Lys 370 375 380 Ser Pro Glu Leu Pro Arg He Leu Arg Glu Phe Leu Gly Lys Ser Glu 385 390 395 400 Pro Glu Arg Gin His 405 (2) INFORMATION FOR SEQ ID NO: 66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 855 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW074 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 7..300 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (64..365) (D) OTHER INFORMATION: /label= SAC_24464 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66: GTCGAC AGC CCT CGA GGG AGC AGA CGC CGC GGG CCA CTG GCT TCC TCT 48 Ser Pro Arg Gly Ser Arg Arg Arg Gly Pro Leu Ala Ser Ser 1 5 10 ACT CAG GAA CCA CGG ATG TCA CCG CCC AGT CAG CTG TGT CTC CTC ACC 96 Thr Gin Glu Pro Arg Met Ser Pro Pro Ser Gin Leu Cys Leu Leu Thr 15 20 25 30 ATT GTC GCC CTG ATT CTG CCT AGT GAA GGG CAG ACA CCA GAA AAA CCC 144 He Val Ala Leu He Leu Pro Ser Glu Gly Gin Thr Pro Glu Lys Pro 35 40 45 AGA TCC AGT TTT ACA GCG CAC CAG AGT TCT GTG ACT ACT CAT GTC CCA 192 Arg Ser Ser Phe Thr Ala His Gin Ser Ser Val Thr Thr His Val Pro 50 55 60 GTT CCA GAT CAA ACT AGC CCA GGA GTC CAG ACC ACT CCT CCC ATC TGG 240 Val Pro Asp Gin Thr Ser Pro Gly Val Gin Thr Thr Pro Pro He Trp 65 70 75 ACC AGT GAA GCT GCG AAG CCA CAG GAA GCC AGA CAG CAG CCA AAA CCA 288 Thr Ser Glu Ala Ala Lys Pro Gin Glu Ala Arg Gin Gin Pro Lys Pro 80 85 90 AGA CCC AGC AAC TGACCGAAAT GGCCACTGCG AATCCAGTGA CAGATCCAGG 340 Arg Pro Ser Asn 95 GCCACTTACA AGCAGCGAGA AAGGTACCCC GGCACTCTCC AGGATCAAAT CTCCCAGCCC 400 ACCCAAAGGT TACATGCCTC CATCCTACAT TGAGAATCCA CTGGATCCCA ATGAGAACAG 460 CCCCTTCTAC TACGACAATA CCACCCTCCG GAAACGGGGG CTGCTGGTGG CGGCAGTGCT 520 GTTCATTACT GGAATTATCA TCCTCACTAG TGGGAAGTGT AGACAGTTCT CTCAGTTATG 580 CCTGAATCGC CACAGGTGAG TGGGAGCCAG CACCCTGATG GGCACCCCAA CTGGAGCCGC 640 CATACCATAC CAGTTCACCA CCCCTGCCTC CCTCCCTCTG CTCCAAGAGC CAACAGAGTG 700 GTCAACATAA ATGGATCCTC AAAGGAAGAG GCCACCGGAG GGAGCCAGGC CTAAGGCTAA 760 ATGGTCTTCC CACCCTGAGG AGAGAGGTCT CCCCAGGCAC TGCTGTGATC CTGCCTATCC 820 TGTTCAGATA AATCCACATG GTCTCTCTTC AAAAA 855 (2) INFORMATION FOR SEQ ID NO: 67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 98 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67: Ser Pro Arg Gly Ser Arg Arg Arg Gly Pro Leu Ala Ser Ser Thr Gin 1 5 10 15 Glu Pro Arg Met Ser Pro Pro Ser Gin Leu Cys Leu Leu Thr He Val 20 25 30 Ala Leu He Leu Pro Ser Glu Gly Gin Thr Pro Glu Lys Pro Arg Ser 35 40 45 Ser Phe Thr Ala His Gin Ser Ser Val Thr Thr His Val Pro Val Pro 50 55 60 Asp Gin Thr Ser Pro Gly Val Gin Thr Thr Pro Pro He Trp Thr Ser 65 70 75 80 Glu Ala Ala Lys Pro Gin Glu Ala Arg Gin Gin Pro Lys Pro Arg Pro 85 90 95 Ser Asn (2) INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4315 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW075 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (3785..4014) (D) OTHER INFORMATION: /label= SAC_24466 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68: GTCGACATGG CGAAGTACTC TAGCCTGGAA GCCAAGCTCT GCCAGGTTGA AAGTAAATAC 60 TTGATACTGC TCCAAGAAAT GAAGACACCA GTTTGCTCAG AAGAACAGGG CCCTGCCAGG 120 GATGTCATAG CCCAGTTGTT GGAGGACGCT CTGCAGGTTG AGAGCCAAGA GCAGCCAGAG 180 CAAGCGTTTG TCAAGCCTCA TCTGGTCAGT GAGTTCGATA TCTACGGGTT TAGGACTGTC 240 CCTGACGATG ATGAGGAAGA GAAATTGGTC GCCAAGGTCC GAGCATTGGA CCTGAAGACT 300 CTGTACCTCA CAGAAAACCA GGAAGTTTCC ACTGGGGTCA AGTGGGAAAA CTATTTTGCA 360 AGCACAATGA ACAGGGAGAT GGTGTGCTCT CCTGAGCTGA AAAACCTGAT CCGAGCAGGC 420 ATTCCCCATG AGCACCGCTC CAAGGTGTGG AAGTGGTGTG TTGACCGTCA CACCAGGAAG 480 TTCAAGGACA GCATGGAGCC AGGCTACTTC CAGGCCTTAC TCCAGAAGGC TCTAGAGAAA 540 CAGAACCCGG CCTCCAAGCA GATTGAGCTG GACCTGCTTC GGACTCTGCC CAATAACAAA 600 CATTACTCCA GCCCCACGTC AGAGGGCATA CAGAAGCTTC GCAATGTCCT GCTTGCCTTC 660 TCATGGAGGA ATCCGGATAT TGGCTACTGC CAAGGCCTAA ACAGGTTGGT GGCAGTGGCG 720 CTCCTTTACC TGGAACAAGA GGATGCTTTC TGGTGTCTCG TTACCATTGT GGAAGTCTTC 780 ATGCCTCGAG ACTATTACAC AAAGACTCTA TTAGGATCCC AGGTGGACCA GCGGGTGTTC 840 AGAGACCTCC TGAGTGAGAA GCTGCCTCGA CTGCACACCC ATTTTGAGCA GTACAAAGTG 900 GACTACACCC TCATCACCTT CAACTGGTTT CTGGTGGTAT TCGTGGACAG CGTTGTCAGC 960 GACATCCTCT TTAAGATATG GGACTCTTTC CTTTATGAGG GACCAAAGGT TATTTTCCGT 1020 TTTGCCCTGG CACTTTTTAA ATACAAGGAA GAGGAGATCC TGAAGCTGCA GGATTCGATG 1080 TCCATTTTCA AGTATCTCCG ATACTTCACT CGCACTATCC TTGATGCCAG GAAGCTGACC 1140 AGCATCTCCT TTGGGGATCT GAACCCCTTC CCCCTGCGCC AGATCCGGAA CCGGAGAGCC 1200 TACCACTTGG AGAAGGTCCG GCTGGAGCTG ACAGAGCTGG AGGCCATTCG AGAGGACTTC 1260 CTGCGTGAGC GGGACACTAG CCCTGACAAA GGCGAGCTGG TTAGCGATGA GGAGGAAGAC 1320 ACTTGAATGA ATCCCCACCC CAGGATGCTG CCTTCCTTCT TGCCTTCCTT CATAACCAAA 1380 AGTAGCAAAG GCGCATCTGC ACATCAGCTG TCAGAGTGAA ACATCTACAG CCTCTGGGCA 1440 CCTGCGGGGC AGATGTCCAA AGCTAAGCTG CACTTTCTCG TCTGCCATGA GGGCAGGGGT 1500 CTGATGGCTT TACAGCCATT TCCATGCCGT GGCATTCAGT CATATGCGTC ATATGCTTGC 1560 TGCCTGATGG GTGAGTCACC AGGCGACTGT TTCCAAGGGC CTGTTTACAT CATCTGCCAG 1620 TTGTATGTTT CACCTACAGA AACTGTTTGA CATTTCCCTG TGCGCTTTCT TTTTATCCAA 1680 GGGCAACTCT GTGGAGGAGT GCACATGGAG CTGCAGCGTG GCTGCATCCA GGGGTAAAAG 1740 GTCACCATAA GAAGAGGGAC CTCTTTAAAA AAAAGCGAGC ACAGAACTGG CCTCCCTAGA 1800 GAGCGTGGGA GCCCTCTGCT GGTGGCTTCG CACTGCCAGC CACTATCCCT TCTGGACTAA 1860 CCTTTGCCCT CCTATACAGC CTTTTCAGAT TGTAGCACTC ACGCTGCTCT GCAGCCAGCC 1920 CCACACTTCT CATTGCCAGC TATTCTGCCA GATGTCTGTC CCAGCTTACA GTGGGGCTAG 1980 CGCATCTGGG AGGTGACTTA TAGACAACAT TCTCCAACTG TGGCTAGATT GGCGTTCCAA 2040 AGGAACCTTA CAGTAACCCA CCCCTGCATA AAGGAACACA GGAAACTCCT ATCTGTGGCT 2100 TGTGGGCTCC TGGATGGCAG TGGCCAGGGC TCTAGAATCT CTTCTGCCCA ACAGCTGGGT 2160 GGGGAGTAGA GCTGACTGCC AGCTTCCTAC ATCTGGAAGC ACCTTTGCTT GGGAACAAGA 2220 GTAATGAGTT CTCCTAGTCT CTGTGTTGCC TGGATCATCC TTGTCCTTAA CAGGGATCTG 2280 AGGACACTGT GGCCTCTGGT ATAGCAGACT CTGGGGACTT GGAACACTTC CTTCTTGAAG 2340 CCCAGAGAGG GTCTGAACAA AAAAGGTTAT TTTTGCTCAG TCCCAGAGCA TCCCTAATGG 2400 TGGCTGTTAT GAGAAAACAT CTTCTTACAC AGTATTATGG GAACACAAGG GAAACAGCCT 2460 CAAGTGGACT ACTTTACACT ACCTAGGGAA AAGAAATTAG AAACAATCCT TAGTGTAAAC 2520 ACACTCAGAC TGAGGAGTGG AGCAAGACAG TTTCGAGAAA CGCTTTTTCC ATGACCCGTT 2580 TTCCTGTTTT TGCTGTCTGC TTTCTAGCAC TTGAATGGCT GAGTCCATTT TCAGCATCTA 2640 AATTTGCTTC ACTTCTCTAA AGTTGCTTCA TATATTACCA TGTAAAAGGA GCTGGTCTCT 2700 ATATTTAGCC AATAGCCCGT CTCTTTTCAG GTATCAGAAA TGTCATCCTT GTGTCTTTGA 2760 GATGATGGTT TGAGGCCCGG CTTCTTGAAG AAGCTGTCTG GAGCTGGACA GTGATCTATC 2820 TCACCACTGT TCCTAGGCCT CCCTGAGACC AAATGCTGGA AGATGCCCCA CCCCCTGTAA 2880 GATGCCGGCT GTCAGCCTTG GGGACAGCTG TTAGGAGGTT AGAGTTGGAG CCCCATGGCT 2940 TAGCTCCAGC CGCTCTGATT TCGGTTGTCA TGTCAATTTC CTACCAGAAG ATCCAGTCCA 3000 AATAAGTATT TGGTGTGGAT GCTCTCAGTG GAGCATTTGG TGTGGATGCT CTCAGTGGTG 3060 GGTTGCTTTC GCCCTGGCAC CAGTGGAGGC ATCTTTAAGT ACTTGGTGAT GCTGAGGACA 3120 GGACCATGTT CCTGGCATGC GGGGCCCTGG GTTCCATCCC AGTGATGAAA AAAAATCTTC 3180 AGTATGTGGG GATTGTGGGG AGGCGCTGTT CTGCCATCCC CTGAGAGACA GCATTAGTTT 3240 CTCAGGCAGT TAGTATCAGT GCCCAGGTAA AAGTCTCAAG AGGTCCCAAA GGGACTCTCC 3300 TCCCTGGAAT AAATGACTCG ATGTCTGCAG AGCGGAGAAG GGACGGTTGC CCTCTTTCCA 3360 GTTTGGGGAC AGAATAACAG AGATTCATCC CAGAGGCACA GCCCCAGTGG TTGAGCCATC 3420 GTCTCTCATG CCCTCGTCAC TGAGATTGTC TTTACCCTCC AGTACTCCTG AGACTCCAGA 3480 CTTCTACCAG ACACCATGGC AGGTACCCCT AAGGTCAGTG GCTGCCTCAG GCTGCTTTTC 3540 ATCTAAACCT TTACCCAGCA TGCAACCCAT GGCTCCTGCC TGGTGAGCCT TGTGGGCTGA 3600 GAAACCCAAA GCACAGCCTC CAGCGCGTGG GTCCAAATGC GTGTGCCACA GTAGGGGAGC 3660 ACCCTGCCCT CAGCACCCCA TATGGTGGGA CTTGCCAGTA TTTCAACTGT TGATACTTTT 3720 ATATTTTCAC TACATTTTAT ATTTTTATAG ACTATTTTAT ATTAAGGTTT TTTCTAGATT 3780 CTGTACAACT TTTATATAAC AAGTTCTATT TTGTGTGCAC ATCTCCCCTG TATGTATTTA 3840 TAGCAACCCA AGCCTCTCAA ATTCCAGGTC CCTCTTGTGC CACCTTTTCC CCTTAGCCTT 3900 GACTGTCACT CTCTTCTGCT CACCGAGGTA GCCTCGGGGG CTACTTCTAG CCACCATGAC 3960 AGCCAGACAG CAGGAACTGG TGTTTGTCAG CTGTGGTCTG TTGATACAGG AAGTACTCTG 4020 GGCAGTAACC CAGTAGCTAT GTTACTGCAC AAGCCCTTCT CGCTTAGTGC AGTGATGTCC 4080 TGGTGCAGCC ACCTGTGGGC GGGTGGCTGG ACCCATCACG AAAGTCCTTG AAGACAGAGG 4140 CTAGATGAAA GCCCAGTGTC TGAGGTCCTT CTGTGGGCAA CTGGAGGACT TGAGGGCACA 4200 CTGCCAAGTG ACTGTCCTTT TATATCCTAG CAGCTTCTGT GCTCACCCTT GAGTTAAATG 4260 TTAGACTTTT AAAGGAAGAA ATAAACTAAT TTGTATTACA TTCTGCCTCG AAAAA 4315 (2) INFORMATION FOR SEQ ID NO: 69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1668 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW076 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (42..281) (D) OTHER INFORMATION: /label= SAC_24409 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69: GTCGACTTTT GCCTTTAAAA TTCTGTTTAC TTAGCATATG TACACGTAAA AGAGAAATCA 60 CCCTTAGATC CCACCCAGCA GAAAACATGC ACAAACCCAA GGTATATGTG AAAGGGAGGG 120 CCCCAGCCCC AAGTTAGCAG TTGGGATGGT GCAATCCTGT GAGTCACAAG CCCATGGCAA 180 GAGGGCTGGA CTAAAGTTTC AACACAGCCA GAACCCCTGC TGCTGGCCCT AAAATAAGCG 240 TGCACCATAG CCAAAGGTCT GTTTGATGCC CTCAAAGTAG TACCGCTGCC AGCCTTGCCG 300 TGTCCGCTCT TCCTCGGGAG CAGGGATGCC GCGGCCCTCC ATGCACAGCT CTGTCTCTCC 360 ATTCTTATCA ATGAAGGTCA AGGTGATGGT CGCGAAGTGC CCCTCTGGCC ATGACTTAAA 420 CCTCCACTTC ATAGCAATAT GTTTCTCAGG AACCAAGTCA GTAAACTCCC CAGTGACGTT 480 ACCATCGACC ATGTGAAACT TCCCTCCTCT GTCTGCTTCC AAGGCCGCAG GAGCATGGGT 540 AAAGGCCTGG ACCAGCTCCT GCGTGGTGAA CACTCTGTAG AGCTCCTCTG GAGAGGTCAG 600 GAAGGTTTCT TTGAGGGTGA TCTTACAAGT GGGTATTTTG ACACCAACAG GTTTGGCCTG 660 GCTTTTTGAA GGAGCACACT TAGCCTTGCA CACTTCCGTT TTTAGTGCTG GTTGGCCCAC 720 TGGGTCTACT GATTCTCCAT TCACTGTGGG CAAGATCATG CCCTGAGTAA ACTCTGTCTT 780 GAGGGTGCTG ATGTAAATTC CCACTGCTTC TCTGAGAAGT TTCACCCCGT CTTCCTTCAT 840 TAAGGCCACG AGACTTGTGT CAGGCTCATC TTTGGCAAGG CTGCTTCTTA GAGCCCTTGT 900 TATGGCAGCG CTCCATCTAG GAAACAGCAG TCAGTCTCTC CTGCTCACTG TTCTCCCTCT 960 CTGTGCTCAA GTCTGTCAGT GCTCGCTGGC CTCTGGCTCT TCCCTTTGGG GAGGGAGCGG 1020 CTGTTCTGCC TGCTTCACCG AGTCTTCACA AGCTGAGGGG ATGAGGCCAG GTTAGTACCA 1080 GGGACCAGCA ACCTTTCAGG GCTCCTTGGG GGTCTCAGGT CCACACACAG TGAGCATCCC 1140 TTGCCAGGTG CCCCATGTAT CTGTCAGTGC TGAGACGCCA AACACACAAC CTGTTCCCAG 1200 CTGCTGCTGG GGGCCACTGT GACCGAGGAG AGTGTGGGGT TGCCAGGGAG AGCGCTGTCC 1260 CTCTGACAGC CTGACCAGAT GATGTAGCTT TGAAAGCCGG CAGCATGTGA GTAGCAAGAT 1320 GTGACCTTGA GCTAGCTGAG CAGAACACAG GTGGATGGGC AGAGGCCCCC ATCCTGGCGA 1380 GCTGAGCCTG GCTGTGTCCT GTCAGGACGC CCTACTCTGT GACCCTACCC TGTGATCTGT 1440 GAAGTGGTGC AGTCGGAAGA CGAGGCTGGA GTCCTTTACA AGTTTCTACA CTAGATTGTA 1500 GCCAGGTTTT CTCCCAGGCC TTAGGCTTTG GTTTACTTTT AATTTTAATT TCACTGTTAC 1560 CCTTGACTAT TGTCCTTTTT GTTGCAGTGT TGGAGAGGCA GGAGGTATTT GTGCCTCATC 1620 TATTACTGCA AAAAAATTAA ATAAATGTAA CAATAAACGT CCTAAAAA 1668 (2) INFORMATION FOR SEQ ID NO: 70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1019 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW078 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (211..743) (D) OTHER INFORMATION: /label= SAC_24345 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70: GTCGACGCCA GCGTGAGCGC CCTGCAGCGC CTGGTGGAGC AGCTGAAGCT GGAGGCCGGC 60 GTGGAGAGGA TCAAGGTCTC TCAGGCAGCT GCAGAGCTTC AGCAGTACTG CATACAGAAT 120 GCATGCAAGG ACGCCCTGCT GCTTGGTGTT CCGGCTGGAA GCAACCCCTT CCGGGAGCCC 180 AGGTCCTGTG CTTTACTTTG AAGACTGGGA AGAAGCTCTC TGAGGAACCT GTGTGTGCAT 240 GGTGATGGAT GACTACCGCC AAGTCCCAAG AAAACAGATT TCAAGAGCCA AATCATTTTC 300 TCTGTGGCCT GGTCCTAGGT CAAAATTCTA CAGAAATCAA TGTTTTGTCT TATTTTTTAA 360 CCTCATTACC AAACTCACTG GGTGCATCTC TCAGTCAAGC CTGTGCGGCC CTGCCTGGGA 420 TGGAGGCATG TTTTGTTTAC TGGGTATTTG CATTTCTGGA TGGAAATGTT GTATTTCCGA 480 AAACTGAGTA TTTGTAATTT TCCTAACATT TTTATACTGT AATAAAAAAT TTTCATAAAA 540 ATTTACAGTT ACTAAATTAG ACAAAGTATA AATTGGGGAA TGATTGATAT GCTGGTTTCG 600 TAAAGGAGGC CTTTCCAGTC CCAGTGAGCA AACGGTCTGA CCTGGACGGG AAGCTGGGGA 660 GCCGCTCCTT AGCACACGGA GCATGGATGT GTTGTTAGGT GGCCCTCCCG TGTGAAGCCA 720 TTAGAACTTT CTTTAGTTCC TGTACTCTAC AACTTATAAT TGTGTCTGAT GGTTTGAAAA 780 GTGTGCTCAT GCCTTTAAAA ATGTTTAAAT GTGATCTACA CTTAGAACGT TGCAATTGGT 840 TAAAAACAAA ATATGAAGAT ATTATAACCT AAAAGAATTC ATGTCACACA TATTTTATTG 900 GGGGTGATGT GCCTTTGATT TAATTGGGGA CACTTTTAGA AGGAAAGTTT GTGTTTGTGA 960 TTATCTTTGA AGAGCTTGGA AATAAAATTT TTGCCTAATT CATCATTTTC CATGAAAAA 1019 (2) INFORMATION FOR SEQ ID NO: 71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 961 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW080 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 629..919 (D) OTHER INFORMATION: /label= SAC_24033 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71: GTCGACGCTG GGCAAAAGAA GGTTCCACCA GAGCCTGTGG GTTTGTCCTT AGGCTAGAGG 60 CCCCAAGATT TGGAACCTGG TGGAATCAGT AGGAGGGACA TTGAAGCTCA CAGATATATC 120 ACACGTTGGT CAGTTGCTTC TGCAACTGGT CCGTTAGGTG CTGTGGGACG AGCCCTTTCC 180 TACCTTCTTC AGCTTCTACA TCCACTGTCT GCCTGTGTCT CAGTTTACAT CTTCCTTTTG 240 AATATGGAAT CTCAAATAGC CCAGGCTAGC TTCAAATTTG TTAAGTAGTT GAGGACAACC 300 TCAATCTTTC TATTCGCTGC CTCCACCTCT CTCAGTTTAC CTTTTTTTTT TTTCTCCTTA 360 GGATTAAGTC CCGTACAGGC CCAGAGTGGT AAGCCATAAC ACCCCTGGTC TTTCTCTCTT 420 CCTCTCAAGA TTTCCTCAGG CTACCCCTTT TCCTTCTAGC TCTCTCTCTC TGCTAACGCC 480 GAGCCCTGAT TGTTAACCTG TGTCTCCCTC TTCATCCTTC TGAGACAATT ACCCAGGATG 540 CGAATGTTCC TCTGTGAGCC CGGGTGTACT GGCTGGGATT GTGCTGGGCG ACTTGGTGCT 600 GACTCTGCTC ATCGCCCTGG CGGTGTACTC TCTGGGCCGC CTGGTCTCTC GAGGCCGAGG 660 GACTGCAGAC GGGACCCGGA AACAGCACAT GGCTGAGACT GAGTCACCTT ATCAGGAGCT 720 TCAGGGTCAG AGGCCAGAAG TATACAGTGA CCTCAACACA CAGAGGCAGT ATTACAGATG 780 AACCCACCCT ATGCCCACCA ACAACCTGAT GCCCGGATCC ACTCATTCCA GACGCTTACT 840 CAACAAACCC TCCCTGGGAT CAGGACTCCC GCTGGAATAA ATATCCACAG AGTGCCCTCT 900 GGGAGATATC TGACCTTGTA CCGTTTCTGT CCCCAAATAA AAGACGAAGC AAAAACAAAA 960 A 961 (2) INFORMATION FOR SEQ ID NO: 72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1890 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW082 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 150..569 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1381..1848 (D) OTHER INFORMATION: /label= SAC_24469 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72: GTCGACCGCG GCCGCGTCGA CGGACTTGCG GTTCCTTCAG CATTCTGCCC GCGCACTGAG 60 TGGCTGTTTC CTGGAGCTAC TGTGTTCCTT CGGGAGTGCA GCAGATCCCG TTCAGAACCT 120 ATTACCAAGA GCCCCGAGCA GGACCCACC ATG CAG TGC TTC AAA TTC ATT AAG 173 Met Gin Cys Phe Lys Phe He Lys 1 5 GTC ATG ATG ATC CTC TTC AAT CTA CTC ATC TTT CTC TGT GGT GCA GCC 221 Val Met Met He Leu Phe Asn Leu Leu He Phe Leu Cys Gly Ala Ala 10 15 20 CTG TTG GCT GTG GGA ATC TGG GTG TCC GTC GAC GGG ACA TCT TTC CTG 269 Leu Leu Ala Val Gly He Trp Val Ser Val Asp Gly Thr Ser Phe Leu 25 30 35 40 AAG GCC TTC GGA TCA CTA TCA TCG AGT GCC ATG CAG TTT GTC AAC GTG 317 Lys Ala Phe Gly Ser Leu Ser Ser Ser Ala Met Gin Phe Val Asn Val 45 50 55 GGC TAC TTC CTC ATC GCC GCT GGT GCT GTA CTC TTT ATT CTT GGT TTC 365 Gly Tyr Phe Leu He Ala Ala Gly Ala Val Leu Phe He Leu Gly Phe 60 65 70 CTG GGC TGC TAT GGT GCT CAC TCC GAG AAC AAG TGT GTG CTC ATG ATG 413 Leu Gly Cys Tyr Gly Ala His Ser Glu Asn Lys Cys Val Leu Met Met 75 80 85 GTG TGT TGG ACC CAG CTC CCC AGG CCC ACA ACC AAG GGT TCC CCC TTC 461 Val Cys Trp Thr Gin Leu Pro Arg Pro Thr Thr Lys Gly Ser Pro Phe 90 95 100 ATC CCT GAC ACC AGC CTC TGG GAT CCC AAA ACC CTA CTC TGG ATT CTG 509 He Pro Asp Thr Ser Leu Trp Asp Pro Lys Thr Leu Leu Trp He Leu 105 110 115 120 GAA GCC TCG CTG TGG GGA CCC CCT GCC TCT TAT GGG AGT GTG CAG GAA 557 Glu Ala Ser Leu Trp Gly Pro Pro Ala Ser Tyr Gly Ser Val Gin Glu 125 130 135 GGT GTG TAT CCC TAAAACGTGT TTCCTTTCTC CACTCAGTTC TTTTCCATTC 609 Gly Val Tyr Pro 140 TCCTCATCAT CTTCATTGCG GAGATTGCAG GGGCCGTGGT TGCTTTGGTG TACACCACAA 669 TGGTGAGGCA CGGGATGGGG CATGGGAGGA AAACTGGAGC AAAGCTCTGA GAGTTGGTGG 729 TGGCCTGTGA ATGGCTACTT CCCCTACCAG TCTATTAATA CTGGCCTGAC CCGTCCAGGC 789 TGAACAATTC CTGACATTTC TGGTGGTGCC TGCTATCGAA AAGGACTATG GTTACCAGAC 849 TGAATTCACC CAAGTGTGGA ACTCTACGAT GGAGGGGGTA AGGTGGGCCG GGAGGATTTG 909 GGAATGGAGA GGAGAAAAAA ATCAAGGCAC CATCAGTTAC CAACCCCATT TTGTCTGCAG 969 CTGCATTGCT GTGGCTTCAA CAATTACACA GATTTTAACT CCTCACGTTT CGTCAAAGAG 1029 AACAAAGTCT TTCCTCCGTT CTGTTGCGCC AACAACACTG ACAGTCATAC AGTTGAACCA 1089 TGCACCGAGG ACAAGGCCAA AAGTATGAAC GTACAGGTAT GTGCTGGTGT GGAATTAGCT 1149 TTTTCGTTTG TGATCCGGTT TCTCTGTGTA GCTGTGGATG TCCTGGAACT CGATATGTAG 1209 ACCAGGCTGG GCTTGAACAG AGATCGACCT GCCTCTGCCT CCTGAGTGCT GGGGTTAAAG 1269 GCCACCATCA CCACCCAGCG CCAGTGTAAT TGCTTTAATG GCTTTACAGT AAGGAGTAAA 1329 GGGGTTGGAG GTAGGGCACT GCCAGCTATA AATACTTTCT TCTCTCTCCC AAGGGTTGTT 1389 TCAAACAGAT TCTGCAGAAA ATCAGAACCA ATGCAGTTAC CGTGGGTGGT GTGGCAGTTG 1449 GAGTTGCGGC CCTAGAGCTG GCTGCCATGG TGGTATCCAT GTATCTATAC TGCAATCTGA 1509 AGTAAGACTG CTTCTTCCTC CTGACTTGTC GTCACATGGA AACCAGGAAG AGGCACTTGG 1569 CACAGCTAAG CAGCAGCAAT GGGTGGAGAT GAAACGTCAT TTGGGCTGGA GTGGATCTGC 1629 CTTTGCTGCT CTGGACTTCG GGCTAATTAG GGACCACCGC TCGGGCTGTG TCTGTCTTGT 1689 TCTTCCACTA CTGGGGCGAG GGGGGCATTG GTCCCAGTCT CTGAGGTAGC CATGTCTGCC 1749 CATCTCCTGA GATTCTTGAT GATCCCAGCA CTCCACTGGT GGATGAAGGC ACTTATAGCC 1809 TGGGCATATT CTAGCACTGC AAAGTCATAG AAGGAATGTA CAGAAGGTGT TTTGGAACTT 1869 ATAAACCAAT GAAAATAAAA A 1890 (2) INFORMATION FOR SEQ ID NO: 73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 140 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:73: Met Gin Cys Phe Lys Phe He Lys Val Met Met He Leu Phe Asn Leu 1 5 10 15 Leu He Phe Leu Cys Gly Ala Ala Leu Leu Ala Val Gly He Trp Val 20 25 30 Ser Val Asp Gly Thr Ser Phe Leu Lys Ala Phe Gly Ser Leu Ser Ser 35 40 45 Ser Ala Met Gin Phe Val Asn Val Gly Tyr Phe Leu He Ala Ala Gly 50 55 60 Ala Val Leu Phe He Leu Gly Phe Leu Gly Cys Tyr Gly Ala His Ser 65 70 75 80 Glu Asn Lys Cys Val Leu Met Met Val Cys Trp Thr Gin Leu Pro Arg 85 90 95 Pro Thr Thr Lys Gly Ser Pro Phe He Pro Asp Thr Ser Leu Trp Asp 100 105 110 Pro Lys Thr Leu Leu Trp He Leu Glu Ala Ser Leu Trp Gly Pro Pro 115 120 125 Ala Ser Tyr Gly Ser Val Gin Glu Gly Val Tyr Pro 130 135 140 (2) INFORMATION FOR SEQ ID NO: 74: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2181 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW083 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (1950..2181) (D) OTHER INFORMATION: /label= SAC_24528 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74: GTCGACCCAC AATCGCCCGA GCACTTGGAA TCACAGCAGA AACGACCCAA TCCTGAGCTC 60 CGTAGAAATG TGACCATCAA AACTGAACTC CCACTAGGCG CACGGCGAAA GATGAAGCCA 120 CTGCTCCCAC GGGTTAGCTC ATACCTGGTG CCCATCCAGT TCCCGGTGAA CCAGTCCCTG 180 GTGTTACAGC CCTCGGTGAA GGTTCCCTTG CCTCTGGCAG CATCTCTTAT GAGCTCAGAG 240 CTTGCCCGTC ATAGCAAGCG AGTCCGCATT GCACCCAAGG TGCTGCTATC CAACGAAGGG 300 ATAGCCCCAC TTCCTGCCAC AGAACCCATG AAGGAGGAGA AACCCCTGCT TGGAGAAGGG 360 CTATTGCCTT TGCTTCCTAT TCAGTCCATT AAGGAAGAAG TAATTCAGCC TGGGGAGGAC 420 ATACCACACT TAGAGAGGCC TATCAAAGTG GAGAGCCCTC CCTTGGAAGA GTGGCCCTCT 480 CCGTGTGCAT CAGTGAAAGA GGAACTGTCC AACTCCTGGG AAGATTCTTC CTGCTCTCCT 540 ACCCCAAAGC CCAAGAAGTC CTATTGTGGG CTTAAGTCCC CAACACGGTG TGTCTCAGAA 600 ATGCTGGTGA CAAAGCGGAG AGAGAAGAGA GAGGTGAGCC GATCTCGGAG GAAGCAGCAC 660 CTTCAGCCAC CCTGTCTAGA TGAGCCTGAA CTCTTCTTCT CAGAGGACTC CAGCACATTT 720 CGGCCAGCCA TGGAGATCCT GGCAGAGTCT TCAGAGCCTG CACCACAGCT CAGCTGCCCT 780 CAGGAGGAGG GAGGGCCCTT CAAGACCCCC ATCAAGGAGA CATTGCCTGT CTCCTCCACT 840 CCTAGCAAGT CTGTGCTCTC TAGAGACCCT GAGTCCTGGA GGCTCACACC CCCAGCCAAA 900 GTTGGGGGGT TAGATTTCAG CCCAGTACGA ACCCCCCAGG GTGCCTTTGG CCCTCTGCCT 960 GACTCGCTGG GGCTTATGGA GCTGAATACC ACACCTCTGA AAAGTGTTCC CCTCTTCGAC 1020 TCACCCCGGG AGCTCCTTAA CTCAGAAGCC TTTGACCTTG CCTCTGATCC CTTTAGCAGT 1080 TCTCCACCAC CACATTTGGA AGCCAAGCCA GGCTCCCCCG AGCTGCAGGT CCCCAGCCTT 1140 TCAGCCAACC GTTCTCTCAC AGAAGGCCTT GTCCTGGACA CAATGAATGA TAGCCTCAGC 1200 AAGATCCTTC TAGACATCAG TTTCCCTGGC CTGGAGGAGG ACCCTCTGGG CCCTGACAAC 1260 ATCAACTGGT CTCAGTTCAT CCCTGAGCTG CGATAGAGGC AGGGTCTTAC CCTTGCCACT 1320 CAAGCCACCA GTTATCCTGG CACTTGTGTG GCTGGATAGT GCAAGGCTCA GTGTACCCCA 1380 AACCGTCTGA GGGAGCTAGC AGGCAAGGGC TGAGCGGTGC CCTTTGACCT AATTATGCCA 1440 AGGTAAAAGC CACGTCTAAG CCACTGCTGG GACCTATGCA AGCAATAGGA TCTCCCAGAG 1500 TCCTCCACTC CCTGCTGGCA AGTGAAGTGG GTGTGACAGA GCCGTGAGGA CCAGGAAATG 1560 CCCACCCATT AGTCACCTGC TGCTCCTGGC AGGATAACCC TTGTAAATGG TGTCAGTTCC 1620 CCAAGTTGTC CTGTAATTAT AAATGTAGCC ATATTCCCTT AGCTCTCATT ATCCAGAGAC 1680 TGCCAGGATG GGTAGGGTGA CAAGGGGTTG CATTAGCTTC TGCTTGTGGC CTTTGGGGGC 1740 AGGACCTGCA GTTCAGCCTC TTCACACTGT GGGTTCTGCT GTAGGCTTCT AGACACACAG 1800 GTGTCCTTGC CAGGACCCCA CTTACTGCCC TTTCCTCACA GCTCCCCCTG GTTCTAAGCC 1860 AGTGGTACTG CATGAAGAAA TCCTGCGGCA AAGCCTATTG GCTCTGGGTG TGTGGGGACG 1920 GGTGTGCCTG AAGCAAAAGC ATGGGTACTC ACGTGAGTCC TTTAGGTGTT TCTCTGATCG 1980 TGTTCCCAAT CATGCCAGGG AGTCTAGCAT TGAGAACTCA GGCTGAGGCC TGAGGAGGAG 2040 GAGGAAGTGA CCACTGACTT GCCTGGCTTC CTTAGCTTGC ACCTGAGTTT TGCAAAAAGC 2100 CACCCTAGAC CCCACTCTAC AAGCTAGCAC AAGAACACTA CTGTAACTAC CTACTGAATA 2160 AAGCCCAGGT GGCCTGAAAA A 2181 (2) INFORMATION FOR SEQ ID NO: 75: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3336 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW084 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (163..391) (D) OTHER INFORMATION: /label= SAC_24854 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75: TTTTTCCACC AAGAGGGAGT CCTTTAATAG ATTGCACAGA CAGACACAAC AGGCCAGCAC 60 CCTGCTTGCA GGCCCAGGCG CTTTGCCAGC AGATGCAATG GCCTCCCCCA CCTGGGTGTG 120 GGCCGCAGGG TGGAGATGAG GTGGTTTAAA AAACACAGCT GTACTAATTC TTCACTTTCA 180 CAGAAAAGAG AAACTTGGGG GAGCAGCTCA CAGGAGAATT TACATAGAGC TGAGTCTGAA 240 TGTCCACCCC TAGAGAAGTT GAACCTCCCC CTGAGCTGTC TGTGCTCAGC AGGGGGCAGA 300 CAGCACATGG AGGGCGCAGG CCAGTCCACA GAGGAGCGCT GACTTAAACA GCTGTCCTCC 360 CTTCCCAGNT GTTAGNATTT CTACACNATG TACATTGTTG TGCTTTATTG CTCCCACCCC 420 AGCCTCTGCC TGAAGCCCAG GGTGGAGGGA GGAACACCTG AACCAGATTC AGCTGGGTGG 480 GAGCACCAAG CCCCCAATGG CTGGTGCTCT GTAAGNTTCT GAGGCTGCCA GGCTCNNGNC 540 ACTCGGAGCT GCAGACCAAG GGTACAGAGC CAGCCGACCA GCCAGCTCTT CTGAGGAGCA 600 GCAGAAACAG AAGGATCAGT GCTGGACAAG ATGCAGGCTG GGTAGGAGCA GGCAGGGTGG 660 AAGGACGAGT GCAAGGCCAT GAGTCTGGGG CAGAGGGTTG TGCACATGGG GCTGTGGGGG 720 CCTGCAGGGC ACCTCACGAG ACAGAACCAT TCTGTAGCAG AGCTTGACGG AGGAAGGGTG 780 TGAGGACCAC TGGCCTGGGG CCCCTTGGAG CACAGAGCTG CTTCCAGTTC ATCAGGGGCT 840 GGCAGTGGCA GGCCCCAGCT CGGGGCGTGT GCATTGGGAG ATTCAGGGAG AACCNGCAGG 900 CAGCCTGTGG GGCTGGGTGA GGAGGGAAGG CTGTGGTGGT ATCTTTGAGT NTGTCTTGGC 960 CGGGCCAGGG GTTAACACAG GATCAGTTGT TCTCAAAGAG TGAGAGCAGA TCATCACTGC 1020 TGTTTGTGGG GAGGTCAGGT GGACCCAGGT AGGAGAGTAG TTCATCAGGA TTGGTCAGTT 1080 CTGGGAGCAG ANCNAGAGCT GGTTCTGAGG CCTCCCCTGC CCCAGTCATG CTGGGAGGCC 1140 CCATCATGCC CGTGGCAGNA TTGAAAGCCA GTTCACTGAT GGGCCCTGTG TTTGGTTGGC 1200 CCAGGGGCTG CCTGGATGCA GGGGAAGGGT TTGGATGGTG TAGCTGGGTG CCTGGGGTGG 1260 GCCCGAGGTT GGGAGTGTGC AGTCCTGGTG GTCCAGGATT ATGGGCTGGG TCCCAGGTGA 1320 CCCTGCCTGG TGCCCATCCT GGCCTGGGAG GCAAGGAGCA GACTTGNNNN GAGTCAGGAG 1380 GCTGCTGGGA ATGTCAGACT GGTAGGAGAT TGGGGGTGGC CCCTGGGGTG AACTCAGCAA 1440 GGTTTGGGGT GGCGGGTGTA GCAGATGGGA AAGATTCTGG GAAGGTTCCA GGCCCCCAGG 1500 AAGTTGGAAC CCTGGCTGGG NTAGTCGNTG GGGGTAGGGN CCNAAGGGGC TGCAATGGGG 1560 CAAANGGGCA GCGCCAGGGC CCAGGGCCGC AATCATCTCC ATCACACTGG GCATGAGCAC 1620 GTGGGCAGGG CTCACAGTAC GGCAGCGCTT CAGCACTGGG CCCGTCCGGC TCCTCCTTGA 1680 TGTGTAGGTC AGGCTTCACA GGCACTGGTT TCCAGCTGCA TGTGGGGTCG ATGGTGATCT 1740 CCTCGTAGTC TGAGTTCTGA ATATAAATCA GGATGCCTAG CATATACTGA TCCACCTCCA 1800 GGCCCTCCAG CAATGCCGTC TTGTTGCACA CCGGGACACC TCCAGGTCCC CCGCTCACAG 1860 TTAAGCTGTA AGTATGACTC CAGGTCAAAG CACTGTATGT GGCGACAGTC GTGACCACGA 1920 GCTGGGAGCT GGATCCTGCG GAAGGTGATG GGGCACTTCA GGGACACCTT GATAGCCGTC 1980 TGCTCCACCC CATCCTCTCC ATTGGGCCCA GGGGTGCCAG GGATGGTGCC GCTACTGAAG 2040 TTCCGCTTTA TCTTGGTGAT GCAGTGCTCA GCTGGCAAGN GGCGCTTCTT GAGGAGACCC 2100 TGCAGCACAG AGCGGACAGA CGGACGGTGC ACCAGCTGCA GCACGAAGAG GTGGGAGCAG 2160 CAGCAGGCGG TGACGGTGAT CTGGATGGTG TTGCGACCCG GCTGGCACAC ATGCTTCAGG 2220 TAGAGGGGCT TGTGCGAGGT CTTGTTGTCT CCACGCTCGA TGCTGAGGGG TGTGNCATTG 2280 ACGCTGACCT GCACCGNNGC CGGCCANTTG GTGGTTCATC TGCCGGTCCT CGTGGTGGTA 2340 GCACTTGAAC TGCGAACTGA GCTCTAAGTC AGGTCTCAGC ATCAGGGTTT TATACACAGA 2400 GTCTCGNAGC TGGAAGACAT GGTTGCTCAC AGCCAGGTTG TGCTGCAGGC GGAAGGGCTC 2460 CAGGACCACC CCATCCCGAA CTGGGAAGGT CAGGCGCAGC TCGTCACAGG GGACGCTTCC 2520 AGAGGGTGAT GGGTGCAAGG AGGCTGAGGC CTGGCTTGAG GTCAGGCAGG AAAGGAGACT 2580 TGACCTCCTG GCTTGGGGAC ACGTAGGGAG CACTGCTGCT AGGCGTCATG GGTGGTGTGG 2640 GATTCCCCGG CAGTGGGGAG CTGGGGTAAG CAGGGATGGA GCGGGAAGGC CCACTCAAGC 2700 CAGGCTGGCT GTAGCTGATG CTGCCCCCGT TGAANCTGGC GCCCTGCCCG TTGAACTGCT 2760 CTGTGGGCTT GTAATGCAGN CCTGTGGGGC CAGGGGCAGA CAGGGACTGG GCCATGCCCT 2820 GCTGCAGGGG GAGTCTGTGT CCTGCGTAGG AGGAGGCAGG GCCAGGGGGC TGCCCGGGAC 2880 CAGGAGCATA CTGGGCAGTG CTGGCTGCAT ACTGGCCNNC TTGCAGATAT TGNTGNCNAG 2940 GATACACCTC TGAGTAGGTC TCTCTTGACC CNCTGTCGAG GCAGCGGCTG CCCCTGGGGA 3000 GGCCCAGGGT AGCCATGCTG AGGCAGTCGC TGTCCTGCAT ACAAGGGTGT CATGCCTGCT 3060 GCCCGTGTAG GATTCATGGC CATGGAGGAA AGGCCTGAGG GGCCCATCAT TCCTCCCATG 3120 CCTGAAGGGT TCATGCCAGG GGGTACACTG GGCCCTCGAG GACCTCCATG CTGCAGAAAC 3180 TGGCTGTTAA AAGATTGCCC AGTCCCCATC GCTCCATATT GGCTTAGCTT CCTGGCTCTN 3240 CTTCTCTTGC AGGGNNGCCA CAGTAGCTGT GGCTGTGGCT GTGGCCGTNC TGCAGCAGCA 3300 GCCATGGCAG CTGCAGCTCT GCTTGTGTGA AGTCAG 3336 (2) INFORMATION FOR SEQ ID NO: 76: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1494 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW088 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 9..686 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (612..909) (D) OTHER INFORMATION: /label= SAC_24336 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76: GTCGACCC GCT GCG GTC TAT CTG GGC AGC ACC ATG CTC GCG CTC CGA AGC 50 Ala Ala Val Tyr Leu Gly Ser Thr Met Leu Ala Leu Arg Ser 1 5 10 GGC CTG AGG ACG GCG CTG GCC CCG CGG GCT CTG ACG CCT CAG GTA TGT 98 Gly Leu Arg Thr Ala Leu Ala Pro Arg Ala Leu Thr Pro Gin Val Cys 15 20 25 30 TCA CCT TTT GCT ACA GGC CCC AGG CAA AGC GAT GGG ACA TTG TAT GAA 146 Ser Pro Phe Ala Thr Gly Pro Arg Gin Ser Asp Gly Thr Leu Tyr Glu 35 40 45 TTC CGC ACC TAC TCT CTG AAG CCC TCA AAG ACA AAT GCG TTC CTG CAG 194 Phe Arg Thr Tyr Ser Leu Lys Pro Ser Lys Thr Asn Ala Phe Leu Gin 50 55 60 AAT TTT CAG AAA TAC GTT CAC CTT CGG ACA GCT CAC TCT GAG ATG ATT 242 Asn Phe Gin Lys Tyr Val His Leu Arg Thr Ala His Ser Glu Met He 65 70 75 GGA TAC TGG ACC GTA GAA TTT GGA GGC AAA ATA AAC AGA GTG TTC CAT 290 Gly Tyr Trp Thr Val Glu Phe Gly Gly Lys He Asn Arg Val Phe His 80 85 90 ATT TGG AAG TAT GAT AAT TTT GCT CAT CGA ACT GCC GTC CGC AAA GCC 338 He Trp Lys Tyr Asp Asn Phe Ala His Arg Thr Ala Val Arg Lys Ala 95 100 105 110 TTG GCC AAG GAT AAG GAA TGG CAA GAA CAA TTC CTC ATT TCA AAT TTG 386 Leu Ala Lys Asp Lys Glu Trp Gin Glu Gin Phe Leu He Ser Asn Leu 115 120 125 GCT TTC ATG GAT GAA CAA GAG GTT GAG ATT ACC TAC TTG GTA CCC TGG 434 Ala Phe Met Asp Glu Gin Glu Val Glu He Thr Tyr Leu Val Pro Trp 130 135 140 TGT AAA ATA AGA ACA CCT CCC AAG GAA GGA GTC TAT GAA CTG GCT ACC 482 Cys Lys He Arg Thr Pro Pro Lys Glu Gly Val Tyr Glu Leu Ala Thr 145 150 155 TTT CAG ATG AAG CCT GGT GGC CCA GCT CTA TGG GGT GAT GCA TTC AAA 530 Phe Gin Met Lys Pro Gly Gly Pro Ala Leu Trp Gly Asp Ala Phe Lys 160 165 170 AGG GCA ATA AAC GCC CAT GTT GAG CTT GGC TAC TCT ACA CTA GTT GGT 578 Arg Ala He Asn Ala His Val Glu Leu Gly Tyr Ser Thr Leu Val Gly 175 180 185 190 GTT TTC CAC ACT GAA TAT GGA GCC CTC AAC AGA GTT CGG GAA AGT GTC 626 Val Phe His Thr Glu Tyr Gly Ala Leu Asn Arg Val Arg Glu Ser Val 195 200 205 AAT TAC CTC GAG TCT CAG CAG AAT ATG TTC CTG ATT CCA ACC TCA TTT 674 Asn Tyr Leu Glu Ser Gin Gin Asn Met Phe Leu He Pro Thr Ser Phe 210 215 220 TCA CCA TTG AAG TAGTTTCCTA CCGAGCGCTG AGCATTCCCA TCACGGAGGT 726 Ser Pro Leu Lys 225 GAGATGCGTT TCCCCCAGAC AATCGCCCTG TTCATTGTCT GAAGGAGGTG CTGAGCTACC 786 GCACTGCCCT CTGCATGTCT GAGACTTCAT GTATCCTTTA CTACCAGTCG CTCAGGAAAT 846 GTTTCTGTCC CTTTTCATGT CTACTGGATG TCAGAAAGTG GTGTTATTAC TCCATGCCCT 906 GGTACTTCAT TGTTCTTCTG TGGTTTTATG ATTAAGTCTT GTCCTCAAAA TATGATTTTG 966 AAATTTTTTC CCTCAAAATA TTTGGAAATT AAATAAATAC AATATCTGCC TTTTTATTGC 1026 GTTCATTTTC CCTGAAATTT TTAACTGTTT TTACCAGTAA TGTTTACTTT GTGATTTCAA 1086 ATGGGATTGA TAGAAGTCAG AGAAAGAACT GGAAGAGCTT GAAGGGGCTC GAGACCCCAT 1146 ATGTACAACA ATGCCAAGCA ACCAGAGCTT CCAGGGACTA AGCCACTACC TAAAGACTAT 1206 ACATGGACTG ACCCTGGACT CTGACCTCAT AGGTAGCAAT GAATATCCTA GTAAGAGCAC 1266 CAGTGGAAGG GGAAGCCCTG GGTCCTGCTA AGACTGAACC CCAGTGAACG TGATTGTTGT 1326 GGGGAGAGTG GTAATGGGGG GAGGATGGGG AGGGGAAGCC CATATAGAAG GGGAGGGAGA 1386 GGGGTTAGGG GGATGTCGGC CCAGAAACCA GGAAGGGGAA TAACAATTGA AATGTAAATA 1446 AGAAATACTC AAGTTAATAA AGATGGAGAA AAGAAAAAGA AAGTCGAC 1494 (2) INFORMATION FOR SEQ ID NO: 77: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 226 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77: Ala Ala Val Tyr Leu Gly Ser Thr Met Leu Ala Leu Arg Ser Gly Leu 1 5 10 15 Arg Thr Ala Leu Ala Pro Arg Ala Leu Thr Pro Gin Val Cys Ser Pro 20 25 30 Phe Ala Thr Gly Pro Arg Gin Ser Asp Gly Thr Leu Tyr Glu Phe Arg 35 40 45 Thr Tyr Ser Leu Lys Pro Ser Lys Thr Asn Ala Phe Leu Gin Asn Phe 50 55 60 Gin Lys Tyr Val His Leu Arg Thr Ala His Ser Glu Met He Gly Tyr 65 70 75 80 Trp Thr Val Glu Phe Gly Gly Lys He Asn Arg Val Phe His He Trp 85 90 95 Lys Tyr Asp Asn Phe Ala His Arg Thr Ala Val Arg Lys Ala Leu Ala 100 105 110 Lys Asp Lys Glu Trp Gin Glu Gin Phe Leu He Ser Asn Leu Ala Phe 115 120 125 Met Asp Glu Gin Glu Val Glu He Thr Tyr Leu Val Pro Trp Cys Lys 130 135 140 He Arg Thr Pro Pro Lys Glu Gly Val Tyr Glu Leu Ala Thr Phe Gin 145 150 155 160 Met Lys Pro Gly Gly Pro Ala Leu Trp Gly Asp Ala Phe Lys Arg Ala 165 170 175 He Asn Ala His Val Glu Leu Gly Tyr Ser Thr Leu Val Gly Val Phe 180 185 190 His Thr Glu Tyr Gly Ala Leu Asn Arg Val Arg Glu Ser Val Asn Tyr 195 200 205 Leu Glu Ser Gin Gin Asn Met Phe Leu He Pro Thr Ser Phe Ser Pro 210 215 220 Leu Lys 225 (2) INFORMATION FOR SEQ ID NO: 78: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1082 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW089 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION : 8 . . 1006 ( ix) FEATURE : (A) NAME/KEY: misc_feature (B) LOCATION: 961..1076 (D) OTHER INFORMATION: /label= SAC_24461 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78: GTCGACC AAG CAA CAG CAG GGA AGT GAA TTT CAG ACA CTG CTG GAG GCT 49 Lys Gin Gin Gin Gly Ser Glu Phe Gin Thr Leu Leu Glu Ala 1 5 10 GAG GAG ACC AAA GCC GCC TCT GAC GCT TCA AAT AAA AAG CTT TGG TCC 97 Glu Glu Thr Lys Ala Ala Ser Asp Ala Ser Asn Lys Lys Leu Trp Ser 15 20 25 30 CTC AGA ACT CTA CCC TTC CAG CCC TGC TCT GAA GCC TCA GAC GTG AGA 145 Leu Arg Thr Leu Pro Phe Gin Pro Cys Ser Glu Ala Ser Asp Val Arg 35 40 45 ACC ATG TCT GTG ACC CTG CAA GCT GTC CTC TAC AGT CTT CAG GAG GAG 193 Thr Met Ser Val Thr Leu Gin Ala Val Leu Tyr Ser Leu Gin Glu Glu 50 55 60 CAG TCC AGG CTC AAG ACG AGG CTG CAG GAA CTA CAG CAG CTG AAA AGG 241 Gin Ser Arg Leu Lys Thr Arg Leu Gin Glu Leu Gin Gin Leu Lys Arg 65 70 75 GAG CGC ATA GAT GTT CCC AGA GAC AAG ATC CCA TTC CCG GTG CCT GAA 289 Glu Arg He Asp Val Pro Arg Asp Lys He Pro Phe Pro Val Pro Glu 80 85 90 GTC CCC GTG GTA TTC CAA GGT CTA ACT AAG CAG AGC GGC CAA GCA CCC 337 Val Pro Val Val Phe Gin Gly Leu Thr Lys Gin Ser Gly Gin Ala Pro 95 100 105 110 AAG TCT CTA GTT TCT AAC TTG AAG ATC TGC TGC CCT CTG CCT GGA GGT 385 Lys Ser Leu Val Ser Asn Leu Lys He Cys Cys Pro Leu Pro Gly Gly 115 120 125 TCT GCT CTG ATC ACC TTT GAT GAC CCC AAA GTG GTT GAG CGG TTG CTA 433 Ser Ala Leu He Thr Phe Asp Asp Pro Lys Val Val Glu Arg Leu Leu 130 135 140 CAA CAA AAG GAA CAT AAA GTT GAC ATC GAG GAC TGC CGG CTG CGG GTG 481 Gin Gin Lys Glu His Lys Val Asp He Glu Asp Cys Arg Leu Arg Val 145 150 155 CAG ATC CAG CCC TTG GAG CTG CCT ATG GTG ACC AAC ATC CAG GTG TCC 529 Gin He Gin Pro Leu Glu Leu Pro Met Val Thr Asn He Gin Val Ser 160 165 170 AGC CAG CCG GAT AGC CAC AGG GTG CTA GTC AGT GGC TTT CCT ACT GGA 577 Ser Gin Pro Asp Ser His Arg Val Leu Val Ser Gly Phe Pro Thr Gly 175 180 185 190 CTT AGG CTG AGT GAG GAG GAG CTA CTG GAC AAG TTA GAG ATC TTC TTC 625 Leu Arg Leu Ser Glu Glu Glu Leu Leu Asp Lys Leu Glu He Phe Phe 195 200 205 GGC AAG GCC AAG AAT GGA GGT GGG GAT GTG GAG ACC CGG GAG ATG CTG 673 Gly Lys Ala Lys Asn Gly Gly Gly Asp Val Glu Thr Arg Glu Met Leu 210 215 220 CAA GGG ACT GTC ATG CTG GGA TTT GCT AAT GAA GAA GTG GCC CAG CAC 721 Gin Gly Thr Val Met Leu Gly Phe Ala Asn Glu Glu Val Ala Gin His 225 230 235 TTA TGC CAG ATT GGC CAG TTC AGA GTC CCA CTG GGT CGG CAG CAG GTC 769 Leu Cys Gin He Gly Gin Phe Arg Val Pro Leu Gly Arg Gin Gin Val 240 245 250 CTT TTG AGG GTC TCT CCC TAT GTG AGT GGG GAG ATC CAG GAA GCT GAG 817 Leu Leu Arg Val Ser Pro Tyr Val Ser Gly Glu He Gin Glu Ala Glu 255 260 265 270 ATC AAA TTC CAG CAA GCA CCT CAT TCA GTG CTG GTG ACG AAT ATT CCC 865 He Lys Phe Gin Gin Ala Pro His Ser Val Leu Val Thr Asn He Pro 275 280 285 GAC GTC CTG GAT GTG CAG GAA CTG CAT GAC ATT CTG GAG ATC CAC TTC 913 Asp Val Leu Asp Val Gin Glu Leu His Asp He Leu Glu He His Phe 290 295 300 CAG AAG CCT ACC CGT GGG GGC GGA GAG GTG GAG GCC CTG GCA GTT GTA 961 Gin Lys Pro Thr Arg Gly Gly Gly Glu Val Glu Ala Leu Ala Val Val 305 310 315 CCT GTG GGG CAG CAG GGC CTG GCT GTC TTT ACT TCT GAG TCA AGC 1006 Pro Val Gly Gin Gin Gly Leu Ala Val Phe Thr Ser Glu Ser Ser 320 325 330 TAGGGCTGCA TGTCCACCTG CTGGGCATGG GACTGCTCAT TGCCTAATGC TACCAAGAAC 1066 AGTGAAAGGC GTCGAC 1082 (2) INFORMATION FOR SEQ ID NO: 79: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 333 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79: Lys Gin Gin Gin Gly Ser Glu Phe Gin Thr Leu Leu Glu Ala Glu Glu 1 5 10 15 Thr Lys Ala Ala Ser Asp Ala Ser Asn Lys Lys Leu Trp Ser Leu Arg 20 25 30 Thr Leu Pro Phe Gin Pro Cys Ser Glu Ala Ser Asp Val Arg Thr Met 35 40 45 Ser Val Thr Leu Gin Ala Val Leu Tyr Ser Leu Gin Glu Glu Gin Ser 50 55 60 Arg Leu Lys Thr Arg Leu Gin Glu Leu Gin Gin Leu Lys Arg Glu Arg 65 70 75 80 He Asp Val Pro Arg Asp Lys He Pro Phe Pro Val Pro Glu Val Pro 85 90 95 Val Val Phe Gin Gly Leu Thr Lys Gin Ser Gly Gin Ala Pro Lys Ser 100 105 110 Leu Val Ser Asn Leu Lys He Cys Cys Pro Leu Pro Gly Gly Ser Ala 115 120 125 Leu He Thr Phe Asp Asp Pro Lys Val Val Glu Arg Leu Leu Gin Gin 130 135 140 Lys Glu His Lys Val Asp He Glu Asp Cys Arg Leu Arg Val Gin He 145 150 155 160 Gin Pro Leu Glu Leu Pro Met Val Thr Asn He Gin Val Ser Ser Gin 165 170 175 Pro Asp Ser His Arg Val Leu Val Ser Gly Phe Pro Thr Gly Leu Arg 180 185 190 Leu Ser Glu Glu Glu Leu Leu Asp Lys Leu Glu He Phe Phe Gly Lys 195 200 205 Ala Lys Asn Gly Gly Gly Asp Val Glu Thr Arg Glu Met Leu Gin Gly 210 215 220 Thr Val Met Leu Gly Phe Ala Asn Glu Glu Val Ala Gin His Leu Cys 225 230 235 240 Gin He Gly Gin Phe Arg Val Pro Leu Gly Arg Gin Gin Val Leu Leu 245 250 255 Arg Val Ser Pro Tyr Val Ser Gly Glu He Gin Glu Ala Glu He Lys 260 265 270 Phe Gin Gin Ala Pro His Ser Val Leu Val Thr Asn He Pro Asp Val 275 280 285 Leu Asp Val Gin Glu Leu His Asp He Leu Glu He His Phe Gin Lys 290 295 300 Pro Thr Arg Gly Gly Gly Glu Val Glu Ala Leu Ala Val Val Pro Val 305 310 315 320 Gly Gin Gin Gly Leu Ala Val Phe Thr Ser Glu Ser Ser 325 330 (2) INFORMATION FOR SEQ ID NO: 80: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2263 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW090 ( ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 335..937 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1355..1434 (D) OTHER INFORMATION: /label= SAC_24197 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80: GTCGACCTTT AAGCTTACCA TCAGAACAAC AAATCAAAAT GTAAACTTAA AATATAACCA 60 AAAGAGGGAC AGCTCTTTAG GAAAAGGAAA AAACCTTAAA TAGTGAATAA ACAACTACAA 120 CCACTTAACC ATTGTAGGCT TAAAAGCAGC CATCAATAAA GAAAGCGTTC AAGCTCAACA 180 TACACACACA CACACACACA CACACACGCT CCCTCCCTCC GGCGCTCTAC TCCGCGCCCG 240 CCCGCCCGCT CGCCCGCCCG CCCGCCTCGC ACGCACCGGC CTCGGCTCCC CGCGCCCGCC 300 GCCGAGCGAA GCTGCTCTGG GATCGGAGCA GCTC ATG GAG AAA GTG CCG GGC 352 Met Glu Lys Val Pro Gly 1 5 GAC ATG GAG ATA GAG CGC AGG GAG AGG AAC GAG GAG CTG TCC GAG GCG 400 Asp Met Glu He Glu Arg Arg Glu Arg Asn Glu Glu Leu Ser Glu Ala 10 15 20 GAG AGG AAG GCG GTT CAG GCT ACG TGG GCC CGG CTG TAT GCC AAC TGC 448 Glu Arg Lys Ala Val Gin Ala Thr Trp Ala Arg Leu Tyr Ala Asn Cys 25 30 35 GAG GAC GTG GGG GTG GCC ATC CTG GTG AGG TTC TTT GTG AAC TTC CCG 496 Glu Asp Val Gly Val Ala He Leu Val Arg Phe Phe Val Asn Phe Pro 40 45 50 TCG GCC AAG CAG TAC TTC AGC CAG TTT AAA CAC ATG GAG GAT CCG TTG 544 Ser Ala Lys Gin Tyr Phe Ser Gin Phe Lys His Met Glu Asp Pro Leu 55 60 65 70 GAG ATG GAG AGG AGT CCT CAG CTG CGG AAA CAT GCC TGC CGG GTC ATG 592 Glu Met Glu Arg Ser Pro Gin Leu Arg Lys His Ala Cys Arg Val Met 75 80 85 GGG GCC CTC AAC ACG GTC GTG GAG AAC CTG CAT GAC CCA GAC AAG GTA 640 Gly Ala Leu Asn Thr Val Val Glu Asn Leu His Asp Pro Asp Lys Val 90 95 100 TCC TCT GTG CTC GCG CTG GTT GGC AAG GCC CAC GCC CTC AAG CAC AAG 688 Ser Ser Val Leu Ala Leu Val Gly Lys Ala His Ala Leu Lys His Lys 105 110 115 GTG GAA CCT ATG TAC TTT AAG ATT CTC TCT GGG GTC ATT CTG GAC GTG 736 Val Glu Pro Met Tyr Phe Lys He Leu Ser Gly Val He Leu Asp Val 120 125 130 ATC GCC GAG GAG TTT GCC AAT GAC TTC CCC GTC GAG ACG CAG AAA GCC 784 He Ala Glu Glu Phe Ala Asn Asp Phe Pro Val Glu Thr Gin Lys Ala 135 140 145 150 TGG ACC AAG CTG CGC GGT CTC ATC TAC AGC CAT GTG ACC GCG GCC TAC 832 Trp Thr Lys Leu Arg Gly Leu He Tyr Ser His Val Thr Ala Ala Tyr 155 160 165 AAG GAA GTG GGC TGG GTA CAG CAG CCT ACC AGC CAC ACT GCC CTC TTC 880 Lys Glu Val Gly Trp Val Gin Gin Pro Thr Ser His Thr Ala Leu Phe 170 175 180 AGG GCC ATA GGA CCC CTC CCA GCT CCC CCC TCC CTG GCA GCA CTT TGG 928 Arg Ala He Gly Pro Leu Pro Ala Pro Pro Ser Leu Ala Ala Leu Trp 185 190 195 GCA GAA GGC TGACTTCTGA AGACACTCCT TGACCTTCCA TTTCTGGGTG 977 Ala Glu Gly 200 CCAAGGAAGC TGGAGGAACC CCTGACTGGA CTTCCCGAAA GGAGGCCTTC ATCATGGCTG 1037 TGGTCTCCCA CGTTACTGGG AGGTGGGGCT GGCTACCTGG ATGCTGAATT TAGCAGAGGG 1097 GAACCCTTCT GCCTCGCAGC AGAGGGCACA CCCTCCTTAG CTTTCACTGT CAAGAGAGGG 1157 ACCTGGCATG TGGCCGGTGG GAAGCAAGGA CAAGCCTTTG AGTCACTTCA GAAAGGAACT 1217 AGCCCTGCTT CACTCTGCCC TACCAGCATG CAGGTTCTCC TCACCATCTC TGAGCATTGC 1277 GCACACACAC GTCTACCATA TACACAGATA TATTCTATAT ACGAGCTCTA TATAAATATA 1337 TATACACACA CACACGTACA TATCTGTCGC GTGCACCTGC AGGCCCAGAA GCCTAGGCCT 1397 CGCACAGCTG TGGGAGACCC GGAAGAGTCC TGGCCGTACT TCAGGGCAGC TCTACCGGGA 1457 GCAGGGAGAA AGCTTGCAAC AGCACGAGAG GGCGGGGCCG GGTGGGAGAG TCGGGGTGAC 1517 TCAGCTCACC CCGCACAGCT CAGTGCCCTG CAATCTTCCC CTTCCGCCCC CCAAAAGAGA 1577 ACACTTGGTT TGCCCGGTGT CGGGGCGCAC ACCTGTAATC CCCGAGTTTG GGACGCAGAG 1637 GAAGGACAAT CTTTGCAAGT CTGAGGTCAG GTGGTCTACA CTTGGTCTCC ATCTTGGTGA 1697 GTTTCCGGCT AGCTGGGGTC GACTCAGGGA GACCCCGTGT CAAACAAAAC AAGAAGCGAA 1757 GAGAAGATCT GGCTCCCCTC CCCTCCCCAA GGGTTTGCCC GACTGACTTG CTCCGGAAAG 1817 GGGCACACCG AGAATTCAGG AGACCCCAGT GGGGTGCTGG CCAGTGTAGG TGTCCGGCGT 1877 TTGGGGGTGG GGTGAGGGGC AGCTTCAGCG TGGAGCCCTA GAATGTCAGC CTCACCCGCT 1937 CACTTCAGAC AGCAGCCAGG CCACAGGACC AGGGGCCATA CTCAAACCCC TCAGCAGAGA 1997 CCAGGGCGCC TCTCTCCTGC CCTCCTCGGG GCCACCTGCC CATCCTCTCC AACTAGTCTC 2057 CGTAACATTC GCTGGGGACC CCGTGTGTAC CCCTTGGTCA CGTGTACTGT CCTGGAGGAC 2117 GTCTTACTGC TGTGGCTACC GTGCCTGCGT CCCCTCTGGT CCCACCCTCA CGCAGCCTTC 2177 CTGTAACTGC CTGTCTTTTT GTAGTTTCTG ATGTTTGTAA CCAGACCCAG CTGTGTCATT 2237 AAACAGGTCT GTTCTTCCTG TAAAAA 2263 (2) INFORMATION FOR SEQ ID NO: 81: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 201 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81: Met Glu Lys Val Pro Gly Asp Met Glu He Glu Arg Arg Glu Arg Asn 1 5 10 15 Glu Glu Leu Ser Glu Ala Glu Arg Lys Ala Val Gin Ala Thr Trp Ala 20 25 30 Arg Leu Tyr Ala Asn Cys Glu Asp Val Gly Val Ala He Leu Val Arg 35 40 45 Phe Phe Val Asn Phe Pro Ser Ala Lys Gin Tyr Phe Ser Gin Phe Lys 50 55 60 His Met Glu Asp Pro Leu Glu Met Glu Arg Ser Pro Gin Leu Arg Lys 65 70 75 80 His Ala Cys Arg Val Met Gly Ala Leu Asn Thr Val Val Glu Asn Leu 85 90 95 His Asp Pro Asp Lys Val Ser Ser Val Leu Ala Leu Val Gly Lys Ala 100 105 110 His Ala Leu Lys His Lys Val Glu Pro Met Tyr Phe Lys He Leu Ser 115 120 125 Gly Val He Leu Asp Val He Ala Glu Glu Phe Ala Asn Asp Phe Pro 130 135 140 Val Glu Thr Gin Lys Ala Trp Thr Lys Leu Arg Gly Leu He Tyr Ser 145 150 155 160 His Val Thr Ala Ala Tyr Lys Glu Val Gly Trp Val Gin Gin Pro Thr 165 170 175 Ser His Thr Ala Leu Phe Arg Ala He Gly Pro Leu Pro Ala Pro Pro 180 185 190 Ser Leu Ala Ala Leu Trp Ala Glu Gly 195 200 (2) INFORMATION FOR SEQ ID NO: 82: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1740 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW092 ( ix) FEATURE : (A) NAME/KEY: misc_feature (B) LOCATION: complement (303..566) (D) OTHER INFORMATION: /label= SAC_24320 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82: GTCGACCTCG GAGCTGGGGA CCGAACCCAG GGCCTTGCGC TTGCTAGGCA AGCGCTCTAC 60 CACTGAGCTA AATCCCCAAC CCCTAGCCCT TTGTTTTTTA AGAAAGTCTA GTGTAGCCCA 120 GGTTGGCCTT AAATTCCTGA TCCTCCTGCC CCTATCTGTA ATCTTGGGAT TATAGGTGTG 180 GGCCATCACA CTGTTTATCC AGTGCTGAAT CAAACCCAGA ATCTTCCACA TGCTAGGCGA 240 GCAGTCTCCT AAATACTACA CGGCTATAGG TTCAGCCTAG ATCTCTCTTT TGAAGCTCTC 300 GTACACCTAT AGGGGCCACT AATCCTAAAG ACGCAGAGGA TGAAAACCAC CAGGCCCAAG 360 GGTTAACGTG GAAAACAGAG CCCTGGTGTC CCCCTGGGGA ACCAGCCCTT CATGTTCTAA 420 GACAGTCATC ACCCAGATTC CTGAAAACAA TAGCGGCTTC TTGTTTAGAA CGGAACCGCA 480 CCTGCTGGAA TACGTGTCAA CAAACAATCG CTTTGTTTTT CATATTCGCC ATCCAAGCTG 540 AGGCAATGGG ACTTCCTGAA GCGAGTACTG GAAGACTTAT TCTTAGAAGA GGACAGAATT 600 CTCATTTTAA CACGAGGCTC AGGGGCCGAG TGCTGGCCAT CTTCCTTCCT TCTTTTGTAC 660 TCCCTGGTGT TCATCTTATT TGGTTTTCAA CAGGTTTATT TCCATTGCAG CCCGGGGCTT 720 CCAACGCCCA AAAACGCCCA GCCCACGATG CCGTAAATGG TGAGCACGCT GGCTTCTGCT 780 TCCTCTCCCT GAGAACCCAG ACCCTTTGTT GTTCCGCCAT TCCAAAAGGC CCTGGGAAGG 840 TTCTTTGCTC CTCTGGTGAC AGGCTTGGGA TGAAGACTTG GGAACTCCTA TTTGCTAAAC 900 TCTCGCTCCT GGCTAAATCT TTCTGCTTGT TCTTTTTCCT CGTCTAATCA TGCTACCTGC 960 TACTACTTTT CCTGATGCAG TCTGACGAAC GTCTGTTGAA CACATCGGGA CAGTTTTAAA 1020 AGGAGTTATT TTGGTGGCAA AGGCGCTCAG TTGTGATTTA AAAGTGTTTT AAGTGATTCA 1080 TCCAAGGTTG TCTCCATGGA CTCCGGAAAT AACCACAGCC AAAATACCCC GGCGAGAGCA 1140 GAATATGAGA GGCAGATAGC ACCTATTATT ACTTTTATCT GGGTGCAGCC GGGCTCCAGA 1200 TTAATGGGGG CAAGCAAAGG TCCAGGCCTC AGACATGGCC AATTTTAAGC AAACTAGTGC 1260 TAGTGTTGAT AAGTATTCAA TAAGGGCTTG GAATCTAATT ATTTGTAAGA AGTGTCTTTG 1320 TTTCCTGATC TGTAAAGGAG ATGGGGAAAT ACTGTGATTT CGTGCCATTT TAAAAAAAAT 1380 GAAAAAGCAA CATAAAAAAA TGCAAATACA GAAGAAAAGA TGTGGGGTTT GAAGTTGGCT 1440 TTAGAGAGCT GTGTAACCTT GGGGAAGTCA CCTCGTCTCT CTGTGACTTG AATTCCTAAT 1500 CAACAATAAT GCTGGGGGAC AAGGTGCTCT CCAAATTCCC CTTCAGATCA GAAAGTCTGG 1560 GATAACTATC CCAGATAGAT CCAAACTTGT AAAGGAATCA AAAGGAATAG TCTAGTGTGA 1620 CAGATAACAC GGACTTGAAA CTTAGTTCAC CTGATATTTC TTAATGACTT AACACCACTA 1680 TACCTCACCC CAGAGCTAGC CTGTCCCCTG TGTGCCCACC AGTAACCTTG AAATGTCGAC 1740 (2) INFORMATION FOR SEQ ID NO: 83: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1385 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW093 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 8..1357 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 798..1385 (D) OTHER INFORMATION: /label= SAC_24538 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83: GTCGACT CTG CCT CAG CCG CTG CCG CCG CCA CTG CTG CTG CAG GAT CCG 49 Leu Pro Gin Pro Leu Pro Pro Pro Leu Leu Leu Gin Asp Pro 1 5 10 CCG CAG CCA CCA GTC TCG CGC GTC GTC GCT CCC TCC TTG GAC AGT AAT 97 Pro Gin Pro Pro Val Ser Arg Val Val Ala Pro Ser Leu Asp Ser Asn 15 20 25 30 TTT ATG AAT AAG CAT CAG AAG CCG GTA CTA ACA GGC CAG CGG TTC AAA 145 Phe Met Asn Lys His Gin Lys Pro Val Leu Thr Gly Gin Arg Phe Lys 35 40 45 ACC CGG AAA AGG GAT GAA AAA GAG AAA TTC GAA CCC ACA GTC TTC AGG 193 Thr Arg Lys Arg Asp Glu Lys Glu Lys Phe Glu Pro Thr Val Phe Arg 50 55 60 GAT ACA CTT GTC CAG GGG CTT AAT GAA GCT GGT GAT GAC CTT GAA GCT 241 Asp Thr Leu Val Gin Gly Leu Asn Glu Ala Gly Asp Asp Leu Glu Ala 65 70 75 GTA GCC AAA TTC TTG GAC TCT ACT GGC TCA CGA CTA GAT TAT CGT CGC 289 Val Ala Lys Phe Leu Asp Ser Thr Gly Ser Arg Leu Asp Tyr Arg Arg 80 85 90 TAT GCA GAC ACA CTC TTT GAT ATC CTG GTG GCT GGC AGC ATG CTT GCC 337 Tyr Ala Asp Thr Leu Phe Asp He Leu Val Ala Gly Ser Met Leu Ala 95 100 105 110 CCT GGA GGA ACA CGC ATA GAT GAT GGT GAC AAG ACC AAG ATG ACC AAC 385 Pro Gly Gly Thr Arg He Asp Asp Gly Asp Lys Thr Lys Met Thr Asn 115 120 125 CAC TGT GTG TTT TCA GCA AAT GAA GAT CAT GAA ACC ATC CGA AAC TAT 433 His Cys Val Phe Ser Ala Asn Glu Asp His Glu Thr He Arg Asn Tyr 130 135 140 GCT CAG GTC TTC AAC AAA CTC ATC AGG AGA TAC AAA TAT TTG GAA AAG 481 Ala Gin Val Phe Asn Lys Leu He Arg Arg Tyr Lys Tyr Leu Glu Lys 145 150 155 GCA TTT GAA GAT GAA ATG AAA AAG CTT CTC CTC TTC CTT AAA GCA TTT 529 Ala Phe Glu Asp Glu Met Lys Lys Leu Leu Leu Phe Leu Lys Ala Phe 160 165 170 TCT GAA GCA GAG CAG ACA AAG TTG GCA ATG CTG TCT GGG ATC CTG TTG 577 Ser Glu Ala Glu Gin Thr Lys Leu Ala Met Leu Ser Gly He Leu Leu 175 180 185 190 GGC AAT GGA ACC CTC CCG GCC ACC ATC CTT ACC AGT CTC TTC ACC GAC 625 Gly Asn Gly Thr Leu Pro Ala Thr He Leu Thr Ser Leu Phe Thr Asp 195 200 205 AGC TTA GTC AAA GAA GGC ATC GCA GCC TCG TTC GCT GTC AAG CTT TTC 673 Ser Leu Val Lys Glu Gly He Ala Ala Ser Phe Ala Val Lys Leu Phe 210 215 220 AAA GCC TGG ATG GCA GAG AAA GAT GCC AAT TCT GTC ACC TCT TCA TTG 721 Lys Ala Trp Met Ala Glu Lys Asp Ala Asn Ser Val Thr Ser Ser Leu 225 230 235 AGA AAA GCC AAC CTG GAC AAG AGG CTG CTT GAA CTC TTC CCA GTG AAC 769 Arg Lys Ala Asn Leu Asp Lys Arg Leu Leu Glu Leu Phe Pro Val Asn 240 245 250 AGA CAG AGT GTG GAT CAT TTC GCC AAG TAC TTC ACT GAC GCA GGA CTG 817 Arg Gin Ser Val Asp His Phe Ala Lys Tyr Phe Thr Asp Ala Gly Leu 255 260 265 270 AAG GAG CTG TCA GAC TTT CTC CGA GTC CAG CAG TCA CTG GGC ACC AGG 865 Lys Glu Leu Ser Asp Phe Leu Arg Val Gin Gin Ser Leu Gly Thr Arg 275 280 285 AAG GAA CTG CAG AAG GAG CTG CAA GAG CGA CTG TCT CAG GAA TGC CCC 913 Lys Glu Leu Gin Lys Glu Leu Gin Glu Arg Leu Ser Gin Glu Cys Pro 290 295 300 ATC AAG GAG GTG GTG CTT TAC GTC AAA GAG GAA ATG AAA AGG AAC GAC 961 He Lys Glu Val Val Leu Tyr Val Lys Glu Glu Met Lys Arg Asn Asp 305 310 315 CTT CCG GAG ACA GCT GTG ATC GGG CTG CTG TGG ACC TGC GTC ATG AAC 1009 Leu Pro Glu Thr Ala Val He Gly Leu Leu Trp Thr Cys Val Met Asn 320 325 330 GCT GTG GAA TGG AAC AAG AAG GAG GAG CTG GTT GCT GAG CAG GCT CTT 1057 Ala Val Glu Trp Asn Lys Lys Glu Glu Leu Val Ala Glu Gin Ala Leu 335 340 345 350 AAG CAC CTG AAG CAA TAC GCT CCC CTG CTG GCC GTG TTC AGT TCC CAA 1105 Lys His Leu Lys Gin Tyr Ala Pro Leu Leu Ala Val Phe Ser Ser Gin 355 360 365 GGC CAG TCA GAG CTT GTC CTC CTG CAG AAG GTT CAG GAA TAC TGC TAT 1153 Gly Gin Ser Glu Leu Val Leu Leu Gin Lys Val Gin Glu Tyr Cys Tyr 370 375 380 GAC AAC ATC CAC TTC ATG AAA GCC TTC CAG AAG ATC GTG GTT CTC TTT 1201 Asp Asn He His Phe Met Lys Ala Phe Gin Lys He Val Val Leu Phe 385 390 395 TAT AAA GCC GAC GTT CTG AGC GAG GAG GCG ATA CTG AAG TGG TAT AAA 1249 Tyr Lys Ala Asp Val Leu Ser Glu Glu Ala He Leu Lys Trp Tyr Lys 400 405 410 GAA GCA CAT GCC GCC AAA GGC AAA AGC GTC TTC CTT GAC CAG ATG AAG 1297 Glu Ala His Ala Ala Lys Gly Lys Ser Val Phe Leu Asp Gin Met Lys 415 420 425 430 AAA TTT GTG GAG TGG TTA CAA AAT GCA GAA GAA GAA TCT GAA TCA GAA 1345 Lys Phe Val Glu Trp Leu Gin Asn Ala Glu Glu Glu Ser Glu Ser Glu 435 440 445 GGT GAA GAA AGC TAAATGTCTC CAGCACACTG CCTAAAAA 1385 Gly Glu Glu Ser 450 (2) INFORMATION FOR SEQ ID NO: 84: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 450 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84: Leu Pro Gin Pro Leu Pro Pro Pro Leu Leu Leu Gin Asp Pro Pro Gin 1 5 10 15 Pro Pro Val Ser Arg Val Val Ala Pro Ser Leu Asp Ser Asn Phe Met 20 25 30 Asn Lys His Gin Lys Pro Val Leu Thr Gly Gin Arg Phe Lys Thr Arg 35 40 45 Lys Arg Asp Glu Lys Glu Lys Phe Glu Pro Thr Val Phe Arg Asp Thr 50 55 60 Leu Val Gin Gly Leu Asn Glu Ala Gly Asp Asp Leu Glu Ala Val Ala 65 70 75 80 Lys Phe Leu Asp Ser Thr Gly Ser Arg Leu Asp Tyr Arg Arg Tyr Ala 85 90 95 Asp Thr Leu Phe Asp He Leu Val Ala Gly Ser Met Leu Ala Pro Gly 100 105 110 Gly Thr Arg He Asp Asp Gly Asp Lys Thr Lys Met Thr Asn His Cys 115 120 125 Val Phe Ser Ala Asn Glu Asp His Glu Thr He Arg Asn Tyr Ala Gin 130 135 140 Val Phe Asn Lys Leu He Arg Arg Tyr Lys Tyr Leu Glu Lys Ala Phe 145 150 155 160 Glu Asp Glu Met Lys Lys Leu Leu Leu Phe Leu Lys Ala Phe Ser Glu 165 170 175 Ala Glu Gin Thr Lys Leu Ala Met Leu Ser Gly He Leu Leu Gly Asn 180 185 190 Gly Thr Leu Pro Ala Thr He Leu Thr Ser Leu Phe Thr Asp Ser Leu 195 200 205 Val Lys Glu Gly He Ala Ala Ser Phe Ala Val Lys Leu Phe Lys Ala 210 215 220 Trp Met Ala Glu Lys Asp Ala Asn Ser Val Thr Ser Ser Leu Arg Lys 225 230 235 240 Ala Asn Leu Asp Lys Arg Leu Leu Glu Leu Phe Pro Val Asn Arg Gin 245 250 255 Ser Val Asp His Phe Ala Lys Tyr Phe Thr Asp Ala Gly Leu Lys Glu 260 265 270 Leu Ser Asp Phe Leu Arg Val Gin Gin Ser Leu Gly Thr Arg Lys Glu 275 280 285 Leu Gin Lys Glu Leu Gin Glu Arg Leu Ser Gin Glu Cys Pro He Lys 290 295 300 Glu Val Val Leu Tyr Val Lys Glu Glu Met Lys Arg Asn Asp Leu Pro 305 310 315 320 Glu Thr Ala Val He Gly Leu Leu Trp Thr Cys Val Met Asn Ala Val 325 330 335 Glu Trp Asn Lys Lys Glu Glu Leu Val Ala Glu Gin Ala Leu Lys His 340 345 350 Leu Lys Gin Tyr Ala Pro Leu Leu Ala Val Phe Ser Ser Gin Gly Gin 355 360 365 Ser Glu Leu Val Leu Leu Gin Lys Val Gin Glu Tyr Cys Tyr Asp Asn 370 375 380 He His Phe Met Lys Ala Phe Gin Lys He Val Val Leu Phe Tyr Lys 385 390 395 400 Ala Asp Val Leu Ser Glu Glu Ala He Leu Lys Trp Tyr Lys Glu Ala 405 410 415 His Ala Ala Lys Gly Lys Ser Val Phe Leu Asp Gin Met Lys Lys Phe 420 425 430 Val Glu Trp Leu Gin Asn Ala Glu Glu Glu Ser Glu Ser Glu Gly Glu 435 440 445 Glu Ser 450 (2) INFORMATION FOR SEQ ID NO: 85: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1463 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW094 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 255..1238 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: 1050..1355 (D) OTHER INFORMATION: /label= SAC_23896 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85: GTCGACCCCG AACACCCACA CTCGGTCCCC AGCCGTTTTT CTCCCAGAGA TCCGGAAGCC 60 CCGACGTCGT GCCCTACACC AAAGATCGAG AAAACCACTC AGACGCGGCT CCTAGGCGGC 120 AGTTCGGTTC CCATAGCAAC CCTCGGAGCA CCCGCATCCC GCTTCCGGCC GGGTGGCTCG 180 GGCGCTCCCG TGACGTCACG GCGCCGCTTT CCGGTGACTG AGTCGAGCTG AGGTTGTTGT 240 GGGCCGGGGG CGCC ATG GGG GCG ACT GGC GAC ACC GAG CAG CCG CGG GGC 290 Met Gly Ala Thr Gly Asp Thr Glu Gin Pro Arg Gly 1 5 10 CCC GGC GGG GCG GAG CGA GGC GGC CTG GAG CTG GGC GAC GCG GGC GCG 338 Pro Gly Gly Ala Glu Arg Gly Gly Leu Glu Leu Gly Asp Ala Gly Ala 15 20 25 GCG GGC CAG CCG GTT CTC ACG AAC CCT TGG AAC ATA ATG ATC AAA CAC 386 Ala Gly Gin Pro Val Leu Thr Asn Pro Trp Asn He Met He Lys His 30 35 40 CGG CAG GTG CAG CGA AGA GGC CGC CGA TCT CAG ATG ACC ACA AGT TTC 434 Arg Gin Val Gin Arg Arg Gly Arg Arg Ser Gin Met Thr Thr Ser Phe 45 50 55 60 ACA GAT CCA GCC ATC TCT ATG GAT CTC CTC CGT GCT GTC CTG CAG CCT 482 Thr Asp Pro Ala He Ser Met Asp Leu Leu Arg Ala Val Leu Gin Pro 65 70 75 AGC ATC AAT GAG GAG ATC CAG AGT GTC TTC AAC AAG TAC ATG AAG TTC 530 Ser He Asn Glu Glu He Gin Ser Val Phe Asn Lys Tyr Met Lys Phe 80 85 90 TTC CAG AAG GCA GCG CTG AAT GTG CGA GAC AAC GTT GGT GAA GAG GTG 578 Phe Gin Lys Ala Ala Leu Asn Val Arg Asp Asn Val Gly Glu Glu Val 95 100 105 GAT GCA GAA CAG TTG ATT CAG GAG GCC TGC CGC AGC TGC CTG GAG CAG 626 Asp Ala Glu Gin Leu He Gin Glu Ala Cys Arg Ser Cys Leu Glu Gin 110 115 120 GCA AAG CTA CTC TTT TCA GAT GGA GAA AAA GTG ATA CCC AGA TTG GCC 674 Ala Lys Leu Leu Phe Ser Asp Gly Glu Lys Val He Pro Arg Leu Ala 125 130 135 140 CAT GAA CTT CCA GGG ATC AAG CGT GGC CGG CAG GCA GAA GAG GAG TCC 722 His Glu Leu Pro Gly He Lys Arg Gly Arg Gin Ala Glu Glu Glu Ser 145 150 155 CAC CGA GGA AGC CCC ATT CCC AAA AAG AGG AAA GGT CGG CCT CCT GGA 770 His Arg Gly Ser Pro He Pro Lys Lys Arg Lys Gly Arg Pro Pro Gly 160 165 170 CAT GTC CTG TCA AAT GAC CGC GCA GCT GCT GGC ATG GTA TGG AAA CCA 818 His Val Leu Ser Asn Asp Arg Ala Ala Ala Gly Met Val Trp Lys Pro 175 180 185 AAA TCC TGT GAA CCA ATT CGC CGA GAA GGC CCC AAG TGG GAC CCA GCT 866 Lys Ser Cys Glu Pro He Arg Arg Glu Gly Pro Lys Trp Asp Pro Ala 190 195 200 CGG CTG AAT GAA TCT ACC ACC TTT GTT TTG GGG TCT CGA GCC AAC AAG 914 Arg Leu Asn Glu Ser Thr Thr Phe Val Leu Gly Ser Arg Ala Asn Lys 205 210 215 220 GCC TTA GGG ATG GGA GGC ACC AGA GGG AGG ATT TAC ATC AAG CAC CCA 962 Ala Leu Gly Met Gly Gly Thr Arg Gly Arg He Tyr He Lys His Pro 225 230 235 CAC CTC TTT AAG TAT GCA GCA GAT CCT CAG GAC AAG CAC TGG CTG GCT 1010 His Leu Phe Lys Tyr Ala Ala Asp Pro Gin Asp Lys His Trp Leu Ala 240 245 250 GAG CAG CAT CAT ATG CGG GCA ACA GGA GGA AAG ATG GCG TAC CTT CTC 1058 Glu Gin His His Met Arg Ala Thr Gly Gly Lys Met Ala Tyr Leu Leu 255 260 265 ATT GAG GAA GAC ATC CGA GAC TTG GCT GCC AGC GAT GAC TAC AGA GGA 1106 He Glu Glu Asp He Arg Asp Leu Ala Ala Ser Asp Asp Tyr Arg Gly 270 275 280 TGC TTG GAC CTG AAG TTG GAG GAG CTG AAG TCC TTT GTT TTG CCA TCC 1154 Cys Leu Asp Leu Lys Leu Glu Glu Leu Lys Ser Phe Val Leu Pro Ser 285 290 295 300 TGG ATG GTT GAG AAG ATG CGG AAA TAC ATG GAG ACA CTA CGG ACA GAA 1202 Trp Met Val Glu Lys Met Arg Lys Tyr Met Glu Thr Leu Arg Thr Glu 305 310 315 AAT GAG CAT CGT GCT GCT GAA GCA ACT CCC CAG ACC TGAGCCGAGT 1248 Asn Glu His Arg Ala Ala Glu Ala Thr Pro Gin Thr 320 325 GTCCTGGCTA CTACACTTGG CAGTCTGCCT CCCAGACCCT CTTTCCCCGC CCGGCTGAGG 1308 CCATCATGGG GATGCGGTCT AGTTGGCTCT TAGCAGCATC AAGCTGTACA TGAGCTAGTT 1368 TGTAGTGACT CACTGCAGAG CCCCCCAGAC TGGCTTGTGG TTCTGTTTCT AAAGTTATTG 1428 GAATAAGAAG CAATTAAACA AGTTTGTAAT AAAAA 1463 (2) INFORMATION FOR SEQ ID NO: 86: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 328 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86: Met Gly Ala Thr Gly Asp Thr Glu Gin Pro Arg Gly Pro Gly Gly Ala 1 5 10 15 Glu Arg Gly Gly Leu Glu Leu Gly Asp Ala Gly Ala Ala Gly Gin Pro 20 25 30 Val Leu Thr Asn Pro Trp Asn He Met He Lys His Arg Gin Val Gin 35 40 45 Arg Arg Gly Arg Arg Ser Gin Met Thr Thr Ser Phe Thr Asp Pro Ala 50 55 60 He Ser Met Asp Leu Leu Arg Ala Val Leu Gin Pro Ser He Asn Glu 65 70 75 80 Glu He Gin Ser Val Phe Asn Lys Tyr Met Lys Phe Phe Gin Lys Ala 85 90 95 Ala Leu Asn Val Arg Asp Asn Val Gly Glu Glu Val Asp Ala Glu Gin 100 105 110 Leu He Gin Glu Ala Cys Arg Ser Cys Leu Glu Gin Ala Lys Leu Leu 115 120 125 Phe Ser Asp Gly Glu Lys Val He Pro Arg Leu Ala His Glu Leu Pro 130 135 140 Gly He Lys Arg Gly Arg Gin Ala Glu Glu Glu Ser His Arg Gly Ser 145 150 155 160 Pro He Pro Lys Lys Arg Lys Gly Arg Pro Pro Gly His Val Leu Ser 165 170 175 Asn Asp Arg Ala Ala Ala Gly Met Val Trp Lys Pro Lys Ser Cys Glu 180 185 190 Pro He Arg Arg Glu Gly Pro Lys Trp Asp Pro Ala Arg Leu Asn Glu 195 200 205 Ser Thr Thr Phe Val Leu Gly Ser Arg Ala Asn Lys Ala Leu Gly Met 210 215 220 Gly Gly Thr Arg Gly Arg He Tyr He Lys His Pro His Leu Phe Lys 225 230 235 240 Tyr Ala Ala Asp Pro Gin Asp Lys His Trp Leu Ala Glu Gin His His 245 250 255 Met Arg Ala Thr Gly Gly Lys Met Ala Tyr Leu Leu He Glu Glu Asp 260 265 270 He Arg Asp Leu Ala Ala Ser Asp Asp Tyr Arg Gly Cys Leu Asp Leu 275 280 285 Lys Leu Glu Glu Leu Lys Ser Phe Val Leu Pro Ser Trp Met Val Glu 290 295 300 Lys Met Arg Lys Tyr Met Glu Thr Leu Arg Thr Glu Asn Glu His Arg 305 310 315 320 Ala Ala Glu Ala Thr Pro Gin Thr 325 (2) INFORMATION FOR SEQ ID NO: 87: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1276 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW095 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 7..876 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (631..798) (D) OTHER INFORMATION: /label= SAC_23802 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87: GTCGAC ATT TTC TCA GAA TCC TAC GGA GGA AAG ATG GCT GCT GGC ATC 48 He Phe Ser Glu Ser Tyr Gly Gly Lys Met Ala Ala Gly He 1 5 10 AGT TTA GAA CTT CAC AAG GCT ATT CAG CAA GGG ACC ATC AAG TGC AAC 96 Ser Leu Glu Leu His Lys Ala He Gin Gin Gly Thr He Lys Cys Asn 15 20 25 30 TTC TCT GGG GTT GCT TTG GGT GAC TCC TGG ATC TCC CCT GTG GAT TCA 144 Phe Ser Gly Val Ala Leu Gly Asp Ser Trp He Ser Pro Val Asp Ser 35 40 45 GTG CTG TCC TGG GGA CCT TAC CTG TAC AGC GTG TCT CTC CTT GAT AAT 192 Val Leu Ser Trp Gly Pro Tyr Leu Tyr Ser Val Ser Leu Leu Asp Asn 50 55 60 AAA GGC TTG GCT GAG GTG TCC GAC ATT GCG GAG CAA GTC CTC AAT GCT 240 Lys Gly Leu Ala Glu Val Ser Asp He Ala Glu Gin Val Leu Asn Ala 65 70 75 GTA AAC AAG GGC TTC TAC AAG GAA GCC ACT CAG CTG TGG GGG AAA GCA 288 Val Asn Lys Gly Phe Tyr Lys Glu Ala Thr Gin Leu Trp Gly Lys Ala 80 85 90 GAA ATG ATC ATT GAA AAG AAC ACC GAC GGG GTA AAC TTC TAT AAC ATC 336 Glu Met He He Glu Lys Asn Thr Asp Gly Val Asn Phe Tyr Asn He 95 100 105 110 TTA ACT AAA AGC ACC CCC GAC ACC TCT ATG GAG TCG AGC CTC GAG TTC 384 Leu Thr Lys Ser Thr Pro Asp Thr Ser Met Glu Ser Ser Leu Glu Phe 115 120 125 TTC CGG AGC CCC TTA GTT CGT CTC TGT CAG CGC CAC GTG AGA CAC CTA 432 Phe Arg Ser Pro Leu Val Arg Leu Cys Gin Arg His Val Arg His Leu 130 135 140 CAA GGA GAC GCC TTA AGT CAG CTC ATG AAC GGT CCC ATC AAA AAG AAG 480 Gin Gly Asp Ala Leu Ser Gin Leu Met Asn Gly Pro He Lys Lys Lys 145 150 155 CTC AAA ATT ATC CCT GAC GAT GTC TCC TGG GGA GCC CAG TCA TCC TCC 528 Leu Lys He He Pro Asp Asp Val Ser Trp Gly Ala Gin Ser Ser Ser 160 165 170 GTC TTC ATA AGC ATG GAA GAG GAC TTC ATG AAG CCT GTC ATC GAC ATC 576 Val Phe He Ser Met Glu Glu Asp Phe Met Lys Pro Val He Asp He 175 180 185 190 GTG GAT ACG TTG CTG GAA CTC GGG GTC AAT GTG ACT GTG TAC AAT GGG 624 Val Asp Thr Leu Leu Glu Leu Gly Val Asn Val Thr Val Tyr Asn Gly 195 200 205 CAG CTG GAT CTC ATT GTG GAC ACC ATA GGT CAG GAG TCC TGG GTT CAG 672 Gin Leu Asp Leu He Val Asp Thr He Gly Gin Glu Ser Trp Val Gin 210 215 220 AAG CTG AAG TGG CCA CAG CTG TCC AGA TTC AAT CAG CTA AAA TGG AAG 720 Lys Leu Lys Trp Pro Gin Leu Ser Arg Phe Asn Gin Leu Lys Trp Lys 225 230 235 GCC CTG TAC ACC AAT CCT AAG TCT TCA GAA ACA TCT GCG TTT GTC AAG 768 Ala Leu Tyr Thr Asn Pro Lys Ser Ser Glu Thr Ser Ala Phe Val Lys 240 245 250 TCC TAT GAG AAC CTA GCG TTC TAC TGG ATC CTA AAG GCG GGT CAC ATG 816 Ser Tyr Glu Asn Leu Ala Phe Tyr Trp He Leu Lys Ala Gly His Met 255 260 265 270 GTT CCT GCT GAC CAA GGG GAC ATG GCT CTG AAG ATG ATG AGG CTG GTT 864 Val Pro Ala Asp Gin Gly Asp Met Ala Leu Lys Met Met Arg Leu Val 275 280 285 ACT CAG CAG GAG TAGCTGAGCT GAGCTGGCCC TGGAGGCCCT GGAGGCCCTG 916 Thr Gin Gin Glu 290 GAGGCCCTGG AGTAGGGCCC AGGATGCAGG TGCTAATGTC TATCCCCGGC GCTCTTCTTC 976 CCGACTCTAC CATGGGATGT AACTCCAGGA GCCCCTGCCA TCTCCGGTAC CAAAAGACTG 1036 TGGCTTCCGT GTCTACTCAG AAATCAGTTC TACTTCGTAA ACAGTGTTTA AAACCAGACT 1096 CATTTAATCA GAGTGAAGGA TTGCAGTCCA TTGGCTTCTT AGCACAGAAG CAGCTGATAA 1156 CACAAGTAAA CCCCAGCCCT TGAGAGGTAG AAGCAAGAGG ATCAGAGGTT CAAGCGCATC 1216 CTCGGCTCCA TCACAAGTTC AAAAGCCGCC TGCACCAAAT GGGAGTCCTT GTCTCAAAAA 1276 (2) INFORMATION FOR SEQ ID NO: 88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 290 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88: He Phe Ser Glu Ser Tyr Gly Gly Lys Met Ala Ala Gly He Ser Leu 1 5 10 15 Glu Leu His Lys Ala He Gin Gin Gly Thr He Lys Cys Asn Phe Ser 20 25 30 Gly Val Ala Leu Gly Asp Ser Trp He Ser Pro Val Asp Ser Val Leu 35 40 45 Ser Trp Gly Pro Tyr Leu Tyr Ser Val Ser Leu Leu Asp Asn Lys Gly 50 55 60 Leu Ala Glu Val Ser Asp He Ala Glu Gin Val Leu Asn Ala Val Asn 65 70 75 80 Lys Gly Phe Tyr Lys Glu Ala Thr Gin Leu Trp Gly Lys Ala Glu Met 85 90 95 He He Glu Lys Asn Thr Asp Gly Val Asn Phe Tyr Asn He Leu Thr 100 105 110 Lys Ser Thr Pro Asp Thr Ser Met Glu Ser Ser Leu Glu Phe Phe Arg 115 120 125 Ser Pro Leu Val Arg Leu Cys Gin Arg His Val Arg His Leu Gin Gly 130 135 140 Asp Ala Leu Ser Gin Leu Met Asn Gly Pro He Lys Lys Lys Leu Lys 145 150 155 160 He He Pro Asp Asp Val Ser Trp Gly Ala Gin Ser Ser Ser Val Phe 165 170 175 He Ser Met Glu Glu Asp Phe Met Lys Pro Val He Asp He Val Asp 180 185 190 Thr Leu Leu Glu Leu Gly Val Asn Val Thr Val Tyr Asn Gly Gin Leu 195 200 205 Asp Leu He Val Asp Thr He Gly Gin Glu Ser Trp Val Gin Lys Leu 210 215 220 Lys Trp Pro Gin Leu Ser Arg Phe Asn Gin Leu Lys Trp Lys Ala Leu 225 230 235 240 Tyr Thr Asn Pro Lys Ser Ser Glu Thr Ser Ala Phe Val Lys Ser Tyr 245 250 255 Glu Asn Leu Ala Phe Tyr Trp He Leu Lys Ala Gly His Met Val Pro 260 265 270 Ala Asp Gin Gly Asp Met Ala Leu Lys Met Met Arg Leu Val Thr Gin 275 280 285 Gin Glu 290 (2) INFORMATION FOR SEQ ID NO: 89: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2421 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW096 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 295..1302 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89: GTCGACGTCT GATTTTACAT TCATGCAGTT GGGAGTAAGA GGAAAAAGAT TCTGAAGTGT 60 GGGGAACTTC ACAAAGAGGG GAACAAAGTC TGTGTCTATG GCTCCAAGGG AGAGAACATC 120 AGAGACACTC TGAGGAAGGA CGGCAGGTTT TGTTCTTTCA TAGAGAATAA CCATTGGAAA 180 CTCATTAATG ACCTGGACAC TATCATAGAA AACACTCAGC CATTTGATGA GTTGGAGGGC 240 AAGCTCTTTC AGGTTGCAGC TGAGCTACCA AAGAACCCTA GGGTAGTCTC TGTC ATG 297 Met 1 CAG AAT TCT GGG TTA GAG AAC AGA GAC TTC CAT AAG CTA GAA GAC TAT 345 Gin Asn Ser Gly Leu Glu Asn Arg Asp Phe His Lys Leu Glu Asp Tyr 5 10 15 ATT GTG AAT GCG AAC CCT ACA TTG AAA GAA GAA GGA GAA AAA CTC AGA 393 He Val Asn Ala Asn Pro Thr Leu Lys Glu Glu Gly Glu Lys Leu Arg 20 25 30 GCA TAC ATC AAG AAA GAA AGT AAA AAA AGA AAG AAA GGT TCC TTA TTC 441 Ala Tyr He Lys Lys Glu Ser Lys Lys Arg Lys Lys Gly Ser Leu Phe 35 40 45 AAA GTG CAT AAA GAA CAC TTT GGG AAA ATA ACA AAA AAT TCT ACT CCT 489 Lys Val His Lys Glu His Phe Gly Lys He Thr Lys Asn Ser Thr Pro 50 55 60 65 GTT AAA GTG CAC AAA CAT CTT TCG AAA GTC AGT GAT TCA GTT GGG TTC 537 Val Lys Val His Lys His Leu Ser Lys Val Ser Asp Ser Val Gly Phe 70 75 80 CTA TGG TGG AAC AAC AAT GGA AAG GAG GGC TGT GCC ACC TGC TTT GTT 585 Leu Trp Trp Asn Asn Asn Gly Lys Glu Gly Cys Ala Thr Cys Phe Val 85 90 95 TTT AAA GGA TTA TAC ATT TTG ACT TGC CGG CAT GTG ATA ACT AGT ATT 633 Phe Lys Gly Leu Tyr He Leu Thr Cys Arg His Val He Thr Ser He 100 105 110 GTG GGT GAA GGC ATA GAT CCA TGT CAG TGG GCA AGC TTA ATT AGT CAG 681 Val Gly Glu Gly He Asp Pro Cys Gin Trp Ala Ser Leu He Ser Gin 115 120 125 TGT GTA AAG GTG ACC TTT GGT TAT GAA GAG TTC CCA CTA GTA GAA GAC 729 Cys Val Lys Val Thr Phe Gly Tyr Glu Glu Phe Pro Leu Val Glu Asp 130 135 140 145 AAG TTT TTT GAG GTT AAA CCT TGG TTT GAG ATA TCT AAT GAA AGC CTT 777 Lys Phe Phe Glu Val Lys Pro Trp Phe Glu He Ser Asn Glu Ser Leu 150 155 160 GAC TAT GCT GTC CTA GAA CTG AGG GAA AAT GGA CAA GAA GTT CCT GCT 825 Asp Tyr Ala Val Leu Glu Leu Arg Glu Asn Gly Gin Glu Val Pro Ala 165 170 175 GGA CTG TAT AAT GGA ATA GGA CCT GTG CCA CTT GGT GGG TTA ATA TAT 873 Gly Leu Tyr Asn Gly He Gly Pro Val Pro Leu Gly Gly Leu He Tyr 180 185 190 ATC ATT GGC CAT CCT GAT GGA GAA AAG AAG TCT ACT GAT GGC TGT GCA 921 He He Gly His Pro Asp Gly Glu Lys Lys Ser Thr Asp Gly Cys Ala 195 200 205 GTG GTC CCT CAA AGT CAT AGA GGG CAA AAA TGT CAG GAA AAT TTT CAA 969 Val Val Pro Gin Ser His Arg Gly Gin Lys Cys Gin Glu Asn Phe Gin 210 215 220 225 GCA AGA GAG AAA GCA AAC TAC TGG ATT TCT ACA TCT TTT TTT CCT ATA 1017 Ala Arg Glu Lys Ala Asn Tyr Trp He Ser Thr Ser Phe Phe Pro He 230 235 240 TAC ACA CAA AGA AGT TTC CAC GAA GTC TTT CAC AAC CAT GAT GTG GTT 1065 Tyr Thr Gin Arg Ser Phe His Glu Val Phe His Asn His Asp Val Val 245 250 255 ACT TAT GAC ACC ACT TTT TTT GGT GGG TCT TCT GGA TCC CCA GTA TTT 1113 Thr Tyr Asp Thr Thr Phe Phe Gly Gly Ser Ser Gly Ser Pro Val Phe 260 265 270 GAT TCT AAT GGT TCA TTG GTG GCC ATG CAT GCT GCT GGC ATC ACT TGT 1161 Asp Ser Asn Gly Ser Leu Val Ala Met His Ala Ala Gly He Thr Cys 275 280 285 ACA GAC CAG AAT GGA GTT TTT AAT ATC ATT GAG TTT GGT TTT ACT ATG 1209 Thr Asp Gin Asn Gly Val Phe Asn He He Glu Phe Gly Phe Thr Met 290 295 300 305 GAA TCC ATT CTT GCT AAT ATT AAG CAA ACT AAA GAG TGG TAT GAT ACC 1257 Glu Ser He Leu Ala Asn He Lys Gin Thr Lys Glu Trp Tyr Asp Thr 310 315 320 ATT TTT GTA AAT GAT CGG GAT GCA GAA ATG CTG AGC ACA GAC TCC 1302 He Phe Val Asn Asp Arg Asp Ala Glu Met Leu Ser Thr Asp Ser 325 330 335 TGAGGACTGG AAAGGGTGTA TTCTAGTTCA CAACTTTAAG GGAATTGCCT AAGGTGTTTT 1362 TCTTCAGATA ATAATGTTTT ATGAACTTTC AAAATGATTA ATTTCACCCA ATAATCATAG 1422 TTCTAGAGTG TATCTTAACT ATCAAGCATT TTCATGGTTT ATTAAAACAA ACAATCAAAA 1482 ACAAAACTAT CAGTTGAACT ATTTGTGTAA AGTAGCATGA AAAAGAGGAT TAAGTGCTGA 1542 TGTGGGATCC GAGGGTCAGG AGATGCTAAG ATGTGAAAAA GTTGAGAGCA TAAACTGGAG 1602 TTATTAGCCA GAAGATTCAT GGAAAAGAAA GAAGCCTACC ACGTTCCTTG AAACTTAAAC 1662 CAATTTCAAA CTCACTCATT TGGTTCTACC CATATCTTCC TTCTCTGCTG ACCAGAGCTC 1722 AGCCAGGACA CTGAATCACA GCGACTTAAC CCTCCCAGGG CCCTGAACAT GGTGGCATTT 1782 CTTCCATTTT GTCTTTTTAA CTTAAGACTT AGATCTGAAA TGAACCCACA TGAAGTGGCA 1842 TGGAAATCAT TGAGCAAGCA AGGAGCTGGT CTCTGCCACA GAATGCATGT ACCTGAGACT 1902 TTCTGGACTT GAGTTGTGGA GAGCAAACAT TGGAATAGGT GGTTTCTACT TGATACGATT 1962 CACAATGGAG AGTGCTAGGA GGATATTGGG CACAACCTAG GACAATTCTC AGCAGTGTGA 2022 CACTCAAGTC TTGGTCCTTT GAAGAGAAAG AAAACTGCGT TCAAGAAGTA ATCTCATCAA 2082 AAACAGAGTC AAGGAGAATT TATGAACAGA AGACCAGAGA TCTTAGATTA TTTGAGAGAA 2142 AGTAGGAATA GATGAGATGC TGAAGGAATG TTGCTGGGAT CCAGCGATTG CTTCAATTCT 2202 TCCTTTATCA TAACTGAAAT ATGTCCTGTA TGAGAGCTAA CATGATCCTA ATCCACAACT 2262 CCCCTTATTT TCCAGACATT TCCTAGTGCT ATTGTGTGAT ATTTTGTGTC CCCTGCCCAA 2322 TGTATTTTTC CCAAATCAAA TACAGGTGAA TCAATTAAAA AACAGTGTAA TATCTGTAGT 2382 AGGTTTTGAA ATATAAGATG AAAAAATTAA AAAGTCGAC 2421 (2) INFORMATION FOR SEQ ID NO: 90: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 336 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90: Met Gin Asn Ser Gly Leu Glu Asn Arg Asp Phe His Lys Leu Glu Asp 1 5 10 15 Tyr He Val Asn Ala Asn Pro Thr Leu Lys Glu Glu Gly Glu Lys Leu 20 25 30 Arg Ala Tyr He Lys Lys Glu Ser Lys Lys Arg Lys Lys Gly Ser Leu 35 40 45 Phe Lys Val His Lys Glu His Phe Gly Lys He Thr Lys Asn Ser Thr 50 55 60 Pro Val Lys Val His Lys His Leu Ser Lys Val Ser Asp Ser Val Gly 65 70 75 80 Phe Leu Trp Trp Asn Asn Asn Gly Lys Glu Gly Cys Ala Thr Cys Phe 85 90 95 Val Phe Lys Gly Leu Tyr He Leu Thr Cys Arg His Val He Thr Ser 100 105 110 He Val Gly Glu Gly He Asp Pro Cys Gin Trp Ala Ser Leu He Ser 115 120 125 Gin Cys Val Lys Val Thr Phe Gly Tyr Glu Glu Phe Pro Leu Val Glu 130 135 140 Asp Lys Phe Phe Glu Val Lys Pro Trp Phe Glu He Ser Asn Glu Ser 145 150 155 160 Leu Asp Tyr Ala Val Leu Glu Leu Arg Glu Asn Gly Gin Glu Val Pro 165 170 175 Ala Gly Leu Tyr Asn Gly He Gly Pro Val Pro Leu Gly Gly Leu He 180 185 190 Tyr He He Gly His Pro Asp Gly Glu Lys Lys Ser Thr Asp Gly Cys 195 200 205 Ala Val Val Pro Gin Ser His Arg Gly Gin Lys Cys Gin Glu Asn Phe 210 215 220 Gin Ala Arg Glu Lys Ala Asn Tyr Trp He Ser Thr Ser Phe Phe Pro 225 230 235 240 He Tyr Thr Gin Arg Ser Phe His Glu Val Phe His Asn His Asp Val 245 250 255 Val Thr Tyr Asp Thr Thr Phe Phe Gly Gly Ser Ser Gly Ser Pro Val 260 265 270 Phe Asp Ser Asn Gly Ser Leu Val Ala Met His Ala Ala Gly He Thr 275 280 285 Cys Thr Asp Gin Asn Gly Val Phe Asn He He Glu Phe Gly Phe Thr 290 295 300 Met Glu Ser He Leu Ala Asn He Lys Gin Thr Lys Glu Trp Tyr Asp 305 310 315 320 Thr He Phe Val Asn Asp Arg Asp Ala Glu Met Leu Ser Thr Asp Ser 325 330 335 (2) INFORMATION FOR SEQ ID NO: 91: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 836 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (vii) IMMEDIATE SOURCE: (B) CLONE: HW097 (ix) FEATURE: (A) NAME/KEY: misc_feature (B) LOCATION: complement (203..553) (D) OTHER INFORMATION: /label= SAC_23978 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91: GTCGACTATT ACTATAGCCT TGTATATACT CCCCTCCGGC CCTGTTTGTC TCAGTCCCAT 60 TCCCTCTTGT CTCTGAGAAT CATCCCCCAG CCCCAAGTTC TCCCTTCTGT CTCCCCCCAC 120 CCCCCCTGCC TCCCATTCTC CTGTCTCTGA ATGCCTTTGC CTGTATAAAG AGTTGGATTC 180 TCCCCTGGTG TCTGTACTGT GTACACACAT CCCTTTGAGA AGCACAAGGA GATGACACGC 240 GCATTGTAAC CTTCACACTG TCTCGGTGGC GACATAAAGG AAGCTGTGAA TTACAAGCTC 300 TGCCTCTTTC TGGCCTCTCC CTCGGCCCCC ATGACCGGGG CACTCTCTGC CCTCCCCACG 360 GCCTTAACAT GTTCCTGCTC CACCTATCCT GGTGCCCTTT GTCTGGCTGA CTGTAGCCTC 420 CCTGAGGGAA GGGATTGCTG GAGAGGTAGC TCCTATCCAG GAATGAAGGA CACTGGCTGG 480 AAACTAAGCC AAGAATGTTA CAGACAGGGG GAGCTGGGGA TTGGTGACTG ACCCTTGCAG 540 TTGGGCAGTG AGTACCCAAG GCCAGAAGCT GAAGCCCTCA TTCATTCAGT GGCCTTTCTT 600 TCCTCAGGGT GCCCAGTGCC CTGTCCTCAC TTTGATGCCT AGGCCCACTG CTTGCATTTT 660 CTGGTGAGCC AGGGCTTGGT CATGTGAGGA AAGAGGTAGG CCTAGAGCAG GAGTTGAAAG 720 CCCTGCTGTT GTGTGTCCCT ACCATACAGG GCTGGCTAAA AGTCGAGGTA GACGCTTATC 780 TAGGAAGCGC AAGGCCCTGG GTTCGGTCCC CAGCTCGGAA AAAAAAGAAC CAAAAA 836 (2) INFORMATION FOR SEQ ID NO: 92: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 318 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC23798 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92: GGGGGATCCG CCCGATCCAA GACTGCCCAG GGTGGCTGCT CCATCTCACC CAGAGCAACC 60 GGAGCTGGAC CTGGGGGTCG GAGCACTTCG AAGGTGATGG GTTATGGTGC CGCCTGCTGG 120 ACATAGTTGT CCAGAGCTCT TCCTGAAAGG TTTGCTACAG GATTCGCCCT TCTCATCCAG 180 TCTAAGAAAC TACTTAGTCA ACTCCTAGTG TCTAAGCAGA AGGCTTCAGC TATGGCTTCT 240 CCCCTTGGGG AGGAAGAGGA AGAGGTACAA ATTCTTGTTT TGCTGCTCCC AGGGAAAAGA 300 TCGGGCTAGA GCGGCCGC 318 (2) INFORMATION FOR SEQ ID NO: 93: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 278 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_23800 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93: GGGGGATCCG CCCGATCACA CGGCTGCCTT CTGGTATACA GCAGAGGGGA ATGCCAAGGT 60 ATAAGTATCC TTCAATTCCT TCTTTGCCAC ATACCAGCAT TTCTTTGCCC TTTTGGCATT 120 CTACCTCTTC TTTGACAGCA CTGAGACTGT TAAGTGCTGC ATACAAGCTA CTTGTCTCCC 180 TATCTGTNNG CACATGTTTC ATGTCATGAA GATGATAAGG TCAGGCAAAG AGGCATGAAG 240 ATTCCTGAAT AGTGCCCAGA TCGGGCTAGA GCGGCCGC 278 (2) INFORMATION FOR SEQ ID NO: 94: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 393 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_23801 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94: GGGGGATCCG CCCGATCCAG TAGCGACAGC CCTGGCCCCT GACGAGGATG GAAGTGACGT 60 TGTAGCNATT GTCTTCCTGT AGCTCATAGA TGGTGCTGTN NATGGTAAAG CGGCTTTGTC 120 TTTCTTTCTG GACCGCATTG CCTGCCAGGN NGACAACGAA CCACCTGCCC TGGAACCGTT 180 CGGTCCAGAA GCCTGGCTGC AGGGGCACAC TGATCGATCC AGTAGCGACA GCCCTGGCCC 240 CTGACGAGGA TGGAAGTGAC GTTGTAGCTA TTGTCTTCCT GTAGCTCATA GATGGTGCTG 300 TACATGGTAA AGCGGCTTTG TCTTTCTTTC TGGACCGCAT TGCCTGCCAG GCCGACAACG 360 AACCACCTGC CCTGGAACCG TTCGGTCCAG AAG 393 (2) INFORMATION FOR SEQ ID NO: 95: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 531 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_23833 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95: GGGGGATCCG CCCGATCTGT ATCTCGTCCC TTGGCTGGCT GAGCCTCTGG AGGAGGTGTC 60 CAAAGCCCCG GTGGATTTCT GTCTCAGGGG TCTCTGTGAG ATTGAACTTG AGACCTTCTA 120 GAATCTCTTC CATGCTGTTG CCCTTTGCTC CCAGGGACAC GACGGCCAAG GCGGCTGAGA 180 TGCTAAGTGG GGAGAAGACA ACATTTTTAT CTGGATTCCT CAAAGCCAGC TTCCTGTAGA 240 GGCTGAAGGC AAAGTCAGTA TTGATGGAAG CCAGTGTGAG ACTGTCCAGT TGTGTCCCCT 300 TGTCTTGGTC TTCATGGAAT AGAGTGTCCT CTCCCAGTAT GCAAATCTGG GAAGCAGAGG 360 AGAGCAGAGC CCGATCGATC AAGATGACTA AGATGCTCAA AGGATTCGAC GCTGTGGGAA 420 ATGCCACAGG TTTCCGGTTC GCCTACACCC CAGCTATGGA GAGCCTCTGT GGATATGTCA 480 CAAGTCCAGA ACCGCAGCGA GGAGTTTCTC ATCGCGGGCC GTTTAAGGAC G 531 (2) INFORMATION FOR SEQ ID NO: 96: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 274 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_23836 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96: GGGGGATCCG CCCGATCATG ATGAATCCCC TGGGACCAAG CTATAACACA CAGTCCTCTG 60 AGAAAAAGGA TTGTGGTTTG CAGCAAATTC AGCCAATTTT GTCAAGCAAT TTGTGAGAGA 120 CACTCCTTAC TTGGTTGTTT CCTTCTCAGT CTTACGGGGT GCCTTATCAC TCCGTGATGG 180 TTCATGGCCA CACAGTCATA TTTCAGGGAG AAGTCCTTGT CGGTCACACC AGTTATCCTT 240 AACAGTGAGG TTAAGCAAAT CATGCCATTG CTGG 274 (2) INFORMATION FOR SEQ ID NO: 97: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 254 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_23853 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 97: GGGGGATCCG CCCGATCGTG TTATTGAGGT CATCCACGGT GGAGATTAGC AGGTGACTCC 60 GTTTTCCTGG AAATGAGTGG AGTTGGGAAG GGGACCCGTG GCCGTGCTCC AGCTATAGTT 120 GGTGGGCGGT GGTTCGCTGC GAGCTTCACA GGTCAGGTTC ACGTTAGTAG GCCCAATGTA 180 CCAGTTGCCT TCATAGCCAG AGATGGACAC TTCGGGTGGA TAAGGTAGGG AAAGGATCGG 240 GCTAGAGCGG CCGC 254 (2) INFORMATION FOR SEQ ID NO: 98: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 255 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_23906 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98: GGGGGATCCG CCCACAGAAC CCAGAGGAAG GAGAGGCTGC TGGGGTGGAG GCCTAGGCGC 60 TGGAGACATG TGGAGTTCTC TAGGGGTCTG CAGCAACCTC GGAAAGCTGG GAGATTCCCT 120 CCTTGAGACT CCTACATATA GAAAACTGAT GCTTCTGTCT CATTCCATGC GGCTTTTCCT 180 GCGGTATTCC TGTAGCGCTT TCTCTGCCAC TGTGTCCATA AACTTAGGGT TATCCTTGGA 240 GACTTCTTCT GGTAC 255 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 219 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_23907 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99: GGGGGATCCG CCCACCCCAT CTAATCCTCT GAGGCTCAGG GTGACTCATT CTTCCTTGGA 60 CCCAGGGGCG GGGCCGACAT TTGTTCCCCC AGTTGGGCCC TGCTGCCCCA GGCCAGTGGC 120 ATTCCCAGTG TCTCCAGCCA CTAAAGCCAC ATTCCTCAGG TAGTTGGTAT TGAAGCAGTT 180 GGCTTGTTTA TCTCCAGGAG ACAAGGTTCG AGCGGCCGC 219 (2) INFORMATION FOR SEQ ID NO: 100: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 182 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_23916 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100: GGGGGATCCG CCCTCGAGCG GCCGCCCACA AGAGATTGAA CCTAGAGCTG TGTGCCTCCT 60 GGGCAAGCAC TCTCTACTGA GCTACATCCC TGTTAAAGTG CCTTTTTTGG GAGCTTTGTC 120 TTCCAGCCTG CCAATCAACC CACTTTATGG GTGTGCCTAG ATTCCCCTTT CTCTGAGTAG 180 GG 182 (2) INFORMATION FOR SEQ ID NO: 101: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 191 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_23922 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101: GGGGGATCCG CCCACTGTTC TCAAACAGTT GCCTAACAAT ACATTTAATT AAGAAATTAT 60 CATAACTGTA TGCTTACACA TATGTGGATA GGCATCAATG AAGATTACAA CAGCTCAGCC 120 ACAGTGCTGC AATGCTCTAC ACTACTACAA AACACCCACC ACGGGCCTGN NACCTGCCCT 180 CGAGCGGCCG C 191 (2) INFORMATION FOR SEQ ID NO: 102: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 234 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_24030 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102: GGGGGATCCG CCCACCATAT CTATACGGCC CTGGAAGAGG AGATAGAGCG AAACAAGCAG 60 AACCCAGTCT ATGCCCCGCT CTACTTNCCT GAGGAGCTGC ACCGAAGGCT GCCCTAGAGC 120 AGGACATGGC CTTCTGGTAT GGGCCCCACT GGCAGGAGGC CATCCCTTAN NNACCAGCCA 180 CACAGCACTA CGTAAAGCGT CTCCACGAGG TGGGAGGTGG GCTAGAGCGG CCGC 234 (2) INFORMATION FOR SEQ ID NO: 103: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 172 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_24078 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103: GGGGGATCCG CCCGATCAAG ATGACTAAGA TGCTCAAAGG ATTCGACGCT GTGGGAAATG 60 CCACAGGTTT CCGGTTCGCC TACACCCCAG CCATGAGAGC CTCTGTGGAT ATGTCCACAA 120 GTCCCAGAAC CCGCAGCGAG GAGTTTCTCA TCGCGGGCCG TTTAAGGAAC GG 172 (2) INFORMATION FOR SEQ ID NO: 104: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 241 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_24105 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104: GGGGGATCCG CCCGATCTGT GCATGTGAGC CGAACAGAAG TCAGCAATAA CCATGTCTTG 60 ATTTACCTGG ATAAGGTGTC AAATCAGACG GTGAACTTGT CCTTCACGGC TCAGCAAGAT 120 ATTCCAATAA GGGACCTGAA GCCAGCCGTA GTGAAAGTCT ACGATTACTA TGAGAAAGAT 180 GAGTTTGCAG TTGCAAAATA CAGCGCTCCC TGCAGCACAG ATTATGGAAA TGCCTGAGGA 240 C 241 (2) INFORMATION FOR SEQ ID NO : 105: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 234 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_24140 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105: GGGGGATCCG CCCGATCCTT AAAGGTCCCA TAACCAAGTA CTCCATGCAG TCATCTCCTC 60 TAACCTGTGG GTCCCCTCCA TTCATTGCAA GCTGCTGGAC ATAGCCTGCT GGGTCCACCA 120 CAAGTACAAC AGTGACAAGT CCAGCACCTA TGTGAAGAAT GGCACATCCT TCGACATCCA 180 CTACGGCTCA GGTAGCCTCT CTGGGTACCT GAGCCAGGAC ACTGTGTTGG TTCC 234 (2) INFORMATION FOR SEQ ID NO: 106: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 217 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_24142 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106: GGGGGATCCG CCCGATCTAT CCGGGTATAT TCGGAACTGT GGAGTCTGAC CGCAGTGCAC 60 TGCTACTCAG CTCACTCTGT CTCTTTCTCA CTGTGGGAGT AGCTATGGGA AAGGTCACAC 120 TTCCTTGCTT TCCCCTCAAA CCAACAGGGC TTTCACTTCT CAGTCTCCCA ACGCACTGCA 180 CACTGCTCCC AGCATCCCGC ACAGTCTCAC CACACAC 217 (2) INFORMATION FOR SEQ ID NO: 107: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 172 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_24192 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107: GGGGGATCCG CCCACATCTC AGCGGTGGGG ACTCAGACAT TCCTGTGTTC CCTCCTTGGC 60 CTCCAGCCTC TCTGTAGGAA CCTCCAGCAG CCTGCCACCA GATTTCCCTT AGCTTCCACT 120 GTCTCCATGA GCTTTAAAAT GTGGGCGGCC GCTCGAGGGC TAGAGCGGCC GC 172 (2) INFORMATION FOR SEQ ID NO: 108: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 212 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_24296 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108: GGGGGATCCG CCCACTTGGC TGACCGCCAG GCGAGTGACT GTGACTCCAG GTTCGCCCAC 60 TACCGCAGCA GATACTGCCT CGCCTATGCC ACCTTCATAG TAGTGGTCCT CCACGGTGAG 120 GATCCTGCCT TTGGTTGCTC TGGCACAGTC GAGAATGAGC TTTTTGTCCA GGGGCTTGAT 180 GGTGAAGGGG TCCAGTGGGC TAGAGCGGCC GC 212 (2) INFORMATION FOR SEQ ID NO: 109: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 210 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_24445 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109: GGGGGATCCG CCCACAGCAT TCGGGTATGA GGCAAGGGGA GTGTTCATTC ACACACACAG 60 TAGCTTCGGG TCTGTGAGGT CTCCTTGTTC CCGGGTAGGT TTCTAAAGAC GGAGAAAAAA 120 ATGATTCTGG TTATCAAGAC TACTGTGACC GTATTAGATC CCAGAATGGG CAAGCATCAG 180 TGTGTGACCA TGCGAACAAA AGGAATTTTT 210 (2) INFORMATION FOR SEQ ID NO: 110: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 200 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_24527 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110: GGGGGATCCG CCCACCATGG TCTCACTCAG AGACGGGTTT GGTCAGTTTT AAGATGAACT 60 CCTTCGGATG TAGTGTCCGT AAGTCCTTAT TATCGCTGTC CATCAATTCA CGATAGGATA 120 GCTGGCTGCG GTGGCAAGTC CGCAGTGGTT GTTCCACCTG CCCACATTAT TCTCTCGTGG 180 CCATGGTTCT TCCCTTAGAG 200 (2) INFORMATION FOR SEQ ID NO: 111: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 400 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_24540 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111: GGGGGATCCG CCCACAGTGG GAAGGATGGA AATAGCTGTC ATCTCTCCAA AACTGAGTTC 60 CTTTCCTTCA TGAACACGGA GCTGGCCGCC TTCACGAAGA ACCAGAAGGA CCCCGGTGTC 120 CTCGACCGCA TGATGAAGAA GCTGGACCTC AACAGTGATG GGCAGCTAGA TTTCCAAGAG 180 TTTCTCAACC TTATTGGTGG CTTAGCTATA GCACCTGCCC ACTCTCGTGG CTGGCCCTCT 240 GCTTATACTC CTTGGACTGC TCCAGGCTGT GTGTTTCCAC GCTTGACCTG CCCACAGAGC 300 CAAAAGAGAC ACATTGGCTA CTTTAACCAC CTTAAAGCGG ACTCCAGGAA TATCACCCAC 360 GGCATGGCCT TTTGCGAACA AATCCCANCA ACCAAAAAAA 400 (2) INFORMATION FOR SEQ ID NO: 112: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 200 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (vii) IMMEDIATE SOURCE: (B) CLONE: SAC_24623 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112: GGGGGATCCG CCCACAGTGC ATATTGGCGG CGCTCGCCTC ATTACGATTC GCCAGCTTGC 60 TTCTCTTGTT CAATTGTTTC TTTTGAAGGC AGAGGATTTT TCTCTTGTGT TTCTGTCTTC 120 TTCAACTTCG ACTTATCGAA TTTCACCTGC CCACTAAACC CACAGCCCAG CCCTCCTTCC 180 TTCCTCCTGT CCTGGAATTG 200

Claims: What is claimed is: 1. Purified and isolated nucleic acid encoding all or a unique fragment of a KIM. 2. Nucleic acid of claim 1 that is RNA. 3. Nucleic acid of claim 1 that is DNA. 4. Nucleic acid of claim 3 that is cDNA. 5. Nucleic acid that is complementary to the nucleic acid of claim 1. 6. Nucleic acid that hybridizes to the nucleic acid of claim 1 or 5. 7. Nucleic acid of claim 1 that is in operative association with an expression control element therefor. 8. Antisense nucleic acid of claim 1 that is sufficient, when internalized within a cell, to disrupt expression of a cellular KIM gene. 9. Purified and isolated nucleic acid encoding all or a unique fragment of a KIM, said nucleic acid having a sequence selected from the sequences listed in TABLE 1. 10. Purified and isolated nucleic acid encoding all or a unique fragment of a KIM, said nucleic acid having a sequence selected from degenerate variants of the sequences listed in TABLE 1. 11. Purified and isolated nucleic acid encoding all or a unique fragment of a KIM, said nucleic acid having a sequence selected from homologous variants of the sequences listed in TABLE 1. 12. Purified and isolated nucleic acid encoding a KIM fusion polypeptide, the sequence of said nucleic acid comprising a KIM sequence selected from the sequences listed in TABLE 1 fused in frame to a sequence encoding a non- KIM polypeptide. 13. Nucleic acid of claim 12 wherein the encoded non-KIM polypeptide is selected from: a secretable leader polypeptide, an immunoglobulin polypeptide, a binding pair partner, a toxin or toxoid, an enzyme, and a detectable polypeptide. 14. A vector comprising a KIM-encoding nucleic acid of any one of claims 1 to 13. 15. A host cell stably transformed or transfected with a vector of claim 14. 16. A method for producing a KIM polypeptide, comprising the steps of growing a host cell of claim 15 under conditions sufficient for the production of polypeptides of vector origin; and, recovering an expressed KIM polypeptide. 17. A purified and isolated polypeptide comprising all or a unique fragment of a KIM, said polypeptide having a sequence selected from the sequences encoded by nucleic acids listed in TABLE 1. 18. A purified and isolated polypeptide comprising all or a unique fragment of a KIM, said polypeptide having a sequence selected from variants of the sequences encoded by nucleic acids listed in TABLE 1. 19. A polypeptide of claim 18 wherein said variant is a splice variant, truncation variant, or substitution variant of an encoded TABLE 1 sequence. 20. A KIM fusion polypeptide, the sequence of said polypeptide comprising all or a unique fragment of an encoded KIM sequence listed in TABLE 1 , fused to a non- KIM polypeptide sequence. 21. A fusion polypeptide of claim 20 wherein the non-KIM polypeptide sequence is selected from: a secretable leader polypeptide sequence, an immunoglobulin polypeptide sequence, a binding pair partner sequence, a toxin or toxoid sequence, an enzyme sequence, and a detectable polypeptide sequence. 22. A conjugate comprising a KIM polypeptide of claim 17, 18 or 19, linked to a detectable moiety, imageable moiety, radiolabeled moiety, or toxin moiety. 23. A KIM fusion polypeptide, the sequence of said polypeptide comprising all or a unique fragment of an encoded KIM sequence selected from nucleic acid sequences listed in TABLE 2, fused to a non-KIM polypeptide sequence. 24. A fusion polypeptide of claim 23 wherein the non-KIM polypeptide sequence is selected from: a secretable leader polypeptide sequence, an immunoglobulin polypeptide sequence, a binding pair partner sequence, a toxin or toxoid sequence, an enzyme sequence, and a detectable polypeptide sequence. 25. A conjugate comprising a KIM polypeptide of claim 23 or 24, linked to a detectable moiety, imageable moiety, radiolabeled moiety, or toxin moiety. 26. An antibody that binds selectively to all or a unique fragment of a KIM polypeptide encoded by a nucleic acid sequence listed in TABLE 1. 27. A conjugate comprising an antibody of claim 26, linked to a detectable moiety, imageable moiety, radiolabeled moiety, or toxin moiety. 28. An antibody that binds selectively to all or a unique fragment of a KIM polypeptide encoded by a nucleic acid sequence listed in TABLE 2. 29. A conjugate comprising an antibody of claim 29, linked to a detectable moiety, imageable moiety, radiolabeled moiety, or toxin moiety. 30. Use in therapy of an antisense KIM nucleic acid of claim 8. 31. Use in therapy of a KIM vector of claim 14. 32. Use in therapy of a KIM polypeptide of claim 17, 18 or 19. 33. Use in therapy of a KIM fusion protein of claim 20 or 21, or of a KIM conjugate of claim 22. 34. Use in therapy of an antibody of claim 26, or of an antibody conjugate of claim 27. 35. A pharmaceutical composition comprising a physiologically acceptable carrier having dispersed therein, to a therapeutically effective concentration: a KIM nucleic acid of claim 8; a KIM vector of claim 14; a KIM polypeptide of claim 17, 18 or 19; a KIM fusion protein of claim 20 or 21; a KIM conjugate of claim 22; an anti- KIM antibody of claim 26; or, an anti-KIM antibody conjugate of claim 27. 36. A method for detecting the presence or status of renal injury or of renal disease, comprising the step of measuring the concentration of a KIM polypeptide in a sample selected from serum, urine or urine sediment of an individual afflicted with, or at risk of developing, renal injury or an impairment of renal function. 37. A method for detecting the presence or status of an abnormal response to tissue injury or other stimulus, comprising the step of measuring the concentration of a KIM polypeptide in a sample selected from serum, urine or urine sediment of an individual afflicted with, or at risk of developing, an autoimmune response or abnormal tissue growth arising from or affecting renal tissue. 38. A method according to claim 36 or 37, wherein said measuring step involves contacting said sample with an anti-KIM antibody of claim 26 or 28, or with a conjugate of claim 27 or 29. 39. A kit for practice of the method of claim 36 or 37, comprising at least one reagent selected from: the anti-KIM antibody of claim 26; the anti-KIM antibody of claim 28; the conjugate of claim 27; and, the conjugate of claim 29. 40. A method for detecting the presence or status of renal injury or of renal disease, comprising the step of measuring the level of a KIM nucleic acid in a sample selected from serum, urine or urine sediment of an individual afflicted with, or at risk of developing, renal injury or an impairment of renal function. 41. A method for detecting the presence or status of an abnormal response to tissue injury or other stimulus, comprising the step of measuring the level of a KIM nucleic acid in a sample selected from serum, urine or urine sediment of an individual afflicted with, or at risk of developing, an autoimmune response or abnormal tissue growth arising from or affecting renal tissue. 42. A method according to claim 40 or 41, wherein said measuring step involves contacting said sample with a KIM nucleic acid of claim 9, 10 or 11; or with a nucleic acid probe that hybridizes to KIM nucleic acid of claim 9, 10 or 11 ; or with a nucleic acid having a sequence selected from sequences listed in TABLE 2; or with a nucleic acid probe that hybridizes to a nucleic acid listed in TABLE 2. 43. A kit for practice of the method of claim 40 or 41 , comprising at least one reagent selected from: the KIM nucleic acid of claim 9, 10 or 11 ; or a nucleic acid probe that hybridizes to KIM nucleic acid of claim 9, 10 or 11 ; or a nucleic acid having a sequence selected from sequences listed in TABLE 2; or a nucleic acid probe that hybridizes to a nucleic acid listed in TABLE 2. 44. A method of imaging cells or tissue expressing or producing a KIM, comprising the steps of contacting the cells or tissue with an imageable KIM-binding reagent; and, imaging an accumulation of the KIM-binding reagent. 45. A method according to claim 44 wherein the cells or tissue are disposed in body tissue of an individual suspected of harboring an imageable locus of KIM expression and/or production. 46. A method of locating a tissue mass abnormally producing or expressing a KIM in an individual suspected of affliction with an abnormal tissue response to injury or other stimulus, comprising the step of: administering an imageable KIM-binding reagent to the individual; and, imaging said tissue mass within the body of the individual. 47. A method according to claim 44 wherein the tissue mass is a tumor arising from or affecting renal tissue of the individual. 48. A method of treating an individual afflicted with, or at risk of developing, a disease or condition contributed to or associated with a dysfunction or dysregulation of a KIM gene or protein, comprising the step of administering to the individual a pharmaceutical composition of claim 35. 49. A method of treating an individual afflicted with, or at risk of developing, a disease or condition beneficially affected by therapeutic administration of a KIM composition of the present invention, comprising the step of administering to the individual a pharmaceutical composition of claim 35. 50. A method according to claim 48 or 49 wherein the disease is a renal disease; or, the condition is an impairment of renal function. 51. A method of inhibiting the growth of KIM-expressing tumor cells, comprising the step of contacting the tumor cells with a pharmaceutical composition comprising involving the step of contacting the cells with: an antisense KIM nucleic acid of claim 8; a KIM fusion protein of claim 20, 21, 23 or 24; a KIM conjugate of claim 22 or 25; an antibody of claim 26 or 28; or an antibody conjugate of claim 27 or 29. 52. A method according to claim 36, 37, 40, 41, 45, 46, 47, 48, 49, or 50 wherein the individual is a human.

Inventors: CATE RICHARD L, HESSION CATHERINE A, SANICOLA-NADEL MICHELE, WEI HENRY, CATE, RICHARD, L., HESSION, CATHERINE, A., SANICOLA-NADEL, MICHELE, WEI, HENRY
Applicants: BIOGEN INC, CATE RICHARD L, HESSION CATHERINE A, SANICOLA NADEL MICHELE, WEI HENRY, BIOGEN, INC., CATE, RICHARD, L., HESSION, CATHERINE, A., SANICOLA-NADEL, MICHELE, WEI, HENRY
Application year: 1998
Main classification: C12N15
IPC codes: A61K38, A61K39, A61K48, A61P13, C07K14, C07K16, C07K19, C12N1, C12N5, C12N15, C12P21, C12Q1, G01N33